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Abstract 
 
Vasculogenesis is the primitive de novo process of formation of new blood vessels 
which involves differentiation of precursor angioblast cells into endothelial cells and 
development of vascular network. Angiogenesis is a complex multistep process of 
formation of new blood vessels from endothelium of pre#existing ones. Interactions 
between several cellular factors including growth factors, cytokines and hematopoietic 
factors lead to activation of various cellular pathways, finally resulting in extracellular 
matrix (ECM) degradation, endothelial cell proliferation, survival and migration. 
Normally, angiogenesis is an essential requirement for vascular development in 
growing embryos as well as in adult tissues, where this process depends on the intricate 
balance between the activities of the pro# and anti#angiogenic factors. Abnormal 
angiogenesis results in aberrant vasculature leading to various pathological conditions. 
The most important factor implicated in angiogenic processes is vascular endothelial 
growth factor (VEGF) and its family of ligands and receptors (VEGFRs). Cellular 
VEGF mediates its angiogenic effect by binding to endothelial cell#specific tyrosine 
kinase transmembrane receptors, VEGFR1 (Flt#1) and VEGFR2 (KDFR/Flk#1), both 
of which have similar structure, with seven extracellular immunoglobulin#like 
domains. Although binding affinity of VEGFR1 for VEGF is several folds more than 
that of VEGFR2, and both receptors undergo VEGF#induced phosphorylation, the 
latter is known to mediate most of the responses of VEGF including cell proliferation, 
migration and survival.  
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Reports suggest that the strategy of blocking cellular VEGF is by far the most superior 
anti#angiogenic strategy in terms of efficacy. Several anti#VEGF molecules have been 
developed or in the phase of development, including monoclonal antibodies, aptamers, 
siRNA, antisense oligonucleotides, fusion proteins, dominant negative proteins and 
peptidomimetics. Fc#fusion proteins which are generated by genetically fusing 
biologically active protein part or the effector molecule or the ligand binding domain 
of a receptor to the Fc region of immunoglobulin, are generally advantageous over 
antibodies due to more target reachability, lower patient dosing, ease of purification, 
lower cost of production and improved product homogeneity.  
 
Anti#angiogenic decoy receptors, are soluble mimics of cellular version, which can 
bind to specific angiogenic ligands with high affinity. The ligands are thus neutralized 
and made unavailable to their cell surface receptors for any interaction and subsequent 
downstream signaling. These decoy receptors are also referred to as molecular traps. 
The extracellular ligand (VEGF) binding domains of cellular receptors, VEGFR1 and 
VEGFR2 have been utilized in generating VEGF traps.  
 
The initial soluble VEGF trap was developed by fusing IgG1#Fc constant region to 
domains D1#D7 of VEGFR1 receptor consisting all seven immunoglobulin#like (Ig) 
extracellular domains (Flt#1#Fc), which had the same binding affinity as full length Flt#
1(1#7)#IgG. This was followed by recombinantly creating various truncated versions 
of the initial trap (Flt#1#Fc) and checking for their improved VEGF#binding affinity.  
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In the current project, an anti#angiogenic molecule has been developed by targeting 
key angiogenic factor, VEGF#A. It is an anti#VEGF fusion trap containing a 
VEGF/PlGF#binding domain linked to a stabilizing human IgG1 Fc domain. The 
VEGF domain consists of the first three VEGF binding Ig#like domains of vascular 
endothelial growth factor receptor 1. Although commercial aflibercept (VEGF#
TrapR1R2) which is an Fc#fusion of D2 domain of VEGFR1 linked to D3 domain of 
VEGFR2, developed by Regeneron Pharmaceuticals Inc. (New York, USA), shows 
high binding affinities and efficacy, it is a chimeric fusion protein with domains of 
both VEGF receptors. Owing to ten times higher binding affinities and multi#ligand 
binding capabilities of VEGFR1 in comparison to VEGFR2, we decided to keep the 
VEGFR1 backbone intact for the VEGF antagonist molecule. Reports indicate that, of 
the various combinations of extracellular domains of recombinant VEGFR1 receptors, 
only the one containing first three domains, show full VEGF#binding activity 
compared to the whole extracellular portion of wild type VEGFR1. Moreover, since 
the second and third Ig#like domains of both VEGF receptors are sufficient for VEGF#
A binding, it was logical to retain the D3 domain of VEGFR1 and not that of VEGFR2 
as that would otherwise introduce an unnatural species, which might pose 
immunogenicity problems when administered in vivo. Since D2 domain requires 
flanking sequences for proper binding to ligand, D1 of VEGFR1 was retained as was 
in the parental Flt#1(1#3)#IgG. Studies suggest that D2 domain of VEGFR2 in spite of 
being the major ligand#binding domain of this receptor, is weaker as compared to 
VEGFR1 (D2). Moreover, similar to VEGFR1 (D2), even VEGFR2 (D2) requires 
flanking sequences for proper spatial conformation during stable ligand binding, which 
is not observed in the design of aflibercept. Additionally, earlier studies indicate that 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
xxvii 
  
the second domain of VEGFR1 is not only critical for high affinity VEGF/PlGF 
interaction, but also capable of initiating a signal transduction cascade upon ligand 
binding.  
 
Hence, with the view to develop a decoy receptor VEGF trap with high affinity for 
VEGF#A and high efficacy as an anti#angiogenic drug, this Fc#fusion protein has been 
developed using recombinant technology. VEGFR1(D1#D3)#Fc fusion gene was 
generated by sequence amplification using overlap PCRs and cloned in pXC17.4 
mammalian expression vector. Mammalian CHOK1SV GS#KO cells were transfected 
with the cloned plasmid and the gene was stably integrated in the host genome. The 
clone expressing highest levels of VEGFR1(D1#D3)#Fc protein was selected and 
propagated in cell culture. However, as is the case with most recombinant Fc#fusion 
proteins, protein clipping was observed in VEGFR1(D1#D3)#Fc, whereby along with 
the intact monomeric form of 78 kDa, a major clipped protein species of ∼40 kDa was 
also present.  
 
In a bid to overcome this problem, another version of the recombinant trap molecule 
containing only D2 and D3 of VEGFR1 with replacement of two amino acids in D3, 
was developed in a similar manner, but observed to be undergoing proteolysis in 
culture. Several parameters were investigated including the effects of culture 
temperature, culture duration and chemical inhibitor supplementation, on protease 
activity in CHOK1SV GS#KO culture expressing the protein of interest. It was 
observed that lowering the culture temperature from 37°C to 30°C and early harvesting 
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reduces the amount of proteolysis. Large scale fed#batch culture of the protein at 
lowered temperature yielded more than 75% reduction in proteolysis. The protein was 
purified by Protein A affinity chromatography followed by strong cation exchange 
chromatography and characterized using various physicochemical and biophysical 
techniques. SDS#PAGE and Western blotting were used to determine the molecular 
weight of the protein under both reducing and non#reducing conditions. RP#HPLC was 
used to separate and provide protein fractions which were directly analyzed by mass 
spectrometry (MALDI#TOF#MS) for intact molecular weight determination. MS 
indicated mass of the protein to be in the range of 137 kDa to 143 kDa which suggested 
partial glycosylation of the protein. Capillary electrophoresis based SDS (CE#SDS) 
with PDA detector, was used to determine the apparent molecular weight and size 
heterogeneity of the protein. Presence of high and low molecular weight aggregates 
along with the protein monomer, was determined to be ∼7% and ∼5% respectively by 
using SEC#HPLC. The pure monomeric protein content was found to be more than 
87%. The isoelectric point of VEGFR1(D1#D3)#Fc was determined by both IEF gel 
and capillary isoelectric focusing (cIEF) and observed to be in the pH range of 8.2#9.4. 
Both analyses revealed presence of several isoforms and/or cleaved species.  
 
The major N#glycan forms present in VEGFR1(D1#D3)#Fc protein were G2FS1, G0F, 
Man5, G1F(1, 6), G1F(1, 3) and G2F. Four unidentified minor peaks were detected 
using capillary zone electrophoresis using laser#induced fluorescence detector (CZE#
LIF). Circular dichroism and fluorescence spectroscopic data suggested that the 
protein was in a properly folded form with intact secondary and tertiary structures and 
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overall three dimensional stability. Stability studies of the protein suggested that the 
protein is stable at #20°C and #70ºC for a six months period as evident from RP#HPLC 
profiles, at various time points and different temperature conditions.  
 
ELISA data for VEGFR1(D1#D3)#Fc also exhibited a strong affinity towards its 
ligands (VEGF165 and VEGF121) with comparable affinity to that of aflibercept 
(VEGF#TrapR1R2) biosimilar. VEGF165, being the most potent and well#studied ligand 
for VEGFR1 and VEGFR2, was used in the various in vitro as well as ligand binding 
studies. This protein was also developed by recombinant technology for in#house 
experiments.  
 
VEGFR1(D1#D3)#Fc protein was shown to be biologically active as was evident from 
its ability to inhibit both endothelial cell proliferation as well as tube formation in 
HUVEC in in vitro assays. In in vivo efficacy studies, the protein showed significant 
reduction in tumor volume in SCID mice with human lung cancer A549 xenografts 
(p<0.05). Histological analysis (haematoxylin and eosin) of tumor sections obtained 
from mice treated with VEGFR1(D1#D3)#Fc, revealed about 60% of viable tumor as 
compared to 80#90% of viable adenocarcinoma observed in sections from untreated or 
placebo#treated mice. Immunohistochemical staining of Ki#67 in tumor sections of 
VEGFR1(D1#D3)#Fc–treated mice, showed lesser staining (∼40%) as compared to 
sections from untreated mice (∼60%) indicating reduction in cell proliferation with 
treatment. VEGFR1(D1#D3)#Fc also exhibited a synergistic effect when combined 
with an anti#VEGF DNA aptamer, RNV66. Immunofluorescence staining with 
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antibody to mouse CD31, an endothelial cell marker, demonstrated the anti#angiogenic 
activity of VEGFR1(D1#D3)#Fc. Tumor sections obtained from mice treated with 
VEGFR1(D1#D3)#Fc, revealed inhibition of new blood vessel formation as compared 
to untreated or placebo#treated animals. Tumor microvessel density determined from 
microscopic observation of CD31 stained vasculature, also corroborated with the 
visual observation with phase contrast fluorescence microscope. Treatment with the 
anti#VEGF agent did not induce any apparent drug#induced chronic toxicity in SCID 
mice, as was evident from normal histopathology in sections obtained from different 
organs of the animals including liver, brain, heart and kidney.  
 
Overall, the VEGFR1(D1#D3)#Fc fusion protein, has potential for development as an 
anti#angiogenic and anti#cancer therapeutic agent. 
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Chapter 1: Literature Review 
 
1.1 Introduction  
  
Angiogenesis, a complex and multistep process of development of new blood vessels 
from pre#existing ones, is an extremely important target for therapy in most human 
malignant and some non#malignant diseases. In cancer, local hypoxia occurs as a result 
of lack of oxygen supply in the tumor microenvironment. Several cellular pro#
angiogenic factors are produced under such hypoxic conditions which induce or 
regulate angiogenesis. Angiogenic factors include various cellular proteins such as 
soluble growth factors and their receptors, membrane bound proteins, those involved 
in cell#matrix and cell#cell interactions such as members of the vascular endothelial 
growth factor (VEGF) [1], epidermal growth factor (EGF) [2, 3], fibroblast growth 
factor (FGF) [4#6], VEGF receptor (VEGFR) [7], angiopoietins (Ang1/2) [8, 9], 
angiogenin [10], Tie#2 receptor [11], tumor growth factors (TGF#α, TGF#β) [12], 
platelet derived growth factor (PDGF) [13], hepatocyte growth factor [14], integrins 
[15], cadherins [16], ephrin [17], eNOS [18], tumor necrosis factor#α (TNF#α) [19] 
and colony#stimulating factors (CSFs) [20, 21]. Tumor hypoxia tilts the balance 
between pro#angiogenic and anti#angiogenic factors in favor of angiogenesis. In fact, 
a recent study has reported that hypoxia#induced angiogenesis is controlled by 
complex regulatory mechanisms, which involve not only the production of angiogenic 
factors such as VEGF, but also the production of VEGF inhibitors including sVEGFR1 
and differential expression of VEGFRs in different cell types [22].  Tumor progression 
and metastasis are dependent on neoangiogenesis or formation of new blood vessels. 
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Angiogenesis also plays a critical role in sustenance and progression of pathological 
conditions other than cancer, such as proliferative retinopathies including neovascular 
or wet form of age#related macular degeneration (AMD), diabetic retinopathy and 
diabetic macular edema (DME), and inflammatory diseases such as rheumatoid 
arthritis (RA) and psoriasis [23#25]. 
 
Blocking of tumor angiogenesis results in inhibition of new vessel formation, which 
in turn cuts off supply of essential nutrients to developing tumor cells. The idea of anti#
angiogenesis therapy targeting diseases like cancer was first proposed by Judah 
Folkman in 1971 [26, 27]. Several anti#angiogenic drugs have been developed over the 
last two decades and some are still at different development stages of pre#clinical and 
human clinical trials [28#30] . Anti#angiogenic therapy can be divided into gene#based 
therapy and protein#based therapy [31]. Gene#based therapies include use of antisense 
oligonucleotides, siRNA, aptamers and catalytic oligonucleotides, including 
ribozymes and DNAzymes and transcription decoys. Protein#based therapeutics 
includes MAbs, peptidomimetics, mimetobodies, fusion proteins and decoy receptors. 
Since VEGF plays a pivotal role in the process of pathological angiogenesis, it is by 
far the most well studied and most efficiently targeted protein in diseases involving 
neoangiogenesis, including cancer.  
 
Cytokines and growth factors can initiate and propagate human diseases by binding to 
their cell surface receptors and are among the most validated therapeutic targets. One 
way to block these ligands other than by small molecule kinase inhibitors or MAbs, is 
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by the use of soluble receptors. Since monomeric soluble receptors generally exhibit 
low affinity towards their ligands or reduced function as agonists, high#affinity 
blockers or ligand traps are created by fusions between the extracellular ligand binding 
domains of the receptor with the constant region (Fc) of human IgG1. This helps in 
monomer dimerization and also increases serum stability of the molecule. Fusion 
proteins code for more than one protein, all of which impart their benefits to the final 
protein. Of all fusion proteins, Fc#fusion proteins are the most commercially successful 
class of drugs [32]. An Fc#fusion is composed of an immunoglobulin (Ig) Fc region 
linked to another peptide, which can be a ligand that gets activated upon binding to its 
receptor, or ligand binding domain(s) of a cellular receptor that binds to its natural 
ligand. The latter form can perform as a decoy receptor in order to inhibit the target 
ligand, for example VEGF. Aflibercept, which is a Fc#fusion protein co#developed by 
Bayer Healthcare and Regeneron Pharmaceuticals is a Food and Drug Administration 
(FDA, USA)#approved drug targeting VEGF [33], used in treatment of metastatic 
colorectal cancer and wet AMD.  
 
VEGFR1 and VEGFR2 extracellular Ig#like domains for example, D1, D2 and D3, 
which bind VEGF with high affinity, can be specifically utilized for the development 
of VEGF trap molecules. The VEGF#TrapR1R2 developed by Regeneron 
Pharmaceuticals, binds to VEGF with great affinity (dissociation constant, Kd~1 
pmol/L) and also binds placental growth factor (PlGF; Kd≈ 45pmol/L) and shows good 
overall efficacy and pharmacological properties. It is currently being tested in human 
clinical trials for several types of diseases involving aberrant angiogenesis.  
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The current research takes advantage of the above mentioned facts to develop a VEGF 
trap, an anti#VEGF molecule with comparable VEGF#A binding affinity as other anti#
VEGF drugs, Genentech’s anti#VEGF antibody, Avastin® and Regeneron’s VEGF#
TrapR1R2. The proposed molecule is an effective anti#angiogenic and thus anti#
carcinogenic agent.  The nucleotide sequence containing the signal sequence and the 
first three Ig#like domains of human VEGFR1, fused in frame to the Fc portion of 
human IgG1, was cloned and expressed in mammalian cell line to generate the Fc#
fusion protein. Further physicochemical characterization of the protein and assessment 
of stability and biological activity were carried out in vitro. Efficacy of this anti#
angiogenic protein was evaluated in an animal model of human cancer. 
 
1.2 Physiological processes of vasculogenesis and angiogenesis 
 
Humans have a closed vascular system which is responsible for carrying essential 
nutrients and oxygen to all tissues and organs. All the major and minor blood vessels 
are lined by an inner monolayer of vascular endothelial cells and an outer layer of cells 
consisting of smooth muscles cells and pericytes and responsible for contraction and 
dilation of the vessels [34]. Primitive blood vessels, by processes such as sprouting and 
branching, are able to associate with smooth muscle cells in order to supply the 
necessary nutrients. The vascular system is vital for blood delivery for tissue repair 
and reproductive functions in adults. The cardiovascular system is the first organ 
system that develops and becomes functional in a growing embryo [23].   
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1.2.1 Vasculogenesis vs. angiogenesis 
 
There are two types of cellular processes which are involved in the formation of blood 
vessels in humans: vasculogenesis and angiogenesis. Vasculogenesis is the de novo 
capillary formation during early embryonic development, from hemangioblasts, which 
are endothelial precursor cells arising from the mesoderm, induced by the fibroblast 
growth factor (FGF) family and takes place in an avascular environment giving rise to 
the body’s primary circulatory system. The hemangioblasts multiply, migrate and 
differentiate into angioblasts which then join together to form the primitive vascular 
network. These in turn give rise to both major blood vessels in the growing embryo 
such as the dorsal aorta and cardinal veins, as well as initiates capillaries and all other 
arteries and veins [35]. In order to further mature the vasculature, another process of 
vascular remodeling occurs whereby smooth muscle cells and pericytes are recruited 
to the existing vessels. In this phase also, there is establishment of endothelial cell 
adherens and tight junctions by the expression of cadherins, occludins and claudins 
which offer mechanical strength to vessel walls while creating permeability barriers 
[36]. 
 
Angiogenesis, on the other hand, is a physiological process of growth and remodeling 
of blood vessels from already existing ones which can occur during developmental 
phases as well as in the adult lifetime, and in pathological conditions. Angiogenesis is 
initiated when cells in an avascular region experience hypoxia shock due to lack of 
oxygen and adaptive responses are mounted in the form of gene expression of several 
pro#angiogenic factors including VEGF by transcription factors, hypoxia inducible 
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factor 1α (HIF#1α) [37], HIF#2α and HIFβ [34, 36] via a hypoxia responsive element 
(HRE) motif. VEGF gene expression in the parenchymal and stromal cells is regulated 
by a variety of stimuli other than hypoxia, such as, growth factors, transformation, 
tumor promoters, p53 mutation [38], nitric oxide (NO) [39] and hormones including 
estrogen and thyroid stimulating hormone (TSH) [40, 41]. Angiogenesis occurs by two 
mechanisms, namely sprouting and non#sprouting processes. Sprouting angiogenesis 
expands the primitive capillary nexus formed during vasculogenesis and forms the 
hierarchical network of blood vessels which spreads by branching out to irrigate all 
parts of developing organs [36]. It is based on endothelial cell migration into 
proteolytically degraded extracellular matrix (ECM), cell proliferation and tube 
formation. In sprouting angiogenesis, VEGF induces endothelial cells expressing 
VEGF receptor 2 (VEGFR2) at the tip of a sprouting vessel to adopt a polarized and 
motile phenotype whereby the vessel extends filopodia projections that sense hypoxia 
and guides the vessels to avascular regions [42]. Migratory response to VEGF is 
reduced in the stalk cells which lie behind the tip cells, which instead proliferate to 
elongate and form lumen of the newly formed sprout [43]. VEGF also induces the 
expression of the delta#like ligand 4 (Dll4) in the tip cells, to bind to Notch 1 or Notch 
4 receptors expressed in the stalk cells resulting in downregulation of VEGFR2 
expression in the stalk cells [44]. In this way, differential VEGFR2 signaling leads to 
motility in the tip cells and reduced motility in the follower stalk cells [36]. In non#
sprouting or intussusceptive angiogenesis, the endothelial cells proliferate within an 
existing vessel and form a lumen that can be divided by fusion or the splitting of 
capillaries.  
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1.3 Tumor Angiogenesis 
 
Tumors employ several additional strategies beyond the physiological mechanisms of 
blood vessel growth in order to adapt and survive. Tumors and tumor vascular network 
are highly heterogeneous in nature. Tumor angiogenesis is a series of sequential linked 
steps that ultimately leads to progressive neoplasm growth and vascular extravasations 
which establishes continuity with the normal circulation. During the initial process of 
tumor formation, “early” and hyper permeable blood vessels known as mother vessels 
(MV) are formed by angiogenic processes from pre#existing capillaries and venules 
which later turn into glomeruloid microvascular proliferations (GMP) and 
subsequently into vascular malformations (VM) over a period of time.  This is followed 
by development of “late” vessels which develop by arterio#venogenesis from 
remodeling and enlargement of existing arteries and veins to form feeder arteries (FA) 
and draining veins (DV) which supply and drain the tumor vasculature [45]. Upon 
emerging from a dormant state, tumors rely on the supply of blood for their oxygen 
and nourishment requirement. However tumor angiogenesis is aberrant as a result of 
genetic mutations, mechanical stress, hypoxia and inflammatory processes resulting in 
heterogeneous and deregulated network of dilated blood vessels with reduced vessel 
density and increased perfusion. Growing tumors secrete a plethora of soluble factors 
including VEGF [46, 47], FGF [48], granulocyte macrophage colony#stimulating 
factor (GM#CSF) [49] and osteopontin [50] which changes the inert bone marrow 
microenvironment into a highly  pro#angiogenic setting. VEGF is secreted by 
endothelial cells as well as the smooth muscle cells and pericytes that are in intimate 
contact with the endothelial cells. The increased levels of VEGF coupled with hypoxia, 
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induce endothelial cell Dll4/Notch signaling which leads to excessive but non#
functional tumor angiogenic sprouts. Other genes that are upregulated in cancers and 
involved in angiogenesis include VE#cadherin [51], Ephrin#2 [52], CD34 [53], 
neuropilin 1 (NRP1) [54] and endoglin [55] and some others in ECM including 
laminin, fibronectin [56], matrix metalloproteinases (MMPs) [57] and collagens type 
I and IV [58, 59]. The basement membrane is progressively degraded as the MV 
develops as a result of increased expression of activated forms of three cathepsins (B, 
S and L) and decreased levels of cysteine protease inhibitors [45]. This results in 
detachment of endothelial cells from the ECM and associated pericytes leading to 
increased vascular cell surface area, enlarged lumen, sprouting and penetrance to 
adjoining regions and subsequently metastasis. Angiogenesis not only plays an 
important role in solid tumors, it has been implicated even in the progression of 
hematolymphoid malignancies such as myelodysplastic syndromes, acute leukemia, 
myeloproliferative neoplasms, multiple myeloma and lymphomas, with upregulation 
of the VEGF/VEGFR system [60]. Figure 1.1 represents the various pro# and anti#
angiogenic factors secreted by a tumor and how a tilt in the angiogenic balance leads 
to various diseases implicated from abnormal blood vessel formation. 
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Figure 1.1 Pathological angiogenesis in tumor development and angiogenic 
balance. Tumors require development of new blood vessels in order to get adequate 
supply of oxygen and nutrients for their growth, and hence release, or utilize pro#
angiogenic molecules. These molecules, of which VEGF is the most potent, tilt the 
angiogenic balance towards formation of new blood vessels or neoangiogenesis, which 
in turn play a very important role in pathogenesis of several diseases including cancer, 
psoriasis and retinopathies. On the other hand, predominance of anti#angiogenic 
factors which inhibit formation of vascular network, lead to development of diseases 
such as stroke and ulcers. 
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1.4 Intraocular neovascularization 
 
In the case of retinopathies in diabetes mellitus and other cases of proliferative 
retinopathies, due to aberrant angiogenesis, there is leakage of blood and fluid from 
the hyper permeable choroidal vascular network beneath the retina. This leads to 
edema of the macula (central portion of the retina) followed by hemorrhage, scarring 
and macular damage. The abnormal angiogenesis or neovascularization in the eye 
resulting in cystoid macular edema (CME) or diabetic macular edema (DME), might 
further lead to detachment and tearing of the retina and subsequent vision loss [61#63].  
 
1.5 VEGF and its isoforms 
 
VEGF protein was initially identified in the 1980s as vascular permeability factor 
(VPF) [64], which was revealed later on by molecular cloning, to be same protein as 
vascular endothelial cell#specific growth factor. The term VEGF was coined by 
Napolean Ferrera in 1989. VEGF structurally belongs to the VEGF#PDGF super#gene 
family and the cysteine knot family of growth factors, where eight cysteine residues 
are conserved in the same positions with two cysteines forming a cross#linking 
sulphydryl bond, while the remaining six forming three intramolecular S#S bonds. 
VEGF protein is a homodimeric glycoprotein and specific for vascular endothelial 
cells which respond to VEGF with increased survival, proliferation, and migration. 
Crystal structure of the receptor binding site of VEGF at 2.5Aº resolution has shown 
that it forms antiparallel homodimer linked by two disulphide bridges between Cys#51 
and Cys#60 [65]. The mode of dimerization of VEGF is similar to that of PDGF [65] 
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but different from that of TGF#β [66]. Even though the VEGF protein resembles 
PDGF, the N#terminal segment of VEGF is helical and not extended.  
 
The VEGF gene located on chromosome 6p21.3 contains eight exons and seven 
introns. VEGF is a heparin binding growth factor that is part of the system that delivers 
oxygen supply and nutrients to tissues and proliferating cells during normal growth 
processes, as well as when blood circulation is inadequate. VEGF also promotes 
creation of new blood vessels after injury, muscle following exercise, and new vessels 
collateral circulation to bypass blocked vessels. The VEGF protein is a 35–45 kDa 
homodimeric protein having related members [67]. The seven  related glycoprotein 
members of the VEGF family include VEGF#A, VEGF#B, VEGF#C, VEGF#D, VEGF#
E, VEGF#F and PlGF [68]. Human VEGF#A has nine isoforms, resulting from 
alternative splicing of VEGF#A mRNA, comprising 121, 145, 148, 162, 165, 183, 189 
and 206 amino acids in distinct monomers respectively VEGF121, VEGF145, VEGF148, 
VEGF162, VEGF165, VEGF165b, VEGF183, VEGF189, and VEGF206, of which VEGF165 
is the most abundant isoform [69]. Figure 1.2 gives a schematic representation of 
generation of various isoforms of VEGF. 
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Figure 1.2 Comparison of structures between different VEGF family members. 
Alternative exon splicing gives rise to several isoforms of VEGF#A and VEGF#B. 
Arrows in VEGF#C and VEGF#D structures, denote sites of proteolytic cleavage 
giving rise to mature mRNA for VEGF#C and VEGF#D. 
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The corresponding mouse isoforms are shorter by a single amino acid. VEGF165 
contains an additional 44 amino acid basic stretch, as compared to VEGF121, as a result 
of which it can bind to heparin and heparin#like molecules such as heparin sulphate 
proteoglycans (HSPG) in the ECM and to a cell surface non#tyrosine kinase 
glycoprotein molecule, known to be involved in axonal guidance, NRP#1. Several 
VEGF#like proteins, called VEGF#F, have also been isolated from snake venoms and 
shown to have biological activity similar to VEGF165 [70]. Vammin (110 residues) and 
VR#1 (109 residues) from the venoms of certain vipers, which share 50% amino acid 
sequence identity with VEGF165, strongly stimulate proliferation of vascular 
endothelial cells in vitro and induce arterial hypotension in rats. Another VEGF#F 
variant from Trimeresurus flavoviridis snake venom, Tfsv#VEGF, efficiently promotes 
vascular permeability similar to VEGF165, while stimulation of endothelial cell 
proliferation by Tfsv#VEGF is negligible [71, 72]. These structurally related VEGF 
proteins are dimeric proteins of approximately 40kDa that once secreted by the 
producer cells, can signal through binding to their cellular receptors. The snake venom 
derived VEGFs bind to VEGFR2 with almost equal affinity as VEGF165, but not to 
VEGR1 or NRP1. The members of the VEGF family regulate a large number of diverse 
functions including modulation of angiogenesis, vasculogenesis, vascular leakage, 
neurogenesis, inflammation, hematopoiesis and lymphangiogenesis which make them 
ideal candidates for research and therapeutic targets for several diseases resulting from 
their impairment [73].  
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1.5.1 Functions of VEGF 
 
VEGF is a known regulator of angiogenesis, vasculogenesis and lymphangiogenesis 
during the normal physiological course of embryonic development, the female 
reproductive system including endometrial and placental proliferation and corpus 
luteum formation, and tissue repair including wound healing and revascularization of 
ischemic tissues [74]. Through childhood until adulthood, VEGF secreted by the 
hypertrophic chondrocytes in the epiphyseal growth plates is essential for cartilage 
remodeling and endochondral bone formation [75]. VEGF is a cytokine which carries 
activating, proliferative and chemotactic signals from hypovascularized tissues to 
endothelial cells of quiescent blood vessels and initiates new vessel sprouting to 
increase perfusion of the target tissue. VEGF is produced by endothelial cells and non#
endothelial cells such as macrophages, activated T cells, platelets, keratinocytes, renal 
mesanglial cells as well as variety of tumor#associated stromal cells [76]. The critical 
role of VEGF in vessel formation during embryo development has been shown in gene 
targeted studies in embryos generated by aggregation of embryonic stem cells (ES) 
with tetraploid embryos (T#ES), where haplodeficiency or overexpression of the 
VEGF gene resulted in embryo lethality within 11 to 12 days due to abnormal blood 
vessel formation [77].  
 
The role of VEGF in developmental processes is well emphasized by studies showing 
that the loss of one VEGF allele results in defective blood vessel formation leading to 
early embryonic lethality. Both in vivo and in vitro, VEGF is the survival factor for 
endothelial cells. In vitro, VEGF inhibits serum#starvation mediated endothelial cell 
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apoptosis by phosphatidylinositol#3 (PI3) kinase/protein kinase B (Akt) mediated 
pathway and induces expression of antiapoptotic proteins including Bcl#2 [78, 79], 
A1[80], XIAP[81] and survivin [82#85]. In vivo, while endothelial cells are the main 
targets of VEGF, it has been implicated that VEGF dependence of blood vessels 
decreases with age or time of formation of the vessels. In other words, “late” or 
established blood vessels are independent of VEGF and capable of proliferating even 
in the absence of the ligand [23, 45], whereas neovascularization requires VEGF. 
 
In pathological angiogenesis, VEGF induces expression of MMPs, serine proteases 
urokinase#type and tissue#type plasminogen activators (tPA), urokinase receptor 
(uPAR) which are consistent with matrix degrading, cellular invasion and tissue 
remodeling properties of the angiogenic factor, as well as induces plasminogen 
activator inhibitor (PAI) in a bid to negate the proangiogenic properties and balance 
the proteolytic activities [20, 86]. That VEGF acts as an intracrine cell survival factor 
in cancerous cells, has been shown in its role in colorectal cancer (CRC), where 
depleting VEGF resulted in decreased cell survival and increased sensitivity to 
chemotherapy [87]. VEGF#B, which has been demonstrated to promote angiogenesis 
in relation to activation via Akt and eNOS associated pathways, might also be involved 
in inflammatory angiogenesis, as was deduced from experiments with knockout mice 
that demonstrate reduced angiogenic responses in collagen#induced arthritis [21]. 
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1.6 VEGF Receptors  
 
The proangiogenic factors work by binding to their cell surface receptors. The VEGF 
ligands by virtue of their N#terminal receptor binding domains [70], bind to their 
specific tyrosine kinase receptors, which become activated through ligand#dependent 
trans#autophosphorylation and transmit intracellular signals for regulating endothelial 
cell proliferation, migration, vascular permeability, vessel dilation [88], secretion and 
survival. There are three known receptors for VEGF, namely, VEGFR1 (or Flt#1), 
VEGFR2 (or KDR in humans/Flk#1 in mice) and VEGFR3 (or Flt#4). VEGF receptors 
bind their specific ligands with different binding affinities [89], tissue distributions, 
cellular functions and signal transduction properties [90]. The different VEGF ligands 
have overlapping binding properties for each of their receptors, which contribute to 
their functional diversities. VEGFR1 is the receptor for VEGF#A, VEGF#B and PlGF, 
whereas VEGFR2 binds VEGF#A, VEGF#C and VEGF#D. VEGFR3, found primarily 
on lymphatic endothelial cells, binds to VEGF#C and VEGF#D with high affinity and 
is responsible for the growth, development and maintenance of lymph vessels. VEGF#
D binds to VEGFR3 with a 20#fold higher affinity than to VEGFR2 [70]. Genetic 
deletion of VEGF#C has been reported to completely ablate the lymphatic vasculature 
in developing mouse embryos, but not VEGF#D deletion. VEGF#B knock#out mice 
resulted in decreased size of heart and dysfunctional coronary vasculature and 
impairment in recovery from coronary ischemia, but not lethality. Additionally, it has 
been shown that VEGF#B, which is found in tissues other than heart, such as, brown 
fat, skin and brain, is also neuroprotective [36]. The function VEGF#B is not only 
restricted to development and regulation of vasculature but also to metabolic pathways, 
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as is demonstrated from studies that show that it is involved in regulation of fatty acid 
uptake by endothelial cells.  
 
Another ligand, VEGFENZ#7, which was originally recognized as the product of an open 
reading frame in NZ#7 strain of parapoxvirus Orf virus genome, has been identified as 
a ligand for VEGFR2 alone [91]. The binding of downstream signaling molecules of 
the receptors depend on the tyrosine residue that is phosphorylated leading to signal 
output which can be further amplified by binding of co#receptors such as neuropilins 
and HSPG. 
 
The VEGF receptors (VEGFRs) have an extracellular portion consisting of seven 
immunoglobulin (Ig) homology domains, a single transmembrane spanning region and 
an intracellular segment containing a split tyrosine#kinase domain. VEGFR1 was the 
first VEGF receptor to be isolated from placental cDNA library in 1990. It was initially 
named as Fms#like tyrosine kinase #1 (Flt#1) due to structural similarity with Fms (M#
CSF receptor). However, while Fms carries five Ig#like domains in their extracellular 
regions, VEGFRs carry 7 Ig#like domains, thereby suggesting that both receptor 
groups (the five Ig#like group members such as Fms, Kit (stem cell factor receptor) 
and PDGF and the seven Ig#like group members such as VEGFRs) belong to the same 
super#gene family. Of the seven Ig#like domains in VEGF receptors, the second and 
the third domains are involved in ligand binding, whereas, the fourth to seventh 
domains are necessary for receptor dimer formation [34].  
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VEGFR1 is expressed on vascular endothelial cells and other cell types such as 
neutrophils, monocytes, macrophages, hepatocytes, hematopoietic stem cells, vascular 
smooth muscle cells, pericytes (mural cells) and endothelial progenitor cells. VEGFR2 
is expressed predominantly on angiogenic vascular endothelial cells and bone marrow 
derived cells (BMDCs) that directly or indirectly contribute to the formation of blood 
vessel walls, and gene deletion of this VEGF receptor has been reported to suppress 
hemangioblast function and inhibit primary vascular plexus formation in 
vasculogenesis, leading to embryonic lethality at early stages [36]. VEGFR1 has been 
shown to modulate vascular development during later stages of embryogenesis, since 
genetic deletion of VEGFR1 results in mice that produce angioblasts but are unable to 
properly assemble blood vessels [36]. VEGFR1 expression has also been demonstrated 
to be upregulated by an HIF#1–dependent pathway [92]. The functions of VEGFR1 
include induction of MMPs, regulation of hematopoiesis, and recruitment of 
monocytes.  
 
VEGF#A binds to VEGFR#1 and VEGFR#2 with different interactions [89]. VEGFR1 
binds to VEGF with at least a 10–50#fold higher affinity, but exhibits a 10#fold lower 
kinase activity than VEGFR2 [65, 93]. In other words, although VEGFR1 binds to 
VEGF with substantially higher affinity than that of VEGFR2 (Kd = 10#30 pM vs. 75#
300 pM), most of the vascular effects of the ligand seem to be mediated by the 
activation of VEGFR2, which acts via Raf#Mek#Erk mediated cell proliferation and 
PI3 kinase#Akt pathways for endothelial survival.  Upon binding with VEGF#A, 
autophosphorylation of VEGFR2 occurs at Tyr 1175, inducing the binding of the 
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receptor kinase domain to the SH2 domain of phospholipase Cγ (PLCγ), which in turn 
activates the downstream protein kinase C (PKC)[94]. The kinase domain of VEGFR1 
shows weak tyrosine kinase activity as compared to VEGFR2 [95, 96] which 
consequently is more potent in direct regulation of angiogenesis, mitogenic signaling, 
and permeability#enhancing effects. Expression of VEGFR2 is 3–5 folds higher in 
tumor vasculature compared to normal vasculature [97].  
 
VEGF also binds to ECM molecules and neuropilin, which enhances VEGF binding 
to VEGFR2 while inhibiting VEGF#VEGFR1 interactions. The association of 
VEGF165 with NRP1 results in a 10#fold increase in the binding affinity of VEGF165 to 
VEGFR2 [34]. VEGF165, which is the predominant splice variant expressed in humans, 
binds heparin, heparan sulfates and neuropilins with low affinity, while the other 
widely expressed splice form in both physiological and pathological conditions, 
VEGF121, is an acidic polypeptide [23] lacking the amino acid sequences of exons 6 
and 7 and thus the heparin binding motif, making it freely diffusible once secreted by 
cells. VEGF121 thus also has reduced mitogenic and migration inducing effects 
compared with VEGF165. Highly basic isoforms VEGF189 and VEGF206 bind heparin 
with high affinity, thus accumulating in the ECM. A recent study has reported that 
VEGF#A acts via interaction with NRP#1 in order to enhance survival of epidermal 
cancer stem cells thereby forming highly aggressive, invasive and vascularized tumors 
[54]. VEGF165b is an endogenous inhibitory form of VEGF which binds to VEGFR2 
with the same affinity as VEGF165 but does not elicit downstream signal transduction 
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[98]. Figure 1.3 gives a schematic representation of VEGF/VEGFR binding and 
subsequent downstream signaling cascade leading to angiogenesis. 
 
Alternative exon splicing of VEGFR1 results in a receptor protein, a 690#amino acid 
polypeptide which is a truncated form of VEGFR1 (sVEGFR1/sFlt#1) with 6 Ig#like 
domains in the amino terminal followed by a 31#amino acid tail derived from the 5’#
region of the thirteenth intron [99], but lacking in the membrane#proximal Ig#like 
domain, the transmembrane spanning region and intercellular kinase domains. sFLT#
1 functions as a soluble decoy receptor inhibiting VEGF signaling by competing with 
VEGFR2 for binding to proangiogenic ligands and sequestering VEGF from VEGFR#
2 binding (which appears to be particularly important during vasculogenesis in the 
embryo), as well as forming inactive heterodimers with the other membrane spanning 
full#length receptor isoforms, VEGFR1 and VEGFR2 [74].  
 
Although VEGFR1 acts as a negative regulator of angiogenesis during development, 
an increasing number of research tends to demonstrate its specific implication as a 
promoter of angiogenesis under pathological conditions [100]. Ligand#VEGFR1 
interaction results in stimulation of angiogenesis and inflammation in non#endothelial 
cells, although stimulation is weaker as compared to ligand#VEGFR2 response. 
Possible mechanism for this may be transphosphorylation of VEGFR2 by the 
autophosphorylated VEGFR1 receptor [101]. 
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1.7 Role of VEGF/VEGFR system in angiogenesis 
 
Overexpression of VEGF contributes to disease, as is evident from the fact that solid 
cancers are unable to grow beyond a limited size without adequate blood supply. In 
fact, a tumor is not able to grow further than 2 mm in diameter without neoangiogenesis 
[102] and beyond the size of 1#2 mm3 tumors become necrotic and apoptotic [103]. In 
arthritis, neovascularization in inflamed synovium results in ingress of a plethora of 
immune cells, growth factors, adhesion molecules and inflammatory cells into the 
joints. Pro#inflammatory cytokines including TNF#α and IL#1 induce VEGF 
production by stimulating synovial fibroblasts [104]. The cyclooxygenase#2 (COX#2) 
mediated pathway is also involved in VEGF#induced angiogenesis [105]. VEGF is 
known to induce venular and capillary leakage and fenestrae or pore formation in the 
some endothelial beds which do not have endothelial fenestrations such as cremaster 
muscle and skin [106]. Nitric oxide (NO) is produced by endothelial cells via activated 
PI3K /AKT pathway, which in turn activates endothelial nitric oxide synthase (eNOS) 
in response to VEGF. NO is a potent vasodilator and maintains blood flow in 
angiogenic blood vessels. VEGF also induces NO#mediated hypotension in vivo [20]. 
NO has a crucial role in angiogenesis by decreasing endothelial cell apoptosis, 
increasing cell proliferation and migration, increasing expression of VEGF or FGF and 
inhibiting the anti#angiogenic molecule, angiostatin [107, 108]. VEGFR2 upon 
activation by VEGF forms the flk#1/KDR#c#src complex, which through the IP3 
second messenger pathway, triggers the release of Ca2+, which in turn leads to the 
constitutive expression of eNOS by endothelial cells. Survival of endothelial cells by 
VEGF is mediated through VEGF/VEGFR2 activation of the signal transduction 
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pathways [109]. Recent studies have also revealed that different VEGF#A isoforms 
elicit differential signal transduction and cellular response upon interaction with the 
same tyrosine kinase VEGFR2 receptor [110, 111].  
 
Angiogenesis is also implicated in the pathogenesis of endometriosis [112] and pre#
eclampsia [113]. In endometriosis, where cells from the endometrium flourish outside 
the uterus in reproductive/adult females, high levels of VEGF have been detected in 
peritoneal fluid of such patients. Treatment with VEGF inhibitors (a truncated, 
inhibitory receptor, sflt#1 and an anti VEGF#A antibody) inhibited the growth of nude 
mouse explants of human endometrium suggesting a new therapeutic advancement in 
the treatment of endometriosis [114]. In pre#eclampsia, there is an increased level of 
placental#derived soluble VEGFR1 (sFlt#1) and reduced level of circulating VEGF and 
PlGF, resulting in endothelial dysfunction and hypertension. This suggests that excess 
circulating sFlt#1 binds VEGF and PlGF, thus  playing a pathologic role [115]. 
 
The VEGF pathway is the best characterized pathway governing angiogenesis and 
blocking this pathway offers potential therapeutic targets against diseases where 
angiogenesis plays a critical pathological role [116]. Targeting VEGF or its 
downstream effectors by inhibiting VEGF binding to its key physiological receptor 
should impede angiogenesis, which can be therapeutic for the aforementioned disease 
conditions.  
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Figure 1.3 Schematic diagram of the VEGF/VEGFR family of proteins and 
downstream signal transduction pathways activated due to their interactions, 
leading to angiogenesis (Chakrabarti et al; Mini reviews in Medicinal Chemistry, 
2014). 
 
1.8 Anti-angiogenic / anti-VEGF Therapies 
 
Several anti#angiogenic drugs are being tested globally in several clinical trials 
sponsored by various pharmaceutical and biotech companies, medical centers and 
national institutes.  Most of the anti#angiogenic drugs display their tumor#inhibitory 
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activity via VEGF/VEGFR system, in different ways. These are, (a) by direct 
suppression of angiogenesis by the drug, (b) by inducing apoptosis in the tumor cells 
or (c) by vascular normalization or decreasing the permeability. Anti#angiogenic drugs 
have certain advantages over traditional anti#cancer drugs. Firstly, anti#angiogenic 
class of drugs can act not only in a broad range of cancers, but in a much broader way 
to treat several diseases other than cancer where neoangiogenesis or abnormal 
vasculature development plays a critical role in either causation or progression. Anti#
angiogenic drugs are relatively less toxic compared to anti#cancer drugs as they target 
only normal endothelial cells, thereby minimizing the harmful side effects of 
chemotherapy which kills not only tumor cells but also normal cells. The probability 
of developing drug resistance in normal endothelial cells with anti#angiogenic drugs is 
much lower than that with classical anti#cancer therapies, since tumor cells mutate 
rapidly in response to chemotherapy and acquire resistance. Moreover, treatment with 
anti#angiogenic drugs is expected to allow for a gradual but chronic control of the 
disease and should be used in combination or as a supplementary therapy with standard 
chemotherapy and radiation therapy for better and long lasting effects. 
 
Blocking of angiogenesis has been achieved by various means including neutralizing 
MAbs against ligands (VEGF) and receptors (extracellular domains of VEGF 
receptors), as well as broad spectrum small molecule inhibitors of receptor tyrosine 
kinase activity. Additionally, there are inhibitors designed to suppress VEGFR activity 
by immunizing patients with VEGFR#derived epitope peptides as immunogens [117], 
and inhibitors that suppress downstream signal transduction pathway, such as PKCβ 
[118, 119]. An orally administered DNA vaccine encoding autologous murine Flk#1 
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(VEGFR2) carried by attenuated strain of S. typhimurium, targeting the upregulated 
receptor in proliferating endothelial cells in tumor vasculature, was verified to be 
effective against metastatic cancer settings in mouse models [103]. All these blocking 
agents have their own advantages as well as disadvantages over each other. Table 1.1 
shows a partial list of anti#angiogenic therapies currently in use or under development. 
Anti#angiogenic therapy can be broadly classified into gene#based therapies and 
protein#based therapies. 
 
1.8.1 Protein-based therapies 
 
Protein therapeutics including recombinant or natural protein based therapies, have 
increased in number since the introduction of human insulin for the treatment of 
diabetes, about 30 years ago. The enhancement of therapeutic potentials of natural 
proteins by protein engineering or production of therapeutic proteins using 
recombinant DNA techniques results in the various classes of such drugs including 
antibodies, enzymes, toxins and fusion proteins. There are several advantages of 
protein therapeutics over gene#based or small molecule drugs. Firstly, proteins possess 
a complex set of functions that cannot be mimicked by other classes of therapeutic 
agents. Secondly, the high specificity of proteins, make them less prone to interfere 
with normal biological functions of the body and  reduces the chances of adverse drug 
reactions [120]. Moreover, since most of the therapeutic proteins are naturally 
produced by the body, they are less likely to elicit immune response and be rejected 
and are usually well#tolerated. In the present scenario, since gene therapy is not 
available for all genetic disorders, protein therapeutics, by virtue of their capacity to 
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replace defective or mutated proteins, have a wider reach in the treatment field. 
However, even though these therapies hold a lot of promise in the treatment of several 
diseases including those involving abnormal angiogenesis, there might be undesirable 
immunogenicity issues in human subjects on repeated administration. But these 
hurdles can be overcome by elucidating the underlying mechanisms for immune 
response and developing preclinical methods to evaluate immunogenicity, thereby 
finding approaches to minimize drug#induced immune responses. Moreover, the 
introduction of various modifications to proteins, such as glycosylation, conjugation 
such as pegylation, Fc#fusions and scaffolding, improves effector functions, stability, 
efficacy and delivery of this class of drugs. Table 1.1 shows different protein#based as 
well as gene#based agents targeting angiogenesis that are already approved by the 
USFDA or in clinical trials or in research and development. For a list of anti#
angiogenic drugs currently used as standard therapy for cancer and eye disorders, 
please refer to Table 1 of our review article “Current Protein#based anti#angiogenic 
Therapeutics”, Mini#Reviews in Medicinal Chemistry, 2014, Vol.14, No.3] [31]. 
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Table 1.1 Important protein/based and gene/based therapeutics in clinic and under development. 
 
 
Class of Drug 
Trade name (generic 
name)/ Company 
Mode of Action 
Year of USFDA approval/ 
Approved Indication 
Non/USFDA Approved Diseases/ Ongoing/ 
completed Clinical Trials 
Protein/based Therapeutics 
Monoclonal Antibody 
(Full length humanized) 
Avastin®/Bevacizumab  
/Genentech/Roche) 
Anti#VEGF#A antibody 
against all isoforms of 
VEGF#A 
Metastatic colon cancer (Feb, 2004) 
Unresectable advanced stages of melanoma 
(2016) (NCT00790010), advanced pancreatic 
cancer (NCT00614653), ovarian cancer 
(NCT02354131), pre# and post#operative ocular 
disorders (NCT01976923, NCT01774474, 
NCT01996826, NCT02590094) 
Lung cancer (2006) 
Glioblastoma multiforme (2009) 
 Advanced renal cell carcinoma in 
combination with interferon (2009) 
Breast cancer (2010, withdrawn in 
2011) 
 
Monoclonal antibody 
(Fab fragment derived 
from Bevacizumab) 
Lucentis® 
/Ranibizumab 
(Genentech/ Novartis) 
Anti#VEGF#A Wet AMD/DME (Aug 2012) 
 
Monoclonal antibody  
M200/Volociximab 
(PDL Biopharma and 
Biogen Idec) 
  
 
Phase II for non#small cell lung cancer 
(NCT00278187), metastatic pancreatic 
(NCT00278187), metastatic melanoma 
(NCT00369395) and ovarian, peritoneal cancers 
(NCT00516841), NCT00635193) 
Targeting a5β1 integrin 
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Continued 
Class of Drug 
Trade name (generic 
name)/ Company 
Mode of Action 
Year of USFDA approval/ 
Approved Indication 
Non/USFDA Approved Diseases/ Ongoing/ 
completed Clinical Trials 
Protein/based Therapeutics 
Humanized monoclonal 
antibody  
Vitaxin 
/Etaracizumab/MEDI#
522 
Targeting avβ3 integrin 
  
In Phase II for metastatic colorectal 
(NCT00027729), androgen#independent prostate 
cancer (NCT00072930), plaque psoriasis 
(NCT00192517) 
Fully human monoclonal 
IgG1 antibody 
IMC#1121B 
/Ramucirumab 
(Cyramza) /ImClone 
/Eli Lilly) 
Anti#VEGFR2 
Metastatic colorectal cancer, gastric 
cancer and non#small cell lung 
cancer (2014) 
Phase II gastrointestinal junction cancer 
(NCT02443883), biliary cancers 
(NCT02520141), pediatric solid tumors 
(NCT02564198) 
Human monoclonal 
IgG1 antibody 
IMC#18F1 /Icrucumab/ 
ImClone 
Anti#VEGFR1 
  
Metastatic carcinoma of the bladder, urethra, 
ureter or renal pelvis, who have had disease 
progression with first line platinum#based 
chemotherapy [121]. 
Soluble VEGFR3 Fusion 
protein 
OPT#302/ Opthea 
Anti#VEGF#C and 
VEGF#D  
In Phase II for wet AMD 
Thioimides Cilengitide 
Cyclic RGD 
pentapeptide (Arg#Gly#
Asp motif) targeted 
against integrins avβ3, 
avβ5 and a5β1    
Phase III/ Glioblastoma[122]  
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Continued 
Class of Drug 
Trade name (generic 
name)/ Company 
Mode of Action 
Year of USFDA approval/ 
Approved Indication 
Non/USFDA Approved Diseases/ Ongoing/ 
completed Clinical Trials 
Gene/based Therapeutics 
siRNA 
Bevaciranib (Cand5)/ 
Opko Health Inc. 
siRNA against VEGF 
mRNA 
  
Phase III for Age#related macular degeneration 
(AMD)[123] was halted since it was unlikely to 
meet primary endpoint.  
siRNA 
AGN211745 or AGN#
745/ Allergan Inc. 
VEGFR1 mRNA 
  
Phase II for AMD halted as it failed to meet a 
key efficacy endpoint of visual acuity. 
siRNA 
PF#04523655 (PF#
655)/Quark Pharma 
  
  
Phase II for AMD (MONET study)[124], DME 
(MATISSE study).  RTP801i, transcription 
factor for HIF#1 
Antisense 
oligonucleotide 
Veglin/ VasGene 
Therapeutics Inc. 
Targeting all VEGF 
isoforms, VEGF#C and 
D 
  
Phase III/ Advanced malignancies (renal, 
thyroid, ovarian, small cell lung, 
bronchoalveolar, T cell lymphoma), 
mesothelioma[125]  
Transcriptional Decoy 
Sp1 decoy 
oligodeoxynucleotide 
Targeting TNFα, 
VEGF, tissue factor 
(TF), TGF#β1   
Suppression of transcription in cancer cell lines 
A549 and U251[126]  
Ribozyme 
Angiozyme (RPI.4610)/ 
Ribozyme 
Pharmaceuticals 
VEGFR1 mRNA, 
sVEGFR1 mRNA 
  
Phase II/ breast cancer[127], metastatic renal 
cancer (NCT00021021)  
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Continued 
Class of Drug 
Trade name (generic 
name)/ Company 
Mode of Action 
Year of USFDA approval/ 
Approved Indication 
Non/USFDA Approved Diseases/ Ongoing/ 
completed Clinical Trials 
Gene/based Therapeutics 
Aptamer 
Pegaptanib (Macugen)/ 
EYE001/Eyetech 
Pharmaceuticals/Pfizer 
Anti#VEGF RNA 
aptamer 
Wet AMD (Dec 2004) 
  
Aptamer 
ARC1905 (or 
Zimura®/anti#C5 
aptamer)/ Ophthotech 
Corporation 
RNA aptamer against 
factor C5 of the 
complement system 
  
Phase II/III/ Neovascular AMD 
(NCT02686658)[128] 
Aptamer 
E10030 
(Fovista/pegpleranib) 
Pegylated DNA 
aptamer against PDGF#
B   
Phase III ongoing/ AMD (NCT01940887)[129, 
130] 
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1.8.1.1 Monoclonal Antibodies 
 
Monoclonal antibodies (MAbs) are one of the most successful classes of 
biotherapeutics in the management of various diseases including cancer, autoimmune 
disorders, infections, cardiology, organ transplantation and hemoglobinuria [131]. In 
2015, the global sales revenue of MAbs was US$91.45 billion, which is estimated to 
be half of sales of all biopharmaceutical products. As of October 2016, there are about 
65 MAbs currently in the market that have got approval in US and Europe in several 
therapeutic indications. Moreover, there are around 300 antibodies still in various 
phases of clinical trials. With the current approval rate of five antibodies per year, it is 
expected to have about 70 MAbs in the market by the year 2020 [132]. Antibodies, are 
the oldest and fastest growing class of protein therapeutics with currently 13 antibodies 
approved by USFDA for various oncology indications and several under development 
[133]. Three of the top ten bestselling drugs (rituximab, bevacizumab, trastuzumab) in 
2014 were anti#cancer MAbs. They are used as vessels in  the targeted delivery of 
chemotherapeutics as well as powerful tools for modulating anti#cancer immune 
responses [133]. The implications of MAbs as diagnostic tools, in basic research and 
as therapeutic agents, have increased in leaps and bounds ever since their discovery in 
1975. MAbs which are produced using recombinant DNA technology, mimic the 
body’s natural antigen#binding antibodies and are used for targeting only one particular 
type of antigen such as a specific protein on cancer cells, thereby blocking the chemical 
signal that might otherwise have evoked a disease condition while marking these cells 
for easy recognition and recruiting other players in the immune system to destroy the 
antigen#containing cells. They have several advantages as therapeutic agents due to 
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their specificity, selectivity, homogeneity, unlimited production source and ease of 
purification. However, they are expensive, require lot of time and effort to produce and 
might sometimes show cross#reactivity with other antigens. Figure 1.4 gives a 
schematic representation of various strategies used by on antibody#based anti#
angiogenic drugs Figure 1.5 gives a schematic overview of the mechanism of action 
of various protein#based and gene#based agents as anti#angiogenic therapeutics. 
 
Figure 1.4. Strategies used by antibody/based therapeutics for inhibiting VEGF 
signaling pathways. Reprinted with permission. (Quincy Siu#Chung; Aflibercept 
(AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular 
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endothelial growth factors; Expert Opinion on Biological Therapy Vol.9:2 (2009) 
pp.263#271. DOI: 10.1517/14712590802666397). 
Bevacizumab binds to VEGF#A, thus inhibiting interaction of VEGF#A to VEGFR1 
and VEGFR2 receptors. Additionally, antibodies against VEGFR1 (IMC#18F1) and 
VEGFR2 (IMC#1121B) block VEGF#A binding to these two cognate receptors. 
 
 
 
Figure 1.5 Mechanism of action of various protein/based and gene/based anti/
angiogenic agents (Chakrabarti et al; Mini reviews in Medicinal Chemistry, 2014). 
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1.8.1.1.1 Monoclonal antibodies against VEGF 
 
1. Bevacizumab  
Bevacizumab (Avastin®, Genentech Inc. South San Francisco, CA, USA) was the first 
anti#angiogenesis molecule to be developed and to get USFDA approval in February 
2004, for the treatment of patients of metastatic colon cancer. It subsequently also got 
approval for treating metastatic breast and lung cancer and glioblastoma multiforme. 
It is also the approved first line treatment for advanced renal cell carcinoma, in 
combination with interferon#α [134]. It is the first full#length humanized anti#VEGF#
A monoclonal antibody with over 90% of human and less than 10% of murine 
components [4] that inhibits angiogenesis by binding to all circulating VEGF#A 
isoforms thus sequestering VEGF which would have otherwise been available for 
interaction with VEGFRs. However, bevacizumab is used in conjugation with standard 
chemotherapy regimens including 5’#fluorouracil (5’FU), leucovorin (LV), oxiplatin 
and irrinotecan, and additional benefit in standalone therapies has not shown much 
significant increase in survival benefits [135]. Used as a combination therapy, 
bevacizumab has been demonstrated to have prolonged progression free survival (PFS) 
in patients with metastatic colorectal, lung, kidney and breast cancers [136#139]. It 
prolongs life in patients of metastatic colorectal cancer who have earlier undergone 
chemotherapy and relapsed, but not in advanced cases even as a combination therapy, 
implying that bevacizumab might only be more effective in early and less severe stages 
of the disease. Bevacizumab, though  not approved for treating ocular neovascular 
diseases, is being used to treat neovascular AMD as an off#label drug, as intravitreally, 
the half#life of bevacizumab is twice as much as that of ranibizumab (approved drug 
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for AMD) probably due to greater size (149 kDa vs. 48 kDa) and the presence of the 
Fc region [140]. Bevacizumab is currently being tested in various cases of eye 
disorders and post#operative ocular conditions: 
(http://www.clinicaltrials.gov/show/NCT01976923),  
(http://www.clinicaltrials.gov/show/NCT01774474), 
(http://www.clinicaltrials.gov/show/NCT01996826).  
2. Ranibizumab 
Ranibizumab (Lucentis®, Genentec Inc., and South San Francisco, CA, USA) is an 
optimized humanized high affinity IgG1 kappa isotype monoclonal antibody fragment 
(Fab) of bevacizumab that neutralizes all VEGF isoforms and bioactive proteolytic 
fragments of VEGF. It is derived from the same parent mouse antibody as 
bevacizumab. Ranibizumab is smaller in size (one third the MW of full#length 
bevacizumab) and thus better suited for intraocular penetration. It also lacks the Fc 
region thus avoiding inflammation via Fc#complement engagement. Apart from these, 
it is affinity matured for stronger ligand binding, being 5#25 fold more potent than 
bevacizumab on a molar basis [140]. It was approved by the USFDA in 2006 for the 
treatment of wet AMD. It was also USFDA approved to treat macular edema following 
retinal vein occlusion (RVO) in 2010 and DME in August 2012. Ranibizumab is being 
used in all age groups of patients, from infants with retinopathy of prematurity to the 
elderly with macular degeneration progressing to impaired vision [141]. A Phase 4 
randomized study to evaluate the efficacy of ranibizumab with aflibercept in DME 
patients, has been recently completed; 
(http://www.clinicaltrials.gov/show/NCT02646670).    
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1.8.1.1.2 Monoclonal antibodies against VEGFR 
 
Antibodies generated against the extracellular domains of VEGFR2 and VEGFR3 have 
been shown to successfully inhibit endothelial microvascular sprouting, migration and 
signal transduction [142, 143]. Treatment with monoclonal antibody against VEGFR3, 
mF4#31C1, in pre#clinical studies, demonstrated inhibition of tumor growth, as well as 
blocked formation of tumor associated lymphatic vessels involved with lymphatic 
metastasis. Pre#existing and mature blood and lymphatic vessels were not affected 
[144].  
 
1. Ramucirumab  
Ramucirumab (or IMC#1121B; trade name Cyramza®) is a fully human monoclonal 
IgG1 antibody against human VEGFR2, developed by ImClone Inc. that blocks VEGF 
binding to VEGFR2, thus inhibiting angiogenesis. Ramucirumab was approved by the 
USFDA in April, 2014, as a single agent or with paclitaxel, for the treatment of 
advanced gastric or gastro#esophageal junction adenocarcinoma, where the disease has 
progressed regardless of fluoropyrimidine# or platinum#containing chemotherapy 
[145]. An international double#blinded Phase 3 clinical trial (REGARD) with 355 
patients indicated survival benefits with median overall survival of 5.2 versus 3.8 
months and 58% reduction in disease progression, with the single line treatment 
(http://clincaltrials.gov/show/NCT00917384) [146]. Ramucirumab was further 
approved by USFDA in combination with docetaxel, for the treatment of metastatic 
non#small#cell lung carcinoma with disease progression on or after platinum#
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containing chemotherapy, in December 2014, after several clinical trials with the agent 
alone and in combination with other chemotherapeutics in multiple cancer types 
including cancers of breast, colon, gastric, bladder, kidney, ovary and lung [147#150]. 
 
2.IMC/1C11 
IMC#1C11 is an anti#angiogenic chimeric anti#kinase insert domain#containing 
receptor (KDR) antibody that blocks VEGF#KDR interaction and inhibits receptor#
induced endothelial cell proliferation. This mouse human chimeric monoclonal 
antibody is used for the treatment of patients with liver metastases from colorectal 
carcinoma. As solid tumors cannot grow efficiently without new blood supply, use of 
IMC#1C11 results in the inhibition of tumor growth and death of tumor cells by 
apoptosis. Directed against human VEGFR2 (IMC#1C11), IgG1, was tested in a dose#
escalating single agent Phase 1 trial of 14 patients of colorectal carcinoma and hepatic 
metastases. After four weeks of therapy, the antibody was demonstrated to be well 
tolerated and safe and drug levels were predicted reliably. However, no information 
on further trials for this molecule is currently available [151]. 
 
3. IMC/18F1 
IMC#18F1 or Icrucumab is a fully human monoclonal IgG1 antibody directed against 
human VEGFR1 that blocks ligand binding and subsequent downstream signaling [60, 
152#154]. A Phase 2 trial was recently completed in 2015 to evaluate the efficacy of 
IMC#18F1 with docetaxel or docetaxel alone in patients with metastatic carcinoma of 
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the bladder, urethra, ureter or renal pelvis, who have had disease progression with first 
line platinum#based chemotherapy (http://clincaltrials.gov/show/NCT01282463). 
Another Phase 2 study is currently ongoing to study the effect of IMC#18F1 in 
combination with capecitabine in previously treated breast cancer patients 
(https://clinicaltrials.gov/show/NCT01234402) [155]. 
 
1.8.1.2 Fc-fusion proteins  
 
Fusion proteins are generated by combining the genes encoding two or more proteins 
where the properties and benefits of both the components are acquired. Clinically and 
commercially, the most successful fusion proteins to date are the Fc#fusion proteins. 
The fragment crystallization region (Fc region) is the tail end of an antibody which 
interacts with various cell surface receptors and some proteins of the complement 
system, mediating the physiological effects of the antibody. The Fc#fusion proteins are 
composed of an immunoglobulin (Ig) Fc region linked to another protein which can be 
of two types. Fc portion can be fused to a protein which has anti#angiogenic properties 
or other potential therapeutic properties. In other words, Fc can be linked to a ligand 
that gets activated upon binding to its receptor and mediates cellular responses. Fc can 
also be fused to a peptide or protein which contains the ligand binding domain(s) of a 
cellular receptor that binds to its natural ligand. The second type of Fc#fusion proteins 
in their soluble form may act as decoy receptors to sequester the specific ligands that 
would have otherwise generated cellular responses leading to pathological conditions.  
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There are several benefits and advantages of Fc#fusion proteins over classical antibody 
or antibody#derived therapeutic proteins [156]. The fusion partner of the Fc domain, 
imparts the therapeutic benefit of the protein, while the Fc region bestows additional 
pharmacokinetic IgG#like properties such as increasing the drug half#life and thus 
serum stability of most biologically active proteins which otherwise have a short serum 
half#life of a few minutes to a few hours, owing to large size and rapid renal clearance 
[157, 158]. For example, recombinant factor VIII#Fc fusion protein (rFVIIIFc) that is 
an engineered version of human factor VIII protein, increased the half#life by 1.5–2 
folds [159]. A non#Fc protein will typically have a shorter serum elimination half#life, 
which leads to decreased tissue exposure resulting in poor pharmacological effects of 
the drug. This in turn will require higher doses of the drug to be administered for 
prolonged period of time in order to achieve therapeutic benefits, thus limiting its 
clinical application. On the other hand, Fc#fusion proteins, owing to their longer serum 
elimination half#life, are required to be administered at lower doses and at less frequent 
intervals, which helps in patient compliance [160]. In addition to this, production costs 
of Fc#fusion proteins are less than that of antibodies, because of the ease of expression 
due to stability of the protein and ease of purification due to the Fc tag, which helps in 
affinity#based chromatographic separation of the fusion protein [158],[161]. In 
addition, polymeric Fc#fusions that interact with high avidity with Fc receptors (FcRs) 
can be designed and generated using multimerizing protein tags. This is possible by 
modification of Fc#fusion proteins to polymerize into well#defined complexes having 
up to 12 fusion partners which help to enhance the cellular signaling for a better 
immune response via cross#linking to multiple low affinity cell surface receptors. 
These types of multivalent proteins can particularly increase efficiency of vaccine 
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therapeutics due to enhanced potency. The Fc region also enables the protein to interact 
with neonatal Fc#receptor (FcRn) located on endothelial, epithelial and circulating 
blood cells [162] in a pH#dependent binding which rescues the protein from being 
degraded in endosomes, a function that serves as a critical role in IgG homeostasis 
[163]. The binding affinity of Fc#fusion protein to FcRn, is however, lower than that 
of the native IgG1 molecule [164]. Owing to the low affinity of FcRs, the strength of 
binding Fc#fusion proteins is dependent on Fc multimerization and treatment with Fc#
fusion drugs lead to aggregate formation with higher avidity for FcγRs [163]. 
Moreover, the Fc domain also interacts with Fc receptors (FcRs) on immune cells 
which is important in stimulation in immunotherapy for solid tumors. 
 
In rFVIIIFc fusion protein, the Fc domain enables the binding of the protein to the 
FcRn receptor thereby forces the same natural pathway that immunoglobulins use to 
escape from intracellular degradation, thus prolonging their plasma half#life [159], 
[165]. A Phase 3 clinical trial for rFVIIIFc (ASPIRE) for prevention and treatment of 
bleeding episodes in previously treated patients with severe hemophilia A, 
demonstrated safety and efficacy as well as prolonged half#life as compared to 
rFVIII[166]. From the biological point of view, the independent folding property of 
the Fc domain, improves the solubility and stability of the partner protein in vivo and 
in vitro [156]. In vivo, the tumor cell penetrance of fusion proteins is much increased 
owing to their smaller size (lower MW) as compared to MAbs. 
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In 2012, the global sales of etanercept ($7.3 billion), the earliest and most 
commercially successful Fc#fusion protein exceeded those of the human IgG 
antibodies bevacizumab ($6.9 billion), rituximab ($6.8 billion) or infliximab ($6.5 
billion) [167]. Humira (adalimumab; Abbott) was the bestselling selling drug in 2015 
with a sales revenue of $8.6 billion, with Enbrel (etanercept; Amgen) coming a close 
third with $6.1 billion. Till 2014, ten Fc#fusions had been approved by USFDA [163] 
which increased to eleven that have been approved for marketing by USFDA [168, 
169] as of May 2015. 
 
Several therapeutic targets exist which can be successfully regulated by Fc#fusion 
proteins. Tumor necrosis factor (TNFα) is the target of Fc#fusion protein, etanercept, 
as well as, full length antibodies (infliximab, adalimumab, golimumab) and antibody 
Fab fragment (cetrolizumab pegol). In a similar fashion, vascular endothelial growth 
factor (VEGF) is the target for Fc#fusion protein, aflibercept, as well as full length 
MAb (bevacizumab) and affinity#matured bevacizumab#derived Fab fragment 
(ranibizumab) [167]. Romiplostim (NPlate®), used to treat thrombocytopenia, is the 
first peptide#Fc fusion (“peptibody”) to be approved for therapeutic use [158]. Another 
mimetic peptide, CNTO 528, which is a 20 amino acid erythropoietin (EPO) 
peptibody, can bind and activate the EPO receptor both in vivo and in vitro, and is 
currently under development [167]. Fc#fusions represent about 20% of all antibody#
based USFDA approved drugs and several second and third generation versions of 
these are currently under development. The majority of Fc#fusions target receptor#
ligand interactions, either in the form of receptor mimics and antagonists to block 
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cellular receptor binding of ligands, or as agonists to regulate receptor function (e.g. 
alefacept, romiplostim). Table 1.2 shows the various Fc#fusion proteins that are 
currently being used as therapeutic agents or are in the different phases of clinical trials. 
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Table 1.2 Key Fc/fusion proteins in clinic as well as under development. 
Drug Company Description (Expression system) 
Year of USFDA Approval 
/Ongoing clinical trial 
/Disease 
Etanercept (Enbrel) Amgen/ Pfizer 
Tumor necrosis factor receptor II (TNFRII) fused to 
human IgG1#Fc. Binds to TNFa (CHO) 
1998/ Rheumatoid arthritis 
Alefacept (Amevive) 
Astellas Pharma / Biogen#
Idec 
ECD1 of lymphocyte function associated antigen 3 
(LFA#3) fused to human IgG1#Fc (CHO) 
2003/ Plaque psoriasis and transplant 
rejection 
Abatacept (Orencia) Bristol#Meyers Squib 
ECD of mutated human cytotoxic T lymphocyte 
associated molecule#4 (CTLA#4) fused to human 
IgG#Fc (CHO) 
2005/ Rheumatoid arthritis 
Rilonacept (Arcalyst) 
Regeneron Pharmaceuticals/ 
Sanofi Aventis 
IL#1R fused to human IgG1#Fc (CHO) 2008/Plaque psoriasis 
Romiplostim (NPlate) Amgen/Pfizer 
Thrombopoietin#binding peptide (TPO) fused to 
aglycosylated human IgG1#FcV(E. coli) 
2008/Thrombocytopenia 
Belatacept (Nulojix) Bristol#Meyers Squib ECD of CTLA#4 fused to human IgG1#Fc (CHO) 
2011/prophylaxis of organ rejection in 
adult kidney transplantation 
Aflibercept (Eylea®; 
VEGF Trap Eye) 
Regeneron Pharmaceuticals/ 
Bayer 
VEGFR1 (D2) and VEGFR2 (D3) fused to human 
IgG1#Fc. Binds to VEGF#A, VEGF#B, PlGF (CHO) 
2011/ wet AMD 
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Continued 
Drug Company Description (Expression system) 
Year of USFDA Approval 
/Ongoing clinical trial 
/Disease 
Aflibercept (Zaltrap®; 
VEGF Trap) 
Regeneron 
Pharmaceuticals/Sanofi 
Aventis 
VEGFR1 (D2) and VEGFR2 (D3) fused to human 
IgG1#Fc. Binds to VEGF#A, VEGF#B, PlGF (CHO) 
Aug 2012/ metastatic colorectal 
cancer in combination with 
chemotherapy (FOLFIRI: 
5’fluorouracil, leucovorin, irinotecan) 
Blisibimod (AMG 
623) 
Anthera /Amgen B#cell inhibitor (E.coli) 
Completed Phase III / systemic lupus 
erythematosus[170]  
FP#1039 
Five Prime Therapeutics 
Inc. 
FGFR1#IIIc domain fused to IgG#Fc. Binds to 
FGF1, FGF2, FGF4 to their receptors (E. coli) 
Completed Phase I/ Advanced solid 
tumors[171, 172] 
Apocept (APG#101) Apogenix CD95 linked to Fc of IgG (CHO) 
Phase II/mylodysplastic syndrome 
(clinical trial ongoing: NCT01736436) 
AMG 386 
(trebananib) 
Amgen Angiopoietin#2 inhibitor (CHO) 
Phase III /ovarian cancer[173] 
(TRINOVA#3/NCT01493505)  
Atacicept 
Merck Serono/ 
ZymoGenetics 
B cell inhibitor (CHO) 
Phase III systemic lupus 
erythematosus[174], rheumatoid 
arthritis[175] 
Eloctate Biogen#Idec Monomeric; FVIII#IgG1 Fc (HEK293) 2014/  hemophilia A 
 Alprolix Biogen#Idec Monomeric; FIX#IgG1 Fc (HEK293) 2014/ hemophilia B 
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Continued 
Drug Company Description (Expression system) 
Year of USFDA Approval 
/Ongoing clinical trial 
/Disease 
LY2189265 
(dulaglutide) 
Eli Lily GLP1 receptor linked to Fc of IgG4 (CHO) 
Phase III/type 2 diabetes (ongoing; 
clinical trial AWARD#10/ 
NCT02597049) 
Sotatercept Acceleron Pharma 
Activin receptor IIA linked to human Fc of IgG 
(CHO) 
Phase II/III /chemotherapy induced 
anemia. USFDA granted orphan drug 
status. 
Briobacept (BR3#Fc) Biogen#Idec/Genentech 
Cytokine receptor BAFF#R (human extracellular 
domain#containing fragment BR3) fusion protein 
with human IgG1 Fc (CHO) 
Phase II/rheumatoid arthritis[176]  
Conbercept (KH902) 
Chengdu Kanghong 
Biotech. Co. Ltd. 
VEGFR1 (D2) and VEGFR2 (D3, D4) fused to 
human IgG1#Fc. Binds to all isoforms of VEGF#A 
(CHO) 
Completed Phase III/ wet AMD[177]  
CNTO 528 Centocor (J & J) 
Erythropoietin mimetic peptide# IgG1 Fc 
mimetibody (CHO) 
Phase I/ anemia models (thalassemia / 
sickle cell)[178, 179] 
CNTO 530 Edison (J & J) 
Erythropoietin mimetic peptide# IgG4 Fc 
mimetibody (CHO) 
Phase I/ anemia models (thalassemia/ 
sickle cell)[180, 181] 
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1.8.1.3 Decoy receptors  
  
A relatively novel and exciting area of anti#VEGF therapy emerging rapidly is the use 
of soluble decoy receptors known as growth factor traps, that prevent VEGF from 
binding to its cellular receptors [182]. A decoy receptor is a soluble mimic of the 
cellular receptor that finds out, binds to and sequesters the ligand molecules that would 
have otherwise interacted with the cell surface receptors and stimulated the cascade of 
cellular response and effects which are unwanted in a pathological scenario [31]. A 
trap molecule ideally consists of the secreted version of cellular receptor developed by 
recombinant methods, having high affinity for ligand. Since monomeric soluble 
receptors generally exhibit low affinity towards their ligands or reduced function as 
agonists, high#affinity blockers or ligand traps are created by fusing extracellular 
ligand binding domains of the receptor with the dimerizing constant region (Fc) of 
human IgG1. Besides, the Fc domain also serves to increase serum stability or extend 
the half#life of the fusion protein. One additional advantage of decoy receptors is that 
being soluble, these receptors are capable of neutralizing angiogenic ligands (e.g. 
VEGF, PlGF) irrespective of their source, that is, secreted by malignant cells, or 
stromal cells or host tissues [183]. VEGFR1 and VEGFR2 extracellular 
immunoglobulin (Ig)#like domains for example, D1, D2 and D3, are known to bind 
VEGF with very high affinity, thus being specifically utilized for development of 
VEGF trap molecules. Khurana et al used a soluble chimeric VEGFR1(D1#D3)#Fc 
protein, which contains the first three Ig#like domains of VEGFR1 fused to a mouse 
IgG Fc fragment, for local application to injured vessels [75, 184, 185]. Figure 1.6 
shows a schematic representation of the decoy receptor, VEGFR1 (D1#D3)#Fc, that 
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has been generated in this study, which has only the first three extracellular ligand 
binding domains of VEGFR1. Figure 1.7 gives the schematic representation of various 
forms for VEGF traps in research and development. 
 
Figure 1.6 Schematic diagram of recombinant anti/VEGF decoy receptor, 
VEGFR1(D1/D3)/Fc. Soluble VEGFR1(D1#D3)#Fc binds to cellular VEGF and 
inhibits VEGF binding to cell surface VEGF receptors. This inhibits VEGF/VEGFR 
interactions and downstream signaling cascade which would otherwise lead to vascular 
permeability and endothelial cell survival. 
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Figure 1.7 Schematic representation of structures of various VEGF Traps. 
VEGFR1, VEGFR2 and VEGFR3 represent cellular receptors for different ligands of 
the VEGF family. VEGF traps are soluble receptor mimics. Various combinations of 
receptor domains are used to construct different forms of traps which bind VEGF. 
Another fusion trap that has been developed and currently under Phase II trial, is a 
soluble VEGFR3(D1#D3)#Fc molecule that binds to VEGF#C and VEGF#D. This 
protein, OPT#302, developed by Australian company, Opthea, blocks the activity of 
VEGF#C and VEGF#D on the VEGFR2 and VEGFR3 receptors on blood and 
lymphatic vessels, thus inhibiting development of wet AMD lesions and preventing 
leakages into associating vessels. 
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1. Aflibercept  
Regeneron Pharmaceuticals Inc. (New York, USA) developed aflibercept (VEGF#
TrapR1R2), an improved version of the parental VEGF trap or Flt#1(1#3)#IgG1, where 
the second Ig#like domain (D2) of VEGFR1 was fused to the third Ig#like domain (D3) 
of VEGFR2. The molecule is a fully human recombinant soluble decoy (VEGF 
receptor fused in line to the Fc region of human IgG1), having high affinity for all 
forms of VEGF#A, VEGF#B and PlGF1 and PlGF2 at very low picomolar 
concentrations (Kd~1 pM) , as compared to bevacizumab at 500 pM [186] However, it 
has no affinity for VEGF#C or VEGF#D even at very high nanomolar concentrations 
[187]. Aflibercept is used under the trade names of “Zaltrap®” and “Eylea®” for 
different indications. 
 
a.  Zaltrap® 
Ziv#aflibercept approved in the US and Europe for treating metastatic colorectal cancer 
is marketed under the trade name “Zaltrap®”. It has minimal interactions with the ECM 
due to removal of the D3 domain of R1, which imparted high positive charge to the 
protein. The positively charged residues caused non#specific interactions of the VEGF 
trap with the negatively charged proteoglycans of the ECM, leading to reduced 
bioavailability of the molecule [93]. The problem of increased toxicity noted with 
adenoviral administration of parental VEGFR1(D1#D3)#Fc fusion [188] was also 
overcome by development of VEGF#TrapR1R2 and tested by Hutter et al who 
overexpressed an adenovirus vector#encoding VEGF#TrapR1R2 in the liver of mice by 
systemic intravenous injection [189, 190]. Aflibercept or VEGF#TrapR1R2, was 
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approved by the USFDA in August 2012 for the treatment of metastatic colorectal 
cancer [187, 191#195] and age related disease of macula [196]. VEGF trap exerts its 
antiangiogenic effects by sequestering cellular VEGF ligands followed by decreasing 
cellular receptor#ligand interaction resulting in regression of tumor vasculature, 
remodeling and inhibition of new tumor vessel growth. The second (D2) and third (D3) 
Ig#like domains are the critical ligand binding domains for both VEGFR1 and 
VEGFR2, as is demonstrated by domain deletion studies [197]. Aflibercept is currently 
undergoing several clinical trials for several diseases involving angiogenesis.  
 
b.  Eylea® 
VEGF Trap#Eye or Eylea®, Regeneron, NY, USA, and Bayer Healthcare, Germany) 
is a VEGF antagonists that binds and inactivates cellular VEGF isoforms and PlGF. 
Eylea®, which is the intravitreal injectable form of aflibercept, is an approved treatment 
in the US and Australia, for eye disorders caused by abnormal blood vessel growth and 
fluid leakage in retina and macula [196].  
 
2. Conbercept (KH902) 
Another recent development in the field of anti#angiogenic fusion protein is 
conbercept, a homodimeric 143 kDa recombinant fusion protein which is composed of 
the domain 2 (D2) of VEGFR1 and domains 3 and 4 (D3, D4) of VEGFR2 and Fc 
region of IgG1s [198, 199]. Conbercept possesses the highest binding affinity to 
VEGF#A165 (Kd = 0.5 pM) while binding all isoforms of VEGF#A, VEGF#B (Kd =8 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
59 
  
pM), VEGF#C and PlGF (Kd= 0.5 pM) with high affinity. It has similar binding 
affinity as aflibercept (0.49 pM), and much higher binding affinity than that of 
bevacizumab (Kd= 58 pM) and ranibizumab (Kd=46 pM) [183, 200]. It is designed for 
use in the treatment of wet AMD as a VEGF antagonist. Extensive structural 
characterization of the protein has been carried out using various analytical methods 
and molecular modeling to explore variations in structure with relation to affinity of 
the fusion protein to its various ligands. Domain 4 of VEGFR2, which has no role in 
ligand binding but stabilizes the VEGF#receptor binding, has a lower pI and lowers the 
overall pI of conbercept (pI = 6.13#6.81 as compared to aflibercept with pI=8.82) as 
well as enhances the association rate of the drug to VEGF. 
 
Conbercept has recently completed Phase 2 clinical trial for assessing the safety and 
maximum tolerable dose in multiple dosing regimens in the treatment of patients with 
choroidal neovascularization (CNV) resulting from wet AMD (AURORA)[201],[202] 
(http://clinicaltrials.gov/show/NCT01157715). Phase 2 trial (HOPE) had earlier 
showed that multiple injections of 0.5 to 2.0 mg/eye/time is a tolerable intravitreal dose 
for the protein (http://clinicaltrials.gov/show/NCT01242254). KH902 has also 
undergone Phase 1 and 2 randomized clinical trials (Frontier#1) for safety and efficacy 
of multiple intravitreal injections of the protein in patients with DME 
(http://clinicaltrials.gov/show/NCT01324869). Consequences of a multicentric Phase 
3 trial (PHOENIX ((http://clinicaltrials.gov/show/NCT01436864) to evaluate efficacy 
of intravitreal injections of KH902 in patients with CNV secondary to AMD, shows  
that conbercept is well tolerated, with visual acuity results similar to other anti#VEGF 
drugs and is required at fewer doses due to improved high half#life of about seven days. 
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No cardiovascular side effects were reported in the study [203]. Additionally, in a 
recently concluded study, conbercept has been observed to be an effective drug in 
pretreatment to vitrectomy in proliferative diabetic retinopathy accelerating post#
operative restoration of visual acuity[204]. Thus conbercept is a new promising multi#
target anti#VEGF drug in treating neovascular AMD patients. Structure of conbercept 
is represented in Figure 1.8. 
 
Figure 1.8 Structure of conbercept. Conbercept was constructed by fusing the 
second domain of VEGFR1 and the third and fourth domains of VEGFR2 to human 
IgG1#Fc. 
 
3. sFLT01 
A recent development in the field of decoy receptors is a novel anti#angiogenic decoy 
receptor, sFLT01, which is fusion of the VEGF/PlGF binding domain of human 
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VEGFR1 or Flt#1 (hVEGFR1) and the Fc domain of human IgG1 through a 
polyglycine linker (9 Gly) [183].  In the construct of sFLT01, the second IgG#like 
domain of Flt#1 is fused to either the Fc region of human IgG or only to the CH3 
domain of IgG1 Fc. This 80 kDa Fc#fusion protein, binds not only to VEGF but also 
to human and mouse PlGF. Inhibition of angiogenesis by targeting only VEGF has 
modest beneficial effects and it has been observed that in many carcinomas, both 
VEGF and PlGF levels are upregulated [5]. Hence, neutralizing both VEGF as well as 
PlGF was more effective than a single target approach. Moreover, targeting serum 
PlGF would be beneficial to the patients as it has been implicated in disease relapse, 
resistance to certain angiogenic therapies and tumor escape. Sequestering circulating 
PlGF with the soluble decoy receptor might help to overcome resistance to VEGFR 
inhibitors. The molecule exhibited robust efficacy in preclinical studies with no 
detectable side effects. The successful AAV2 (adeno#associated virus serotype 2)–
mediated intravitreal gene delivery of this molecule suggests promise in the treatment 
of retinal neovascularization [205]. Structure of sFLT01 molecule is schematically 
represented in Figure 1.9.  
Figure 1.9 Structure of sFLT01 molecule (Reprinted by permission from Macmillan 
Publishers Ltd: Gene therapy; Pechan et al; 2009. 16(1): p. 10#16. DOI 
doi:10.1038/gt.2008.115; copyright (2009)[205]. In the figure, “sp” denotes signal 
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peptide and “D2” denotes IgG#like second domain of FLT#1, whereas “CH2” and 
“CH3” denote human IgG1 Fc domains. The black block represents the 9Gly 
polylinker region 
 
4. VEGF Grab 
Scientists at the Korea Advanced Institute of Science and Technology (KAIST) have 
developed a novel glycosylated soluble VEGF blocker, which consists of the second 
and third domains of VEGFR1 fused to IgG1#Fc, with three potential glycosylation 
sites introduced in D3 domain by site directed mutagenesis [206]. Figure 1.10 
schematically represents the structure of VEGF Grab. The parental VEGF trap 
consisting of the first three Ig#like domains of VEGFR1 linked to Fc, has a very high 
pI of 9.4 owing to a basic patch in the D3 domain which accounts for its non#specific 
binding to ECM, leading to poor pharmacokinetic profile, decreased efficacy and toxic 
side effects. This glyco#engineered protein, by virtue of its additional N#glycosylation 
sites (R135S, K138T and R172N) provides a negative charge to the molecule, 
increases solubility, imparts resistance to proteolysis, decreases non#specific ECM 
binding, increases serum half#life, thus enhancing pharmacokinetic profile[206]. The 
protein was capable of binding to VEGF#A, VEGF#B and PlGF with higher (in case of 
VEGF#A and PlGF) or similar (in case of VEGF#B) affinity as Regeneron’s VEGF#
TrapR1R2, and demonstrated high efficacy in suppressing tumor angiogenesis, 
progression and metastasis in breast cancer model. Toxicity profiles were also 
improved when compared to VEGF#TrapR1R2. Thus, the limitations of clinical efficacy 
with the currently available VEGF blocker and their drawbacks, including acquisition 
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of resistance and activation of compensatory pathways resulting from elevated 
circulating VEGF#B and PlGF can be bypassed using the novel glycosylated decoy 
receptor. 
 Figure 1.10 Schematic representation of structure of VEGF Grab and the model 
structure of the VEGF/A/VEGFR1 D2/D3 complex (Reprinted by permission from 
the American Association for Cancer Research: Jung Eun Lee et al, Novel 
glycosylated VEGF decoy receptor fusion protein, VEGF#Grab, efficiently suppresses 
tumor angiogenesis and progression, Molecular Cancer Therapeutics, 2015 
Feb;14(2):470#9. DOI: 10.1158/1535#7163.MCT#14#0968#T. Copyright (2015) 
[206]). VEGF#A dimer is represented in yellow and green, VEGFR1 D2 and D3 are 
colored in tan and mustard respectively. Residues indicated by blue sticks represent 
target sites for mutagenesis. 
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5. VEGF Sticky/trap 
More recently, scientists have developed novel locally acting angiogenic inhibitors, 
known as VEGF Sticky#traps [132, 162]. In certain non#malignant cases, such as 
abnormal retinal angiogenesis in diabetic retinopathy, wet macular degeneration or 
retinopathy of prematurity, excess production of VEGF often leads to blindness if left 
untreated. In such cases where systemic angiogenic inhibitors might cause detrimental 
side effects in elderly patients, pregnant women, newborns or patients undergoing 
surgery, it is useful to have a locally acting angiogenic inhibitor to improve clinical 
outcome. VEGF Sticky#trap is constructed by genetically fusing the original VEGF#
TrapR1R2 (D2 domain of VEGFR1 and D3 domain of VEGFR2) to modified Fc region, 
which has the CH2 domain removed (to ensure shorter serum half#life) and replaced 
by hinge and poly#glycine#serine linker. Additionally, in order to take advantage of the 
interactions between the heparan sulphate proteoglycans (HSPGs) found in the ECM 
and the heparin#binding domains (HBDs) in exons 6 and 7 of VEGF, the trap molecule 
also incorporates the HBDs from exons 6 and 7 as well as exon 8 for proper disulfide 
bond formation. It binds to VEGF165 with a Kd of 13.9 pM. Figure 1.11 (B) represents 
the structure of VEGF Sticky#trap. The novel non#systemically acting fusion protein 
remains at the site of administration and exerts its anti#angiogenic effects by virtue of 
its ability to bind or stick to the HSPGs of the ECM and does not leak into circulation. 
It is engineered in such a way as to possess a short serum half#life in its soluble form. 
Another advantage of Sticky#trap is that, when applied in the eye, it does not 
compromise systemic physiological functions of VEGF, like wound healing. 
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Figure 1.11 Structure of VEGF/TrapR1R2 and VEGF Sticky/trap (Reprinted with 
permission: Favara, D.M. and A.L. Harris, VEGF sticky‐trap: the first report of a non‐
systemically acting angiogenesis inhibitor. EMBO molecular medicine, 2014. 6(5): p. 
577#579. DOI: 10.1002/emmm.201404026 [132]). 
 
6. VEGFR31/Ig 
The VEGF#C/VEGFR3 is the most critical pathway for lymphangiogenesis. VEGF#C 
overexpression is known to stimulate lymphatic endothelial cell proliferation 
migration upon binding to its receptor VEGFR3, which is expressed on lymphatic 
endothelial cells. An important cause of tumor progression is lymphatic metastasis and 
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induction of the VEGF#C/VEGFR3 pathway is critical for increasing tumor metastasis 
via the lymphatic system. A novel receptor#immunoglobulin (Ig) fusion protein, 
VEGFR31#Ig, is developed as a blocker for both angiogenesis and lymphangiogenesis 
as it binds with high affinity simultaneously to both VEGF#A and VEGF#C, 
respectively [207]. The molecule has VEGF#A and VEGF#C binding affinity similar 
to that of VEGF#TrapR1R2 and sVEGFR3 (soluble fusion protein VEGFR3#Ig), 
respectively. The construct consists of VEGFR312 (the first two domains of VEGFR3) 
and VEGFR12R23 (or VEGF#TrapR1R2) genetically fused to the heavy chain constant 
region of human IgG1 and human κ light chain constant region, respectively. Figure 
1.12 gives a schematic representation of VEGFR31#Fc and VEGFR31#Ig. The fusion 
protein has shown promising results in being able to successfully inhibit primary tumor 
growth as well as lung metastasis in several hepatocellular carcinoma animal models.  
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Figure 1.12 A schematic representation of the structure of VEGFR31/Fc and 
VEGFR31/Ig.VEGFR31#Ig, an IgG#like protein molecule, was able bind both VEGF#
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A and VEGF#C, thus capable of blocking tumor angiogenesis as well as 
lymphangiogenesis. It consists of the first 2 domains of VEGFR3 (VEGFR312) and 
VEGF#Trap (VEGFR12R23), fused to heavy chain and light chain (κ) constant region 
of human IgG1 respectively. VEGFR31#Fc was generated by genetically linking in 
tandem of the first 2 domains of VEGFR3 (VEGFR312) and the first 2 domains of 
VEGF#Trap to human IgG1#Fc. Adapted with permission from the American 
Association for Cancer Research:  Dapeng Zhang et al., Cancer Research, 2010; 70(6): 
p. 2495#2503; DOI: 10.1158/0008#5472. 
 
7. HB/002.1 
Anti#tumor drugs including antibodies and Fc#fusion proteins face problems of poor 
penetration and retention in tumor tissues, by virtue of their large size, high positive 
charge and high target#binding affinity. In an attempt to overcome these hitches, 
scientists have engineered a recombinant protein consisting of the second domain (D2) 
of VEGFR1 plus five amino acids upstream at the N terminal  (S129#R133) and two 
amino acids downstream at the C terminal (N227 and T228), flanking sequences 
genetically fused to human IgG1#Fc [208]. Figure 1.13 gives the schematic 
representation of the engineered structure of HB#002.1. This small size fusion protein, 
HB#002.1, has a MW of ∼80 kDa as compared to aflibercept (∼110 kDa) and 
bevacizumab (∼160 kDa). HB#002.1 also has a near neutral pI of 6.7, as compared to 
aflibercept (8.82) and bevacizumab (7.6), owing to removal of basic amino acid 
containing regions of the receptor VEGFR1 backbone, which in turn decreases its non#
specific binding to negatively charged proteoglycans of ECM. The molecule has a very 
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good tissue penetration and retention, excellent pharmacokinetic profile and robust 
anti#tumor efficacy in comparison to bevacizumab, which makes it a promising 
candidate for anti#angiogenic therapeutic approach. 
 
 
Figure 1.13 Schematic diagram of HB/002.1 engineered structure (Reprinted with 
permission from Biomed Central: Liu L et al; A novel engineered VEGF blocker with 
an excellent pharmacokinetic profile and robust anti#tumor activity. BMC cancer, 
2015. 15(1): p. 170. DOI: 10.1186/s12885#015#1140#1 [208]). The molecule contains 
the D2 domain of VEGFR1 plus 5 and 2 amino acids at the 5’ and 3’ flanking region 
respectively. Signal peptide derived from the heavy chain of mouse IgG1 (leader 
sequence). 
 
8. FP3 
FP3 is another soluble VEGF#binding chimeric fusion decoy receptor consisting of the 
second extracellular domain of VEGFR1 and the third and fourth extracellular domains 
of VEGFR2 fused to Fc region of human IgG1 [169]. Figure 1.14 gives a 
diagrammatic representation of the FP3 construct. The fourth domain was introduced 
to stabilize the dimerization of the receptor protein. The molecule has demonstrated 
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very good anti#tumor activity in preclinical studies in animal models of breast cancer. 
FP3 is currently in a Phase 1 clinical trial for cancer, and in a Phase 3 trial for AMD 
[153]. 
 
Figure 1.14 Structure of VEGF receptors and FP3 (Reprinted with permission from 
Springer Clinical and Translational Oncology, Ketao Jin et al; FP3: a novel VEGF 
blocker with antiangiogenic effects in vitro and antitumour effects in vivo; Clinical and 
Translational Oncology, 2011. 13(12): p. 878#884. DOI: 10.1007/s12094#011#0749#z 
[169]. VEGF receptor 1 and VEGF receptor 2 both contain seven extracellular 
domains, which differ between the two receptors and are responsible for VEGF 
binding. The soluble FP3 was created by fusing domain 2 of VEGFR1 and domains 3 
and 4 of VEGFR2 with Fc portion of human IgG1.  
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1.9 Project Overview 
 
 
1.9.1 Rationale  
 
VEGF#TrapR1R2 developed by Regeneron Pharmaceuticals Inc., binds the VEGF 
ligand with an 800#fold higher affinity (Kd≈1 pmol/L) than the monoclonal antibody, 
bevacizumab [209], binds PlGF, shows good overall efficacy and pharmacological 
properties, and is currently being tested in human clinical trials for several diseases 
involving neoangiogenesis [191, 193#195]. It is already known that VEGF binds to 
VEGFR1 with a higher affinity (with D2 being the key VEGF binding domain [90]) 
than to VEGFR2 (Kd=10#30 pM vs. 75#300 pM). Additionally, soluble parental 
VEGFR1(D1#D3)#Fc has a 500#fold higher binding affinity for VEGF than VEGFR2#
Fc[209]. These results from previous studies, form the basis for the current research 
aimed at developing a VEGF trap protein with a VEGFR1 and not a VEGFR2 
backbone. Moreover, binding affinity of D1#D3 domains of VEGFR1 is very similar 
to that of D2(R1)–D3(R2) in VEGF#TrapR1R2 (Kd =1#5 pM) [209]. 
From the literature, an earlier trap, Flt#1(1#3)#IgG1, is known to have a similar Kd for 
VEGF (≈5 pM) [93] as VEGF#TrapR1R2, but a poor pharmacokinetic profile when 
administered subcutaneously. The current research intended to produce and 
characterize an efficacious and modified parental VEGFR1(D1#D3)#Fc trap molecule, 
rationale for which is given below.  
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Although aflibercept (VEGF#TrapR1R2) is in the US market, the parent molecule 
VEGFR1 (D1#D3)#Fc, where D1#D3 are the first three IgG#like domains of VEGFR1, 
has not been exploited as a drug molecule. We developed an efficacious anti#
angiogenic decoy receptor molecule containing the first three ligand binding domains 
of VEGFR1, with some sequence modification in the constant IgG1 Fc region, based 
on the following assumptions.  
1. The molecule has comparable binding affinity towards VEGF#A as 
Regeneron’s VEGF#TrapR1R2. The second and third Ig#like C2#type 
(immunoglobulin#like) domains of both VEGFR1 and VEGFR2 [89] are 
sufficient for VEGF#A binding [210], [89, 103].  
2. The D2 domain of VEGFR2 is known to be the region where VEGF#A 
specifically binds and stimulates the activation of the proangiogenic signaling 
pathway [211]. 
3. Even though ligand binding has been mapped to the D2 domain of VEGFR1 
[212, 213], VEGFR1(D2) alone is not capable of binding to VEGF and requires 
flanking domains on either side (D1 and D3) for complete binding and to 
maintain the ligand binding site in a specific spatial conformation [90],[214]. 
The structure of the proposed molecule is based on this arrangement. 
4. Since the proposed trap contains natural ligand binding domains (D1, D2 and 
D3), it is assumed to have less immunogenic propensity than a “foreign” 
looking fusion molecule containing D2 from VEGFR1 and D3 from VEGFR2. 
Moreover, because of parental trap’s presumed low immunogenicity, we also 
assumed it to have longer half#life. 
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The objective of this study was to develop a molecule with a tremendous potential to 
be an effective anti#angiogenic drug for the treatment of several malignant and non#
malignant diseases involving neoangiogenesis. The purified protein was characterized 
and tested for its stability and efficacy, both in vitro and in vivo. 
 
1.9.2 Hypothesis 
 
The study investigates the hypothesis that a fusion protein consisting of the constant 
region of IgG1#Fc, fused to the first three extracellular domains of human VEGFR1, 
can be generated using recombinant DNA technology, which upon expression and 
purification, can be used as a promising candidate for diseases related to abnormal 
angiogenesis including cancer. The Fc#fusion protein will act as a trap for cellular 
VEGF#A, thereby inhibiting VEGF/VEGFR interaction and subsequent 
neoangiogenesis. 
1.9.3 Aims and Objectives 
 
The research hypothesis was addressed by pursuing four distinct aims which are as 
follows: 
Aim 1: Development of an in#house ligand for VEGFR1 (D1#D3)#Fc, which is 
recombinant VEGF165 protein. 
Aim 2: Development of VEGFR1(D1#D3)#Fc protein using recombinant DNA 
technology, followed by purification of the fusion protein. 
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Aim 3: Characterization of VEGFR1(D1#D3)#Fc in terms of its MW, purity, secondary 
and tertiary structures, isoelectric point, ligand#binding and stability. Thermal stability 
of VEGFR1(D1#D3)#Fc protein determined over a wide range of temperature 
conditions and time period, would help assess the duration and temperature of storage 
of the anti#angiogenic agent. 
Aim 4: Assessment of biological activity of the angiogenesis#inhibiting protein, 
VEGFR1(D1#D3)#Fc, in vitro, using primary vascular endothelial cell based assays 
and in vivo using an animal model of human cancer. 
 
The different aims are discussed in the following chapters in the thesis: 
Aim 1: Chapter 2 (Expression and Purification of VEGF165). 
Aim 2: Chapter 3 (Cloning, expression and purification of VEGFR1(D1#D3)#Fc fusion 
protein). 
Aim 3: Chapter 4 (Physicochemical characterization of VEGFR1(D1#D3)#Fc protein) 
and Chapter 5 (Determination of stability of VEGFR1(D1#D3)#Fc protein). 
Aim 4: Chapter 6 (In vitro studies for determination of biological activity of 
VEGFR1(D1#D3)#Fc and Chapter 7 (In vivo efficacy assessment of VEGFR1(D1#D3)#
Fc protein). 
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Chapter 2: Expression and Purification of VEGF165 
 
Aim: The aim of this chapter was the in#house production of ligand for VEGFR1(D1#
D3)#Fc. The ligand, VEGF165, which is known to have a very high affinity for binding 
cellular VEGFR1 and soluble decoy VEGFR1 traps, would be assayed for its binding 
ability to VEGFR1(D1#D3)#Fc. VEGF165 will be subsequently used to activate 
angiogenesis, whereby its binding to VEGFR1(D1#D3)#Fc, will inhibit angiogenesis 
in in vitro bioassays.  
  
2.1 Introduction 
 
VEGF165, which is the predominant and most potent angiogenic factor in humans and 
the major isoform of VEGF#A, was produced by recombinant DNA technology. The 
protein was purified by chromatographic techniques. VEGF165 was subsequently used 
in in vitro studies bioassays as the ligand for the proposed VEGFR1(D1#D3)#Fc fusion 
receptor. 
 
The VEGF165 gene was obtained from a commercial source (synthesized by GenScript, 
Piscataway, New Jersey, US) and was first cloned in bacterial cloning vector, pGEMT#
Easy, and subcloned in#frame into the mammalian expression vector, pEE14.4 [high 
level protein expression system – Glutamine synthase (GS) system; Lonza Biologics, 
Slough, UK] using EcoR1 and HindIII restriction sites. Prior to restriction digestion, 
plasmid DNA was isolated from E.coli harboring the gene. Following stable 
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transfection of mammalian CHOK1SV, positive clones expressing VEGF165 protein 
from different stages of clone development were selected on the basis of protein 
productivity, as estimated qualitatively by Coomassie staining and Western blotting 
and quantitatively by ELISA. These clones were propagated in culture. The best clone 
was selected based upon protein expression levels, and subsequently purified by 
column chromatography. Recombinant human VEGF165 is a disulfide#linked 
homodimeric glycoprotein. The protein is made of two polypeptide chains containing 
165 amino acids each. The expected MW of glycosylated VEGF165 homodimer is ~44 
kDa and that of the monomer is ~22 kDa. 
The purified VEGF165 protein was used in in vitro studies as ligand for the 
VEGFR1(D1#D3)#Fc decoy receptor protein. The in vitro studies included VEGF165#
induced endothelial cell proliferation and endothelial capillary network formation and 
subsequent inhibition of these VEGF165# induced processes, by VEGFR1(D1#D3)#Fc 
receptor mimic. 
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2.2 Materials and Methods 
  
Flow Chart of Work 
 
 
2.2.1 Plasmid DNA isolation from VEGF165 clones in cloning and expression 
vectors 
  
VEGF165 was ligated to pGEMT#Easy cloning vector (Promega; Catalogue# A137A) 
and E.coli XL1#Blue competent cells were transformed with the ligated vector. Upon 
blue white screening based on alpha#complementation of the beta galactosidase gene, 
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positive clones with desired insert were selected on LB ampicillin agar plates. White 
colonies were inoculated for overnight growth of bacterial cultures at 37°C in 5 mL 
LB media containing 50 mg/mL ampicillin.  Plasmid DNA from XL1#Blue colonies 
harboring vector containing VEGF165 gene, was extracted using alkaline lysis method. 
The overnight culture in 15 mL centrifuge tubes, was spun at 4000 rpm for 10 min. 
The supernatant was carefully discarded, so as not to dislodge the bacterial pellet. Each 
tube was inverted on tissue paper to remove the traces of media or given a short spin 
to the tube before pipetting out the supernatant. Next, 150 µL of resuspension solution 
[25 mM Tris#HCl (pH 8.0), 50 mM glucose, 10 mM EDTA (pH 8.0), 100 ag/mL of 
RNase A] was added to the pellet, incubated at room temperature for 5 min and the 
tube was vortexed for less than 10 sec. After mixing thoroughly by pipetting up and 
down, the resuspended cell pellet was transferred to a 1.5 mL microfuge tube. 150 aL 
of freshly prepared lysis solution (1% SDS and 0.2M sodium hydroxide) was added to 
the microfuge tube and this was then gently inverted 4#5 times before incubating on 
ice for no longer than 5 min. Finally 250 aL neutralizing solution (3 M potassium 
acetate, pH 4.8) was added and the contents were mixed thoroughly by inverting the 
tube 8#10 times.  The tube was centrifuged at 13,000 rpm for 10 min and the pellet 
discarded. The supernatant containing DNA was collected in a fresh 1.5 mL 
microcentrifuge tube. Diatomaceous earth column was prepared in the meantime, by 
placing a filter paper (Whatman No 3) in a spin column. 500 aL of diatomaceous earth 
(50 mg/ml) was added and a vacuum applied to the column, so that the bed of the 
diatomaceous earth is formed. To the DNA#containing supernatant, was added an 
equal volume (∼600 µL) of binding buffer (6 M guanidine hydrochloride) and this was 
mixed well by pipetting. Next, the supernatant#binding buffer mixture was added onto 
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the prepared column with diatomaceous earth bed. Vacuum was applied while ensuring 
not to dry the column completely.  The column was washed with 70% ethanol. To 
ensure complete removal of ethanol, the column fitted on the collection tube was 
centrifuged at high speed for 1 min. The flow#through was discarded. The plasmid 
DNA was eluted in 50 µL of sterile MilIi Q water. DNA concentration was estimated 
using NanoDropTM 1000 Spectrophotometer. 
The VEGF165 gene, after nucleotide sequence confirmation, was cloned in mammalian 
expression vector pEE14.4. After transformation of XL1#Blue competent cells, the 
positive colonies (clones) were screened and plasmid DNA was isolated as previously 
described.  
  
2.2.2 Restriction Digestion of pGEMT-Easy/VEGF165 plasmid with EcoR1- HindIII 
  
A total of 1 µg of plasmid DNA was digested using EcoR1 (Catalog#R0101S; Lot# 
0321201; NEB, Ipswich, Massachusetts, USA) and HindIII (NEB; Catalog#R0104S; 
Lot#65) since this released the cloned VEGF165 gene (591 bp) from the pGEMT#Easy 
vector. For 50 µL of reaction, 4–5 units of each of the enzymes (2–2.5 µL) in NEB 
Buffer 2 was used to digest plasmid DNA at 37ºC for 2 hr. 
 
2.2.3 Restriction Digestion of pEE14.4/VEGF165 plasmid with EcoR1 and HindIII 
 
A total of 1 µg of plasmid DNA was digested using EcoR1 (NEB; Catalogue# R0101S; 
Lot# 0321201) and HindIII (NEB; Catalogue# R0104S; Lot# 65) since this released 
the cloned VEGF165 gene (591 bp) from the pEE14.4 vector. 
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The 50 µL restriction digestion reactions were incubated at 37ºC for 2 hr and analyzed 
by agarose (1%) gel electrophoresis. 
 
2.2.4 Sequencing of pGEMT-Easy/VEGF165 and pEE14.4/VEGF165  
 
Positive clones were confirmed by DNA sequencing of cloned VEGF165 gene, in both 
cloning and expression vectors, to validate the correct insert sequence and gene 
orientation. Sequencer used for nucleotide sequencing was ABI Prism 3100 Genetic 
Analyzer from Applied Biosystems (Foster City, California, USA). Sequencing of 
pGEMT#Easy/VEGF165 clone#2 (positive clone) was performed using the following 
sequencing primers: 
P#2 (forward): 5’(GTTTTCCCAGTCACGAC)3’ 
P#1 (reverse): 5’(AACAGCTATGACCATG)3’ 
 
Sequencing of pEE14.4/VEGF165 clone#6 (positive clone) was performed using 
following primers: 
P#3 (forward primer): 5’( TAACGGTGGAGGGCAGTGTAGT) 3’ 
P#4 (reverse primer): 5’(ATAAGCTGCAATAAACAAGTT) 3’ 
All primers were designed using Vector NTI® software (Thermo Fisher Scientific). 
Figure 2.1 represents the sequence map of pEE14.4/VEGF165 obtained from Vector 
NTI®. 
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Sequencing PCR protocol:    
Step 1: 96°C, 2 min 
Step 2: 96°C, 10 sec 
Step 3: 50°C, 5 sec 
Step 4: 60°C, 4 min 
Step 5: Repeat steps 2 – 4, 29 more times 
Step 6: 4°C, α 
The sequencing PCR was set up as in Table 2.1. 
Table 2.1 Preparation of sequencing PCR master mix.  
Components Volume for 1 
rxn. (µL) 
Final conc. 
2.5 X sequencing buffer 2 1 X 
Big Dye Terminator v3.1 Ready pre#mix 
(Applied Biosystem) 
1 # 
Forward or Reverse Primer (10µM) 1 0.4 µM 
Template, Plasmid DNA (pEE14.4/VEGF165) 1 200 ng 
Total volume 5 1 X 
 
2.2.4.1 Post Sequencing PCR reaction clean-up of the product  
 
Each 5 µL sequencing PCR product, was mixed with 30 µL injection solution 
(MontageTM SEQ96 Sequencing reaction cleanup kit; Catalogue# LSKS09624) and 
transferred to individual well of a 96#well sequencing plate and applied vacuum at 22 
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psi for 2–3 min. 30 µL injection solution was pipetted into the wells of the plate and 
vacuum applied again. After removing vacuum, another 30 µL injection solution was 
added to the wells and mixed by pipetting. The solutions were finally transferred to the 
corresponding wells of a 96#well optical plate for nucleotide sequencing. 
 
2.2.5 Transient transfection of plasmid DNA (pEE14.4/VEGF165) in HEK293T 
cells  
 
One million HEK293T adherent cells were seeded per well of a 6#well plate in 2 mL 
of complete growth medium (DMEM + 10% FBS + 4 mM glutamine), the previous 
night, to give 60#70% confluence on the day of transfection. One hour prior to 
transfection, medium was changed to that containing no serum (1 mL of 
OptiMEM/well). A total of 4 µg of plasmid DNA containing insert was utilized for 
each transfection. Vector pEE14.4 DNA without insert was used as a negative control. 
Lipofectamine [LipofectamineTM2000 Transfection Reagent (1mg/mL); 
Catalogue#11668019, Lot#1270980; Invitrogen, Carlsbad, California, USA] was used 
as the transfection agent. The DNA to LipofectamineTM (weight/volume) ratio was 
kept at 1:3. A total of 4 µg of DNA to be tested, was added to 250 aL in serum#free 
media and mixed gently. Similarly appropriate volume (12 µL) of LipofectamineTM 
was diluted in 250 aL serum#free media. Dilutions were prepared and kept at room 
temperature for 5 min. 250 aL of diluted Lipofectamine™ 2000 was added to diluted 
DNA, mixed gently and incubated at room temperature for 30 min to allow DNA#
Lipofectamine™ 2000 complexes to form. DNA#Lipofectamine™ 2000 complex (500 
µL) was added directly to each well containing cells, and mixed gently. It was then 
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incubated for 5 hr at 37°C in a CO2 incubator. The culture supernatant (spent media) 
was discarded and the cells supplemented with 2 mL/ per well with media containing 
serum and the plate incubated at 37°C in a 5% CO2 incubator. Next morning, the 
culture supernatants were harvested and the cells were supplemented with 2 mL/ per 
well with media containing no serum, and the plate placed at 37°C and 5% CO2. After 
72 hr, the supernatants were harvested and assayed by Western blotting to check for 
the presence of the desired VEGF165 protein. 
 
2.2.6 Protein Analysis 
 
The expressed VEGF165 protein in the cell culture supernatant was analyzed by SDS#
PAGE and Western blotting. 
 
2.2.6.1 SDS-PAGE of supernatants of transfected HEK293T 
 
Seventy two hours post transfection, cell culture supernatants were collected and 
analyzed using SDS#PAGE. 
 
1. Preparation of resolving gel 
The resolving/separating gel (15%) was prepared according to Table 2.2. The gel 
casting frame was set on the casting stand on a flat surface after clamping two clean 
glass plates in between the frames. All reagents were combined (except TEMED) in a 
small beaker in the order listed in Table 2.2. When ready to pour the gel, TEMED was 
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quickly added and mixed by swirling gently. The solution was dispensed between the 
glass plates covering 3/4th of the space ensuring that no air bubbles were generated. 
The remaining acryl amide solution was ejected back into the small 
beaker.  Polymerization of this solution indicated the completeness of polymerization 
of the gel between the plates. The surface of the gel was layered with water carefully 
with a pipette. The set up was left undisturbed at room temperature for 25#30 min for 
the gel to polymerize. 
 
Table 2.2 Preparation of 15% resolving gel for SDS/PAGE. 
Sr. No. Reagents Volume 
1 H2O 2.4 mL 
2 Acrylamide/ Bis#acrylamide (30%/ 0.8% w/v) 5 mL 
3 1.5M Tris pH 8.8 2.5 mL 
4 10% SDS 100 aL 
5 10% APS 200 aL 
6 TEMED 10 aL 
 
2. Preparation of stacking gel 
Stacking gel (5%) was prepared according to Table 2.3 given below. Water from 
the top of the resolving gel was removed. Stacking gel was added until an 
overflow and ensuring that no air bubbles were trapped. The well#forming comb 
was inserted between the glass plates without trapping air under its teeth. The gel 
was allowed to polymerize for 20#30 min. 
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Table 2.3 Preparation of 5% stacking gel for SDS/PAGE. 
Sr. No. Reagents Volume 
1 H2O 2.8mL 
2 Acrylamide/ Bis#acrylamide (30%/ 0.8% w/v) 0.85mL 
3 0.5M Tris pH 6.8 1.25mL 
4 10% SDS 50 aL 
5 10% APS 25 aL 
6 TEMED 5 aL 
 
3. Sample Preparation 
To 100 aL of each sample, appropriate reducing or non#reducing 6X SDS sample 
buffer (375mM Tris#HCl, pH 6.8, 12% SDS, 60% glycerol, 0.06% bromophenol blue 
with or without 9% 2#mercaptoethanol or 0.6M DTT) was added. Samples were boiled 
at 95°C for 10 min and then allowed to cool. The samples were then centrifuged at 
5000 rpm for 5 min and loaded on the gel. 
 
4. Electrophoresis 
The gel cassette was removed from the casting stand and the comb removed. The glass 
plates were placed in the electrode assembly with the short plate on the inside and the 
buffer dam plate opposite the gel cassette assembly. The assembly was placed into the 
electrophoresis tank. The inner chamber was completely filled with 1X electrophoresis 
buffer (25mM Tris, 192mM glycine, 0.1% SDS, pH 8.3). A maximum of 10 µL of 
sample or MW marker, was slowly pipetted into respective wells. The tank was 
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covered with the lid, aligning the electrodes (black or red) appropriately. The 
electrophoresis tank was connected to the power supply. The gel was run at 150V till 
the samples were in the stacking and then at 200V when the samples entered the 
separating gel. The gel was allowed to run till the dye front reached the bottom of the 
plates. The gel was taken out of the plates gently using the gel scrapper and carefully 
proceeded towards Coomassie blue staining or Western blot transfer as per 
requirement. 
 
2.2.6.2 Western Blot of supernatants of transfected HEK293T  
 
Transfected HEK293T cell supernatant samples (of 72 hr) were electrophoresed using 
SDS#PAGE and then blotted on to nitrocellulose membrane for transfer at 100 V for 
60 min. Primary antibody used for probing VEGF165 was bevacizumab (Avastin®) 
(1mg/mL; 1:5000 dilution in 0.1% TBST) followed by addition of secondary antibody 
(HRP conjugated goat anti human IgG (H+L); Jackson; Catalogue#109#035#088; 
1:5000 dilution in 0.1% TBST). Detection of protein of interest was achieved using 
DAB#urea hydrogen peroxidase. Western blotting was carried out according to the 
following protocol: 
 
1. Preparation of membrane  
Pieces of nitrocellulose membrane and filter papers were cut as per the size of the gel. 
The membrane and the filter pads along with the sponge pads were soaked in the 
Western transfer buffer. 
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2.  Assembling of Trans/blot® cell and electrophoresis 
A sandwich was made as below:  
Trans#blot® cassette (black side below) – sponge – filter pads – gel – membrane – filter 
pads – sponge pads – upper side of the Trans#blot® cassette (white). This sandwich was 
made with care removing all the air pockets, ensuring good transfer. The cassette was 
placed in the transfer unit tank, with the black side of the cassette facing towards the 
black side of the transfer unit, and chilled 1X Western transfer buffer was added with 
an ice#cooling unit. Transfer was allowed to take place for 60 min at 100V. The 
membrane was removed carefully from the Trans#blot® cassette and stained with 
Ponceau stain to ensure proper transfer. The Ponceau stain was poured out and the 
membrane was washed with distilled water. 
 
2.  Blocking of membrane  
The membrane was blocked using 5% skimmed milk (1g in 20 mL 0.1% or 1 X TBST) 
for 1 hr at room temperature followed by incubation at 4°C overnight. 
 
3. Addition of antibodies 
The membrane was washed thrice with 1X TBST for 5 min each time. It was then 
incubated with primary antibody against VEGF (Avastin®; 1mg/mL; 1:5000 dilution 
in 0.1% TBST) for 2 hr with shaking at 20 rpm, (also can be done at 4°C overnight). 
Membrane was again washed thrice with 300 µL 1X TBST for 5 min each. Washing 
was followed by incubation with secondary antibody (HRP#conjugated goat anti#
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human IgG (H+L) specific antibody; Jackson, Catalogue# 109#035#088; Jackson 
ImmunoResearch laboratories, Pennsylvania, USA) at 1:5000 dilution (1 µL in 5 mL   
0.1% TBST). Following incubation with secondary antibody, another three washes 
with 1X TBST were given for 5 min each. 
 
4. Developing Blot with DAB/Urea 
A single tablet of DAB was dissolved in 5 mL of distilled water, and a single tablet of 
urea dissolved in 5 mL distilled water, was added to it. This 10 mL solution was added 
to the blot. The reaction was stopped by pouring the solution out, when an even 
development of protein band was visualized on the blot. The membrane was washed 
with distilled water and the band pattern analyzed. 
 
2.2.7 ELISA for quantitation of VEGF165 
 
MaxiSorpTM micro#titer plate (Nunc; Catalogue# 439454) was coated with 100 µL of 
different dilutions of supernatants of transiently transfected HEK293T cells with 
pEE14.4/VEGF165 and different dilutions of standard VEGF121 [in#house produced, 
Reliance Life Sciences Pvt. Ltd.] Probing was done using anti#VEGF primary 
antibody, Avastin® (1mg/mL; 1:10,000 in 0.1% BSA in 1XPBST). 100 aL of the 
primary antibody was added to each designated well and incubated at 37°C for 2 hr. 
Detection of VEGF165 was performed using HRP conjugated goat anti#human IgG 
(H+L) secondary antibody (Jackson; Catalogue# 109#035#088) at 1:5000 dilution. 100 
aL of the secondary antibody was added to each designated well and incubated at 37°C 
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for 1 hr. Washing of wells was done with 300 aL 1 X PBST thrice, followed by twice 
with 300 aL 1 X PBS. TMB/H202 (Catalogue# T0440; Sigma, St. Louis, Missouri, 
USA) was added to each well (100 aL) and incubated until color developed. The 
reaction was stopped by addition of 1N H2SO4 and absorbance was read at 450 and 
620 nm. Using a similar protocol, VEGF165 expressed by different clones at various 
stages of clone development after stable transfection in CHOK1SV cells, was also 
estimated. 
 
2.2.8 Stable transfection (Electroporation) of mammalian cells with VEGF165 
 
 
VEGF165 gene cloned in mammalian expression vector, pXC17.4, was used to transfect 
mammalian host cell, CHOK1SV, by electroporation, for stable integration in host 
genome and subsequent substantial protein production upon transcription and 
translation of genome. 
 
2.2.8.1 Recombinant clone details 
 
Clone: pEE14.4/VEGF165; clone#6 
Plasmid DNA yield: 1.5 µg/µL (Plasmid megaprep was performed using Qiagen kit 
with manufacturer’s protocol; Qiagen, Hilden, Germany). 
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2.2.8.2 Linearization of recombinant plasmid 
 
A total of 150 µg of pEE14.4/VEGF165 clone#6 plasmid DNA, was digested with PvuI 
(NEB; Catalogue# R0150L; Lot#36) for linearization. Restriction digestion reaction 
was carried out at 37°C for overnight. 
 
 
Figure 2.1 Vector map of pEE14.4 with the insert VEGF165 (Vector NTI®, Thermo 
Fisher Scientific Inc., Waltham, USA). 
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2.2.8.3 Ethanol precipitation of digested recombinant plasmid  
 
To 200 µL of PvuI digested DNA, 1/10th volume (20 µL) of 3M sodium acetate and 
2.5 volume of absolute ethanol (500 µL) was added, mixed well and incubated at #
80ºC for 1 hr. The reaction was centrifuged at 13,000 rpm for 20 min at 4ºC. The 
precipitated DNA was washed with 70% ethanol and resuspended in 250 µL of 0.22 
µm# filtered endotoxin#free Tris#EDTA buffer. 
2.2.8.4 Quantitation of digested recombinant plasmid 
 
The quantity of plasmid DNA was determined spectrophotometrically using 
NanoDropTM 1000 Spectrophotometer (Thermo Scientific). 2 µL of DNA sample was 
used for quantitation using this method. 
 
2.2.8.5 Electroporation of CHOK1SV    
                  
Recombinant DNA used for electroporation: 40 µg (conc. of DNA=378.3 ng/µL; DNA 
volume used =106 µL) 
 
Cell details (CHOK1SV) 
Passage number of CHOK1SV cells on day of electroporation: 2 
Cell viability on day of electroporation: 80% 
Media used: CDCHO without L#glutamine 
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Electric pulse details  
Electroporator: Bio#Rad (Hercules, California, USA) 
Cuvettes used: 0.4 cm  
Cell suspension (700 µL) + DNA (106 µL containing 40 µg)  
Pulse conditions: 297 V, 900 µF Capacitance, Infinite c Resistance; Time Constant of 
17.6 ms. 
 
Electroporated cells were plated onto ten 96#well plates for clone selection. Plates were 
incubated at 37ºC and 10% CO2.  50 µM MSX was added to each well after 24 hr to 
inhibit endogenous GS enzymatic activity in CHOK1SV cells. Plates were regularly 
monitored for appearance of colonies after 21 days post plating of cells. 
 
2.2.8.6 VEGF165 clone propagation 
 
Clones started appearing following three weeks of incubation of cells plated in 96#well 
culture plates. The clones were transferred to the subsequent higher volume plates and 
flasks depending on their VEGF165 protein productivity as determined by ELISA as 
well as SDS#PAGE and Western blots. 
Table 2.5 summarizes the various stages of development of high VEGF165 # yielding 
clones, starting from analysis of CHOK1SV cultures at 96#well plate through roller 
bottle stage. 
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2.2.9 Purification of VEGF165 protein 
 
VEGF165 is a basic protein (isoelectric point of 8#8.5) [216, 217]. It is a disulphide#
linked glycosylated homodimer with two polypeptide chains containing 165 amino 
acids each. The protein was purified from the CHOK1SV cell culture supernatant by 
ion#exchange chromatography followed by affinity chromatography. Since the protein 
has a high isoelectric point, at pH conditions less than the pI, the protein will have a 
net positive charge and hence will be attracted towards the negatively charged resins 
of the cation exchange chromatographic column. 
 
2.2.9.1 Step 1: Cation exchange chromatography  
 
The column was operated using a liquid chromatographic system, AKTA Prime (GE 
Healthcare Life Sciences). The pI of VEGF165 obtained from culture supernatant was 
found to be 7.8. The protein was exposed to sodium acetate buffer having a pH of 4.5, 
thus giving it a net positive charge, making it possible to bind to a strong cation 
exchanger such as SP Sepharose.  
A total of 200 mL of roller bottle harvest was purified by SP Sepharose column. 
Conductivity of load was 53.8 mS/cm. Column was equilibrated with buffer A at a 
flow rate of 0.7 mL/ min before sample injection. For elution, a three CV gradient of 
target 100% buffer B was set (gradient length=15 mL). Flow#through and buffer 
washes were collected separately after passing 3 CV of buffer A, 3 CV of Milli#Q 
water and 3 CV of 0.5M NaOH followed by 20% ethanol for column storage. 
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Column and matrix 
Column: 5#mL HiTrap#SP XL column [diameter=1.6 cm, length=2.5 cm, column 
volume=5 mL] (GE Healthcare Life Sciences) 
Chromatography matrix: SP Sepharose (Hi#Trap SP XL) from GE Healthcare 
 
Buffers 
Buffer A: 10 mM sodium acetate buffer pH 4.5. Conductivity of the solution was 
observed to be 904 µS/cm. 
Buffer B: 10 mM sodium acetate buffer containing 0.8 M NaCl (pH 4.5). Conductivity 
of the solution was 88.3 mS/cm. All buffers were filtered through 0.45 µm filter to 
remove particulate matter.  
 
2.2.9.2 Step 2: Heparin Sepharose Chromatography  
 
Heparin is a highly sulphated glycosaminoglycan capable of binding a wide range of 
biomolecules including growth factor proteins. Heparin coupled to Sepharose matrix 
via the N#hydroxysuccinamide coupling method, acts as an affinity ligand for 
molecules as well as a high capacity cation exchanger due to its anionic sulphate 
groups.  
The column was equilibrated with 1 X PBS (pH 7.4) at a flow rate of 1 mL/min, before 
injecting the load. For elution, a gradient of length 15 mL was set with target of 100% 
buffer B. 
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Sample 
Protein fractions #13–15 eluted from SP Sepharose column (∼2 mL) were pooled and 
concentrated using 5 kDa Amicon ultra Centrifugal filter device (Amicon ultra#15; 
ultracel#5; Catalog#UFC900524; Lot#R7BN24244; Millipore, Massachusetts, 
USA).). Concentrated protein solution had a pH of 5.57 and a conductivity of 53.03 
mS/cm. 
 
Column and matrix 
Column: 5#mL Heparin Sepharose 6 Fast Flow column [diameter=1 cm, length=6.4 
cm, area=0.785 cm2, column volume=5 mL] (GE Healthcare Life Sciences, 
Marlborough, Massachusetts, USA). 
Chromatography matrix: Heparin Sepharose of GE Healthcare 
 
Buffers 
Buffer A: 1 X PBS buffer (pH 7.4). Conductivity of buffer = 16.74 mS/cm 
Buffer B: PBS buffer containing 1M NaCl (pH 7.4) 
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2.3 Results 
 
 
2.3.1 Agarose gel electrophoresis of digested plasmid samples 
 
The restriction enzyme#digested plasmid DNA samples obtained from VEGF165 clones 
were electrophoresed in a 1% w/v agarose gel at 100 V for 40 min, viewed under UV 
light and documented using a gel imaging and documentation system (Image Master 
VDS; GE Biosciences, Pharmacia Biotech, Piscataway, New Jersey, USA). PCR Sizer 
100 bp DNA ladder (Norgen Biotek; Catalogue# 11400) and 1 kb DNA ladder (NEB; 
Catalogue# N3232) were loaded on agarose gels as appropriate MW markers. Figure 
2.2 shows the gel image of restriction digestion products of VEGF165 containing 
vectors. 
 
Figure 2.2 Agarose gel image of EcoR1 and HindIII digested VEGF165 clones. 
Expected fragment size (591 bp) upon double digestion of pGEMT#Easy/VEGF165 and 
pEE14.4/VEGF165 plasmid DNA samples with EcoR1 and HindIII, was observed in all 
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the above clones. Two clones, VEGF165/pGEMT#Easy/clone#2 and 
VEGF165/pEE14.4/clone#6 were subjected to nucleotide sequencing for sequence 
confirmation. 
 
2.3.2 Sequencing of pGEMT-Easy/VEGF165 and pEE14.4/VEGF165 
 
On sequencing VEGF165/pGEMT#Easy#clone#2 and VEGF165/pEE14.4#clone#6 using 
respective sequencing primers, the following nucleotide sequence for VEGF165 gene 
was obtained, which was aligned with standard VEGF165 sequence (GenBank 
accession number AF486837.1). 
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Corresponding protein sequence of VEGF165 (165 amino acids) is as follows: 
 
VEGF165 gene cloned in both pGEMT#Easy and pEE14.4 vectors, showed 100% 
homology with standard VEGF165 sequence. The pEE14.4/VEGF165 clone#6 was used 
for transient expression in HEK293T cells. 
 
2.3.3 SDS-PAGE analysis of VEGF165 in supernatants of transiently transfected 
HEK293T 
 
Supernatants from transiently transfected HEK293T cells were harvested and analyzed 
for presence of VEGF165 using SDS#PAGE (Figure 2.3). 
 
Figure 2.3 SDS/PAGE for VEGF165 from supernatants of transient transfected 
HEK293T cultures.  
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The expected MW of glycosylated homodimer VEGF165 secreted in HEK293T culture 
was approximately 45 kDa. Monomer MW expected under reduced condition was ∼22 
kDa. Secreted VEGF165 protein in culture supernatants of transfected cells, appear to 
accumulate within 72 hr of transfection, as is evident from non#reduced and reduced 
forms of VEGF165 detected by SDS#PAGE.  
 
2.3.4 Western blot analysis of VEGF165 in supernatants of transiently transfected 
HEK293T 
 
Supernatants collected from HEK293T cells transiently transfected with 
pEE14.4/VEGF165, were analyzed by Western blotting for detection of expressed 
VEGF165 protein (Figure 2.4). 
 
Figure 2.4 Western Blot for VEGF165 from supernatants of transient transfected 
HEK293T cultures.  
VEGF165 was detected in culture supernatants of transiently transfected cells using 
anti#VEGF antibody, Avastin® as the primary antibody at 1:5000 dilution and 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
99 
  
peroxidase#affinipure goat anti#human IgG (H+L) as secondary antibody, also at 
1:5000 dilution. 
 
2.3.5 Stable transfection of VEGF165 in CHOK1SV      
 
Plasmid DNA from pEE14.4/VEGF165 clone#6 was extracted using Qiagen kit 
according to manufacturer’s protocol and DNA was quantitated using NanoDropTM 
1000 Spectrophotometer. Following DNA linearization using PvuI restriction enzyme 
and ethanol precipitation of the digested plasmid (Figure 2.5), DNA was again 
quantitated spectrophotometrically. Table 2.4 tabulates the plasmid DNA 
concentrations prior to stable transfection. 
 
Table 2.4 Plasmid DNA quantitation before stable transfection of VEGF165 in 
CHOK1SV cells. 
 
      
 
Sample Conc. (ng/µL) 260:280 260:230 
Uncut Plasmid pEE14.4/VEGF165 1.543 µg/µL 1.9 2.24 
PvuI#digested plasmid before 
ethanol precipitation 
99.2 ng/µL 
1.64 1.65 
PvuI#digested plasmid after ethanol 
precipitation 
378.3 ng/µL 
1.81 1.82 
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Figure 2.5 Agarose gel image of pEE14.4/VEGF165 plasmid DNA (uncut and 
linearized). 
Plasmid DNA extracted from pEE14.4/VEGF165 clone#6 was digested with PvuI 
enzyme which linearizes the plasmid. The linearized plasmid was then precipitated by 
ethanol in cold and stored at #70°C until it was used for electroporation of CHOK1SV 
cells for stable transfection. 
 
2.3.6 VEGF165 stable clone development 
 
 
2.3.6.1 ELISA for VEGF165 at 96-well plate stage  
 
CHOK1SV clones containing VEGF165 started to appear after 21 days following 
incubation in ten 96#well plates. ELISA to determine the concentrations of VEGF165 
expressed by the various clones during the different stages of clone propagation (96#
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well plate  24#well plate  6#well plate T#25 flask  T#75 flask  T#175 flask 
Roller bottle) was performed as per protocol discussed in section 2.2.7. Figure 2.6 
shows the ELISA data at 96#well plate stage of clone development.  
 
Figure 2.6 Graphical representation of ELISA data for detection of VEGF165 at 
96/well plate stage. Two VEGF165 clones, P3G4 and P4B9 were observed to be 
expressing the highest concentrations of the desired protein in culture supernatants. 
 
2.3.6.2 Western blot of stably transfected CHOK1SV cell culture supernatants at different 
stages of clone development. 
 
The supernatants harvested from transfected CHOK1SV cells, were analyzed by 
Western blotting for the presence of VEGF165 during different stages of propagation 
of pEE14.4/VEGF165#transfected clones. This included analysis at 24#well plate 
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(Figure 2.7), 6#well plate (Figure 2.8), T#25 flask (Figure 2.9 & 2.10) and roller bottle 
(Figure 2.11).  
 
Figure 2.7 Western Blot for VEGF165 at 24/well plate stage (non/reduced). Under 
non#reduced condition, the dimeric protein (∼45 kDa) was detected in culture 
supernatants of all VEGF165 clones at 24#well plate stage. 
 
Figure 2.8 Western Blot for VEGF165 at 6/well plate stage (non/reduced). Under 
non#reduced condition, the dimeric protein (∼45 kDa) was detected in culture 
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supernatants of all VEGF165 clones at 6#welll plate stage, with clone P4B9 expressing 
the highest level of protein. 
 
 
Figure 2.9 Western Blot for VEGF165 at T/25 flask stage (reduced).  
The standard protein used in Western blotting was recombinant human VEGF165 
expressed in E.coli (ProSpec; Catalogue# CYT421). The E.coliproduced VEGF165 is 
a dimeric, non#glycosylated polypeptide chain of 165 amino acids, having a MW of 
38.23 kDa. The monomeric bacterial#expressed protein thus has a MW of 19.11 kDa. 
The VEGF165 protein monomer obtained from CHOK1SV clones, possesses a higher 
MW of ~22 kDa under reduced conditions, due to glycosylation in the polypeptide 
chains as a result of expression in mammalian cells. 
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Figure 2.10 Western Blot for VEGF165 at T/25 flask stage (non/reduced).  
25 µL of supernatant sample containing VEGF165 was loaded for each clone at T#25 
stage and detected by Western blotting. Expression level for all 14 clones at T#25 stage 
was ∼1 µg/mL, with that of clone P4B9 being highest at 1.43 µg/mL. 
 
 
Figure 2.11 Western Blot for VEGF165 at Roller Bottle stage: Clone# P4B9.  
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Out of 6 clones at T#175 stage, clone# P4B9, was found to have good expression level 
of VEGF165, and hence propagated in roller bottle for increased expression levels. 
According to ELISA, concentration of VEGF165 from clone P4B9 in a roller bottle was 
452 µg/ mL. 
 
2.3.6.3 Summary of VEGF165 clones at different stages of clone development 
 
CHOK1SV/VEGF165 clone# P4B9 exhibited maximum expression of VEGF165 
throughout the different stages of clone development, as quantitated by ELISA. Table 
2.5 summarizes the expression levels of various high yielding clones at the different 
clone development stages of the product. 
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Table 2.5 Summary of VEGF165 clone development through various stages of 
selection. 
Stage Number 
of Clones 
obtained 
Clone Names Conc. of VEGF165   
96#
well 
plate 
23 P1C7, P1E2, P1G2, P2C9, P2C11, 
P3B9, P3C3, P3C5, P3C10, 
P3D12, P3G2, P3G3, P3G4, 
P4A6, P4A10, P4B9, P4C2, P5G1, 
P5G5, P7B8, P9F2, P10C9, 
P10G6  
P4B9: 0.137 µg/mL  
24#
well 
plate 
23 P1C7, P1E2, P1G2, P2C9, P2C11, 
P3B9, P3C3, P3C5, P3C10, 
P3D12, P3G2, P3G3, P3G4, 
P4A6, P4A10, P4B9, P4C2, P5G1, 
P5G5, P7B8, P9F2, P10C9, 
P10G6  
All except P2C11 and 
P10G6 showed high 
protein expression (as 
per Western blot) 
6#well 
plate 
16 P1C7, P1E2, P1G2, P2C9, 
P2C11,P3C3, P3G2, P3G4, 
P4A10, P4B9, P4C2, P5G5, P7B8, 
P9F2, P10C9, P10G6 
P1E2, P3G2, P4B9 and 
P10C9 expressed high 
protein (as per Western 
blot) 
T#25 
flask 
14 P1C7, P1E2, P1G2, P2C9,  P3C3, 
P3G2, P3G4, P4A10, P4B9, P4C2, 
P5G5, P7B8, P9F2, P10C9 
P4B9: 1.43 µg/mL  
T#75 
flask 
7 P1C7, P1G2, P1E2, P3G2, P4B9, 
P5G5, P10C9  
P1C7:1.5 1 µg/mL            
P4B9: 1.12 µg/mL  
T#175 
flask 
6 P1C7, P1G2, P3G2, P4B9,  P5G5, 
P10C9 
P4B9: 1.43 µg/mL     
P10C9: 0.48 µg/mL  
P1C7: 0.32 µg/mL  
Roller 
Bottle 
1 P4B9  P4B9: 452 µg/ mL or 
452 mg /L 
 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
107 
  
2.3.7 Purification of VEGF165 
 
2.3.7.1 SDS-PAGE of VEGF165 purified by SP Sepharose chromatography 
 
VEGF165 was purified using cation exchange chromatography. The elution fractions # 
13–18 were analyzed by SDS#PAGE (10% resolving gel and 8% stacking gel) under 
non#reduced conditions. Bovine serum albumin (BSA; MW of 66.5 kDa) was loaded 
(10 µg) as a control for the run (Figure 2.12). 
 
 
Figure 2.12 SDS/PAGE of VEGF165 purified by SP Sepharose strong cation 
exchanger. Loaded 20 µL of each eluted fraction on a 10% SDS#PAGE gel and 
electrophoresed at 150 V in stacking gel and 200 V in running gel followed by staining 
in Coomassie blue stain overnight. About 3 mg of protein was obtained after 
purification of VEGF165 by ion exchange chromatography. 
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2.3.7.1.1 Protein Estimation of SP Sepharose-purified VEGF165 
 
Bradford colorimetric protein assay was used to determine total protein concentration 
in purified fractions# 13–18. The results are summarized in Table 2.6. 
 
Table 2.6 Estimation of SP Sepharose/purified VEGF165 protein concentration by 
Bradford assay. 
Elution 
Fraction# 
Conc. of VEGF165 
(µg/mL) 
13 653.429 
14 694.099 
15 700.478 
16 560.925 
17 158.214 
18 7.496 
 
Approximately 2.8 mg/mL of protein was obtained from the purified fractions after SP 
Sepharose chromatography, according to quantitation by Bradford assay. 
 
2.3.7.2 .SDS-PAGE of VEGF165 purified by heparin Sepharose chromatography 
 
The purified fractions obtained after SP Sepharose chromatography were pooled and 
concentrated using a 5 kDa membrane filter (Amicon ultra® Centrifuge Filter Devices; 
Millipore; Catalogue# UFC900524; Lot# R7BN24244) and subjected to heparin 
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Sepharose chromatographic purification (Figure 2.13) The greatest amount of purified 
VEGF165 protein was obtained in elution fractions # 4#7. 
 
Figure 2.13 SDS/PAGE of VEGF165 protein purified by heparin Sepharose® 
chromatography. 20 µL of each fraction collected during the chromatographic 
process, was loaded onto the gel.  Purified fractions pooled together yielded about 1.6 
mg/mL of purified protein. 
 
2.3.7.2.1 Protein Estimation of heparin Sepharose-purified VEGF165 using Bradford 
assay 
 
Post affinity chromatographic purification of VEGF165, the eluted fractions # 4#7 were 
pooled and concentrated using Millipore Amicon ultra#4, with a 30 kDa filter 
membrane (Catalogue# UFC803096; Lot# R7NN14721) and total protein estimated 
using the Bradford’s assay. Table 2.7 tabulates the result of protein estimation in 
purified fractions after heparin Sepharose® purification. 
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Table 2.7 Estimation of Heparin/Sepharose/purified VEGF165 protein 
concentration by Bradford assay. 
 
 
 
 
 
 
2.3.7.2.2 SDS-PAGE of concentrated purified VEGF165 
 
The purified fractions after affinity chromatography (fractions# 4#7) were pooled and 
concentrated using a 30 kDa membrane filter, and run on SDS#PAGE under both non#
reduced and reduced conditions. The expected VEGF165 protein band was observed 
under both conditions (Figures 2.14 & 2.15). 
 
Figure 2.14 SDS/PAGE of purified and concentrated VEGF165 (reduced)    
Fraction# Conc. of VEGF165 
(µg/mL) 
4 439.713 
5 506.699 
6 400.638 
7 218.820 
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Figure 2.15 SDS/PAGE of purified and concentrated VEGF165 (non/reduced)    
Concentration of purified VEGF165 as determined by Bradford assay was 6.09 mg/mL. 
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2.4 Discussion 
 
Sequence of VEGF165 gene cloned in cloning and expression vectors, was confirmed 
by nucleotide sequencing. Firstly, sequencing PCR was set up using sequencing 
primers, followed by sequencing reaction clean#up, as it is important to remove 
unincorporated terminator fluorescent dyes, residual salts, primers, enzymes and 
dNTPs [218]. The excess dyes tend to form dye peaks or “dye blobs” which can 
obscure portions of the sequencing chromatogram or compromise the base calling 
accuracy of sequencing analysis software. The excess salts and other ion#carrying 
molecules tend to compete with the dye#labeled sequencing product for migration into 
capillaries during injection, thus lowering the signal intensity of sequencing data.  
 
After confirmation of gene sequence, transient transfection was carried out in 
HEK293T cells to check for protein expression. HEK293T cell is a highly transfectable 
derivative of human embryonic kidney 293 cell (HEK293) containing the SV40 large 
T#antigen allowing episomal replication of vectors carrying SV40 region of replication 
and early promoter region, thus producing high titers of both cellular and secreted 
proteins [219]. In transient transfection of mammalian cells, the cloned DNA used to 
transfect the host, enters the nucleus of the cells but does not integrate into the 
chromosome. This results in the presence of several copies of the gene leading to high 
expression of the protein. Transcription of the transfected gene is analyzed 24–96 hr 
after introduction of the DNA into the cells. Transient transfection is an important tool 
to study the expression of the recombinant protein of interest, obtain correctly folded 
and glycosylated protein within a short time and study the effects of the protein on the 
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cell. Expression of monomeric (∼22kDa) and dimeric forms of VEGF165 (∼45kDa) was 
observed under reduced and non#reduced condition respectively, using SDS#PAGE gel 
and Western blotting, with supernatants collected from transiently transfected 
HEK293T cells with pEE14.4 mammalian vector containing the gene of interest. 
 
This was followed by stable transfection of the gene in mammalian cell line by 
electroporation. Electroporation is a highly efficient, reproducible and most commonly 
used method of introducing a large quantity of genetic material in the form of plasmid 
DNA into mammalian cells in tissue culture.  When cells are placed in a cuvette 
between two electrodes and a high voltage is applied, due to the generated electric 
field, the integrity of the cell membrane is temporarily disrupted, as pores are formed 
in the membrane within 3 milliseconds of the exposure. These pores increase in size 
up to 120 nm by 20 milliseconds. Within the small window of time of this temporary 
event, the cells can take up plasmid DNA following which the pores reseal [220]. The 
mammalian cells become stably transfected when the foreign genetic material gets 
integrated with the nuclear genome of the host and starts replicating as part of the 
genome. The transfected cells are grown under selection pressure until about ten 
doublings following which individual colonies are picked up and expanded as clones 
(cell lines) through various propagatory phases of cell culture (clone development) and 
finally expressed protein of interest is harvested and purified. Cell line development 
technology used here was Lonza Biologic’s proprietary Glutamine Synthetase (GS) 
system. Glutamine synthetase is an essential enzyme for mammalian cells for the 
synthesis of glutamine, especially in conditions where glutamine is not externally 
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added to the culture media. Since CHO cells have a very active GS enzyme and can 
survive easily in absence of external glutamine, methionine sulfoximine (MSX) is used 
to inhibit endogenous GS enzyme, thus allowing only transfectants having additional 
GS activity to survive. The GS system uses GS as selectable marker permitting 
transfected cells to survive in a glutamine#free media, and GS inhibitor, MSX, as a 
selection drug to enrich clones with high protein productivity [221, 222]. Stable 
transfection of the gene in mammalian CHOK1SV cells lead to generation of 23 stable 
clones which were screened through the various stages of clone development, to arrive 
at the highest VEGF165#yielding clone, P4B9. CHOK1SV culture for this clone from 
roller bottle was harvested and purified by two steps of protein purification, namely, 
ion exchange chromatography and affinity chromatography.  
 
Ion exchange chromatography separates proteins based on net surface charge and is 
ideal for reducing high MW aggregates, charge#variants and residual host cell protein 
and DNA. A strong cation exchanger has a negatively charge resin support across a 
wide pH range and attracts overall positively charged proteins. Isoelectric point (pI) of 
a protein is the pH at which the protein carries no net charge.  If the pH or ionic 
concentration of the mobile phase is adjusted such that the pH is lower than the pI of 
the protein, the protein will have a net positive charge and can be separated by binding 
to a cation exchange chromatographic column.  
 
Hi#Trap SP#XL are strong cation exchangers prepacked with SP (sulphopropyl) 
Sepharose® XL media (having long chains of dextran coupled to a robust, 6% highly 
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cross#linked agarose matrix) used for protein capture using ion–exchange 
chromatography. Using SP sepharose chromatographic separation method, about 2.8 
mg/mL purified protein was obtained which was further purified by heparin#sepharose 
affinity chromatography. The final purified and concentrated VEGF165 protein was 
estimated to be about 6 mg/mL.  
 
The VEGF165 protein was stored at #70°C until further use as a ligand in various in 
vitro studies and binding assay for the key molecule, VEGFR1(D1#D3)#Fc, which has 
a high affinity for this VEGF#A isoform. Development of decoy receptor for VEGF, 
which is VEGFR1(D1#D3)#Fc protein, is discussed in the following chapter (Chapter 
3). 
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Chapter 3: Cloning, Expression and Purification of 
VEGFR1(D1-D3)-Fc fusion protein 
 
Aim: The chapter aims at development of anti#angiogenic molecule, VEGFR1(D1#
D3)#Fc, through cloning, expression and purification of the fusion protein. This section 
deals with generation of the VEGFR1(D1#D3)#Fc fusion gene by PCR, cloning of the 
gene into mammalian expression vector and development of the high yielding clone 
followed by purification of the protein from cell culture supernatant. 
 
3.1 Introduction 
 
The objective of this study was to generate an anti#VEGF decoy receptor belonging to 
the class of Fc#fusion proteins, having the minimal VEGF#binding domains of the 
highest#affinity VEGF receptor. VEGFR1 was selected as the receptor backbone with 
the first three immunoglobulin#like extracellular VEGF#binding domains (D1, D2 and 
D3) of VEGFR1, fused to the Fc (hinge#CH2#CH3) region of human IgG1. Five amino 
acids (EPKSC) from the twelve residues present in IgG1 hinge region were removed, 
in accordance to the construct of commercial VEGF trap, aflibercept. 
 
VEGFR1(D1#D3)#Fc fusion gene was generated by recombinant DNA technology. 
The fusion gene was cloned into mammalian expression vector and then used to 
transfect a mammalian cell line. The protein was expressed and secreted into the 
culture medium from which it was purified. 
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3.2 Materials and Methods  
 
3.2.1 Cloning of VEGFR1(D1-D3)-Fc gene 
 
The VEGFR1(D1#D3)#Fc fusion gene was first generated using PCR techniques from 
clones of VEGFR1 and a monoclonal antibody, pre#existing in our laboratory. From a 
previously cloned VEGFR1 sequence in mammalian expression vector, pEE14.4, the 
VEGFR1 “signal” sequence (26 amino acids) followed by the sequence of the first 
three extracellular domains “D1+D2+D3”, was amplified by PCR primers P#3 and P#
5. A 17 bp sequence from the Fc (CH2) region of a cloned monoclonal antibody 
sequence was added to the VEGFR1 portion as an overhang sequence, using PCR 
primers P#3 and P#8. Similarly, Fc region was generated by amplifying the Fc (CH2#
CH3) of heavy chain of a monoclonal antibody devoid of 15 nucleotides [amino acid 
sequence: EPKSC] of the hinge region. This sequence was derived from the sequence 
of aflibercept/VEGF#TrapR1R2 (Regeneron Pharmaceuticals Inc.). Primers used for this 
amplification were P#6 and P#7. A 17 bp overhang sequence of VEGFR1 (D3) was 
subsequently added to the Fc sequence by PCR, using primers P#9 and P#7. Finally, 
overlap PCR was performed to generate the full length VEGFR1(D1#D3)#Fc fusion 
gene using primers P#3 and P#7. Alternatively, the fusion gene can be generated by 
overlap PCR using primers P#3 and P#15.  
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Flow chart of process of generation of fusion gene: 
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Alternative strategy for generating VEGFR1 (D1/D3)/Fc fusion gene             
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Nucleotide sequence of VEGFR1(D1/D3)/Fc gene (1707 base pairs): 
 
 5’ HindIII site + Kozak + Signal + VEGFR1#Fc + STOP codon + EcoRI site 3’ 
 
AAGCTTGCCGCCACCATGGTCTCTTACTGGGATACCGGAGTGCTGCTGTG
CGCTCTGCTGTCCTGTCTGCTGCTGACTGGTTCCTCAAGTGGTTCCAAACT
GAAAGACCCTGAGCTGTCTCTGAAGGGGACTCAGCACATTATGCAGGCT
GGTCAGACCCTGCATCTGCAGTGCCGCGGGGAGGCAGCTCACAAATGGA
GTCTGCCAGAAATGGTGTCTAAGGAGAGTGAACGTCTGTCAATCACCAA
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ATCCGCATGCGGCAGAAACGGAAAGCAGTTCTGTAGTACTCTGACCCTGA
ACACTGCACAGGCCAATCATACCGGCTTTTACTCATGCAAGTATCTGGCT
GTGCCCACAAGCAAGAAAAAGGAGACTGAATCTGCAATCTACATTTTCAT
CAGTGATACCGGCCGGCCCTTTGTCGAAATGTATTCCGAGATCCCTGAAA
TCATTCACATGACAGAGGGACGCGAACTGGTCATCCCATGTCGAGTCACT
AGCCCCAATATCACAGTGACTCTGAAAAAGTTCCCTCTGGACACTCTGAT
TCCAGATGGCAAACGTATCATTTGGGACTCAAGGAAGGGCTTCATCATTT
CCAACGCCACATACAAAGAGATCGGGCTGCTGACTTGCGAAGCTACCGT
GAACGGTCATCTGTACAAGACAAATTATCTGACTCACAGACAGACCAAT
ACAATCATTGATGTGCAGATTTCCACCCCCAGGCCTGTCAAGCTGCTGAG
AGGCCATACCCTGGTGCTGAACTGTACAGCCACCACACCACTGAATACCC
GCGTCCAGATGACATGGAGCTATCCCGACGAGAAAAACAAGCGAGCATC
TGTGAGGCGGAGAATCGATCAGTCCAACAGCCACGCCAATATTTTCTACT
CCGTCCTGACCATCGACAAGATGCAGAACAAGGATAAGGGACTGTATAC
ATGTCGCGTGCGAAGCGGTCCCTCTTTCAAATCAGTCAATACCTCAGTCC
ACATCTACGACAAGGCATTCATCGACAAAACTCACACATGCCCACCGTGC
CCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAA
ACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGG
TGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGT
GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGG
ACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCT
CCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA
GAACCACAGGTGTACACCCTGCCCCCATCGCGGGATGAGCTGACCAAGA
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ACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATC
GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTC
ACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCG
TGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTG
TCTCCGGGTAAATGAGAATTC 
 
 
Protein sequence of VEGFR1(D1/D3)/Fc (561 amino acids residues) 
 
Green : Signal peptide; Yellow : VEGFR1(D1); Light blue : VEGFR1(D2); Grey : 
VEGFR1(D3); Dark blue : Hinge (without EPKSC) of IgG1; Red : CH2 domain of Fc; 
Pink : CH3 domain of Fc. 
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3.2.1.1 Amplification of individual VEGFR1 and Fc gene fragments from pre-existing clones 
 
VEGFR1 gene cloned in pEE14.4 and Fc gene fragment of antibody cloned in pEE14.4 
(available with Reliance Life Sciences Pvt. Ltd.) were used as templates for 
amplification of the respective gene fragments using PCR.  Proof reading polymerase 
was used for all gene amplifications. [Native Pfu (Catalogue# 600136#81; Lot# 
0660489; Stratagene, San Diego, California, USA)/ Pfu Turbo (Catalogue# 600252#
52; Lot# 0006140547; Agilent, Santa Clara, California, USA)]. All PCR and 
sequencing primers were designed using Vector NTI® software (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). 
 
3.2.1.1.1 VEGFR1 gene amplification from plasmid pEE14.4/VEGFR1  
 
Plasmid pEE14.4 containing VEGFR1 gene, was used as a template to amplify 
VEGFR1 (D1#D3) fragment using primers P#3 and P#5.  
 
Primer sequences: 
P#3 (forward primer): 5’(TAACGGTGGAGGGCAGTGTAGT) 3’ 
P#5 (reverse primer): 5’ (GATGAATGCCTTGTCGTAGATGTG) 3’ 
 
Expected PCR product size: 1146 bp 
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PCR protocol 
Step 1: 95°C, 2 min 
Step 2: 95°C, 30 sec 
Step 3: 60°C, 30 sec 
Step 4: 72°C, 120 sec 
Step 5: Repeat steps 2#4, 29 more times 
Step 6: 72°C, 5 min 
Step 7: 4°C, α 
 
 
PCR master mix 
Component Volume (µL) for 1 
rxn. 
Plasmid (pEE14.4/VEGFR1) 1.0 
10µM Forward Primer (P#3) 1.0 
10µM Reverse Primer (P#5) 1.0 
10 X Pfu rxn. Buffer 
Stratagene; Catalogue# 600153#82; Lot# 0460388 
5.0 
10mM dNTPs (Invitrogen; Catalogue# 46#0578; Lot# 
1190283) 
1.0 
Pfu Turbo DNA pol (2.5U/µL) 
Agilent; Catalogue# 600252#52; Lot# 006110862 
0.2 
Sterile Milli#Q 40.8 
Total volume 50.0 
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3.2.1.1.2 Fc gene amplification from plasmid pEE14.4/monoclonal antibody heavy chain  
 
Plasmid pEE14.4 containing a monoclonal antibody was used as template to amplify 
Fc region using primers P#6 and P#7.  
 
Primer sequences: 
P#6 (forward primer): 5’(GACAAAACTCACACATGCC) 3’ 
P#7 (reverse primer): 5’(CAAATGTGGTATGGCTGA) 3’ 
Expected PCR product size: 719 bp 
PCR master mix 
Component Volume (µL) for 1 rxn. 
Plasmid (pEE14.4/antibody clone) 1.0 
10µM Forward Primer (P#6) 1.0 
10µM Reverse Primer (P#7) 1.0 
10 X Pfu rxn. Buffer 
Stratagene; Catalogue# 600153#82; Lot# 0460388 
5.0 
10mM dNTPs (Invitrogen; Catalogue# 46#0578; Lot# 
1190283) 
1.0 
Pfu Turbo DNA pol (2.5U/µL) 
Agilent; Catalogue# 600252#52; Lot# 006110862 
0.2 
Sterile Milli#Q 40.8 
Total volume 50.0 
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PCR protocol 
Step 1: 95°C, 2 min 
Step 2: 95°C, 30 sec 
Step 3: 53.1°C, 30 sec 
Step 4: 72°C, 80 sec 
Step 5: Repeat steps 2 #4, 29 more times 
Step 6: 72°C, 5 min 
Step 7: 4°C, α 
 
3.2.1.2 Generation of 17 bp overhang sequences in VEGFR1 and Fc gene fragments 
 
3.2.1.2.1 Generation of 17 bp overhang sequence of Fc gene in VEGFR1 
 
Amplified VEGFR1 (1146 bp) fragment was purified from agarose gel using 
QIAquick gel extraction kit and used to amplify a 1163 bp fragment with a 17 bp 
additional  sequence of Fc gene. This Fc overhang generation at the 3’ end of VEGFR1, 
was achieved by using reverse primer P#8 containing the 17 bp sequence from Fc.  
Primers used for amplification were P#3 and P#8.  
Primer sequences: 
P#3 (forward primer): 5’ (TAACGGTGGAGGGCAGTGTAGT) 3’ 
P#8 (reverse primer): 
 5’(CATGTGTGAGTTTTGTCGATGAATGCCTTGTCGTAGATGTG)3’ 
Expected PCR product size: 1163 bp 
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PCR master mix 
Component Volume (µL) 
for 1 rxn. 
1147 bp amplicon from  step 1 (PCR product of P#3/P#5) 0.5 
10µM Forward Primer (P#3) 1.0 
10µM Reverse Primer (P#8) 1.0 
10 X Pfu Native Plus Buffer 5.0 
10mM dNTPs (Invitrogen; Catalogue# 46#0578; Lot# 
1190283) 
1.0 
Pfu Native DNA pol (2.5U/µL) 
Agilent; Catalogue# 600135; Lot# 006110862 
0.4 
Sterile Milli#Q 41.1 
Total volume 50.0 
 
Gradient PCR (58ºC ± 10) was used for gene amplification.  
 
 
 
 
 
 
 
 
Gradient PCR reaction conditions 
95ºC 5 min 1 cycle  
95ºC 30 Sec 
30 cycles 
 
58ºC 30 sec 
Gradient of 
58+10ºC 
72ºC 120 sec  
72ºC 7 min 1 cycle  
15ºC Hold   
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3.2.1.2.2 Generation of overhang 17 bp sequence of VEGFR1 (D3) in Fc gene fragment 
 
Amplified Fc (719 bp) fragment was purified from agarose gel using QIAquick gel 
extraction kit and used to amplify a 736 bp fragment with an additional 17 bp sequence 
of VEGFR1(D3). This 17 bp overhang generation at the 5’ end of Fc was achieved by 
using forward primer P#9 containing the 17 bp VEGFR1 (D3) sequence. Primers used 
for amplification were P#9 and P#7. 
Primer sequences:  
P#9 (forward primer): 
5’(ACGACAAGGCATTCATCGACAAAACTCACACATGCC)3’ 
P#7 (reverse primer): 5’(CAAATGTGGTATGGCTGA) 3’ 
 
PCR master mix 
Component Volume (µL) for 1 rxn. 
719 bp amplicon (gel eluted) 3 
10µM Forward Primer (P#9) 1.0 
10µM Reverse Primer (P#7) 1.0 
10x Cloned Pfu Reaction Buffer; Stratagene; 
Catalog#600153#82; Lot# 1060300 
5.0 
10mM dNTPs (Invitrogen; Catalog# 46#0578; 
Lot#1190283) 
1.0 
Pfu Turbo DNA pol (2.5U/µL) 
Agilent; Catalog# 600252#52; Lot#0006140547 
0.4 
Sterile Milli#Q 38.6 
Total volume 50.0 
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Expected PCR product size: 736 bp. 
Gradient PCR (55ºC ± 10) was used for gene amplification.  
 
 
 
 
 
 
 
3.2.1.3 Purification of PCR products  
 
PCR products were purified from agarose gel using QIAquick Gel Extraction kit 
(Qiagen). After agarose gel electrophoresis, DNA fragments were excised from 
agarose gel with a clean, sharp scalpel. Gel slices were weighed in a colorless tube. 
Three volumes of Buffer QG were added to 1 volume of gel (100 mg ~100 µL). Gel 
pieces were incubated at 50°C for 10 min (or until the gel slices completely dissolved). 
To help dissolve the gel pieces, they were mixed by vortexing the tube every 2–3 min, 
during incubation. On complete dissolution, the color of the mixture became yellow 
(similar to the colour of Buffer QG without dissolved agarose. One gel volume of 
isopropanol was added to the sample and mixed. QIAquick spin column was placed in 
a 2 mL collection tube. To bind DNA, the sample was added to the QIAquick column, 
and centrifuged for 1 min, after which, the flow#through was discarded and the 
Gradient PCR reaction conditions 
95ºC 5 min 1 cycle  
95ºC 30 Sec 
30 cycles 
 
55ºC 30 sec 
Gradient of 
55+10ºC 
72ºC 120 sec  
72ºC 7 min 1 cycle  
15ºC Hold   
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QIAquick column placed back in the same collection tube. 0.5 mL of Buffer QG was 
added to the QIAquick column and centrifuged for an additional 1 min. To wash, 0.75 
mL of Buffer PE was added to the QIAquick column and centrifuged for 1 min. The 
flow#through was discarded and the QIAquick column was centrifuged for an 
additional 1 min at ≥10,000 x g (~13,000 rpm). The QIAquick column was placed into 
a clean 1.5 mL microcentrifuge tube. To elute DNA, 25 µL of Buffer EB (10 mM Tris#
Cl, pH 8.5) or sterile Milli#Q was added to the center of the QIAquick membrane and 
the column was centrifuged for 1 min at maximum speed.  
 
3.2.1.4 Cloning of individual VEGFR1 and Fc fragments with overhang sequences  
 
Cloning of VEGFR1(D1#D3) (1163 bp) and Fc (736 bp) fragments was carried out in 
pCR#Blunt II#TOPO vector (Invitrogen; Catalogue# 45#0031; Lot# 1242746). The 
individual gene fragments containing the overhang regions, were cloned in the vector 
in order to generate sufficient amounts of these fragments via PCR amplification, 
which would be required to generate the overlap fusion gene. Figure 3.1 and Figure 
3.2 give schematic representations of the vector construct and the work#flow of cloning 
PCR fragments into the vector, respectively. Figure 3.3 represents the genes of interest 
ligated to pCR#Blunt II#TOPO cloning vector. 
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Figure 3.1 Schematic representation of pCR/Blunt II/TOPO vector (Invitrogen). 
 
Few characteristic features of pCR/Blunt II/TOPO vector 
1. The vector possesses blunt ends for cloning PCR products amplified with 
proofreading polymerases.  
2. The vector has lethal E.coli ccdB (control of cell death) gene whose product traps 
DNA gyrase. 
3. The ccdB gene is fused to C#terminus end of lacZa gene, and disruption of ccdB#
lacZa gene fusion allows growth of only positive recombinants upon 
transformation. 
4. Cells containing non#recombinant gene, get killed on plating due to expression of 
the ccdB gene. 
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Figure 3.2 Schematic diagram of work flow for cloning PCR fragments into pCR/
Blunt II/TOPO vector and ligation reaction (Invitrogen). 
 
Figure 3.3 Schematic representation of cloning vector containing inserts 
(VEGFR1 or Fc gene fragments). 
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3.2.1.4.1 Cloning of individual PCR fragments in pCR BluntII-TOPO vector  
 
1. Ligation and transformation 
VEGFR1 and Fc gene fragments (4 µL of PCR products containing ∼20#30 ng DNA) 
were individually ligated to pCR Blunt#II TOPO vector (10 ng/µL). A total of 2 µL of 
ligated vector was used to transform E.coli TOP10 competent cells (100 µL). After 
giving heat shock to cells, transformed cells were plated onto LB/Kanamycin (50 
µg/mL) plates and incubated at 37ºC overnight. TOP10 cells were purchased from Life 
Technologies (Carlsbad, California, USA) and were made chemically competent using 
calcium chloride treatment. 
 
2. Selection of positive clones 
Plasmid DNA was isolated from colonies on LB/kanamycin plates. Restriction 
digestion of 2 µg of each plasmid with EcoR1 (NEB; Catalogue# R01015; Lot# 
0321201) was performed to check for release of insert (VEGFR1 or Fc gene fragment). 
Restriction digestion reactions were incubated at 37°C for 2 hr. The positive clones 
which released the insert upon restriction digestion, were subjected to nucleotide 
sequencing to confirm sequence.  
 
Primers used for sequencing of VEGFR1/TOPO clones: 
P#10 (forward primer): 5’(GCAAGCTTGCCGCCACCATG) 3’ 
P#11 (reverse primer): 5’(ACAGTCCCTTATCCTTGTTCTGC) 3’ 
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Primers used for sequencing Fc/TOPO clones: 
P#12 (forward primer): 5’(CCCTGAGGTCAAGTTCAACT)3’ 
P#13 (reverse primer): 
5’(GCGAATTCTCATTTACCCGGAGACAGGGAGAGGCTC) 3’ 
 
3.2.1.4.2 Generation of overlap PCR product using alternate PCR strategy  
 
VEGFR1 (479 bp) fragment was first generated by PCR with primer pairs P#14/ P#8. 
This was followed by overlap PCR#1 with VEGFR1 (479 bp) and Fc (736 bp) using 
primer pairs P#14/ P#15. The resulting amplicon of 1181 bp, was an intermediate fusion 
gene. The final overlap PCR (overlap PCR#2) of gene fragments 1181 bp and 
VEGFR1 (1163 bp) using primer pairs P#3/P#15, resulted in the required VEGFR1(D1#
D3)#Fc full length fusion gene (1865 bp). 
 
Primers used for generating overlap PCR product: 
P#14 (Forward Primer): 5’ (GGCAAACGTATCATTTGGGA) 3’ 
P#8 (Reverse Primer):  
5’ (CATGTGTGAGTTTTGTCGATGAATGCCTTGTCGTAGATGTG) 3’ 
P#15 (Forward Primer): 5’(CAAATGTGGTATGGCTGATTATGAT) 3’ 
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PCR master mix for overlap product 
Components 
Volume (µL) 
for 1 rxn. 
Template 1_VEGFR1#Fc_1181bp fragment (35ng/µL) 1.5 
Template 1_VEGFR1_1163bp fragment (75ng/µL) 0.7 
10X Native Plus Pfu buffer 5 
10 mM dNTP mix 1.5 
10 µM Forward Primer (P#3) 2.5 
10 µM Reverse Primer (P#15) 2.5 
Native Pfu DNA pol (2.5U/µL) 0.5 
Milli#Q water 35.8 
Total 50.0 
 
 
 
 
 
 
PCR protocol 
Step 1: 95°C, 2 min 
Step 2: 95°C, 30 sec 
Step 3: 66°C, 30 sec 
Step 4: 72°C, 80 sec 
Step 5: Repeat steps 2 #4, 29 more times 
Step 6: 72°C, 5 min 
Step 7: 4°C, α 
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3.2.1.4.3 Cloning of overlap PCR product in cloning vector pCR Blunt II-TOPO  
 
1. Ligation and transformation 
The 1.86 kb fusion gene was ligated to Zero Blunt II–TOPO and used to transform 
TOP10 competent cells following earlier protocol. Figure 3.4 shows a schematic 
representation of cloned fusion gene in the TOPO cloning vector.  
 
2. Selection of positive clone  
Plasmid DNA was isolated from colonies obtained on LB/kanamycin (50 µg/mL) 
plates. Restriction digestion of plasmids was performed using EcoR1, followed by 
agarose gel electrophoresis of digested plasmids. 
 
3. Sequencing of positive clone  
The positive clone was confirmed by sequencing of corresponding plasmid DNA using 
a total of 16 pairs of gene#specific and vector#specific primers (P#1, P#2, P#12, P#16, 
P#13, P#17, P#14, P#18, P#19, P#20, P#11, P#6, P#21, P#22, and P#23). The nucleotide 
sequences of these sequencing primers are given in Appendix 1.  
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Figure 3.4 Schematic representation of pCR/Blunt II/TOPO vector containing 
fusion gene. 
 
3.2.1.5 Subcloning of fusion gene in mammalian expression vector pXC17.4 
 
VEGFR1(D1#D3)#Fc fusion gene in cloning vector, was subcloned in expression 
vector in order to drive the synthesis of the desired protein. The cloning vector was 
digested with HindIII and EcoRI restriction enzymes for cloning into expression 
vector, Lonza GS System pXC#17.4 plasmid. The expression vector was similarly 
digested with EcoR1 and HindIII enzymes. The expression plasmid links the 
expression of the desired protein to the glutamine synthetase (GS) gene in CHOK1SV  
cells which  have mutations in both copies of the GS gene, so that, in the absence of 
glutamine, which is an amino acid that is essential for growth, they require the 
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expression of GS on the expression plasmid, for survival. In CHOK1SV#GSKO cell 
lines, both alleles of the endogenous glutamine synthetase gene have been knocked 
out, leading to a dependence on exogenous glutamine. Once the insert was cloned into 
expression vector, individual bacterial colonies were selected based on insert release 
upon restriction digestion with EcoR1 and HindIII, followed by sequence analysis. The 
plasmids were verified for proper nucleotide sequence and correct orientation within 
the plasmid, using appropriate primers. Based on this information, a single clone was 
selected for generation of a sufficient quantity of plasmid for transfection of 
CHOK1SV#GSKO cells. 
 
3.2.1.5.1 Restriction Digestion of insert [VEGFR1(D1-D3)-Fc] and vector [pXC17.4] with 
EcoR1 and HindIII and ligation  
 
Plasmid DNA isolated from positive clone harboring the fusion gene, was digested 
with EcoR1 (NEB; Catalogue# R0101S; Lot# 0331210) and HindIII (NEB; 
Catalogue# R0104S; Lot# 0680901). Similarly, pXC17.4 vector was digested with 
EcoR1 and HindIII restriction enzymes. Reactions were incubated at 37°C for 5 hr and 
analyzed on a 1% agarose gel to check for digested products. The digested fragments 
of interest were purified from gel and quantitated by NanoDropTM 1000 
spectrophotometer as well as gel electrophoresis.  
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3.2.1.5.2 Ligation of VEGFR1(D1-D3)-Fc in pXC17.4 and transformation of competent 
cells 
 
Ligation of the double#digested insert and vector was carried out using T4 DNA ligase 
(5U/µL; NEB; Catalogue# M02025) in 10 X T4 DNA ligase buffer (NEB; Catalogue# 
B0202S; Lot# 1007) and rATP (Stratagene; Catalogue# 211190#56; Lot# 1150178) at 
16ºC overnight. EcoR1 and HindIII digested vector and insert were ligated (in 1:5 
ratio) and used to transform TOP10 competent cells. TOP10 cells were purchased from 
Thermo Fisher Scientific and made chemically competent by calcium chloride 
treatment. Cells were plated on LB/ampicillin plates and plasmid DNA isolated from 
colonies obtained after overnight growth, using in#house protocol. Restriction 
digestion of plasmid DNA using EcoR1 and HindIII was used to check for insert (1.7 
kb fusion gene) release, followed by sequence confirmation. Figure 3.5 schematically 
represents cloned VEGFR1(D1#D3)#Fc fusion gene in expression vector. 
  
Figure 3.5 Schematic representation of expression vector containing 
VEGFR1(D1/D3)/Fc gene. 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
140 
  
3.2.2 Transient Transfection of HEK293T cells with VEGFR1(D1-D3)-Fc gene 
 
HEK293T cells were transiently transfected with non#linearized 
pXC17.4/VEGFR1(D1#D3)#Fc clone#13 plasmid DNA. 4 µg of plasmid DNA was 
used to transfect HEK293T cells using LipofectamineTM2000 (Invitrogen#Life 
Technologies; Catalogue# 11668#027)#mediated transfection protocol. The ratio of 
DNA (in µg): LipofectamineTM 2000 (in µL) while preparing complexes, was fixed at 
1:3. Cells were seeded at density of one million cells in 2 mL of DMEM in each 
experimental well of a 6#well plate. The protocol followed was same as that used for 
transfection of VEGF165 gene (Chapter 2, Section 2.2.5). 
 
3.2.3 Stable Transfection (Electroporation) with VEGFR1(D1-D3)-Fc 
 
Cell details: CHOK1SV GS/KO cells 
Glutamine is a non#essential amino acid which most mammalian cells including CHO 
(Chinese hamster ovary) cells are able to produce using the GS (glutamine synthetase) 
enzyme.  In the absence of endogenous glutamine in cell culture, GS, which 
synthesizes glutamine from glutamate and ammonia, is essential for survival of cells 
in culture. CHOK1SV GS#KO host cell line is a derivative of Lonza’s suspension 
adapted CHOK1SV host cell line, in which both alleles of endogenous glutamine 
synthetase gene have been “knocked out” which makes the cells dependent on 
exogenous glutamine source. Hence only recombinants which have the GS gene in the 
plasmid can survive (positive clones).  
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Passage number of cells on day of electroporation: 4 
Cell viability on day of electroporation: 92% 
Media used: CDCHO without L#glutamine  
 
Electric pulse details  
Electroporator (Bio#Rad; 0.4 cm cuvettes); cell suspension (700 µL) in plain CDCHO 
medium without glutamine + DNA (50 µg) 
Pulse conditions: 298 V, 900 µF Capacitance, Infinite c Resistance; Observed Time 
Constant of 18.6 ms.  
The transfected cells were mixed with CDCHO medium without glutamine and plated 
onto ten 96#well plates for clone selection (100 µL/well). Cells were incubated at 37ºC 
in a 10% CO2 incubator. Clone selection was done by adding 25 µM MSX to each well 
after 24 hr, since MSX acts as an inhibitor of endogenous GS activity in CHO cells. 
 
3.2.4 VEGFR1(D1-D3)-Fc fusion protein analysis 
 
Transformants started appearing in 96#well plates by the end of third week following 
electroporation. The clones were propagated through various stages of cell culture (96#
well plate, 24#well plate, T#25 and T#75 flask). Cell culture supernatants were analyzed 
for expression levels of VEGFR1(D1#D3)#Fc protein at each stage of clone 
development, using ELISA and Western blotting. Clones were transferred to the 
subsequent higher level of propagation, based on their yields, as determined by ELISA. 
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Capture antibody used for detecting the protein was HRP#labeled goat anti#human IgG 
Fc gamma (Jackson; Catalogue# 109#036#098). 
 
3.2.4.1 Comparative ELISA for checking binding affinity of VEGFR1(D1-D3)-Fc 
 
MaxisorpTM micro#titer plate was coated with standard VEGF121 (0.862 mg/mL) at 250 
ng/ 100 µL/well and incubated overnight at 4°C. Blocking was done using 1% BSA in 
1 X PBST at 37°C for 1 hr followed by washing of the wells thrice with 1 X PBST. 
Supernatant samples containing VEGFR1(D1#D3)#Fc were taken as test samples, and 
aflibercept was used as a positive control. Concentrations of test and standard, ranging 
from 200 ng/mL, 100 ng/mL, 50 ng/mL, 25 ng/mL, 12.5 ng/mL, 6.25 ng/mL, 3.125 
ng/mL and 1.56 ng/mL were prepared in 1 X PBS, and added to the plate. The plate 
was incubated at 37°C for 1 hr for binding to VEGF165. For capturing, antibody used 
was peroxidase#affinipure F(ab’)2 fragment goat anti#human IgG Fc gamma antibody 
(Jackson Catalog# 109#036#098) at a dilution of 1:40,000 (1 µL in 40 mL 0.1% BSA 
in 1 x PBST). Incubation with antibody was performed at 37°C for 1 hr. The wells 
were washed thrice with 1 X PBST followed by two washes with 1 X PBS. 
Colorimetric detection was achieved using TMB/H2O2 (Sigma; Catalogue# T0440) 
substrate and reaction stopped with 1N H2SO4. Absorbance was measured at 450 nm 
and 620 nm. 
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 3.2.4.2 Western Blotting for VEGFR1(D1-D3)-Fc Protein 
 
Western blotting for VEGFR1(D1#D3)#Fc protein in culture supernatants of clones, 
was performed following the similar protocol as mentioned in Chapter 2, Section 
2.2.6.2. The capture antibody used for binding to VEGFR1(D1#D3)#Fc protein was 
peroxidase#affinipure F(ab’)2 fragment goat anti#human IgG Fc gamma antibody 
(Jackson Catalog# 109#036#098). A dilution of 1:10,000 in 0.1% TBST) of the 
antibody was incubated with the blot for 2 hr at room temperature with shaking at 20 
rpm. The blot was developed using DAB#Urea. 
 
3.2.5 Proteolysis inhibition assays 
 
As is the case with most recombinant fusion proteins, the expressed VEGFR1(D1#D3)#
Fc was observed to be undergoing cleavage/ proteolysis early on in culture, as evident 
from SDS#PAGE and Western blot data. Hence, it was logical to inhibit this proteolysis 
to the maximum extent possible. Therefore, a few studies were carried out to explore 
the impact of specific parameters. 
 
3.2.5.1 Inhibition of VEGFR1(D1-D3)-Fc degradation using ferric citrate (10.5 X) 
 
VEGFR1(D1#D3)#Fc clones used for this study were pXC17.4/VEGFR1(D1#D3)#
Fc/clones # P11G10 and P8D6. Seeding density of these clones in each of two T#25 
flasks was 2 x 105 cells/mL in 10 mL of CHCHO medium. The concentration of 
inhibitor (ferric citrate; 1000 X from Lonza; Catalogue# BE02#043E) used was 10.5 X 
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and cultures were incubated with the inhibitor at 37°C in a 5% CO2 incubator. 500 µL 
supernatant was collected on days 1, 3, 5, 7 and 10 for checking the cell count, cell 
viability and expression of VEGFR1(D1#D3)#Fc by Western blotting. 
 
3.2.5.2 Inhibition of VEGFR1 (D1-D3)-Fc degradation using ferric citrate (12 X and 120 X) 
and low temperature 
 
VEGFR1(D1#D3)#Fc clone used for this study was pXC17.4/VEGFR1(D1#D3)#
Fc/clone# P8D6. Seeding density in T#175 flasks for the clone was 2 x 105 cells / mL 
in 50 mL of medium. Concentrations of inhibitor (ferric citrate) used were 12 X and 
120 X from 1000 X stock.  Cultures were incubated at 37º C and 30º C under 5% CO2. 
500 µL supernatant was collected on days 1, 2, 4, 7 and 11 for checking cell count, cell 
viability and protein expression by Western Blotting. Cultures were harvested on day 
11 and purified by Protein A chromatographic column.  
 
3.2.5.3 Inhibition of VEGFR1(D1-D3)-Fc degradation at low temperature and early 
harvesting  
 
VEGFR1(D1#D3)#Fc/pXC17.4/CHOK1SV GS#KO clone# P8D6 was used for this 
study with a seeding density of 2 x 105 cells / mL in 50 mL medium in each of seven 
T#175 flasks.  Cultures were incubated at 30ºC and 5% CO2 and harvested on day 6 in 
an attempt to reduce accumulation of proteolytic products, by early harvesting. 
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3.2.5.4 Inhibition of VEGFR1(D1-D3)-Fc degradation with protease inhibitor cocktail and 
low temperature 
 
CHOK1SV GS#KO/P8D6 cultures in T#175 flasks were incubated with protease 
cocktail inhibitor (PIC) (Complete EDTA#free Protease Inhibitor Cocktail Tablets, 
Roche; Product# 11873580001) at 37ºC and 30ºC and 5% CO2.  500 µL of supernatant 
samples were collected on days 2, 5, 8 and 12 for checking cell count, viability and 
VEGFR1(D1#D3)#Fc protein expression. 
 
3.2.5.5 Inhibition of VEGFR1(D1-D3)-Fc degradation using protease inhibitor cocktail and 
ferric citrate at low temperature 
 
Clone pXC17.4/VEGFR1(D1#D3)#Fc/P8D6 was seeded in T#175 flasks with a seeding 
density of  2 x 105 cells / mL in 50 mL of CDCHO. The concentration of ferric citrate 
used was 12 X. Cultures were incubated with PIC at 30ºC and 5% CO2. Supernatants 
were collected on days 1, 5, 7, 9, 12 and 13 for analysis cell count, cell viability and 
expression of VEGFR1(D1#D3)#Fc. 
 
3.2.6 Cloning and expression of a modified protein, VEGFR1(D2-D3*)-Fc 
 
3.2.6.1 Generation of VEGFR1(D2-D3*)-Fc fusion gene 
 
Using an alternative strategy as shown below, fusion gene between VEGFR1(D2+D3) 
and Fc of IgG1 were generated, where the proteolytic site RG in D3 domain of 
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receptor, was replaced. The primer pair P#3 and P#24 was used to amplify the final 
overlap product or fusion gene (1861 bp), using a gradient PCR. 
 
 
Strategy to generate VEGFR1(D2/D3*)/Fc fusion gene: 
“*” denotes amino acid replaced 
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Expected PCR product size: 1886 bp 
 
Gradient PCR (68ºC ± 5) was used for gene amplification. 
 
 
 
 
 
 
 
PCR master mix 
Component Volume (µL) for 1 
rxn. 
Template 1: 576 bp amplicon from step 5 0.31 
Template 2: 1336 bp amplicon from step 6 0.83 
10µM Forward Primer (P#3) 2.5 
10µM Reverse Primer (P#24) 2.5 
10x Cloned Pfu Reaction Buffer; Stratagene; Catalogue# 
600153#82; Lot# 1060300 
5.0 
10mM dNTPs (Invitrogen; Catalogue# 46#0578; Lot# 1190283) 2.0 
Pfu Turbo DNA pol (2.5U/µL) 
Agilent; Catalogue# 600252#52; Lot# 0006140547 
1.0 
Sterile Milli#Q 35.86 
Total volume 50.0 
Gradient PCR reaction conditions 
95ºC 5 min 1 cycle  
95ºC 30 Sec 
30 cycles 
 
68ºC 30 sec 
Gradient of 68 
+ 5ºC 
72ºC 120 sec  
72ºC 5 min 1 cycle  
15ºC hold   
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3.2.6.2 Restriction digestion of insert [VEGFR1(D2-D3*)-Fc] gene and vector (pXC17.4) 
with EcoR1 and HindIII and ligation  
 
Amplified insert DNA (1.886 bp fusion gene product) was digested with EcoR1 (NEB; 
Catalogue# R0101S; Lot# 0331311) and HindIII (NEB; Catalogue# R0104L; Lot# 
0691306). Similarly, pXC17.4 vector was digested with EcoR1 and HindIII restriction 
enzymes. Reactions were incubated at 37°C for 3 hr and analyzed on a 1% agarose gel 
to check for digested products. The digested fragments of interest were purified from 
gel and quantitated by NanoDropTM 1000 spectrophotometer as well as gel 
electrophoresis. Concentration of gel eluted /purified digested insert was 29.4 ng/µL 
whereas that of digested vector was 368.9 ng/µL. 
 
3.2.6.3 Ligation of VEGFR1(D2-D3*)-Fc to pXC17.4 and transformation of competent cells 
 
Ligation of the double#digested insert and vector was carried out using T4 DNA ligase 
(5U/µL; NEB; Catalogue# M02025) in 10 X T4 DNA ligase buffer (NEB; Catalogue# 
B0202S; Lot# 1007) and rATP (Stratagene; Catalogue# 211190#56; Lot# 1150178) at 
16ºC overnight. EcoR1 and HindIII digested vector and insert were ligated (in 1:5 
ratio) and used to transform TOP10F’ competent cells. TOP10F’ cells were purchased 
from Thermo Fisher Scientific and made chemically competent by calcium chloride 
treatment. Following transformation, plasmid DNA was isolated from colonies 
obtained after overnight growth, using an in#house protocol as mentioned earlier. 
Restriction digestion of plasmid DNA using EcoR1 and HindIII was used to check for 
insert (1.4 kb fusion gene) release, followed by sequence confirmation. 
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The presence of the gene of interest was confirmed by sequencing of regions from 
plasmid, using gene#specific primers P#12, P#13, P#5, P#6, P#9, P#25, P#27, P#28, P#21, 
P#23, P#29, P#30 and P#31. Plasmid DNA isolated from the positive clone, was used to 
transiently transfect HEK293T cells. 
Nucleotide sequences of the sequencing primers have been listed in Appendix 1. 
  
3.2.6.4 Transient transfection of HEK293T cells with VEGFR1(D2-D3*)-Fc gene 
 
HEK293T cells were transiently transfected with non#linearized 
pXC17.4/VEGFR1(D2#D3*)#Fc clone#12 plasmid DNA. 4 µg of plasmid DNA was 
used to transfect HEK293T cells using LipofectamineTM2000 (Invitrogen#Life 
Technologies; Catalogue# 11668#027)#mediated transfection. The ratio of DNA (in 
µg): LipofectamineTM 2000 (in µL) while preparing complexes was kept at 1:3. One 
million cells were seeded in 2 mL of DMEM per experimental well in 6#well plate. 
The protocol followed was same as that used for transfection of VEGF165 and 
VEGFR1(D1#D3)#Fc genes. 
 
3.2.7 Purification of VEGFR1(D1-D3)-Fc protein 
 
By virtue of the signal peptide, expressed VEGFR1(D1#D3)#Fc is translocated to 
extracellular environment during cell culture fermentation, and gets accumulated in 
the cell culture medium during entire fermentation process. The cell culture process 
was continuously monitored for cell viability and harvest collected from cell culture 
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fermentation was processed to purify the protein by two chromatographic steps. From 
bioreactor run for batch#1, a total volume of 3.3 liters of harvest at the end of 15 days 
was stored at #20°C and subsequently thawed at 2#8°C for 24 hr and then at room 
temperature for 6 hr prior to purification. Total amount of protein present in day 15 
harvest, as determined by Bradford’s assay, was about 2 gm. Similarly, for harvest at 
the end of eight days, (batch#2) purification was carried out by chromatographic 
techniques. The three steps involved in purification of protein were as follows: 
 
1. Clarification of cell culture supernatant 
The downstream processing of VEGFR1(D1#D3)#Fc was initiated by centrifugation of 
the fermentation harvest for removal of cells and cell debris components. 
Centrifugation was done at 800xg for 15 min. followed by filtration through a 0.22 µm 
membrane filter. Filtered harvest was loaded onto a pre#equilibrated Protein A column.  
 
2. Chromatography step/1 : Protein A affinity  
This step of purification is the capture step for concentrating the protein of interest. 
Protein A, a 42 kDa cell wall protein from bacterium Staphylococcus aureus has a 
strong affinity (Kd=10#7 M) towards the IgG#Fc region [223]. Fc#fusion proteins bind 
to the Protein A column due to this high affinity [224]. Protein A column used for 
purification of batch#1 harvest was XK26 (GE Healthcare) with an internal diameter 
of 26 mm, 13 cm bed height and volume of 70 mL. The chromatography matrix used 
was MabSelect Xtra (GE Healthcare). The column was first regenerated using with 3 
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CV buffer E (1% OPA; pH 1.9) and followed by 3 CV Milli#Q at a flow rate of 
1mL/min. Column was next equilibrated with 3 CV of buffer A (20 mM sodium 
phosphate buffer with 150 mM NaCl pH 7.2; observed conductivity of 16.23 mS/cm) 
at a flow rate of 1.0 mL/min. Clarified harvest was kept on ice and loaded at a flow 
rate of 0.8ml/min. After loading was completed, the column with bound protein was 
washed extensively with the buffer A to remove non#specifically bound impurities 
such as host cell proteins. Column was subsequently washed with buffer B (20 mM 
NaOH, 1M NaCl, 100 ppm Tween 80, pH 7.2; observed conductivity 77.9 mS/cm) and 
buffer C (30 mM orthophosphoric acid, 7 mM NaCl, 100 ppm Tween 80; pH 5.8; 
observed conductivity 2.929 mS/cm) at a flow rate of 0.8 ml/min. Step elution was 
performed to elute bound VEGFR1(D1#D3)#Fc protein using low pH buffer D (30 mM 
sodium phosphate buffer, 7 mM NaCl, 100 ppm polysorbate 80 pH 2.8; observed 
conductivity of 3.19 mS/cm). The elution pool was collected based on 
spectrophotometric reading at A280 at the column outlet. After elution, the column was 
regenerated with buffer E (100 mM of orthophosphoric acid (OPA), pH 1.9; observed 
conductivity of 8.15 mS/cm) and stored in 20% ethanol. The pH of eluted fractions 
was adjusted to 7.0 using 2 M Tris base and stored at #20°C until further purification. 
Elution fractions were concentrated (~10 times) using Amicon®ultra#15, ultracel 50 
kDa filter from Millipore (Massachusetts, USA). SDS#PAGE analysis and Bradford 
assay for total protein was performed with concentrated elution fractions. For 
purification of day 8 harvest from batch#2, the load containing about 440 mg of protein 
was loaded onto a XK50/30 column with internal diameter of 50 mm, height of 12.5 
cm and volume of 280 ml. Chromatographic matrix used was MabSelect Xtra (GE 
Healthcare Life Sciences). 
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3. Chromatography step/2 : Cation exchange  
 
The pH of load (Protein A#purified VEGFR1(D1#D3)#Fc pooled fractions) was 
adjusted to 4.5 before loading onto column. Conductivity of load was observed to be 
3.19 mS/cm. A neutralized pool of elution fraction was loaded onto cation exchange 
column which was in bind and elute mode. The SP Sepharose ion exchange column 
used was XK16/20 (GE Healthcare Biosciences AB, Uppsala, Sweden) with a bed 
volume of 30 mL, internal diameter of 16 mm, height of 15 cm and a binding capacity 
of 5 mg/mL. After loading onto a cation exchange column, the column was washed 
with buffer A (50 mM sodium phosphate buffer pH 4.5; observed conductivity of 3.66 
mS/cm). Bound antibody was eluted using salt gradient of 10 CV between buffer A 
and buffer B (50 mM sodium phosphate buffer, 0.3 M sodium chloride pH 7.0; 
observed conductivity of 34.7 mS/cm) at a flow rate of 3 mL/min. The elution fractions 
were collected based on spectrometric reading A280nm at the column outlet. Samples 
were concentrated and diafiltered with formulation buffer by tangential flow filtration 
operation (TFF) and formulated by adding additional formulation buffer components, 
sucrose and polysorbate 20. Formulated drug substance was filtered through 0.22µ 
syringe filter and stored at #70ºC with proper labeling for long term storage. 
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3.3 Results 
 
 
3.3.1 Agarose gel electrophoresis of amplified gene fragments 
 
PCR amplified gene fragments were run on 1% agarose gels with appropriate MW 
markers to ascertain their correct sizes (Figure 3.6). 
 
3.3.1.1 Amplification of VEGFR1 and Fc gene fragments 
 
Figure 3.6 Agarose gel image of amplified VEGFR1 and Fc fragments from 
cloned VEGFR1 and monoclonal antibody plasmids.  
Both VEGFR1(D1#D3) and Fc fragments were successfully amplified from 
corresponding pEE14.4 plasmids using primer pairs P#3/P#5 and P#6/P#7 respectively. 
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3.3.1.1.1 Electrophoresis of purified PCR products 
 
Purified PCR fragments for VEGFR1 (1146 bp) and Fc (719 bp) were checked by 
running an agarose gel (Figure 3.7). 
 
Figure 3.7 Agarose gel image of purified VEGFR1 and Fc gene fragments.  
 
3.3.1.2 Agarose gel electrophoresis of individual VEGFR1 and Fc fragments with overhang 
sequences 
 
The amplified VEGFR1 and Fc gene fragments containing the corresponding overhang 
sequences, were analyzed by agarose gel (Figures 3.8 & 3.9). 
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Figure 3.8 Agarose gel electrophoresis image of amplified VEGFR1 fragment 
with Fc overhang. Primer pair P#3/P#8 amplified VEGFR1 containing a 17 bp 
overhang of Fc (CH2) using gradient PCR. 
 
 
Figure 3.9 Agarose gel image of amplified Fc fragment with VEGFR1overhang.  
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VEGFR1(D1#D3) with 17 bases overhang portion of Fc region (1163 bp) fragment, 
was successfully amplified by gradient PCR at annealing temperatures of 49.4°C to 
68°C. Similarly, using gradient PCR, the 736 bp Fc (CH2) fragment containing 17 
bases VEGFR1(D3) overhang was amplified with primer pair P#9/P#7. 
  
3.3.1.2.1 Electrophoresis of purified fragments with overhangs 
 
 
The VEGFR1 and Fc gene fragments containing corresponding overhang sequences, 
were purified by gel elution and further analyzed by agarose gel electrophoresis 
(Figures 3.10 & 3.11).   
 
Figure 3.10 Agarose gel image of purified VEGFR1 fragment with Fc overhang. 
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Figure 3.11 Agarose gel image of purified Fc fragment with VEGFR1overhang. 
 
3.3.2 Cloning of VEGFR1 and Fc fragments with overhangs in pCR-Blunt II-TOPO 
vector 
 
Positive clones obtained following transformation were subjected to restriction 
digestion with EcoR1, since the pCR#Blunt II#TOPO vector has two EcoR1 sites 
(Figure 3.1) on either end of the blunt#ended PCR product (insert). Expected 
fragments on EcoR1 digestion of VEGFR1/TOPO clones (3501 bp and 1181 bp), were 
observed in seven clones. Clone#6 was selected for plasmid isolation for gene 
amplification in subsequent steps of fusion gene generation. 
 
Expected fragments on EcoR1 digestion of Fc/TOPO clones, 3501 bp, 713 bp and 41 
bp, were observed in seven clones. Clone#4 was selected for plasmid isolation. The 
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amplified fragment was used for subsequent PCRs to generate the fusion gene (Figure 
3.12). 
 
Figure 3.12 Agarose gel image of restriction digestion of VEGFR1/TOPO/TOP10 
clones and Fc/TOPO/TOP10 clones.  
VEGFR1 and Fc gene fragments in pCR Blunt II#TOPO cloning vector, released gene 
products of expected size, upon digestion with EcoR1, confirming positive clones. An 
antibody gene cloned in the same vector and digested with EcoR1, was used as a 
positive control for the restriction enzyme. 
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3.3.2.1 Generation of VEGFR1 with overhang fragment from TOP10/ TOPO/VEGFR1 
clone#6 
 
Gradient PCR using primer pair P3/P8 was used to amplify VEGFR1 gene fragment 
containing 17 bp overhang sequence of Fc region, from TOP10/TOPO/VEGFR1 
clone#6. The amplified products were analyzed by agarose gel electrophoresis (Figure 
3.13). 
 
 
Figure 3.13 Agarose gel image of amplified VEGFR1 gene fragment from cloned 
plasmid.  
The VEGFR1 fragment with 17 bases overhang of Fc sequence was successfully 
amplified from cloned TOPO plasmid DNA (clone #6) with primer pair P#3/P#8 using 
gradient PCR. 
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3.3.2.2 Generation of Fc with overhang fragment from TOP10/TOPO/Fc clone#4 
 
Gradient PCR using primer pair P9/P15 was used to amplify Fc gene fragment 
containing 17 bp overhang sequence of VEGFR1 region, from TOP10/TOPO/Fc 
clone#4. The amplified products were analyzed by agarose gel electrophoresis (Figure 
3.14). 
 
Figure 3.14 Agarose gel image of amplified Fc gene fragment from cloned 
plasmid. 
The Fc (CH2) fragment containing 17 bases overhang of VEGFR1(D3) region was 
successfully amplified by gradient PCR using primer pair P#9/P#15, from cloned 
TOPO plasmid DNA (clone#4).  
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3.3.2.3 Agarose gel electrophoresis of PCR products at different steps for generating 
VEGFR1 (D1-D3)-Fc fusion gene 
 
VEGFR1(D1#D3)#Fc fusion gene was generated using overlap PCRs as described 
earlier. Amplified gene products after each PCR step, were analyzed on 1% agarose 
gels (Figure 3.15). 
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Figure 3.15 Generation of VEGFR1(D1/D3)/Fc fusion gene. (i) Fragment 
generation. Agarose gel of PCR amplified product with primer pair P#14/P#8 (ii) 
Overlap PCR#1. Agarose gel of overlap PCR #1 products with primer pair P#14/P#15 
(iii) Overlap PCR#2. Agarose gel with overlap PCR #2 products with primer pair P#
3/P#15 (iv) Final purified fusion gene. VEGFR1 (D1#D3)#Fc fusion gene product after 
gel purification. 
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3.3.2.4 Cloning of fusion gene in cloning vector Zero Blunt II-TOPO 
 
Transformed colonies were selected and plasmid DNA was extracted from bacterial 
colonies. The plasmid DNA samples were analyzed by 1% agarose gel electrophoresis 
to confirm the size (Figure 3.16). This was followed by restriction digestion of 
plasmids with EcoR1 enzyme. VEGFR1(D1#D3)#Fc/TOPO/TOP10 clone #14 released 
the expect insert of size 1842 bp (Figure 3.17) The clone was further confirmed to be 
carrying the fusion gene in the correct orientation (Figure 3.18).  
 
 
Figure 3.16 Agarose gel image of plasmid DNA isolated from VEGFR1(D1/D3)/
Fc/TOPO clones. The plasmid DNA of clone#14 was observed to have a MW > 5 kb, 
while the plasmid DNA from other clones without the gene of interest, appeared to be 
running at ~3.5#4.0 kb. The size of empty pCR#Blunt II#TOPO vector was 3.519 kb. 
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Figure 3.17 Agarose gel image of VEGFR1(D1/D3)/Fc/TOPO clones digested with 
EcoR1. Clone#14 was confirmed to be a positive clone carrying gene of interest, since 
it released cloned fragment upon EcoR1 digestion of plasmid DNA. 
3.3.2.4.1 Validation of clone by amplification of plasmid with vector-specific and gene-
specific amplifications  
 
 
Figure 3.18 Agarose gel image showing gene amplification for VEGFR1(D1/D3)/
Fc clone validation. 
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Positive clone#14 was verified for the presence of the fusion gene by amplification of 
VEGFR1(D1#D3) and Fc gene–specific regions from plasmid DNA, using touch#down 
PCRs. VEGFR1(D1#D3)#Fc#specific primers used were P#10/P#20 and P#18/P#21. 
IgG1#Fc specific primers P#12/P#13 were used to amplify the CH2#CH3 region of 
human immunoglobulin heavy chain.  
 
3.3.2.4.2 Sequencing of positive clone with fusion gene 
 
Sequencing of TOPO/VEGFR1(D1#D3)#Fc clone#14 was performed using gene#
specific and vector#specific primers.  
Nucleotide sequence of VEGFR1(D1#D3)–Fc/ TOPO clone#14 showed a match in all 
but one nucleotide (position 450) to the reference sequence. However, the amino acid 
sequence showed 100% match since the mutation (GA) which was in the wobble 
position of the corresponding codon, resulted in the same amino acid (Glu; GAG  
GAA at amino acid position 150). Glycerol stocks of this positive clone were prepared 
and stored at #70°C for future use. 
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3.3.3 Subcloning of fusion gene in pXC17.4 
 
3.3.3.1 Restriction digestion of insert (VEGFR1(D1-D3)-Fc/TOPO clone#14 plasmid DNA) 
and vector (pXC17.4) with EcoR1 and HindIII restriction enzymes  
 
Plasmid DNA (4µg) for VEGFR1(D1#D3)#Fc/TOPO clone#14 and 4 µg of pXC17.4 
vector were digested with EcoR1 and HindIII restriction enzymes. The digested 
products were run on a 1% agarose gel (Figure 3.19). 
 
 
Figure 3.19 Agarose gel image of uncut and digested plasmids.  
Digestion of DNA isolated from TOPO/VEGFR1(D1#D3)#Fc/TOP10 plasmids as well 
as pXC17.4 plasmid, with EcoR1 and HindIII, yielded expected fragments upon 
double digestion. 
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3.3.3.2 Agarose gel electrophoresis of purified and double-digested insert and expression 
vector  
 
Digested insert and vector were purified from agarose gel using QIAquick gel 
extraction kit and analyzed on a 1% agarose gel (Figure 3.20). 
 
Figure 3.20 Agarose gel electrophoresis of purified linearized vector and insert. 
After purification and quantification, the linearized vector and gene of interest, were 
ready for ligation and transformation followed by positive clone selection. 
 
3.3.3.4 Restriction Digestion of pXC17.4/VEGFR1(D1-D3)-Fc/TOP10 clones with EcoR1 
and HindIII 
 
Plasmid DNA isolated from pXC17.4/VEGFR1(D1#D3)#Fc/TOP10 clones, were 
analyzed by agarose gel electrophoresis (Figure 3.21). Expected size (1.7 kb) of fusion 
gene insert was released on restriction digestion of plasmid DNA of 
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pXC17.4/VEGFR1(D1#D3)#Fc/TOP10 clone#13 with EcoR1 and HindIII (Figure 
3.22). 
 
Figure 3.21 Agarose gel image of plasmid DNA isolated from pXC17.4/VEGFR1 
(D1/D3)/Fc clones.  
Clone#13 was observed to be carrying the gene of interest, since it migrated at around 
9 kb. Expected size of VEGFR1(D1#D3)#Fc fragment cloned in pXC17.4 (8.594 kb) 
was observed in case of plasmid DNA isolated from clone#13. 
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Figure 3.22 Agarose gel image of double digested pXC17.4 vector containing 
VEGFR1(D1/D3)/Fc cloned gene to analyze insert release.  
The cloned fusion gene fragment was observed to be released, upon digestion of 
plasmid DNA of clone#13, with EcoR1 and HindIII.  
 
3.3.4 Sequencing of positive pXC17.4/VEGFR1(D1-D3)-Fc clone 
 
Sequencing of DNA prepared from pXC17.4/VEGFR1(D1#D3)#Fc/clone#13, 
confirmed the presence of VEGFR1(D1#D3)#Fc fusion gene. 
Plasmid DNA was isolated from pXC17.4/VEGFR1(D1#D3)#Fc/clone#13 using 
Maxiprep kit (Qiagen; Catalogue# 12162). This was followed by linearization of the 
plasmid using PvuI restriction digestion and ethanol precipitation of the DNA.  
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3.3.5 Transient Transfection of HEK293T with pXC17.4/VEGFR1(D1-D3)-Fc  
 
Presence of VEGFR1(D1#D3)#Fc protein expressed in culture, was detected using 
Western blotting of supernatant samples from transfected HEK293T at different time 
points (Figure 3.23). 
 
 
Figure 3.23 Western Blotting for VEGFR1(D1/D3)/Fc detection in transiently 
transfected supernatants of HEK293T. 
Supernatants of transfected HEK293T cells were collected at various time points 
following transfection (6, 24, 48, 72 and 120 hr) and subjected to Western blotting to 
detect expressed VEGFR1(D1#D3)#Fc protein under reduced conditions. Expected 
protein band of reduced monomeric protein was observed at ∼78 kDa. However, two 
additional bands were also observed at ∼40 kDa and ∼30 kDa, which might be the 
cleaved products of the protein. 
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 3.3.6 Linearization of recombinant plasmid 
 
Plasmid DNA was digested with restriction enzyme PvuI (NEB; Catalogue# R0150L; 
Lot# 36) for linearization. Fragments were analyzed on a 1% agarose gel (Figure 
3.24).   
Figure 3.24 Agarose gel image of DNA of pXC17.4/VEGFR1(D1/D3)/Fc clone#13; 
Uncut and PvuI digested plasmid DNA. 
 
3.3.7 Electroporation of CHOK1SV GS-KO with VEGFR1(D1-D3)-Fc 
 
Mammalian CHOK1SV GS#KO cells were stably transfected by electroporation. 
Recombinant DNA used for electroporation was 50 µg (conc. =712.9 ng/µL; 
volume=70 µL). Transfected cells were plated in ten 96#wells and incubated at 37ºC 
for about three weeks until colonies of transformed clones were visible.  
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3.3.8 VEGFR1(D1-D3)-Fc fusion protein analysis 
 
About 100 colonies of the transfected CHOK1SV GS#KO mammalian cells were 
observed to be growing in the 96#well plates after three weeks of fusion gene transfer 
by electroporation. The level of protein expressed by clones in cell supernatants was 
analyzed by ELISA and Western blotting. 
 
3.3.8.1 ELISA for detection of VEGFR1(D1-D3)-Fc 
 
Thirty five clones were transferred from 96#well plates to 24#well plate based on their 
VEGFR1(D1#D3)#Fc protein expression levels determined by ELISA. Of the 35 
clones, 15 clones were selected for transfer to T#25 stage and further eight of them 
were transferred to T#75 flasks (Figure 3.25). Clone# P6H10, which was the highest 
yielding clone till T#75 stage, was later replaced by the next best clones, P8D6 and 
P8D11, based on Western blot data. These clones were selected for further expansion 
in roller bottles. Cell banks of these clones were also prepared and cells were 
cryopreserved in liquid nitrogen for future use. 
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Figure 3.25 VEGFR1(D1/D3)/Fc protein expression levels by ELISA at different 
stages of clone development.  
Clone# P8D6 was selected as the best clone and subsequently taken forward in all the 
other experiments. 
 
3.3.8.2 Western Blot analysis for VEGFR1(D1-D3)-Fc Protein 
 
VEGFR1(D1#D3)#Fc fusion protein was being expressed by stably transfected 
CHOK1SV GS#KO cells as was evidenced from Western blots. The intact secreted 
glycosylated protein dimer was observed at its expected size of 156 kDa in the non#
reducing Western blot. However, in the reducing blot, along with the monomeric 
protein (78 kDa), another non#specific band was observed at ~40 kDa, which probably 
was a cleaved product. Degradation was observed to be progressively increasing with 
number of days in culture. When clones were growing at 37ºC and 5% CO2, in 24#well 
plates, along with the expected protein of interest, an additional protein band at roughly 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
176 
  
half the size of the intact monomeric protein, appeared under reduced conditions 
(Figures 3.26 & 3.27). When the clones were transferred to T#25 flasks, the amount 
of cleaved protein was almost equal to the amount of intact protein as observed from 
reducing blot (Figure 3.30). Western blot and Coomassie blue staining of the samples 
at T#25 stage under non#reducing conditions, indicate proteolysis (Figures 3.28 & 
3.29). A T#75 flask stage, the amount of cleaved product in culture supernatants was 
more than the amount of intact protein, indicating progressive cleavage of desired 
protein with time in culture, and accumulation of the cleaved product in cell culture 
supernatants (Figure 3.31). 
 
The two highest protein#yielding clones, P8D6 and P8D11 were selected and 
propagated in separate roller bottles in 200 mL CDCHO media. Culture supernatants 
were collected on days 2, 4, 5, 8 and 10 and degradation profile of VEGFR1(D1#D3)#
Fc was assessed by Western blot under reducing condition (Figure 3.32). Of the two 
clones, the degradation profile of clone# P8D11 was unsatisfactory, and hence clone# 
P8D6 was selected for subsequent studies on inhibition of protein degradation in 
culture. Densitometric analysis of protein on Western blots for samples in 24#well 
plate, T#25 and T#75 flasks, revealed progressive degradation of VEGFR1(D1#D3)#Fc 
in culture (Figure 3.33). 
 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
177 
  
 
Figure 3.26 Western Blot for VEGFR1(D1/D3)/Fc at 24/well stage (non/reduced). 
   
 
Figure 3.27 Western Blot for VEGFR1(D1/D3)/Fc at 24/well stage (reduced).   
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Figure 3.28 Western Blot for VEGFR1(D1/D3)/Fc at T/25 stage (non/reduced). 
   
 
Figure 3.29 SDS/PAGE for VEGFR1(D1/D3)/Fc at T/25 stage (non/reduced).  
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Figure 3.30 Western Blot for VEGFR1(D1/D3)/Fc at T/25/well stage (reduced).   
 
 
Figure 3.31 Western Blot for VEGFR1(D1/D3)/Fc at T/75/well stage (reduced).   
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Figure 3.32 Western Blot for VEGFR1(D1/D3)/Fc at roller bottle stage. 
 
 
Figure 3.33 Densitometric analysis of VEGFR1(D1/D3)/Fc protein degradation 
profile at different stages of development of clone P8D6.  
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GelQuant.NET software provided by biochemlabsolutions.com was used for 
quantification of proteins from gel and Western blot bands. Densitometric scanning of 
bands of 78 kDa intact monomeric protein, and cleaved 40 kDa product, from Western 
blots of proteins were performed at 24#well plate, T#25 and T#75 flask stages for clone 
P8D6. Percentage of intact monomer dropped from 81.7% in 24#well plate stage to 
64.16% at T#25 and 35.9% at T#75 stage, whereas the cleaved protein increased from 
18.3% at 24#well stage to 64.1% at T#75. Thus, with an increase in culture volume 
resulting in increased cell numbers, proteolytic enzymes released in the culture media 
tend to accumulate and get carried over to the next stage of propagating culture. 
 
3.3.9 Proteolysis inhibition assays 
 
3.3.9.1 Inhibition of VEGFR1(D1-D3)-Fc degradation using ferric citrate (10.5 X) 
 
Two VEGFR1(D1#D3)#Fc clones, #P8D6 and #2, were cultured in presence and 
absence of ferric citrate (10.5 X) for a period of 7 days, and the supernatants were 
analyzed for protein degradation profile, using Western blots (Figures 3.34 & 3.35). 
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Figure 3.34 Western Blot for VEGFR1(D1/D3)/Fc in presence and absence of 
ferric citrate (10.5 X) under reducing conditions (days 1 and 3).  
For both the clones (#P8D6 and #2), the degree of protein clipping was not very 
different, suggesting that there was only a minor clone to clone variation between 
CHOK1SV GS#KO subclones, with respect to their repertoire of proteolytic enzymes. 
Since both clones were harvested at the same time for these experiments, the duration 
and levels of enzymatic action on them were not very dissimilar, and other factors like 
degree of post#translational modification like glycosylation might be playing a role, in 
the clone to clone product variation. 
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 Figure 3.35 Western Blot and densitometric analysis for VEGFR1(D1/D3)/Fc in 
presence and absence of ferric citrate (10.5 X) under reducing conditions (days 5 
and 7).   
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Partial inhibition of VEGFR1(D1#D3)#Fc protein degradation was observed by 
addition of ferric citrate (10.5 X) in culture as evident from Western blot data under 
reducing conditions (Figure 3.35A). On densitometric analysis of the data, it was 
observed that for clone#P8D6 (Figure 3.35B), the relative amount of degraded protein 
(40 kDa) on day 5 in culture, decreased from 56% to only 4.84% upon addition of 
inhibitor. On day 7, percent degradation dropped from 59.5 to 12.28. In case of clone 
#2 relative amount of degraded protein dropped by about 89% with addition of 
inhibitor on day 5, and by 75% on day 7 in culture (Figure 3.35C).  
 
3.3.9.2 Inhibition of VEGFR1 (D1-D3)-Fc degradation with 12 X and 120 X ferric citrate 
and low temperature. 
 
VEGFR1(D1#D3)#Fc clone #P8D6 was cultured in presence and absence of 12 X and 
120 X ferric citrate, at both 37°C and 30°C, for 11 days, and supernatants at different 
time points were analyzed by Western blotting for difference in degradation profiling 
(Figures 3.36, 3.37 & 3.38). 
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Figure 3.36 Western Blot for VEGFR1(D1/D3)/Fc in presence and absence of 
ferric citrate (12X, 120X); reducing conditions (days 2 and 4) at 37°C.  
 
Densitometric scanning of image revealed that in the absence of inhibitor, the relative 
amount of intact protein present in day 4 culture supernatant was only 21%, whereas 
the presence of 12 X ferric citrate increased amount of intact protein to 77.8%. 
Addition of the highest concentration of ferric citrate (120 X), decreased clipping 
considerably and improved the protein quality with more than 92% of the protein being 
present in its intact form at 37°C. 
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Figure 3.37 Western Blot for VEGFR1 (D1/D3)/Fc in presence and absence of 
ferric citrate (12X, 120X); reducing conditions (days 4, 7 and 11) at 37°C.  
 
It is evident from the Western blot data (Figure 3.37), that although increasing 
inhibitor concentration helps in reduction of protein degradation, beyond a certain 
duration, high concentrations of inhibitor do not have much effect in reducing protein 
clipping in culture. This is probably because, with increase in time in culture, there is 
an increase in cell number. However, there is also increased cell lysis or necrosis 
leading to a surge in secreted proteolytic enzymes which cannot be fully controlled by 
the inhibitor even at high concentrations. 
 
Densitometric analysis of the Western blot image revealed that the ratio of relative 
amounts of unclipped protein (78 kDa) to clipped protein species (40 kDa) on day 11 
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at 37°C without inhibitor was 38:62, suggesting more than 60% protein degradation. 
On the other hand, when cells were cultured in presence of high concentration of ferric 
citrate, the ratio of unclipped to clipped protein improved to 68:33, suggesting 
accumulation of only about 33% degraded/clipped protein in the culture medium, 
indicating almost 50% reduction in proteolysis in the presence of inhibitor at 37°C. 
 
 
Figure 3.38 Western Blot for VEGFR1(D1/D3)/Fc in presence and absence of 
ferric citrate (12X, 120X); reducing conditions (days 4, 7 and 11) at 30°C.  
 
Densitometric scanning of Western blot image (Figure 3.38) demonstrated that at low 
culture temperature of 30°C, ratio of relative amount of intact to clipped protein species 
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was 78:22, in absence of any inhibitor on day 11. However, upon addition of ferric 
citrate (120 X), the ratio almost remained constant (79:21) on day 11, suggesting that 
at longer duration in culture, the effect of low temperature alone is sufficient to reduce 
proteolysis and inhibitor does not have much effect. It was also observed that in a 
shorter culture period (on day 7) and under 30°C, more than 80% of intact protein was 
present in harvest, whereas only 41% of intact protein existed in harvest of culture 
growing at 37°C. 
 
 
Figure 3.39 Western Blot for VEGFR1(D1/D3)/Fc in harvests of cultures grown 
in absence of ferric citrate at 30°C.  
 
From the blot (Figure 3.39), it is evident that even in the absence of any inhibitor, 
lowered culture temperature can play a significant role in reducing proteolytic 
degradation or clipping of recombinant fusion protein. Triplicates of VEGFR1(D1#
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D3)#Fc clone P8D6 culture, grown at 30°C and harvested at an early time point when 
cell viability was >80%, demonstrated the effect of low culture temperature and early 
harvest on proteolysis. If the protein is to be produced in large scale bioreactors of 
mammalian cell culture, then addition of inhibitor in the beginning and removal of it 
at the end of fermentation, would add to the cost of production. Hence culturing cells 
for protein production at lowered temperature of 30°C and without any inhibitor, 
would be cost effective and involve a lower number of steps during downstream 
processing. 
 
3.3.9.3 Inhibition of VEGFR1(D1-D3)-Fc degradation with protease inhibitor cocktail and 
low temperature 
 
Western blots to detect VEGFR1(D1#D3)#Fc in culture supernatants, were performed 
in order to analyze degradation profile of VEGFR1(D1#D3)#Fc, when cultured in 
presence and absence of protease inhibitor cocktail (PIC) at 37°C and 30°C (Figures 
3.40 & 3.41).  
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Figure 3.40 Western Blot (reduced) for VEGFR1(D1/D3)/Fc in presence of 
protease inhibitor cocktail at 37°C and densitometric quantitation of protein. 
 
 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
191 
  
 
 
Figure 3.41 Western Blot (reduced) for VEGFR1(D1/D3)/Fc in the presence of 
protease inhibitor cocktail at 30°C and densitometric quantitation of protein. 
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Controls in the form of conventional production of the Fc#fusion protein, have been 
utilized in the assays to demonstrate the effect of low temperature and protease 
inhibitors. For example, the control, for demonstrating the effect of 30°C as compared 
to conventional temperature of 37°C, can be observed in Figure 3.37, lane numbers 3, 
6 & 9 (culture grown at 37°C without any inhibitor, on day 4, 7 & 11 respectively) as 
compared to Figure 3.38, the same lane numbers (culture grown at 30°C without 
inhibitor for same days). From densitometric analysis of gel bands, we observed that 
as compared to 37°C, culture grown at 30°C without any inhibitor, had an intact protein 
to clipped protein ratio of 100:0 (day 4), 91:9 (day 7) and 88:12 (day 11) as compared 
to a substantial increase in the amount of clipped protein (40:60 on day 4 and 50:50 on 
day 11).  
 
Similarly, for demonstrating the effect of inhibitors, clones were cultured in the 
absence and presence of ferric citrate and protease inhibitor cocktail. Ratio of intact to 
clipped protein in harvest of day 11 culture, grown at 37°C in the absence of ferric 
citrate, was 38:62, which improved to 68:32 upon addition of ferric citrate (Figure 
3.37, lane numbers 6 and 7). Similarly, in day 12 cell culture harvest of VEGFR1(D1#
D3)#Fc clone P8D6, at 37°C in the absence of protease cocktail inhibitor (PIC), the 
intact to clipped protein was observed to be 68:32, which improved to 74:26 in the 
presence of PIC (Figure 3.40B).  At a culture temperature of 30°C, there is a 
synergistic effect of low temperature and protease inhibitors, on protein clipping as 
evident from densitometric analysis of the blot (Figure 3.41B). 
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3.3.9.4 Inhibition of VEGFR1(D1-D3)-Fc degradation with protease inhibitor cocktail and 
ferric citrate at low temperature 
 
Western blots of VEGFR1(D1#D3)#Fc expressing CHOK1SV GS#KO culture 
supernatants, were used to analyze proteolysis patterns of cultures, grown in presence 
and absence of combination of ferric citrate (12 X) and PIC, at both 37°C and 30°C 
(Figures 3.42, 3.43 & 3.44). 
 
Figure 3.42 Western Blot (reduced) for VEGFR1(D1/D3)/Fc in presence of 
protease cocktail inhibitor and ferric citrate on days 1 and 5 at 30°C. 
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Figure 3.43 Western Blot (reduced) for VEGFR1(D1/D3)/Fc in presence of 
protease cocktail inhibitor and ferric citrate at 30°C on days 7 and 9. 
 
Figure 3.44 Western Blot (reduced) for VEGFR1(D1/D3)/Fc in the presence of 
protease cocktail inhibitor and ferric citrate on days 12 and 13 at 30°C. 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
195 
  
Although a combination of ferric citrate and PIC was able to decrease clipping of 
VEGFR1(D1#D3)#Fc in a synergistic manner at a lower culture temperature of 30°C, 
the amount of desired intact protein was reduced. This might be due to decrease in 
growth and productivity of cells under the stress of high concentrations of inhibitors. 
 
3.3.10 Development of VEGFR1(D2-D3*)-Fc protein 
 
3.3.10.1 Generation of VEGFR1(D2-D3*)-Fc fusion gene  
 
VEGFR1 domains D2 and D3 were amplified from pXC17.4/VEGFR1(D2#D3)#Fc 
clone#13, using the primer pair P#3/P#25 (step 1). Next, a 239 bp fragment of VEGFR1 
domain D2 along with signal sequence, was amplified using P#3/P#26 (step 2). In step 
3, primers P#27/P#31 were used to amplify a fragment with signal sequence, D2 and 
D3 sequence ending just before the site of nucleotide modification. In the following 
steps, nucleotide modification (arginine codon AGA to lysine codon AAA) in D3 was 
achieved by site directed mutagenesis using PCR primer pair P#28/P#29 for. IgG1#Fc 
region was amplified along with modified D3 domain with primer pair P#30/P#24 using 
site directed mutagenesis. The final overlap product of 1861 bp was generated by PCR 
using primer pair P#3/P#24 (Figure 3.45). 
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Figure 3.45 Agarose gel image of gel eluted PCR product of VEGFR1(D2/D3*)/
Fc overlap fragment. 
 
3.3.10.2 Restriction digestion of insert [VEGFR1(D2-D3*)-Fc] fusion gene and vector 
(pXC17.4) with EcoR1 and HindIII  
 
The overlap DNA fragment was digested with EcoR1 and HindIII for subsequent 
ligation to EcoR1 and HindIII digested vector pXC17.4 (Figure 3.46).  
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Figure 3.46 Agarose gel image of EcoR1+ HindIII digested VEGFR1(D2/D3*)/Fc 
fusion gene. Digested overlap PCR product, yielded expected DNA of 1.4 kb.  
 
3.3.10.3 Transformation of TOP10F’ with ligated VEGFR1(D2-D3*)-Fc fusion gene 
 
After ligation of EcoR1 and HindIII digested fusion gene and pXC17.4 vector, using 
T4 DNA ligase, E.coli TOP10F’ competent cells were transformed and plasmid DNA 
isolated from colonies obtained by blue#white screening (Figure 3.47). This was 
followed by confirmation of positive clone by insert release of 1.4 kb using EcoR1 and 
HindIII digestion (Figure 3.48). 
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Figure 3.47 Plasmid isolation for pXC17.4/VEGFR1(D2/D3*)/Fc/TOP10F’ 
clones. Plasmid DNA from clone#12 appeared to have expected MW of 8.3 kb 
[pXC17.4 (6.9 kb) with insert (1.4 kb)]. 
 
Figure 3.48 Restriction digestion of pXC17.4/VEGFR1(D2/D3*)/Fc plasmids with 
EcoR1 and HindIII. Digestion of plasmid DNA from pXC17.4/VEGFR1(D2#D3*)#
F/clones #1#5 and clone#12 released the gene fragment with expected size of 1.4 kb. 
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3.3.10.4 Sequencing of pXC17.4/VEGFR1(D2-D3*)-Fc/TOP10F’ clone#12  
 
Nucleotide sequencing of the modified fusion gene confirmed a 100% match with 
theoretical sequence of pXC17.4/VEGFR1(D2#D3*)#Fc.  
After deleting domain D1 of VEGFR1, modifying RG to KA (denoted by “*” in D3) 
and deletion of the EPKSC amino acid residues of the hinge, the total number of amino 
acids in the protein sequence was 459 (1377 nucleotides), a difference of 102 amino 
acids from VEGFR1(D1#D3)#Fc sequence. The amino acid sequence of the new 
molecule, VEGFR1(D2#D3*)#Fc is as follows: 
 
Green : Signal peptide; Light blue : VEGFR1(D2); Grey : VEGFR1(D3); KA: amino 
acid change; Dark blue : Hinge (without EPKSC) of IgG1; Red : CH2 domain of Fc; 
Pink : CH3 domain of Fc 
MW of VEGFR1(D2#D3*)#Fc is 63 kDa which includes 50.49 kDa for MW of 
VEGFR1(D2+D3) and 12.5 kDa accounting for 5 N#linked glycan moieties (two each 
in D2 and D3 and one in CH2 of IgG1#Fc). 
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3.3.10.5 Transient transfection of HEK293T cells with VEGFR1(D2-D3*)-Fc 
 
Transient transfection of cloned VEGFR1(D2#D3*[RGKA])#Fc /pXC17.4 plasmid 
in HEK293T cells was performed. Expression of protein was observed using Western 
blotting of supernatants of transfected cultures at 24 hr, 48 hr and 72 hr (Figure 3.49).  
 
Figure 3.49 Western Blot of VEGFR1(D2/D3*)/Fc in transiently transfected 
HEK293T cell supernatants. 
 
A clipped product of ~35 kDa was clearly observed in addition to the expected 
monomeric protein band at 63 kDa under reduced conditions in Western blotting with 
culture supernatants at different time points post transfection. 
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Thus, modified VEGFR1#Fc protein containing only D2 and D3 domains of VEGFR1 
and a replacement amino acid site (RG to KA) prone to proteolytic cleavage, was 
observed to be undergoing clipping in animal cell culture, as was the case with 
VEGFR1(D1#D3)#Fc protein. Hence, further development of this protein was 
abandoned and the original molecule VEGFR1(D1#D3)#Fc was used for all subsequent 
studies. 
 
3.3.11 Scale-up production of VEGFR1(D1-D3)-Fc protein (batch#1 and 
batch#2) 
 
VEGFR1 (D1#D3)#Fc clone# P8D6 was cultured in a 4 liter capacity bioreactor in fed#
batch mode and harvested on day 15 (batch#1). SDS#PAGE and Western blots were 
used to analyze supernatants for profiling of the expressed fusion protein. 
 
3.3.11.1 SDS-PAGE and Western blotting of bioreactor supernatants (batch#1) 
 
VEGFR1(D1#D3)#Fc expressing clone# P8D6 was cultured in bioreactor for 15 days 
at 30°C, and expression levels of protein were analyzed on different days, using SDS#
PAGE and Western blotting, under non#reducing and reducing conditions (Figure 
3.50). Densitometric analysis of proteins from blots under reducing conditions, was 
performed to assess percentage of protein undergoing clipping (Figure 3.51). 
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Figure 3.50 SDS/PAGE and Western Blots of supernatant samples of bioreactor 
culture (batch#1) on different days (non/reducing and reducing).  
 
Figure 3.51 Densitometric analysis of VEGFR1(D1/D3)/Fc protein from 
bioreactor on different days (reduced blot).  
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From densitometric analysis of protein bands, it was evident that after a period of time 
(between day 8 and 12) the protein clipping process increased, and the cleaved species 
accumulated in culture. Beyond day 13, levels of intact protein started to decrease until 
a point where the ratio of amounts of intact to clipped species was about 70:30. 
 
Due to increased protein clipping observed in VEGFR1(D1#D3)#Fc protein with 
prolonged duration in cell culture (batch#1), another fed#batch mode of fermentation 
was carried out and harvested at an earlier time point (batch#2). SDS#PAGE and 
Western blots were used to analyze supernatant samples of batch#2 culture for 
profiling of expressed protein (Figure 3.52). 
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Figure 3.52 SDS/PAGE and Western Blots of supernatant samples of bioreactor 
culture (batch#2) on different days (non/reducing and reducing).  
Degradation or clipping of VEGFR1(D1#D3)#Fc appeared to be reduced by a 
significant amount in batch#2 harvest as compared to batch#1 harvest, as observed 
from the above figure. 
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3.3.12 Purification of VEGFR1(D1-D3)-Fc protein by chromatography 
techniques 
 
3.3.12.1 Purification of VEGFR1(D1-D3)-Fc by Protein A chromatography 
 
Figure 3.53 shows the chromatogram of Protein A column chromatographic 
purification of VEGFR1(D1#D3)#Fc protein. 
 
Figure 3.53 Protein A chromatogram for VEGFR1(D1/D3)/Fc protein. 
 
Upon purification of VEGFR1(D1#D3)#Fc protein from clarified culture harvest using 
Protein A affinity chromatography, a single elution peak was obtained, which was 
collected as a few fractions. Western blotting where 1 µg of the protein was loaded in 
designated wells showed the presence of the clipped product under reducing conditions 
(Figure 3.55).  However, with increase in the number of days in culture, an increase 
in the clipped species was observed suggesting duration of culture is a very important 
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parameter in terms of protein degradation. When compared to aflibercept, a standard 
Fc#fusion protein of VEGFR, it was observed that the standard too, showed several 
clipped species, as evident from Western blot (Figure 3.60).  
 
3.3.12.1.1 SDS-PAGE of Protein A-purified VEGFR1(D1-D3)-Fc 
 
The elution fractions and flow through collected during purification by Protein A 
column, were loaded onto 10% SDS#PAGE under both reducing and non#reducing 
conditions and stained with Coomassie blue (Figure 3.54).   
 
Figure 3.54 SDS/PAGE of Protein A/purified VEGFR1(D1/D3)/Fc protein. 
(Marker used was ProSieve® unstained protein markers, 5#225 kDa from Lonza). 
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Protein A#purified VEGFR1(D1#D3)#Fc from batch#1 which was harvested on day 15, 
showed presence of considerable amounts of clipped protein species along with the 
intact desired protein. However, protein from batch#2 harvested on day 8, primarily 
comprised the intact protein. Concentration of protein in pooled peak fractions was 
about 1 mg/mL.  
3.3.12.1.2 Western Blotting of Protein A-purified VEGFR1(D1-D3)-Fc 
 
 
Figure 3.55 Western Blots of Protein A/purified VEGFR1(D1/D3)/Fc protein. 
 
3.3.12.2 Purification of protein by cation exchange chromatography (SP Sepharose) 
 
A polishing step of cation exchange chromatography using SP Sepharose column was 
applied to pooled eluted fractions of Protein A#purified VEGFR1(D1#D3)#Fc. Figure 
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3.56 shows the chromatogram for cation exchange chromatography for VEGFR1(D1#
D3)#Fc protein. 
 
Figure 3.56 Chromatogram of VEGFR1(D1/D3)/Fc purification by SP Sepharose 
ion exchange chromatography.  
 
While the protein eluted in a single peak, there was some protein loss in flow#through 
as well as washes with buffer A, in this bind#elute mode of chromatographic 
purification.  
 
3.3.12.2.1 SDS-PAGE of SP Sepharose-purified protein 
 
SDS#PAGE and Western blotting were used to analyze the protein purified by SP 
sepharose chromatography (Figures 3.57 & 3.58). 
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Figure 3.57 SDS/PAGE of SP sepharose/purified VEGFR1(D1/D3)/Fc fractions.  
Fractions collected in the bind#elute mode of chromatography were quantitated for 
their protein load using Bradford’s assay and 2 µg of each fraction was loaded onto 
SDS#PAGE gel. All elution fractions containing protein were pooled and total amount 
of protein in the pooled fraction was determined to be about 100 mg. 
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3.3.12.2.2 Western Blotting of SP sepharose-purified VEGFR1(D1-D3)-Fc 
 
 
Figure 3.58 Western Blots of SP sepharose/purified VEGFR1(D1/D3)/Fc 
fractions.  Densitometric analysis of protein bands in image revealed an average ratio 
of relative amounts of intact to clipped protein to be 92:8 in the eluted fractions # 23 #
31. These fractions were pooled to get the final purified protein. 
 
3.3.13 Formulation of VEGFR1(D1-D3)-Fc protein 
 
The Protein A and SP Sepharose#purified sample was concentrated and buffer 
exchange was performed to finally formulate the buffer in the following formulation 
buffer. 
Formulation buffer composition: 
10 mM sodium phosphate pH 6.2, 40 mM NaCl, 0.03% (w/v) polysorbate 20, 5% (w/v) 
sucrose. 
The buffer had the same composition as aflibercept/Eylea® formulation buffer.  
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3.3.13.1 SDS-PAGE of formulated VEGFR1(D1-D3)-Fc 
 
2 µg of formulated protein was electrophoresed using a 10% polyacrylamide gel under 
both non#reducing as well as reducing conditions (Figure 3.59). 
 
 
Figure 3.59 SDS/PAGE of formulated VEGFR1(D1/D3)/Fc protein.  
      
Aflibercept, commercial VEGF#TrapR1R2, and some other Fc#fusion proteins, were 
found to be existing in their clipped as well as intact forms, similar to Protein A#
purified VEGFR1(D1#D3)#Fc protein, as was evident from SDS#PAGE of these 
purified proteins (Figure 3.60). 
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Figure 3.60 SDS/PAGE of different Fc/fusion proteins.  
 
2 µg of each of the in#house produced Fc#fusion proteins was loaded on a 10% SDS#
PAGE gel under reducing conditions. It was observed that all the Fc#fusions, which 
are recombinantly produced in mammalian CHOK1SV GS#KO cells, underwent 
clipping in culture, albeit to different degrees. 
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3.4 Discussion 
 
Generation of VEGFR1(D1#D3)#Fc fusion gene using multi#step polymerase chain 
reactions, was followed by cloning of the gene in a cloning vector (Zero Blunt II#
TOPO) and subsequently, an expression vector (pXC17.4). Mammalian CHOK1SV 
GS#KO cells were stably transfected with the plasmid and protein expressed 
extracellularly, was purified from the culture supernatant harvest. Since, the protein 
expressed was observed to be clipped/cleaved, with presence of a product of about 40 
kDa, along with the expected 78 kDa monomeric protein, focus was shifted to 
inhibiting proteolysis before proceeding with the future aims. 
 
In an attempt to inhibit proteolytic degradation (clipping) of the VEGFR1(D1#D3)#Fc 
molecule, a modified protein containing only two domains of VEGFR1 (D2 and D3) 
fused to IgG1#Fc, was designed and generated. The D1 domain of VEGFR1 was 
omitted in this protein as inspired by already developed anti#VEGF Fc#fusion traps, 
VEGF#TRAPR1R2 (aflibercept) [93] and VEGF Grab (KAIST, Korea) [206]. Due to 
high positive charge as a result of multiple basic amino acids present in D3 and a high 
pI, the parental molecule Flt#1(1#3)#Fc, had non#specific ECM binding, poor 
pharmacokinetic profile, shorter half#life in circulation, low efficacy and even toxic 
side effects [206]. In order to overcome this inherent property, the D3 domain was 
modified in a way such that, amino acid site containing arginine and glycine (RG) 
considered to be a proteolytic site [225], are replaced by amino acids with similar 
properties, lysine and alanine (KA) respectively. However, even the modified fusion 
protein was observed to be undergoing proteolytic clipping, upon expression in culture. 
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We investigated the effects of different culture parameters like culture temperature, 
culture duration, and chemical inhibitor supplementation, on protease activity in 
CHOK1SV GS#KO culture expressing recombinant Fc#fusion protein, VEGFR1(D1#
D3)#Fc. Proteins produced in bacterial and mammalian host cells by recombinant DNA 
technology, often are fully or partially degraded in culture. This poses a major 
challenge to the biotech industry [226] where efficient and high productivity is 
required at lower costs. Some of the reasons for low levels of production of 
recombinant proteins in mammalian cell culture are, loss of gene expression due to 
structural changes in the recombinant gene, loss of a gene from a plasmid, loss of 
plasmid, instability of plasmid, metabolic pressure on host cells resulting in toxic 
metabolite accumulation, oxygen depletion, inefficient chromosomal integration, 
action of host cell#related proteases, protein aggregation, protein misfolding and 
improper cleavage of signal peptide. Degradation of recombinant proteins in culture is 
a common but serious problem [225, 227]. The most common strategies adopted to 
control proteolysis are media optimization, lowering culture temperature [228],[229, 
230], genetic engineering by mutating known protease sites in gene of interest, 
isolating and analyzing the type of protease secreted by CHO cells and inhibiting 
specifically, use of protease inhibitors and early product harvesting as lysis of non#
viable cells in culture releases proteases which accumulate over time and degrade the 
desired product.  
 
VEGFR1(D1#D3)#Fc protein was expressed in two host cells, HEK293T and 
CHOK1SV GS#KO. Recombinant protein expression levels were checked by Western 
blotting for VEGFR1(D2#D3)#Fc in the cell culture supernatants of transfected 
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cultures. Protein expressed from both mammalian host cell lines, was clipped, as 
detected by Western blots. Hence, host specific cleavage of the recombinant protein 
was not evident from this study. Furthermore, upon checking degradation pattern of 
the same protein in two different CHOK1SV GS#KO clones (clone#P8D6 and 
clone#2), it was observed that the degradation pattern was similar in both clones. 
However, the amount of degradation was varying, which might be dependent on the 
levels of productivity of the clones. This clone to clone variation with respect to the 
susceptibility of expressed proteins to proteases might be because CHO is not a clonal 
cell line due to the dynamic nature of its functional genome and potential to evolve 
[231]. 
 
One way to minimize protease accumulation is to reduce the clumping of cells in 
culture. When clumping or aggregation occurs, the overall surface area exposed to 
available medium is reduced, resulting in reduced growth rate, cell densities, and 
productivity. Also, cells in the centre of a large clump, are more prone to the stress of 
limiting nutrients and toxic build#up, leading to programmed cell death or apoptosis 
followed by lysis and protease release. Iron is essential for cell respiration and 
metabolism and protects cells from oxidative damage. Ferric citrate is a soluble iron 
source for serum#free medium. It has been previously shown to inhibit 
metalloproteases probably by blocking zinc atoms in the catalytic domain of the 
enzymes [232]. Rosenmund et al have also shown that in physiological conditions, 
serine proteases are susceptible to non#transferrin#bound Fe3+ [233]. Upon addition of 
ferric citrate to cell culture at a concentration of 10 X, it was observed that cell count 
and viability for clone P8D6, increased with days in culture at 37°C, as compared to 
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control with no ferric citrate. The addition of protease inhibitor cocktail (serine and 
cysteine proteases inhibitors) to culture, increased cell viability with increased number 
of days in culture, as compared to control without inhibitor (25% vs. 76% on day 12).  
 
It has been already reported that lowering of culture incubation temperature from 37°C 
to 34°C, 33°C, or even 28°C, increases the product quality in terms of reducing 
clipping of protein [234, 235]. At culture temperature of 30°C, although growth of 
cells was suppressed, cell viability remained high for a prolonged period of time. As 
part of validation, a large#scale production of VEGFR1(D1#D3)#Fc was carried out in 
a 4#liter bioreactor in a fed#batch mode. VEGFR1(D1#D3)#Fc producing clone# P8D6 
was cultured in a roller bottle at 37°C until a one#liter inoculum was ready to be seeded 
in a bioreactor containing 4 liters of CDCHO medium. During inoculum preparation 
in roller bottles, ferric citrate (12 X) was added to the culture medium in an attempt to 
have a minimum amount of carry#over clipped species in the bioreactor. No additives 
in the form of protease inhibitors were added to the bioreactor, as it would have 
implications from a regulatory point of view during large scale production. Under fed#
batch mode of culture, the cells were grown in the bioreactor at 30°C for eight days 
and supernatants were analyzed every day using SDS#PAGE and Western blots. 
Reduction in the levels of protein degradation was observed. Since the stability of the 
expressed Fc#fusion protein appeared to decrease with time in culture, the culture was 
harvested at an earlier time point to ensure minimum proteolysis. Protein A 
chromatography of VEGFR1(D1#D3)#Fc from clarified harvest, resulted in purified 
protein which contained clipped species along with the intact protein. The purified 
protein underwent one more round of purification step in the form of ion exchange 
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chromatography, before being formulated. Ion exchange chromatography takes into 
account the unique relationship between the net surface charge of a specific protein 
with many ionizable groups and pH. It is a reversible interaction between a charged 
molecule and molecules of opposite charge in a chromatographic resin, which favors 
binding or elution resulting in separation. For a protein having a basic isoelectric point 
(pI), cation exchange chromatography is the most used ion exchange chromatography 
applied as a polishing step after the Protein A chromatography. Ion exchange 
chromatography is ideal for reducing high MW aggregate, charge#variants, residual 
DNA and host cell protein, leached Protein A and viral particles. The theoretical pI of 
VEGFR1(D1#D3)#Fc is 9.04. Hence a cation exchanger was used to purify the protein 
of interest. Sulphopropyl or SP sepharose, a cation exchanger is based on a highly 
cross#linked, bead formed 6% agarose matrix with sulphopropyl strong cation 
exchange groups. Chromatographic matrix used was SP Sepharose Fast Flow and 
column was XK16/20 from GE Healthcare. Following purification, the protein was 
buffer exchanged to formulation buffer. Formulation buffer used for VEGFR1 (D1#
D3)#Fc protein had similar composition as buffer for commercial aflibercept. Stability 
and physicochemical characterization of this protein, as well as biological activity and 
therapeutic efficacy were determined and discussed in subsequent chapters. 
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Chapter 4: Physicochemical characterization of VEGFR1(D1-
D3)-Fc protein 
 
Aim: The aim of this chapter was physicochemical characterization of purified 
VEGFR1(D1#D3)#Fc protein. This was achieved by performing a host of 
characterization techniques ranging from SDS#polyacrylamide gel electrophoresis and 
Western blotting to RP#HPLC, MS, FS, CD, CE and SEC. The binding affinity of the 
decoy receptor towards its cellular ligand, VEGF165 was also studied using ELISA. 
 
4.1 Introduction 
 
Since therapeutic proteins are complex macromolecules produced by recombinant 
technologies using living systems (mammalian cells in this case), there is a high 
likelihood of chemical/enzymatic modifications, sequence variation generated from 
proteolysis or errors in transcription or translation, post#translational modifications and 
protein degradation, resulting in a heterogeneous mix of molecules. As opposed to 
active ingredients produced synthetically by chemical processes, those produced by 
biotechnological processes are often much more complex with respect to structure, size 
and sensitivity to various cellular degradation pathways. The biological activity of such 
a product (biopharmaceutical) is largely dependent on the conformational and three 
dimensional structure of the molecule, a change in which, may result in drastic changes 
in its functional activity, stability, solubility and toxicity. Hence, a detailed 
characterization of the protein was necessary prior to its use in subsequent assays. 
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4.2 Materials and Methods  
 
4.2.1 Western Blotting 
 
The capture antibody used to detect VEGFR1(D1#D3)#Fc protein was peroxidase#
affinipure F(ab’)2 fragment goat anti#human IgG Fc gamma antibody (Jackson; 
Catalogue# 109#036#098). A dilution of 1:10,000 (in 0.1% TBST) of the antibody was 
incubated with the blot for 2 hr at room temperature with shaking at 20 rpm. The blot 
was developed using DAB#Urea (Sigma; Catalog# D4418), whereby a solution was 
prepared by dissolving a single DAB tablet in 5 mL of distilled water and adding this 
to a 5 mL solution of a single urea tablet in water. The reaction was stopped by pouring 
out the solution and washing the membrane with distilled water to analyze protein 
bands. 
 
4.2.2 SDS-PAGE 
 
In SDS#PAGE, a uniform negative charge coat is imparted by SDS binding to protein 
analytes, which equalizes the charge to mass ratio of all separating investigational 
proteins. The relative mobility of protein is solely dependent on the sieving action of 
the polyacrylamide gel which in turn is proportional to the MWs of the proteins. 
Coomassie blue dye was used to stain the proteins in SDS#PAGE gels. Detailed 
protocol for SDS#PAGE is given in Chapter 2, Section 2.2.6.1. 
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4.2.3 Reverse phase High performance liquid chromatography (RP-HPLC) 
 
 
Figure 4.1 Schematic representation of RP/HPLC work/flow. 
 
RP#HPLC was performed at various stages of product development to assess its quality 
and profile. Work flow of RP#HPLC is represented schematically in Figure 4.1. 
Analysis was carried out with 10 µg of protein on a covalently#bonded analytical 
pentyl#silane (C5) column with dimensions of 150 X 4.6 mm (Discovery Bio Wide, 
Supelco; pore size 250A°; particle size of 5 µm; Catalogue# 568422#U) using mobile 
phase buffer A as 0.1% TFA in water and buffer B as 0.1 % TFA in 90% acetonitrile 
in water. Acetonitrile is the most commonly used organic modifier with trifluoroacetic 
acid (TFA) as the most common ion#pair reagent as buffer. 
Column oven temperature was 60°C, and a flow rate of 1 mL/min was used to resolve 
proteins under non#denaturing condition, and detected by UV detector at 215 nm. The 
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total run time was 35 min. Gradient for elution was kept at 0–100% B in 35 min as 
follows: 
Time (min) 0.01 3.0 22.0 23.0 26.0 27.0 35.0 
% B 35 35 50 100 100 35 35 
% A 65 65 50 0 0 65 65 
 
During fed#batch mode of culture of VEGFR1(D1#D3)#Fc clone#P8D6, culture 
supernatants were analyzed every few days by RP#HPLC to analyze the profile of the 
protein being expressed. Protein fractions from analytical runs with bioreactor 
supernatants or Protein A#purified VEGFR1(D1#D3)#Fc, were concentrated ten times 
using Amicon®ultra#4, ultracel 30k filter before further analysis.  
 
4.2.4 Mass Spectrometry (MS) 
 
Intact mass analysis for VEGFR1(D1#D3)#Fc was performed by MALDI#TOF MS. 
The work flow of MALDI#TOF MS is schematically represented in Figure 4.2. 
Sinapinic acid, a highly laser light absorbing small organic molecule, was used as a 
suitable matrix for diluting the protein. About 10 µg of protein (reduced and non#
reduced) was required for performing intact mass analysis. 
The samples were desalted and buffer exchanged in 50 mM ammonium bicarbonate of 
pH 7.5 by centrifugal ultrafiltration (Amicon ultra#0.5 mL, 10 kDa MW cut off, 
14000g, 15 min, 4°C). Five microliters of 10 mg/mL of sinapinic acid was mixed with 
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5 µL of 1 mg/mL sample. One microliter of the sample was spotted on the plate and 
after drying, the sample was used for MALDI#TOF analysis.   
  
 
Figure 4.2 Schematic representation of MALDI/TOF mass spectrometry. 
Purified VEGFR1(D1#D3)#Fc was subjected to RP#HPLC and all 4 peaks were 
collected separately. The major peak (peak 3), was dried under vacuum and sent to 
Centre for Cellular and Molecular Platforms (C#CAMP), Bangalore, for the intact mass 
analysis using MS. Myoglobin was used for calibration. The samples were analyzed 
on AB SCIEX MALDI#TOF 5800 (AB SCIEX, Framingham, Massachusetts, USA). 
4.2.5 Size Exclusion Chromatography (SEC) 
 
The overall molecular size and the presence of aggregated species were determined by 
size#exclusion HPLC analysis. SEC experiments were performed on a Shimadzu liquid 
chromatography system (LC#2010CHT). 
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The column used was analytical gel filtration chromatographic TSK column 
(Catalogue# 08541; Tosoh#Gel, G#3000 SWXL; Tosoh, Tokyo, Japan), with 
dimensions of 7.8 mm internal diameter; 30 cm length; 5 micron particle size and pore 
size of 250°. A total of 15 ag of protein was injected onto the column. Mobile phase 
used was 20 mM phosphate buffer containing 400 mM sodium chloride, pH 7.0. Flow 
rate was 0.5 mL/min and run time was 35 min with UV detection at 214 nm 
wavelength. 
 
4.2.6 Capillary Electrophoresis-SDS (CE-SDS) 
 
The instrument used for analysis of protein by CE#SDS, was Beckman Coulter CZE 
PA800 Plus (Beckman Coulter, Inc., Brea, California, USA). The instrument was 
equipped with a photodiode array (PDA) detector. A SDS#MW analysis kit used for 
the purpose of analysis contained SDS#MW size standard (10–225 kDa), SDS#MW gel 
buffer (pH 8.0, 0.2% SDS), SDS#MW sample buffer (100 mM Tris#HCl pH 9.0, 1% 
SDS) and internal standard (10 kDa protein). 
 
The signal intensity and resolution of the kit used are sensitive to the salt concentration 
in the protein sample, and the sample loading efficiency is reduced if final salt 
concentration is above 50 mM.  Hence the sample was desalted by adding 1 mL of 
protein sample to a Centricon YM#10, followed by addition of 1 mL SDS#MW sample 
buffer. The tube was centrifuged at 7,000 g for 20 min. Next, 2 mL of sample buffer 
was added and tube centrifuged at 7,000 g for 20 min. The Centricon was inserted 
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upside#down to drain the suspended protein solution (in the filter membrane) into a 
new vial and centrifuged at 5,000 g for 3 min. The collected protein was transferred to 
a sterile tube and sample buffer was added to give a final volume of 1 mL with the 
recommended protein concentration within the range of 0.2#2 mg/mL. Very high 
protein concentration results in insufficient SDS binding, giving broad peaks and poor 
resolution, whereas very low protein concentration gives rise to low signal. Reduction 
of the disulfide bonds provides a more accurate assessment of the MW of a protein, 
and gives additional structural information on a given protein. Hence, the sample was 
diluted with the SDS#MW sample buffer for a total 95 aL volume to give a final protein 
concentration in the range of 0.2 mg/mL to 2 mg/mL. This was followed by addition 
of 2 aL of internal standard and 5 aL of 2#mercaptoethanol. The vial was capped 
tightly, sealed with parafilm and contents were mixed thoroughly. The mixture was 
heated in a water bath at 100°C for 3 min. The vial was placed in a room#temperature 
water bath to cool for 5 min before injection into the system. Comparison of reduced 
versus non#reduced state of a protein also yielded important structural information. 
The protein of interest was alkylated to minimize any heterogeneity created from 
partial auto#reduction of the protein. A 250 mM solution of iodoacetamide (IAM) was 
used as an alkylation reagent. Before electrophoresis, 2 µL of internal standard and 5 
µL of IAM was added to the diluted protein sample which was then mixed and heated 
at 70°C for 3 min.  
After completion of the run, the MW of the protein of interest was obtained from a 
standard calibration curve obtained by plotting migration time of each protein in the 
size standard versus their known MWs. 
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4.2.7 Circular Dichroism (CD) 
 
The instrument used to obtain protein CD spectra was J#710 CD spectropolarimeter 
(Jasco, Oklahoma City, Oklahoma, USA). Protein samples were diluted with 5 mM 
phosphate buffer, pH 7.0. For far UV CD spectra, 5 µM of protein was analyzed. Data 
generation/acquisition parameters included a path length of 1 nm, data pitch of 1 nm, 
bandwidth of 2 nm, response time of 4 sec, and accumulation of 2 at a scanning speed 
of 50 nm/min from 200#260 nm. The raw data was analyzed further to assess the exact 
percentage of secondary structure elements, using web#based software programs. 
 
4.2.8 Fluorescence Spectroscopy (FS) 
 
 
Purified protein was diluted with 5 mM phosphate buffer, pH 7.0. The instrument used 
for FS analysis was FP#8000 spectrofluorometer (Jasco). 10 µM protein was used for 
analysis using a cell path length of 10 mm. The fluorescence spectra was scanned in a 
range of 300#400 nm. Data was acquired at a scan speed of 200 nm/min. 
 
4.2.9 Differential Scanning Calorimetry (DSC)  
 
Malvern MicroCal VP#DSC calorimeter (Malvern Instruments Ltd., Malvern, UK) 
which is a highly sensitive, high throughput and fully automated system, was used for 
analysis of thermodynamic properties of VEGFR1(D1#D3)#Fc protein using DSC. The 
concentration of protein sample used was 1.0 mg/mL in 5 mM phosphate buffer with 
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0.3M NaCl, pH 7.0. The thermal core of the system consisted of a sample cell for 
protein and a reference cell for buffer, inside an insulating jacket, both of which were 
maintained at the same temperature when heated at a constant scan rate. Initially, a 
buffer#buffer run was done followed by a protein#buffer run and final data was 
obtained by subtracting the buffer#buffer scan from protein#buffer scan. Heat is 
absorbed as the protein unfolds, creating a temperature difference (hT) between the 
cells, resulting in a thermal gradient. Protein unfolding (melting), being an 
endothermic process, is observed as a positive displacement in the signal (heat 
capacity). The midpoint of ‘melting’ transition is the Tm which is the temperature at 
which 50% of the protein is in native and 50% is in denatured state, assuming a two#
state transition (Figure 4.3). The area under the curve represents enthalpy (hH) of the 
process, which is the measure of the heat absorbed during the transition. Cp 
represents the change in heat capacities between the folded and unfolded state of the 
protein. During sample run, the temperature was set at 20#130°C.  
 
Figure 4.3 Differential scanning calorimetry (Image taken from website of Malvern 
Instruments Ltd., Malvern, UK).  
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Tm represents transition temperature, Hcal represents calorimetric enthalpy, HvH 
represents van’t Hoff enthalpy and Cp represents heat capacity of the protein. 
 
4.2.10 N-glycan Analysis 
 
Glycosylation profiling of VEGFR1(D1#D3)#Fc was carried out by CZE. There are 
three steps to carry out glycolysis analysis of a protein by CZE: 
1. Release of N#linked oligosaccharides from peptide backbone using 
endoglycosidase enzyme. Peptide N#glycosidase F (Pause F) is the most widely 
used endoglycosidase enzyme which releases the intact glycans as 
glycosylamines which are readily converted to reducing glycans in the 
commonly used phosphate buffer. This enzymatic release of glycans also 
converts asparagine to aspartic acid at the N#glycosylation site of the protein. 
This chemical change and shift in the MW of the deglycosylated peptide is 
often used to determine the glycosylation site using mass spectrometers with 
high mass accuracy and resolution. 
2. Labeling of released glycans with charged fluorophores. The most commonly 
used fluorophore used are negatively charged 8#aminopyrene#1,3,6#
trisulfonate (APTS), 8#aminonapthalene# 1,3,6#trisulfonate (ANTS), or 2#
aminopyridine (2#AP) and 2#aminobenzamide (2#AB) which are net positively 
charged labels. The fluorophores are commonly attached to the reducing end 
of the glycan molecules through reductive amination to permit their detection 
through laser#induced fluorescence (LIF). Since not all N#glycans possess 
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electrical charges, the derivatization procedure introduces ionic groups needed 
for electromigration of neutral glycans. Separation is based on electrophoretic 
mobility and hydrodynamic volume. 
3. Sample analysis using CE with laser#induced fluorescence detector (CZE#LIF). 
The coupling of CE with on#column LIF detector makes the analysis highly 
sensitive. The charged labels used for LIF#labeled carbohydrates provides the 
advantage of picomole sensitivity. 
 
The instrument used for CZE#N#glycan was PA 800 plus Pharmaceutical Analysis 
System from Beckman Coulter. The advantages of using CE for glycoanalysis are that 
the method is fast (few minutes), efficient, automated, very sensitive, requires small 
sample volume (∼10 aL), easy for multiplexing and utilizes different modes of 
separation. 
 
4.2.11 Isoelectric focusing (IEF)  
 
IEF is a technique to determine the isoelectric point (pI) of a protein using SDS#PAGE 
or CE, both of which require electrophoresis of IEF gel. The gel was pre#run with 
ampholyte solution at 2#8°C at 2 watts for 10 min, 4 watts for 10 min, 6 watts for 10 
min and 8 watts for 10 min. The IEF gel was then loaded with 5 µg of protein and IEF 
marker ranging pH 3#10 (Serva; Catalogue# 39212) and ran at 10 watts, 1500 V, 100 
mA for 3 hr at 2#8°C, using a Bio#Rad horizontal isoelectric focusing apparatus. After 
electrophoresis, gel was stained with silver nitrate. Staining was performed by fixing 
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the SDS#PAGE gel in 40% ethanol and 10% acetic acid, followed by sensitizing in 
0.02% sodium thiosulphate and impregnating with 0.1% silver nitrate solution. Gel 
was developed using freshly prepared solution of 3% sodium carbonate and 0.05% 
formaldehyde. 
 
4.2.12 Capillary Isoelectric Focusing (cIEF) 
 
In cIEF, the high resolving power of conventional IEF technique is coupled to the 
advantages of automation and speed. One of the principle differences between IEF in 
a gel and in a capillary is that in cIEF the movement of the focussed proteins past the 
detector has to be carried out in the abasence of an on#line imaging detection system 
[236]. In cIEF, the protein or peptide molecules are separated on the basis of their 
isoelectric point (pI). The standard CE systems facilitates the use of fused silica 
capillaries of 50#70 µm internal diameter. While migrating in the separation channel, 
the analyte ions traverse at different electrophoretic mobilities and separate into zones 
according to their mass to charge ratios. PA 800 Plus Pharmaceutical Analysis System 
from Beckman Coulter was used for determining pI of the protein of interest [237]. 
The analyte(s) (protein of interest) together with a carrier ampholyte, standard pI 
markers and stabilizers are premixed before filling in the capillary. Stabilizers are high 
conducitivity molecules used in order to minimize distortions on the pH gradient at 
both electrodes and sample loss and increase resolution and reproducibility. Electrical 
voltage is applied between two buffer reservoirs placed on either side of the capillary 
containing a strong acid (anolyte) and a strong base (catholoyte), thereby introducing 
hydronium ions from the anolyte and hydroxyl ions from the catholyte, at opposite 
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ends of the capillary. Carrier ampholytes are aliphatic oligo#amino#oligo#carboxylic 
acid molecules of varying length and branching and containing ionizable acidic and 
basic functional groups. Since the ampholyte molecules are very small in size, they 
have high electrophoretic mobilities and move quickly in the capillary channel, and 
with higher number of such molecules, are able to form a smooth pH gradient along 
the length of the channel. In the molecular environment, each amphoteric molecule 
becomes neutral at a pH where its positive and negative charges are balanced (pI). 
After the carrier ampholytes have formed a pH gradient according to their individual 
pIs, mobilization using either pressure, gravity or chemical method enables detection 
of the pI markers and the protein of interest across the detection window. Three pI 
markers (protein or peptide markers of known isoelectric points), close to the pI of the 
protein of interest were used for verification of linearity of pH gradient and  determine 
the unknown pI. The slower moving analyte ions form bands or focus at different 
capillary locations according to their pIs. Detection in cIEF takes place at a wavelength 
of 280 nm since ampholytes have lower UV#absorbance at 280 nm. The carrier 
ampholyte used was Pharmalyte (pH range 8 #10.5) purchased from GE Healthcare 
(Catalog#17#0455#01). Ten microlitres of VEGFR1(D1#D3)#Fc protein (concentration 
of 5#10 mg/ml) was used for analysis by cIEF. 
 
4.2.13 Quantitative estimation of host cell DNA as a cell line derived component 
 
Whenever a recombinant protein is expressed and purified from mammalian cell 
culture, a major challenge is the accurate detection and sensitive quantitation of the 
host cell DNA (CHO cell DNA) contamination in the purification process and drug 
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substance. To ensure safety of the protein produced, host cell DNA contaminants were 
quantitated, using a test based on in vitro amplification of CHO specific region using 
specific probe with the help of commercially available kit from Life Technologies. The 
two components of the kit were: 
1. PrepSEQ™ residual DNA sample preparation kit used for CHO DNA 
extraction from the given protein sample (Catalogue#4413686) 
2. ResDNASEQ™ quantitative CHO DNA kit used for quantitation of CHO 
DNA in the protein sample (Catalogue# 4402085) 
 
For sample preparation (digestion), 100 aL of sample (pH 6#8) was added to 2 mL 
safe#lock round bottom tube (in triplicate). Next, 10 aL 5M NaCl was added to each 
sample followed by the addition of 70 aL Proteinase K mix per 100 aL of each sample. 
The tubes were vortexed briefly and centrifuged followed by incubation at 56°C for 30 
min with intermittent vortexing and quick spin. After digestion, 360 aL lysis solution 
was added per 100 aL sample. To this solution, was added 30 aL of well mixed 
magnetic particles and 300 aL binding solution, inverted tube thrice and vortexed for 
5 min followed by centrifuging at maximum speed for 15 sec. The tube was placed in 
magnetic stand for 5 min before opening it for supernatant removal and addition of 
300 aL wash solution. After centrifugation at maximum speed for 15 sec, the tube was 
placed in a magnetic stand for 2 min before discarding the supernatant and washing, 
as before. After air#drying the pellet, DNA was eluted using 50 al elution buffer, 
followed by heating at 70°C for 7 min and centrifugation at maximum speed for 15 
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sec. 10 µL of DNA was used for analysis by PCR. Quantitation was done by real time 
PCR using CHO specific primers. The real time PCR program was as follows: 
 
TaqMan probe used to increase the specificity, consisted of a short stretch of 
nucleotides which binds to specific DNA sequence, with a fluorophore attached to the 
5’#end of the oligonucleotide and a quencher at the 3’#end. The quencher molecule 
quenched the florescence emitted by the fluorophore when excited by the cycler’s light 
source via Fluorescence Resonance Energy Transfer (FRET).  As long as the 
fluorophore and the quencher were in proximity, quenching inhibited any fluorescence 
signals. Fluorescence detected in the real#time PCR thermal cycler was directly 
proportional to the fluorophore and the amount of DNA template present in the PCR. 
An increase in DNA lead to an increase in fluorescent intensity and was measured at 
each cycle thus allowing DNA concentration to be quantified. Relative concentrations 
of DNA present during the exponential phase of the reaction were determined by 
plotting fluorescence against cycle number on a logarithmic scale whereby 
exponentially increasing quantity gave a straight line graph. A threshold for detection 
of fluorescence above background was determined. The cycle at which the 
fluorescence from the sample crossed the threshold, was called the cycle threshold 
(Ct). Amount of DNA was determined by comparing the results to a linear standard 
  
Enzyme Activation 
 
PCR 
40 Cycles 
 Hold Denature Anneal/extend 
Temp  95°C 95°C 60°C 
Time  10 min 15 sec 1 min 
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curve produced by plotting the Ct for the serial dilutions of a known amount of DNA 
to the concentrations of DNA. Quantification assay was used to quantitate the 
unknown sample by interpolating quantity from the standard curve. The instrument 
used for detection of host cell DNA was 7500 Real Time PCR system (Applied 
Biosystems). 
 
4.2.14 Estimation of free cysteine residues  
 
It is necessary to determine the concentration of reduced cysteine in a purified protein 
due to the reactivity of the amino acid which might lead to protein modification.  
Cysteine plays a major role in intercellular defense mechanism through its thiol 
functional group by preventing oxidative damage caused by reactive oxygen and 
nitrogen species [238]. Cysteine may remain free or form intra or inter#molecular 
disulfide bonds, which can lead to conformational rigidity to a protein or play a role in 
protein misfolding resulting in instability, aggregation and precipitation of protein. 
Cysteine is an amino acid formed by the oxidation of two cysteine molecules that 
covalently link via a disulfide bond. It is a sulfur#containing oxidized dimer form of 
cysteine. However, not all cysteine molecules are involved in disulfide paring. Some 
cysteine molecules may be present as free cysteine as well. The presence of free 
cysteine in a protein can be quantitatively determined by Ellman reaction based 
spectrophotometric method [239]. DNTB or 5, 5’#dithiobis#(#2#nitrobenzoic acid) was 
reduced by sulfhydryl (SH) groups in VEGFR1(D1#D3)#Fc protein to form one mole 
of 2#nitro#5#mercaptobenzoic acid per mole of SH which had an intense yellow color 
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and was measured at 405 nm. Stock solution of 0.01 M DTNB was prepared by 
dissolving 99 mg DTNB in 25 mL methanol. 
 
To approximately 900 µL of 0.5 mg/mL protein sample, was added 300 µL of 1M Tris 
base pH 8.0. To the above solution was added 60 µL of DTNB stock reagent and 
incubated for 20 min. Post incubation, color development in the samples was measured 
at 405 nm. A standard curve was prepared by using different concentrations of cysteine 
hydrochloride ranging from 0.001 mM to 0.01 mM. The number of free cysteine 
residues in VEGFR1(D1#D3)#Fc protein was estimated from the standard curve.  
 
4.2.15 ELISA for determining binding affinity of Protein A-purified VEGFR1(D1-
D3)-Fc to ligands VEGF121 and VEGF165 
 
In order to assess the binding affinity of VEGFR1(D1#D3)#Fc protein to its ligand, 
VEGF, a comparative binding ELISA was performed. Two VEGF isoforms, VEGF165 
and VEGF121, known to have very high affinity for cellular VEGF receptor 1 were used 
in the ligand binding assay. MaxiSorpTM micro#titer plates (Nunc) was coated with 
VEGF165 (conc. 3.3 mg/mL) and VEGF121 (conc. 0.9 mg/mL). Dilutions were prepared 
in 1X PBS at a concentration of 250 ng/100 µL/well. Coating was allowed to take place 
at 4°C overnight, following which plate was washed with 1X PBS (300 µL/well). 
Contents of the plate were flicked off from the plate and 300 µL of 1% BSA in 1X 
PBST was added to each well and blocking allowed for 1 hr at 37°C. During the 
incubation period, dilutions of test sample were prepared in the range of 200 ng/mL to 
1.5 ng/mL in 0.1% BSA/1X PBST (or 0.1% BSA in 0.05% PBST). In a similar manner 
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dilutions of standard (aflibercept) were also prepared. The plate was washed thrice 
with 300 µL/well of wash buffer (0.05% PBST). Standard and test samples were 
subsequently added to respective wells of the plate and the plate was incubated at 37°C 
for 1 hr. After 1 hr, the plate was washed thrice with 0.05% PBST wash buffer. Goat 
anti#human IgG#Fc specific HRP labeled secondary antibody (Jackson; 
Catalogue#109#036#098) at 1:40,000 dilutions (in 0.1% BSA in 1X PBST) was added 
to each well and incubated at 37°C incubator for 1 hr. This was followed by 3 washes 
with 0.05% PBST.  After flicking off contents from last wash, 100 µL of 1X TMB 
substrate was added to each well and the plate was incubated in dark for 30 min. The 
reaction was stopped by addition of 100 µL 1N H2SO4 to each well, and absorbance 
was read in ELISA plate reader at 450 nm and 620 nm. 
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4.3 Results 
 
 
4.3.1 RP-HPLC of purified and formulated VEGFR1(D1-D3)-Fc 
 
RP#HPLC profile of VEGFR1(D1#D3)#Fc protein eluted as two major peaks (3 & 4) 
with two pre#peaks (1 & 2), is represented in Figure 4.4.  
   
 
Figure 4.4 RP/HPLC chromatogram of VEGFR1(D1/D3)/Fc. (A) Black line 
represents RP#HPLC profile of VEGFR1(D1#D3)#Fc before formulation (3 mg/mL); 
red line represents profile of VEGFR1(D1#D3)#Fc after formulation (5 mg/mL). (B) 
VEGFR1(D1#D3)#Fc elutes as four peaks, with two prominent ones (peaks 3 & 4). 
 
Analysis by SDS#PAGE was performed for all the four individual peak fractions eluted 
from an RP#HPLC chromatographic column. Figure 4.5 shows the gel electrophoresis 
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image of all four chromatographic peaks run under non#reducing and reducing 
conditions. 100 µl of purified VEGFR1(D1#D3)#Fc was injected in the column five 
times and peak fractions were collected in each run. The corresponding peaks from all 
runs were pooled, dried under vacuum to a volume of about 200 µl and protein 
quantitated using Bradford assay. SDS#PAGE analysis was carried out with 3 µg of 
protein in each peak fraction. 
      
Figure 4.5 SDS/PAGE of VEGFR1(D1/D3)/Fc protein peaks eluted in RP/HPLC 
chromatography.  
 
From gel electrophoresis, it was observed that peak 3 and peak 4 have almost similar 
mobility profile, whereas pre#peak 2 migrates with slightly less mobility indicating 
higher MW. Protein concentration of pre#peak 2 was also less than that of the peaks 3 
and 4. Pre#peak 1 which showed protein concentration of less than detectable limit 
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appears to be an oxidized form of the protein with less hydrophobicity, and hence 
eluted first. Peak 3 and peak 4 appear to be isoforms of VEGFR1(D1#D3)#Fc. The 
major peak (peak 3) was selected for further analysis by MS to detect intact mass.  
 
4.3.2 Mass spectrometry for VEGFR1(D1-D3)-Fc 
 
External calibration of the system was carried out using myoglobin (MW 16.95 kDa) 
which is a MW marker and a standard calibrant for mass spectroscopy (Figure 4.6). 
MALDI#TOF MS spectra for analysis of intact mass for VEGFR1(D1#D3)#Fc is 
represented in Figure 4.7. 
 
Figure 4.6 Spectra for calibration of MALDI/TOF/TOF using myoglobin.  
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Figure 4.7 MALDI/TOF/TOF MS spectra for intact mass analysis of VEGFR1/
Fc, peak 3. 
 
The MALDI#TOF MS spectrum of protein from peak 3 of VEGFR1(D1#D3)#Fc, 
showed three different charge states of the sample. The mass profile indicated that the 
peak sample had mean mass in the range of 61500 Da to 72500 Da with +2 charge 
state. This implies a mass in the range of 137,000 Da to 143,000 Da. 
The most abundant species with +2 charge state, showed a m/z (mass/charge) value of 
69633.0625, indicating a mass of 139262.125. The second most abundant ionic species 
with +1 charge state had a m/z of 138258.0469, indicating a mass of 138257.0469. The 
least abundant ionic species generated from the molecule had a m/z of 46604.1289, 
thereby a mass of 139803.3867. The actual mass thereby is the average of the mass of 
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the three ionic species, which is 139107.5195. Thus, the most abundant glycosylated 
isoform of the protein showed a mass of 139.1 kDa  
 
The VEGFR1(D1#D3)#Fc is a dimeric protein with MW of approximately 63 kDa 
without glycosylation. The protein has six potential N#linked glycosylation sites each 
in a monomeric chain contributing to another 30 kDa. Assuming glycosylation in all 
the possible sites, the glycosylated molecule will have a mass of 156 kDa. Non#
glycosylated form of the monomer chain has a MW of 126 kDa. Hence, the observed 
mass of the peak sample analyzed by MS (139.1 kDa) implied that the protein was a 
partially glycosylated form of VEGFR1(D1#D3)#Fc. 
 
4.3.3 Size Exclusion Chromatography (SEC) of VEGFR1(D1-D3)-Fc 
 
SEC#HPLC separation technique used for purity profiling of VEGFR1(D1#D3)#Fc, is 
represented in Figure 4.8. 
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Figure 4.8 SEC/HPLC profile for VEGFR1(D1/D3)/Fc protein. 
 
Recombinant proteins produced in mammalian cell culture may contain significant 
levels of dimers and higher order forms or aggregates. Hence, SEC#HPLC was 
performed to determine the various forms of VEGFR1(D1#D3)#Fc present in the 
purified protein which might affect its solubility, stability and immunogenicity. It was 
observed that the 87.22% of VEGFR1(D1#D3)#Fc protein was present in its native 
monomeric form.  A total of 7.78% of high MW species (HMWS) was detected which 
may include higher order forms of the protein such as dimers, polymers, oligomers and 
aggregates. These were eluted first owing to their larger size which made them unable 
to enter the stationary phase pores of the column, and were only able to get into the 
inter#particle space. On the other hand, 5.01% of low MW species (LMWS) which 
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may include fragments, clipped or degraded protein species, was detected by SEC#
HPLC. These LMWS were able to penetrate the stationary phase pore system and 
eluted from the column after the intact monomer had eluted. Hence the purity of the 
protein as determined by SEC was estimated to be over 87%. 
 
4.3.4 Capillary Electrophoresis-SDS (CE-SDS) 
 
SDS gel for size separation of proteins, provides an effective protein sieving range of 
10 kDa to 225 kDa, within which the logarithm of protein molecular mass is linear 
with its reciprocal electrophoretic mobility. This allows for the MW of an unknown 
protein to be estimated from the migration time. However, as a result of glycosylation 
in the protein, owing to expression in mammalian cell line, the observed MW was 
higher than the predicted MW (Figure 4.9). 
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Figure 4.9 CE/SDS separation of VEGFR1(D1/D3)/Fc protein of non/reduced 
and reduced preparation of the sample. 
 
From the plot of absorbance versus migration time for non#reduced VEGFR1(D1#D3)#
Fc, the MW of the protein appeared to be around 150 kDa (theoretical MW of dimer 
is ∼156 kDa), while the MW of reduced protein was observed to be in the range of 90 
– 100 kDa (theoretical MW of monomeric VEGFR1(D1#D3)#Fc is 78 kDa). The data 
clearly showed that glycoproteins behave anomalously, although the discrepancy may 
be attributed to other technical variable factors like capillary dimension, field strength, 
protein concentration and temperature. 
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4.3.5 Circular dichroism (CD) spectroscopy of VEGFR1(D1-D3)-Fc 
 
The far CD spectrum of VEGFR1(D1#D3)#Fc protein is represented in Figure 4.10. 
 
Figure 4.10 CD spectrum of VEGFR1(D1/D3)/Fc.  
 
In the far UV region, CD spectrum can be analyzed to give contents of regular 
secondary structure including α#helix and β#sheets.  The far UV CD spectrum was 
obtained by scanning of wavelength range 200#260 nm. The CD spectrum was 
characterized by a single minima at 218 nm which is a signature of β#sheet structure. 
It is known that proteins with well#defined antiparallel β#sheets have a minimum at 
218 nm and a positive at 195 nm [240]. The spectrum was deconvoluted using BeStSel 
(beta structure selection) online platform (http://bestsel.elte.hu/) [241]. According to 
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this analysis, the predicted α#helix content was 9.5%, while the antiparallel β#sheets 
content was 33% and parallel β#sheets content was 33.5%. No turns were predicted. 
This was in conjunction with the spectral minimum obtained at 218 nm suggesting 
predominant β#sheet content in VEGFR1(D1#D3)#Fc protein.  
 
4.3.6 Fluorescence Spectroscopy (FS) of VEGFR1(D1-D3)-Fc 
 
Fluorescence spectrum of VEGFR1(D1#D3)#Fc is represented in Figure 4.11. 
 
Figure 4.11 Fluorescence spectroscopic data for VEGFR1(D1/D3)/Fc. 
Fluorescence spectra was scanned from 300–400 nm. From spectroscopic data of 
VEGFR1(D1#D3)#Fc, wavelength excitation maximum was shown to be at 330 nm 
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which corresponds to emission maximum of hydrophobic or buried tryptophan. This 
suggested that tryptophan moieties were deeply buried without getting exposed to the 
local environment (solvent, denaturants, surfactants and presence of nearby protonated 
amino acid residues) thus minimizing fluorescence quenching. In other words, the 
fluorescence data indicated stable tertiary structure of the protein as the chromophores 
show strong emission at 330 nm. Overall the fluorescence data indicated intact tertiary 
structure of protein and proper folded conformation. 
 
4.3.7 Differential Scanning Calorimetry (DSC)  
 
A buffer#buffer scan was performed with both cells containing phosphate buffer, to get 
a good baseline, followed by a protein#buffer scan. Scanning was performed at a 
temperature range of 20°C to 130°C (Figure 4.12). 
 
Figure 4.12 DSC plots of VEGFR1(D1/D3)/Fc protein showing buffer/buffer and 
protein/buffer scans. (A) Buffer#Buffer scan (B) Protein#Buffer scan. 
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Final DSC data for protein was obtained by subtracting the buffer#buffer scan from 
protein#buffer scan (Figure 4.13). Since the instrument is very sensitive to any 
differences in the cells including air in either cell, or differences in the volumes loaded, 
data obtained can be unusable. DSC measured thermal transition of protein of interest 
as they are heated and cooled, by comparing the amount of energy required to heat the 
protein, to the amount of energy needed to heat the buffer of the protein at constant 
pressure (Cp). 
 
Figure 4.13 Differential scanning calorimetric plot of VEGFR1(D1/D3)/Fc 
protein. The plot of temperature versus heat capacity of the protein showed two 
melting temperatures for the protein. 
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From the DSC plot, the thermal transition of VEGFR1(D1#D3)#Fc protein appeared to 
be taking place over a broad temperature range of about 10°C. The Tm of the protein 
was found to be at two temperatures; Tm1 at 98.3°C and Tm2 at 107.9°C, indicating a 
non#cooperative transition. This may be due to the presence of more than one domain 
in the protein molecule involving more than one transitions during DSC measurements 
[242]. It is known that the IgG#Fc domain folds separately, independent of its fusion 
partner, in Fc#fusion proteins, thus increasing the solubility and stability of the partner 
in vitro and in vivo [243]. In fact, the two domains of Fc region, CH2 and CH3 have 
different structures and fold independent of each other, with CH3 possessing higher 
stability than CH2 [244]. DSC analysis of Fc by Gordana et al, revealed that CH3 
domain has two non#two state transition temperatures (Tm). The first Tm at 77.8°C is 
believed to be due to melting of CH3 dimer while the second Tm at 82.6°C represents 
denaturation of the CH3 domains. When partnered with another protein as in 
recombinant protein, the IgG1#Fc domains are stabilized and hence overall melting 
temperature increases as indicated by the elevated Tm. 
 
4.3.8 N-Glycan Analysis 
 
N#Glycan profiling for VEGFR1(D1#D3)#Fc fusion protein is represented in Figure 
4.14. 
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Figure 4.14 Electropherogram of released N/glycan structures of VEGFR1(D1/
D3)/Fc. 
Capillary zone electrophoresis profiles of N#glycans on VEGFR1(D1#D3)#Fc protein 
were obtained using an LIF detector. The samples were reduced and decarboxy 
methylated, following which the reduced and decarboxy methylated samples were 
further digested with N#glycosidase F enzyme. The released N#glycans were then 
fluorescent labeled using APTS derivatization procedure and tested on CZE system by 
using fluorescent LIF detector [245]. Results of glyco#analysis for VEGFR1(D1#D3)#
Fc protein are tabulated in Table 4.1. 
From available primary amino acid sequences of human VEGFR1 and IgG1# Fc (CH2#
CH3), presence of six sites for N#glycan attachment, can be predicted for 
VEGFR1(D1#D3)#Fc at the following amino acid positions: 
VEGFR1(D1) # Position [32#123]: Glycosylation site: 100 
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VEGFR1(D2) – Position [151#214]: Glycosylation sites: 164, 196 
VEGFR1(D3) # Position [230#327]: Glycosylation sites: 251, 323 
CH2 of IgG1#Fc : Glycosylation site: 180 
 
Table 4.1 Results of glyco/analysis for VEGFR1(D1/D3)/Fc. 
 
 
The extent of N#linked glycans present in VEGFR1(D1#D3)#Fc protein was estimated 
according to the abundance of each species in the spectra. In the protein, the major 
glycan forms present are G2FS1, G0F, Man5, G1F(1, 6), G1F(1, 3), G2F and four 
unidentified minor peaks, which were resolved in less than 11 minutes (Figure 4.15). 
N/Glycan analysis of VEGFR1(D1/D3)/Fc 
Peak No. Glycan Structure Migration Time Area Percent 
Peak 1 Unidentified 8.233 4.09 
Peak 2 Unidentified 8.537 6.38 
Peak 3 Man5 8.621 9.89 
Peak 4 G2FS1 8.917 30.33 
Peak 5 G0F 9.262 29.81 
Peak 6 Unidentified 9.542 0.80 
Peak 7 G1F (1,6) 9.787 8.82 
Peak 8 G1F (1,3) 9.950 4.46 
Peak 9 Unidentified 10.179 0.89 
Peak 10 G2F 10.463 4.52 
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From UniProt knowledgebase of protein sequence data, the non#IgG fusion part of 
VEGFR1(D1#D3)#Fc protein is predicted to carry five N#linked glycosylation sites. 
The N#glycan with terminal fucose 
 (G0F) content of the protein was found to be 29.81%, whereas more than 30% was in 
the form of sialated N#glycan (G2FS1). 
 
 
Figure 4.15 Structures of various biantennary oligosaccharides present in 
VEGFR1(D1/D3)/Fc. 
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Man5: Mannose 5 
G2FS1: Monosialylate, galactosylated, biantennary complex, core substituted with 
fucose 
G0F: Asialo, agalacto, biantennary complex, core substituted with fucose 
G1F (1, 6): Asialo, mono#galactosylated, biantennary complex, core substituted with 
fucose 
G1F (1, 3): Asialo, mono#galactosylated, biantennary complex, core substituted with 
fucose 
G2F: Asialo, galactosylated, biantennary complex, core substituted with fucose 
 
Glycosylation patterns of Fc#fusion proteins largely depend on the production 
platform, expression host, fermentation condition and purification steps involved. 
Even the local protein structure can affect the structure of the glycans [246]. The 
glycosylation profile of the protein influences it’s in vitro and in vivo efficacy by 
impacting its pharmacokinetics and pharmacodynamics properties [247]. Recombinant 
proteins produced in CHO cells primarily contain biantennary fucosylated neutral 
glycans containing variable levels of terminal galactose including G0F, G1F and G2F, 
where G refers to the number of galactose residues and F refers to fucosylation of the 
initial N#acetyl glucosamine (GlcNAc) residue and some high#mannose (Man5–Man9) 
structures at the Fc site [248], [249]. Fc#fusion proteins have more complex N#glycan 
structures than MAbs, with higher mannose and sialic acid content, as is evident from 
the glycan profile of VEGFR1(D1#D3)#Fc protein. N#glycosylation in protein is 
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responsible for Fc structure stabilization as well as remarkable heterogeneity of 
glycated isoforms [250], which is evident in the profiling of VEGFR1(D1#D3)#Fc 
protein by cIEF. Sialic acid content of fusion protein, which modulates the 
pharmacokinetics and was found to be about 30%. Higher levels of sialic acid correlate 
with increased serum half#life of the protein [251]. 
 
4.3.9 Isoelectric Focusing (IEF) 
 
 
Figure 4.16 IEF gel for determination of pI of VEGFR1(D1/D3)/Fc.  
 
VEGFR1(D1#D3)#Fc protein was analyzed by isoelectric focusing#polyacrylamide gel 
electrophoresis (IEF#PAGE) in a carrier ampholyte#based gel with a pH gradient of 3#
10 (Figure 4.16, lanes 1&2). The band of the protein was observed to be located in the 
range between pH 8.3 and 9.5 as marked by the molecular standard marker (lane#M in 
Figure 4.16). In each of lanes #1 and #2, 5 µg of VEGFR1(D1#D3)#Fc protein was 
loaded and detection was achieved by silver staining of the gel. The pI of VEGFR1(D1#
D3)#Fc protein appeared to be in the range of 8.3 and 9.5. Predicted pI of VEGFR1(D1#
D3)#Fc from online computational tool, ExPASy, using UniProt reference seqeunce, 
was 9.04. 
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4.3.10 Capillary Isoelectric Focusing (cIEF) 
 
 
Figure 4.17 cIEF profile of VEGFR1(D1/D3)/Fc protein. 
CE is extensively used to measure the pI of a protein with high resolution as well as 
linearity over a broad pH range. Observed pI of the protein using cIEF was found to 
be in the range of 8.2#9.4. The protein was resolved according to the range of protein 
sizes of the pI markers (7.0 and 10.0). Pharmalyte carrier ampholytes in the pH range 
of 8#10.5 formed a stable linear pH gradient with an even conductivity across the gel. 
VEGFR1(D1#D3)#Fc did not exhibit a single peak of a particular pI value, instead it 
presented as multiple peaks in the range between pH 8.2–9.4. (Figure 4.17). This may 
be attributed to the various isoforms or the cleaved species present along with the 
sample. The sample analyzed by cIEF was about 88% pure as determined by SEC. The 
protein on analysis by IEF gel was observed to have a pI in the range of 8.3–9.5. As 
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observed earlier from N#glycan profiling, the protein exhibited several isoforms as a 
result of glycosylation at six potential N#linked glycosylation sites. As opposed to IEF 
gel, cIEF by virtue of its high resolution, was able to separate and resolve the different 
glycoforms of the protein.  
 
4.3.11 Host cell DNA estimation 
 
Host cell DNA contaminants are major process#related impurities during production 
of recombinant therapeutic proteins. Since these pose a major risk of infection and 
oncogenicity, they must be accurately evaluated and their quantity kept as low as the 
safety limit suggested by regulatory authorities like FDA, EU and WHO. Table 4.2 
gives the results of host cell DNA estimation for VEGFR1(D1#D3)#Fc protein.  
 
Table 4.2. Estimation of host cell DNA in VEGFR1(D1/D3)/Fc protein. 
Sample 
Host cell DNA (picogram/mg) 
(Limits: Not more than 20 pg/mg) 
VEGFR1(D1#D3)#Fc 
1 mg/mL 
1.5 pg/mg 
  
Genomic DNA was extracted from 100 µL of a 1 mg/mL protein solution of 
VEGFR1(D1#D3)#Fc. Upon spiking with 30 pg of a standard CHO genomic DNA, 
recovery was 83.3%. Ct value was undetected and the amount of the host cell DNA 
present in 1 mg of protein was 1.5 pg. 
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Residual host cell DNA was determined and observed to be less than 20 pg/mg in the 
sample, which was well within acceptable limits given by WHO guidelines. According 
to FDA, the safety limit of presence of impurities such as host cell DNA is less than 
100 pg of DNA per milligram of protein [252]. 
 
4.3.12 Estimation of free cysteine residues  
 
Protein bound free thiol (SH#, sulfhydryl) groups were assayed by quantitative titration 
with Ellman’s reagent (DTNB). This method takes advantage of the redox potential of 
the SH group as well as a colorimetric reagent which turns yellow upon reaction with 
the SH group [DTNB + SH ###> 2#nitro#5#thiobenzoic acid (yellow)]. A standard plot 
was generated using known concentrations of cysteine, which is a reactive sulfhydryl 
compound, and then the amount of free cysteine determined for a protein solution was 
compared to the known protein concentration. 
Figure 4.18 displays the standard curve plotted with different concentrations of 
cysteine hydrochloride in mM range, versus absorbance at 405 nm. 
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Figure 4.18 Standard curve obtained with Cysteine HCl. 
 
A total of 0.5 mg/ml of VEGFR1(D1#D3)#Fc protein sample (corresponding to 
0.003203 mM) was analyzed for free thiol group (SH) estimation by Ellman’s assay. 
MW of VEGFR1(D1#D3)#Fc, non#reduced and fully glycosylated dimer is 156124.4 
g/mole. Average absorbance of the protein at 405 nm upon reaction with DTNB was 
observed to be 0.012. From the standard plot, the number of moles of cysteine per mole 
of the protein was estimated to be 0.01. 
 Table 4.3 Results for free cysteine determination in VEGFR1(D1/D3)/Fc. 
Sample 
Average 
OD405nm Cysteine conc 
(mM) 
Protein conc. 
(mM) 
Number of moles of 
Cysteine per mole 
of protein 
VEGFR1(D1/
D3)/Fc 
0.012 0.00004 
 
0.003203 
 
0.01 
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Table 4.3 tabulates results of the analysis which indicated that VEGFR1(D1#D3)#Fc 
had negligible number of free cysteine residues in the molecule. All the cysteines in 
the Fc#fusion protein appeared to be paired to form disulfide bonds. From UniProt 
protein sequence database, theoretical number of disulfide linkages in VEGFR1(D1#
D3)#Fc is six, with three in the VEGFR domains and three in Fc region, at the following 
amino acid positions: 
1. Linkage between 53#107 
2. Linkage between 158#207 
3. Linkage between 252#311 
4. Linkage between 340#343 
5. Linkage between 375#435 
6. Linkage between 481#539 
 
Amino acid sequence of VEGFR1(D1#D3)#Fc showing position of intramolecular 
disulfide linkages: 
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4.3.13 ELISA for determining binding affinity of Protein A-purified VEGFR1(D1-
D3)-Fc to ligands VEGF121 and VEGF165 
 
A ligand#binding assay relies on the affinity of binding of ligand to the decoy receptor. 
Ligand for VEGFR1(D1#D3)#Fc is a VEGF#A isoform. This assays provides a measure 
of interaction between ligand and its receptor as well as the strength or affinity of 
binding, as compared to a known high#affinity receptor#ligand interaction. Results of 
ELISA for determining binding affinity of VEGFR1(D1#D3)#Fc is graphically 
demonstrated in Figure 4.19. 
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Figure 4.19 ELISA for binding affinity of VEGFR1(D1/D3)/Fc to ligands 
VEGF121 and VEGF165. 
 
The results indicated that the Fc#fusion decoy receptor, VEGFR1(D1#D3)#Fc, had 
strong binding affinity towards both VEGF#A ligands, VEGF165 and VEGF121. This 
was also comparable to the affinity of aflibercept, a commercial anti#VEGF molecule, 
to VEGF#A isoforms. 
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4.4 Discussion 
 
Due to high structural heterogeneity of biopharmaceuticals including fusion proteins 
produced in cell cultures, and sensitivity to a variety of enzymatic/chemical 
modifications and degradation, a detailed characterization and sensitive analytical 
tools are required for assuring product quality and safety [253]. The process of 
characterization is complicated and unique to the individual protein and basically 
refers to the procedures carried out after protein purification. These include 
measurements of the protein size, MW, spectral studies, structural studies, nativeness 
and post#translation modifications. The VEGFR1(D1#D3)#Fc fusion protein was 
characterized by several techniques including SDS#PAGE, Western blotting, MS, CD, 
FS, SEC, CE and DSC.  
 
Western blotting was performed with culture supernatants of VEGFR1(D1#D3)#Fc 
clones to detect the presence of protein of interest, and assess the levels of protein 
expressed by densitometric analysis. Moreover, since the recombinant Fc#fusion 
protein, VEGFR1(D1#D3)#Fc undergoes degradation/clipping in culture, Western 
blots were used to detect the relative amounts of intact and clipped protein species with 
help of specific antibodies against the human IgG1#Fc protein [227]. This analytical 
technique uses gel electrophoresis to separate native proteins by 3#D structure or 
denatured proteins by the length of the polypeptide. The separated proteins were 
subsequently transferred to a membrane (nitrocellulose or PVDF), where they were 
stained with antibodies specific to the target protein. Immunoblotting with antibodies 
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to either the human IgG (Fc#region) or to the fusion protein partner will confirm the 
presence of recombinant protein of interest [254]. 
 
Separation of a biopharmaceutical such as fusion protein, using SDS#PAGE under 
reducing and non#reducing conditions, was important for establishing approximate 
MW of the molecule, and its stability/integrity under different conditions. In the case 
of Fc–fusion, which is homodimeric in nature, there should be the presence of one 
band (that of the dimeric form) under non#reducing condition, and one band 
representing the monomers, under reducing condition [159, 255]. This is because, 
under reducing conditions created by adding beta#mercaptoethanol or dithiothreitol, 
the disulfide bridges in polypeptide chains are reduced, allowing separation of chains 
or subunits [256]. The presence of a band with a slightly higher MW than the expected 
band of a monomer, suggested glycosylation of the polypeptide chain, and appearance 
of diffused bands indicated the presence of impurities or contaminants of degraded or 
truncated form of the recombinant protein [257]. From Western blotting and SDS#
PAGE images, the MW of the homodimeric VEGFR1(D1#D3)#Fc was observed to be 
∼156 kDa. Upon reduction of dimeric protein, monomer generated was detected with 
a MW of ∼78 kDa. 
 
RP#HPLC is an essential tool used in biotechnology industry for separation and 
analysis of proteins and peptides and their characterization with respect to identity and 
impurities [258, 259]. This chromatographic method separates molecules on the basis 
of hydrophobicity and uses a hydrophobic stationary phase and a polar (aqueous) 
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mobile phase. Hydrophobic molecules in the mobile phase get adsorbed to the 
hydrophobic stationary phase, and the hydrophilic molecules in the polar mobile phase 
elute first from the column. The hydrophobic molecules can be eluted from the column 
by decreasing the polarity of the mobile phase using an organic solvent. RP#HPLC can 
be used to separate two proteins of nearly identical structure and composition. The 
technique is used to separate and purify different isoforms of recombinant fusion 
protein, if any, because of the excellent resolution that can be achieved by this method. 
This is due to the high recovery, high productivity and very good reproducibility of 
repetitive separations carried out over a long period of time as a result of the stability 
of the silica#based sorbent particles under a wide range of mobile phase conditions. 
The RP#HPLC chromatogram for VEGFR1(D1#D3)#Fc revealed separation of the 
protein into 4 peaks, with 2 small pre#peaks (retention times for peaks 1 and 2 were 
12.0 and 13.0 min respectively) and 2 major peaks (retention times for peaks 3 and 4 
were 13.5 and 14.0 min respectively). From chromatographic profile, the 2 major peaks 
were considered to be the glycosylated isoforms of the protein and based on SDS#
PAGE profiling, peak 3 was further analyzed by MS for confirmation.  
 
MALDI#TOF MS is suitable for intact mass analysis of higher MW compounds 
including proteins with high ion detection efficiency. Driven by the need to identify, 
characterize, and quantify the Fc#fusion protein at a very high sensitivity, MS–based 
analytical experiments were carried out. MS measures the MW/intact mass of the 
protein, detects and characterizes post#translational modifications and potentially 
identifies any covalent modification that might alter the mass of the protein. The basic 
principle of this major analytical tool was to separate or differentiate charged (ionized) 
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particles with different masses based on their different mass to charge (m/z) ratio in an 
electric field. MS determined the MW of the species with high precision and detection 
sensitivity [260]. The two primary methods of ionization of whole proteins, are 
electrospray ionization (ESI) and matrix#assisted laser desorption/ionization 
(MALDI), using either time#of#flight (TOF) MS or Fourier transform ion cyclotron 
resonance (FT#ICR). In MALDI, protein samples are embedded into a specific matrix 
whose molecules absorb the impending laser beam while transferring energy to 
analyte. On the other hand, in ESI, analyte samples are directly injected into the 
ionization chamber, where the peptides are broken down into smaller ions which are 
directed towards a detector via a mass analyzer, for generation of MS spectra with each 
peak corresponding to m/z ratio of individual ionized species. MALDI is usually 
coupled to TOF analyzers for direct measurement of mass of intact peptides, while ESI 
is coupled to ion#traps and triple quadrupole analyzers for generation of fragment ion 
spectra of precursor ions. MALDI#TOF MS analysis is very sensitive and fast, and 
once the protein sample is mixed with the matrix on a MALDI target, the MS spectrum 
can be generated within a few seconds. The MALDI#TOF MS spectrum of 
VEGFR1(D1#D3)#Fc (major glycosylated isoform) showed three different charge 
states of the sample. The mass profile indicated that the peak sample had average mass 
in the range of 61500 Da to 72500 Da with +2 charge state. This implies a mass in the 
range of 137,000 Da to 143,000 Da, indicating a partially glycosylated form of 
VEGFR1(D1#D3)#Fc protein. The most abundant glycosylated isoform of the protein 
was observed to have a mass of 139.1 kDa.  
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Overexpression of therapeutic proteins from mammalian cell culture can lead to 
partially processed, inactive or misfolded protein resulting in formation of protein 
aggregates. Several other factors such as storage time, storage temperature, agitation, 
post#translational modification, protein concentration, ionic strength of protein 
solution, formulation buffer components and protein surface contacts also cause an 
increase in aggregation of the protein. Protein aggregates are of two types; disulfide#
linked or covalently (irreversible) bound and non#disulfide#linked or non#covalently 
(reversible) bound aggregates. Covalent aggregates formed by non#native 
intermolecular disulfide bonds, can be dissociated only with the use of reducing agents. 
Non#disulfide linked aggregates, which are primarily formed through weak 
interactions, due to exposure of buried hydrophobic residues to aqueous environment 
by local unfolding or electrostatic association of charged residues, can be reversed 
through use of chaotropic agents or by increasing the ionic strength of the buffer [261]. 
In a Fc#fusion protein, the majority of the aggregates are formed via disulfide linkages 
while only a small proportion is formed through non#covalent association. Aggregation 
results in decreased production of therapeutic biomolecules and has also been 
implicated in immunogenicity in animal models and also for therapeutics, which is 
undesirable for a drug [262, 263]. The stability of the VEGFR1(D1#D3)–Fc protein 
under 5 different temperature conditions over a period of 6 months, was evaluated 
using Western blotting and RP#HPLC. The aggregate formation in the protein was 
assessed, since a protein product intended for use as a drug with a long shelf#life, 
should be stored in low concentrations to avoid aggregation leading to instability. The 
protein was demonstrated to be stable at #70°C and #20°C during the 6#month period, 
with #70°C being a marginally better condition.  
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The purified VEGFR1(D1#D3)#Fc molecule was analyzed for formation of protein 
aggregates with the help of SDS#PAGE, SEC and CE techniques. SEC which is also 
known by other names, such as steric#exclusion chromatography, gel#filtration 
chromatography, gel#permeation chromatography and liquid#exclusion 
chromatography, is the most favored and routinely used technique for investigating the 
native structure of a recombinant fusion protein as well as monitoring protein 
aggregation, due to its speed and reproducibility [264]. This technique separates 
protein on basis of its size and sometimes MW, in a small well#defined time and narrow 
bands, leading to good sensitivity, and with minimum sample loss, as the solutes do 
not interfere with the stationary phase by means of adsorption or partitioning. Larger 
protein molecules do not enter the gel pores and thus flow through the column, whereas 
smaller molecules have a longer retention time. SEC plays a major role in analysis of 
biotherapeuticals by measuring the levels of soluble high molecular weight (HMW) 
aggregates that impact the safety and efficacy of the protein. Low valency HMW 
aggregates such as dimers, might indicate partial denaturation or perturbation in the 
structure of the protein also affecting stability, while high valency multimeric forms of 
HMW aggregates might elicit immunogenic and anaphylactic response [265]. Hence 
SEC coupled to HPLC (SEC#HPLC) was used to characterize the high and low MW 
variants of VEGFR1(D1#D3)#Fc protein. From SEC, it was observed that 7.78% of 
HMW species were present along with 5.01% of LMW fragments. Monomeric 
VEGFR1(D1#D3)#Fc protein was present as 87.22% of the total protein.  
 
Another method used to determine protein size as well as aggregates, was CE. This 
powerful technique used widely for protein analysis, has several advantages over 
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traditional HPLC in terms of simplicity, speed, automation, ruggedness, different 
mechanisms for selectivity, low cost, efficiency and higher resolution for smaller 
sample size. CE#SDS which has emerged as a robust replacement for SDS#PAGE, is 
used to determine the apparent MW of proteins and to evaluate the size heterogeneity, 
purity, stability, aggregate formation and protein glycosylation, prior to its use in the 
clinic [266]. In contrast to conventional SDS#PAGE, CE#SDS offers direct on#column 
UV or fluorescence detection, automation, enhanced resolution and reproducibility, 
accurate quantification of proteins, and determination of MW [267]. Separation of 
proteins by molecular sieving electrophoresis using a gel matrix is also known as 
capillary gel electrophoresis (CGE), where it is important to denature the protein using 
SDS, an anionic detergent which imparts an overall negative charge to the protein by 
binding to the protein in a ratio of 1:1.4 of protein. As a result of constant mass to 
charge properties of the SDS#bound protein, it migrates on the basis of MW. 
Now a days, polymer materials used as sieving matrices for CE#SDS, are water soluble 
linear or slightly branched polymers such as linear polyacrylamide, polyethylene 
oxide, polyethylene glycol, dextran, and pullulan [268], which, in comparison to cross#
linked polyacrylamide gel matrices, add a great deal of flexibility to CE#SDS.  The 
method is based on differential migration of SDS#protein complexes in a narrow fused#
silica capillary, filled with a low viscous gel, under the influence of applied electric 
field. Detection of proteins was performed based on their absorbance at 220 nm. From 
the plot of absorbance versus migration time for reduced VEGFR1(D1#D3)#Fc, MW 
was observed to be in the range of 90–100 kDa, which is higher than the theoretical 
MW of VEGFR1(D1#D3)#Fc monomer (78 kDa), indicating significant glycosylation. 
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To further investigate VEGFR1(D1#D3)#Fc in terms of protein structure, 
conformations and dynamics, the traditional and widely used method of FS, was 
utilized. It is known that total fluorescence of a protein is a mixture of the fluorescence 
from individual aromatic residues. In proteins, though all three emitting amino acids, 
tyrosine (Tyr), tryptophan (Trp) and phenylalanine (Phe) account for intrinsic UV 
fluorescence, Trp is the dominant fluorophore. These amino acids residues can be 
followed in order to know the folded/unfolded state of the protein since their quantum 
yields (fluorescence properties) are sensitive to the changes in their local 
microenvironment, which changes upon change in protein conformation. Both Trp and 
Tyr have a wavelength of maximum absorption at around 280 nm, but at 295 nm, only 
Trp gets excited and not the weaker Tyr. Since only few Trp residues are present in 
most proteins (there are only eight residues in VEGFR1(D1#D3)#Fc), it is easy to 
interpret its spectral data. Moreover Trp is sensitive to changes in its local 
microenvironment than the other two amino acids, as a result of the large redistribution 
of electron density in the asymmetric indole ring after excitation of photons, and 
tendency of its excited#state to donate electrons [269]. On the other hand, there is no 
redistribution in the symmetric rings of Tyr and Phe. The absorbance of proteins at 280 
nm is due to both Trp and Tyr (extinction coefficients 5563 cm#1/M and 1220 cm#1/M, 
respectively), but at wavelengths above 295 nm, the absorption is mainly due to Trp. 
Emission of protein is dominated by Trp emission which absorbs at the longest 
wavelength and also has the longest extinction coefficient. The emission maximum for 
Trp in non#polar solvents is around 328#330 nm, while that in polar solvents is about 
350 nm (red shift). Emission peak of Trp ranges from 300#350 nm depending on the 
polarity of the solvent. The local microenvironment around the fluorophore determines 
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the emission intensity and wavelength of a particular protein. In general, the more 
buried these residues are within the protein, the less fluorescence quenching they will 
experience, including a reduced solvent#induced fluorescence quenching. Stokes shift, 
a fundamental to the sensitivity of fluorescence techniques, brings the emission to 
longer wavelengths (red region) of decreased intensity, in case of exposure of 
fluorophores to solvent. Fluorescence intensity of a protein can either increase or 
decrease during folding, with Trp fluorescence often used as a means of determining 
both stability and folding of a protein. From the FS data of VEGFR1(D1#D3)#Fc, the 
maximum fluorescence intensity of emission was observed at a wavelength of ∼330 
nm. The fluorescence of Trp residues located on the surface of the protein have a 
greater possibility of being quenched by neighboring residues or solvent interaction, 
as compared to those residues buried deeply inside the protein, due to limit 
accessibility of the quencher. The data suggests that quenching of fluorescence as a 
result of solvent interaction or due to quenching properties of adjacent amino acid 
residues did not take place, indicating proper folding of the protein and buried Trp 
moieties. 
 
CD is a form of light absorption spectroscopy. It studies optical properties of a protein 
by measuring the difference in absorption between left#handed circularly polarized 
light and right#handed circularly polarized light that arise due to structural asymmetry 
as in proteins. CD is a valuable spectroscopy technique for examining the secondary 
structure, protein folding and structural integrity in a wide range of wavelengths. It 
also studies conformational stability of a protein in solution, under different stress 
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conditions such as thermal denaturing and pH stability.  CD is excellent for finding 
solvent conditions that increase the melting temperature and/or the reversibility of 
thermal unfolding, conditions which generally enhance shelf#life of a protein. The 
analyte should contain only those chemicals necessary to maintain protein stability at 
the lowest possible concentrations, since presence of additional protein or peptide 
contributes to CD signal. CD also uses very little amount of sample (~200 µL of 0.5 
mg/mL solution). Proteins are most stable in the vicinity of isoelectric pH (pI). At pH 
values outside of range for the particular protein, the protein tends to destabilize due 
to peptide bond hydrolysis or disulfide bond cleavage, unfold or even racemise. One 
of the strengths of CD is that various aspects of protein structure can be determined. 
In the far UV, the peptide bond is the principal absorbing group. Studies in this region 
can give information on the secondary structure. In the near UV, the aromatic amino 
acid side chains (Phe, Tyr, Trp) absorb in the range 250 to 290 nm. The tertiary folding 
of the polypeptide chain can place these side chains in chiral environments, thus giving 
rise to CD spectra which can serve as characteristic fingerprints of the native structure. 
The chromophores present in a protein such as the peptide bond, the aromatic side 
chain and disulfide bond, can give rise to CD signals, with intensity partly related to 
how near these chromophores are to chiral centers. The existence of ordered secondary 
structure of the protein is established from CD spectrum in the far UV range, which is 
dominated by amide bond absorption, as peptide bonds absorb below 240 nm. There 
is a strong ππ* transition centered around 190 nm whereas a weak but broad nπ* 
transition around 220 nm. In fact it is possible to estimate content of α#helix in a protein 
from values of CD signals at 208 nm and 220 nm [270]. There are a number of existing 
softwares based on algorithms, which use the data from CD spectrum at far UV, to 
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predict the composition of secondary structures for the protein. The near UV CD 
spectrum of a protein provides a valuable fingerprint of the tertiary structure of the 
protein as it reflects the environment of the aromatic side chains. However, the amount 
of protein required for evaluation of near UV CD spectra is higher than that required 
to generate far UV spectrum (0.1 mg versus 1 mg of protein). Moreover, information 
on tertiary structure of protein can be also obtained from fluorescence spectroscopic 
data of the protein. The far UV CD spectrum for VEGFR1(D1#D3)#Fc showed a 
minimum peak at 218 nm indicating a predominant β#sheet content. When the 
spectrum was deconvoluted using an online platform (http://bestsel.elte.hu/), the total 
β#helix content was found to be 66.5% with 33% antiparallel and 33.5% parallel β#
sheets. Alpha helix content was only 9.5%. There were no turns and remaining 24% 
might be accounting for random coiled structures in the protein. It had been earlier 
reported by Gordana et al that the CD spectrum of Fc fragment  shows secondary 
structure comprising primarily of β#sheets [244]. 
 
In order to further determine the thermal stability of VEGFR1(D1#D3)#Fc, DSC was 
used. DSC is used to characterize stability of a biomolecule (protein) in dilute solution 
directly in its native form by measuring the changes in the partial molar heat capacity 
(Cp) associated with the thermal denaturation of the protein, when heated at a constant 
pressure [271]. A biomolecule in solution exists in equilibrium between its native or 
folded and denatured or unfolded conformations. The major stabilizing forces in a 
protein which must be overcome for the protein to unfold and denature, are 
hydrophobic interactions and hydrogen bonds [272]. The change in heat capacity of a 
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protein is reflected in its ability to absorb heat and acquire an increase in temperature. 
Thermal unfolding of protein takes place over a range of temperature characteristic of 
the protein giving rise to an endothermal peak. The higher the thermal transition 
midpoint (Tm), the higher the energy input required to disrupt the hydrophobic core of 
the protein, and more stable the molecule. The peak represents the temperature where 
one half of the protein is folded, while area under the curve represents calorimetric 
enthalpy (H). DSC measures the enthalpy (hH) of unfolding that results from heat#
induced protein denaturation. The stability of the protein is measured by the difference 
in Gibbs free energy of the two states of the protein (native/ folded state and denatured/ 
unfolded state). If the transition occurs as a sharp endothermic peak at one Tm or 
within a narrow temperature range, the transition is supposed to be highly cooperative.  
DSC data for VEGFR1(D1#D3)#Fc showed two thermal transition midpoints (Tm), one 
at 98.3°C (Tm1) and the other at 108.7°C (Tm2). Some proteins with more than one 
structural domain or with different regions of activity can possess more than one Tm. 
Focus on one or two Tm values will depend on the Tm which shows the greatest effect 
due to formulation changes. DSC data suggests non#cooperative folding 
thermodynamics for VEGFR1(D1#D3)#Fc protein in solution. Since the protein 
consists of VEGFR1(D1#D3) domains and Fc domains, they may be folding 
separately, have different folding and unfolding conformations as a result of disruption 
of secondary or tertiary structures during induced thermal transition. 
 
Most therapeutic proteins produced in mammalian cells by recombinant technologies, 
are glycosylated. N#linked glycosylation occurs through the amide nitrogen of 
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asparagine side chains and O#linked glycosylation through the hydroxyl oxygen of 
serine and threonine side chains, by covalent linkages. Glycosylation of proteins, the 
most common post#translational modification, has essential roles in immune/antibody 
effector functions, immunogenicity, plasma clearance of the therapeutic protein and 
conferring resistance towards cellular or serum proteases [225]. N#glycans affect many 
properties of glycoproteins including their conformation, solubility, antigenicity, and 
recognition by glycan#binding proteins. These glycosylated variants thus need to be 
identified and characterized as well as controlled for limited therapeutic use [273]. 
Glycosylation can also influence pI and half#life of a protein drug [274]. Minor 
changes in glycan distribution can lead to change in activity of the protein, and hence 
it is a challenge for biopharmaceutical industries, to minimize glycan heterogeneity 
and improve analytical techniques or assays to detect these minute changes across the 
batch samples. The task of characterization of glycoproteins remains an analytical 
challenge due to the vast heterogeneity of glycoproteins.  
 
Capillary zone electrophoresis (CZE) is an excellent tool for characterization of 
glycoproteins as a result of advantages of automation, short analysis time and ability 
to separate as well as quantify isomeric species. N#glycans present in VEGFR1(D1#
D3)#Fc were identified using CE#LIF. The major glycan forms present in the fusion 
protein were G2FS1, G0F, Man5, G1F (1, 6), G1F (1, 3), G2F along with four 
unidentified minor peaks. N#glycosylation is known to stabilize CH2 domain of Fc, 
help in folding of Fc region and prevent aggregation. Glycans that are known to have 
crucial impact on the pharmacokinetics and pharmacodynamics of Fc#fusion proteins 
are mannose, sialic acids, fucose and galactose. MAbs  are often glycosylated to a 
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lesser degree than Fc#fusion proteins, typically containing a single glycosylation site 
at Asn297 in the CH2 domain of IgG Fc [32, 275]. On the other hand, receptor domains 
of Fc#fusion proteins, generally contain one or more glycosylation sites, both N#linked 
and O#linked [276]. Oligosaccharide structures in Fc#fusion proteins are generally 
more varied in their receptor domains with a core fucose and bisecting GlcNAc 
(complex and high mannose; bi#, tri#, and tetra#antennary), than IgG#Fc (complex, 
bianntennary). N#glycans with terminal GlcNAc residues are known to have a higher 
clearance rate [251]. Levels of sialic acid residues are also greater in Fc#fusion 
proteins, which tend to shift the pI of Fc#fusion proteins to an acidic pH range. It also 
imparts more charge heterogeneity on the fusion protein. In VEGFR1(D1#D3)#Fc 
protein, the sialated content was observed to be high (30.33%). Mannosylated glycans 
can influence the pharmacokinetics of the molecule, leading to reduced exposure and 
lower efficacy. In recombinant antibodies, levels of high#mannose glycans can range 
from 1% to more than 20%, whereas only trace amounts (<0.1%) of high#mannose 
glycans are present in endogenous human IgG [277]. Mannose 5 content of 
VEGFR1(D1#D3)#Fc was observed to be 9.89%. Fc#fusion proteins with terminal N#
acetylglucosamine residues, are thought to be cleared by means of N#
acetylglucosamine in the asialoglycoprotein mannose receptor, a glycan specific 
receptor expressed by sinusoidal liver cells [278, 279]. Core fucose in the glycan 
moiety, reduces binding of IgG antibody to IgG Fc receptor IIIa, as compared to IgG 
lacking fucose. This results in decreased antibody#dependent cell#mediated 
cytotoxicity (ADCC) function of the antibody [247]. Glycoproteins with high sialic 
acid, N#acetylneuraminic acid (NANA) content, also have a significant impact on the 
pharmacokinetics of Fc#fusion molecules by increasing circulating half#life and 
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enhanced in vivo efficacy of the protein. This is attributed to decreased hepatic and 
renal clearance of the protein and reduced proteolytic degradation due to presence of 
the charged glycans (terminal sialic acid) [274]. 
 
Knowledge of isoelectric point (pI) is necessary because it helps in purification of the 
protein using ion#exchange chromatography. It is also important in pharmacokinetics 
and pharmacodynamics (PK/PD) studies, where bioavailability of the drug depends on 
its interaction with ECM, which in turn depends on the net charge on the protein. 
Hence, isoelectric focusing to detect the pI of VEGFR1 (D1#D3)#Fc was performed by 
both IEF SDS#PAGE and CE. The principle of electrophoretic separation of proteins 
is based on the differential rate of migration of charged species under the application 
of an electric field and in the direction of the current. Isoelectric focusing is used to 
separate amphoteric compounds like protein in order of their isoelectric points (pI) in 
a steady#state pH gradient. It is an electrophoretic process in a pH gradient set up 
between a cathode and an anode with the cathode at a higher pH than the anode. Due 
to both positively and negatively charged amino acids, the proteins possess amphoteric 
properties and are positively charged at pH values below their pI and negatively 
charged above it. This allows the proteins to migrate towards their individual pI. The 
separation of the constituent proteins happens on a non#sieving medium such as 
polyacrylamide gel in presence of carrier ampholytes (numerous zwitterions with a 
range of defined isoelectric points), which establish a pH gradient increasing from 
anode to cathode, under the influence of electrical force, thereby allowing for protein 
species to migrate and focus/concentrate at their isoelectric points. A steady#state is 
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eventually established where the electrokinetic transport of proteins in the focused 
zone is balanced by the diffusion of the protein out of the zone.  
In both IEF methods performed, SDS#PAGE gel and CE electropherogram indicated 
multiple protein peaks in the pI range of 8.2–9.5. Theoretical pI of the protein, based 
on its amino acid sequence is 9.04. VEGFR1(D1#D3)#Fc protein has six potential N#
linked glycosylation sites, five in the non#Fc partner and one in the CH2 domain of 
IgG1#Fc region of the fusion. N#glycan analysis by CE confirmed the presence of six 
major glycan peaks in the molecule. Thus, the multiple peaks observed in cIEF 
indicated the different isoforms of VEGFR1(D1#D3)#Fc as a result of different 
glycosylated variants. However, the pI of VEGFR1(D1#D3)#Fc was observed to be in 
the similar pI range of both parental Flt#1(1#3)#Fc (9.4) and aflibercept (8.82). Hence, 
it can be predicted that the molecule will not have an improved pharmacodynamics 
profile owing to its tendency to bind to the negatively charged ECM proteins and hence 
lower bioavailability. 
 
Biological products such as recombinant proteins, produced widely by mammalian 
cells like CHO, are mostly intended for use as therapeutic benefits preceding their 
efficacy evaluation in animal models. The recombinant proteins are usually composed 
of the desired substance along with multiple product#related and process#related 
impurities. Host cell DNA, a process#related impurity derived from the manufacturing 
process, is a latent risk factor due to its oncogenicity, infectivity and 
immunomodulatory effects and hence must be accurately determined. Levels of host 
cell DNA contamination were determined using quantitative real time PCR and found 
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to be 1.5 pg per mg of protein which was well within the acceptability guidelines. The 
FDA guidelines recommend that the acceptable host cell DNA in biopharmaceutical 
drugs should be less than 100 pg/dose, while the acceptable limit of host cell DNA 
permitted by the European Union (EU) is not more than 10 ng/dose [280]. 
 
By means of DTNB titration, it was verified that VEGFR1(D1#D3)#Fc protein had no 
free cysteine or thiol groups. This suggested that the protein was stable in extracellular 
environment, as unpaired highly reactive thiol groups in free cysteine, often lead to 
protein agglomeration and precipiation as a result of thio#thiol interactions. 
 
Binding affinity of the Fc#fusion protein, which is a decoy receptor for ligand, VEGF, 
was also analyzed in comparison to that of known VEGF receptor, aflibercept. ELISA 
to determine comparative binding, revealed that VEGFR1(D1#D3)#Fc had strong and 
comparable binding affinity to its major cellular ligand, VEGF#A. Two major isoforms 
of VEGF#A, namely VEGF165 and VEGF121, were used in the binding assay and found 
to possess similar affinity towards VEGFR1(D1#D3)#Fc as for aflibercept (VEGF#
TrapR1R2). Since VEGFR1(D1#D3)#Fc demonstrated very similar affinities for VEGF 
as compared to aflibercept, it is expected to show comparable functional efficacies in 
vitro and in vivo.   
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Chapter 5: Determination of stability of VEGFR1(D1-D3)-Fc 
protein 
 
Aim: The aim of this chapter was to determine the thermal stability of VEGFR1(D1#
D3)#Fc over a wide range of  temperature conditions as well as time period. This would 
ultimately help in prediction of conditions under which the protein drug candidate 
would be stable for long#term storage. 
 
5.1 Introduction 
 
Protein stability is a quality of the protein to maintain its original character in spite of 
being acted upon by certain factors such as pH, temperature, redox potential, 
conductivity and protein concentration. It is the net balance of forces determining 
whether the protein is in the denatured (unfolded) state or its native (folded) 
conformation, defined by the difference between free energies of these two states. 
 
Proteins are sensitive to environmental factors. Conditions of relative humidity, light, 
ionic content, oxidation, sheer and long#term storage, may lead to degradation of the 
product. Biopharmaceutical products, in which the active component is usually 
proteins or polypeptides, maintain their molecular conformation, integrity and 
biological activity, based on non#covalent and covalent forces. In order to maintain the 
biological activity and potency of the product as well as to avoid degradation, stringent 
conditions are necessary for their storage. The objectives of stability studies were to 
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evaluate the quality of drug substance under storage conditions over a specific time 
frame. Suitable storage and shipment conditions for drug substance can be 
recommended from such studies. Stability testing also enables drug manufactures to 
establish shelf lives and storage conditions for their products. The product is first 
purified and then subjected to conditions for accelerated or forced degradation, in order 
to assess the limits of stability of the particular protein under the testing parameters 
[281]. Samples from pilot scale batch are analyzed for a stability parameter over 
specific time intervals. Tests and assays based on purity, identity, quality, potency and 
safety are conducted depending on the type of product and its intended use. The 
following sensitive analytical methods were chosen as stability indicating assays and 
the product quality attributes were measured at various interim time points for a batch 
of VEGFR1(D1#D3)#Fc. 
1. Physical appearance  
2. Purity and band migration by SDS PAGE (reducing and Non#reducing) 
3. Protein related impurities by Western Blot (reducing) 
4. Purity and protein concentration by RP HPLC 
 
5.2 Materials and Methods  
 
To determine the stability of the fusion trap protein in vitro, 1 mL of purified 
VEGFR1(D1#D3)#Fc protein (1 mg/mL) was aliquoted in glass vials and kept in 
stability chambers of varying temperatures and analyzed at different time points (0 hr, 
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15 days, 1 month, 2 months, 3 months and 6 months) using a range of techniques such 
as SDS#PAGE, Western Blotting and RP#HPLC.  
 
The following temperatures were chosen for evaluating stability: #70°C, #20°C, 2#8°C, 
25°C and 40°C. The accelerated stability assessment temperature was chosen as 25oC, 
while 40oC was chosen as a stressed condition. A summary of stability conditions for 
drug substance is shown in Table 5.1. Composition of the buffer in which the drug 
substance is stored was as follows: 
10 M sodium phosphate, 40 mM NaCl, 0.03% (w/v) polysorbate 20, 5% (w/v) sucrose, 
pH 6.2. 
 
5.2.1 SDS-PAGE 
 
Various analytical methods such as SDS#PAGE and SEC are employed to monitor and 
control the formation of protein aggregates in a reliable and reproducible manner 
during therapeutic protein production. SDS#PAGE with Coomassie staining of protein 
was performed at each of the time points to detect and evaluate the stability of the 
protein during storage. The lower limit of detection limit of protein by Coomassie is 
100#200 ng /protein band. SDS#PAGE was used to evaluate the band migration and 
aggregate formation in the protein solution under storage conditions. For SDS#PAGE, 
2 µg of each protein sample (from varying stability conditions) was loaded onto a 1.5 
mm thick, 10% gel, and stained using Coomassie Brilliant Blue stain, under both 
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reducing and non#reducing conditions. A detailed protocol for SDS#PAGE is described 
in Chapter 2 (Materials and Methods section 2.2.6.2). 
 
5.2.2 Western Blotting 
 
Western blotting (also known as immunoblotting because of the ability of a specific 
antibody to detect a protein from a mixture of proteins) is used as a widely accepted 
tool to analyze the protein of interest and its degradation profile, during the course of 
stability studies.  
 
Western blotting of samples for stability analyses, was carried out in order to provide 
analysis of the molecular entity and the quantitative detection of degradation products 
that may result from deamidation, oxidation, sulfoxidation, aggregation or 
fragmentation upon storage. One microgram of purified protein used for stability 
analyses, was loaded onto SDS#PAGE gels and analyzed by Western blotting 
technique for each temperature and duration. Details of the technique are mentioned in 
Chapter 2 (Materials and Methods section 2.2.6.2). 
 
5.2.3 RP HPLC  
 
RP#HPLC was selected as an analytical method for stability analysis as it is a sensitive 
tool for determination of product quality under storage conditions. It provides 
information about oxidizing and reducing impurities and protein#related impurities. 
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Analysis by RP#HPLC was carried out with 10 µg of protein on a C5 column with 
dimensions of 150 X 4.6 mm (Discovery Bio Wide, Supelco; pore size 250A°; particle 
size of 5 µm; Catalogue# 568422#U) using mobile phase buffer A (0.1% TFA in 
water), and buffer B (0.1 % TFA in 90% acetonitrile in water). Column oven 
temperature was kept at 60°C and a flow rate of 1 mL per min was used to resolve 
proteins under non#denaturing condition and detected by UV detector at 215 nm. The 
total run time was 35 min. Gradient for elution was kept at 0 – 100% B in 35 min. 
 
Table 5.1 Time points for drug substance storage at different temperatures. 
Temperature Duration of stability study in months 
#70 + 3 °C  0.5 1 2 3 6 
#20 + 3 °C 0 0.5 1 2 3 6 
5 ± 3 °C  0.5 1 2 3 6 
25 ± 3 °C  0.5 1 2 3 6 
40 ± 3 °C  0.5 1 2 Not studied Not studied 
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5.3 Results 
 
5.3.1 Western Blot of stability samples 
 
Western blotting was performed to analyze stability profiles of protein samples under 
reducing and non#reducing conditions for different storage temperatures and time 
periods (Figures 5.1, 5.2 & 5.3). 
 
Figure 5.1   Western Blot for “0” hour stability samples. 
Purified VEGFR1(D1#D3)#Fc (1mg/mL) in appropriate buffer at room temperature 
was analyzed by Western blotting, with 1 µg of the protein loaded on a SDS#
polyacrylamide gel under reducing as well as non#reducing conditions. Protein was 
captured using HRP#conjugated goat anti#human IgG Fc gamma antibody (Jackson; 
Catalogue# 109#036#098) and developed using DAB chromogen (Sigma; Catalogue# 
D4418). From the blots, the expected protein band of VEGFR1(D1#D3)#Fc monomer 
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(∼78 kDa) (55% from densitometric analysis) was observed along with clipped 
products of 40 kDa (28%) and 30 kDa (17%) under reducing condition. Under non#
reducing condition, VEGFR1(D1#D3)#Fc dimer along with aggregates, was observed.  
     
Figure 5.2 Western blots (reducing) of VEGFR1(D1/D3)/Fc samples analyzed for 
stability at 0.5, 1, 2, 3 and 6 months. (A) 0.5 months, reducing condition, (B) 1 month, 
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reducing condition, (C) 2 months, reducing condition, (D) 3 months, reducing 
condition and (E) at 6 months under both reducing and non#reducing conditions. 
 
Figure 5.3 Western blots (non/reducing) of VEGFR1(D1/D3)/Fc samples 
analyzed for stability at 0.5, 1, 2, 3 and 6 months. (A) at 0.5 month, (B) at 1 month, 
(C) at 2 month, (D) at 3 month.  
 
From Western blot data under reducing conditions, it was evident that with increasing 
time of storage from 15 days to 6 months, there was progressive increase in degradation 
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of VEGFR1(D1#D3)#Fc fusion protein at 25°C to a large extent, and at 2#8°C, to a 
lesser extent. Protein stored at 40°C started to degrade after 15 days and by the second 
month, almost the entire protein was degraded. Protein stored at #20°C and #70°C have 
almost similar degradation profile, with #70°C appearing to be the ideal storage 
temperature. 
 
5.3.2 SDS-PAGE of stability samples 
 
 
SDS#PAGE was performed to analyze stability profiles of VEGFR1(D1#D3)#Fc 
protein samples stored under a wide range of temperatures (40°C, 25°C, 2#8°C, #20°C 
and #70°C) and for definite time periods (0, 0.5, 1, 2, 3 and 6 months) (Figures 5.4, 
5.5 & 5.6).  
 
Figure 5.4 SDS/PAGE of 0 hour/stability sample. 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
287 
  
From SDS#PAGE analysis of initial time point or “0 hour” sample, it was observed 
that under reducing conditions, 88% of the protein was in the form of intact monomeric 
VEGFR1(D1#D3)#Fc, and 12% in clipped form (40 kDa). Densitometric analysis of 
gel image was performed using GelQuant.NET software.    
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Figure 5.5 SDS/PAGE (reducing) of VEGFR1(D1/D3)/Fc samples analyzed for 
stability at 0.5, 1, 2, 3 and 6 months. (A) 0.5 months, reducing condition, (B) 1 month, 
reducing condition, (C) 2 months, reducing condition, (D) 3 months, reducing 
condition and (E) at 6 months under both reducing and non#reducing conditions. 
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Figure 5.6 SDS/PAGE (non/reducing) of VEGFR1(D1/D3)/Fc samples analyzed 
for stability at 0.5, 1, 2, 3 and 6 months. (A) at 0.5 month, (B) at 1 month, (C) at 2 
month, (D) at 3 month.  
SDS#PAGE data for stability determination of protein at all experimental temperatures 
correlated, with Western blot data for the same conditions. This data was further 
correlated with RP#HPLC data of the stability samples. 
 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
290 
  
5.3.3 RP-HPLC of stability samples 
 
Stability profile of VEGFR1(D1#D3)#Fc under different temperatures and for different 
duration of time, were analyzed using RP#HPLC (Figures 5.7 to 5.12). 
 
 
 Figure 5.7 RP/HPLC profile of VEGFR1(D1/D3)/Fc at 0 hour. The protein 
generated four peaks under reverse#phase chromatography which represented the 
different glycoform variants. 
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Figure 5.8 RP/HPLC profile of VEGFR1(D1/D3)/Fc after 0.5 month of storage. 
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Figure 5.9 RP/HPLC profile of VEGFR1(D1/D3)/Fc after 1 month of storage. 
 
 
Figure 5.10 RP/HPLC profile of VEGFR1(D1/D3)/Fc after 2 months of storage. 
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Figure 5.11 RP/HPLC profile of VEGFR1(D1/D3)/Fc after 3 months of storage. 
 
Figure 5.12 RP/HPLC profile of VEGFR1(D1/D3)/Fc after 6 months of storage. 
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RP#HPLC is sensitive to protein modification under altered conditions and thus able 
to separate protein degradation products, such as products of oxidation and 
deamidation. With increase in time and temperature, both these processes set in. 
Development of a peak, slightly towards the left of the main peak, was observed with 
decrease in height of the peak for the native molecule. This usually occurs as a result 
of oxidation of methionine residues in the protein by oxygen, light or metal catalysis, 
which apart from resulting in loss of its biological activity, also makes the protein more 
hydrophilic. Oxidized protein impurities thus elute before the intact native protein in 
RP#HPLC [282]. Deamidation is another very common degradation process that 
occurs in biotherapeutics and results in loss of its activity. It is the conversion of an 
asparagine residue to aspartic acid or isoaspartic acid, thus adding an acidic group to 
the protein. At neutral pH, the protein thus becomes slightly more hydrophilic. 
Aspartic acid is slightly more hydrophobic than asparagine under acidic conditions and 
hence peptide or protein fragments containing the deamidation product, elute slightly 
later than fragments with asparagine or intact protein.   
 
At 2#8°C, the RP#HPLC profile indicated that beyond one month, the processes of 
protein modification initiated, as was evident from the emerging impurity peaks. At 
temperatures higher than 2#8°C, degradation started within 15 days as was also evident 
from Western blot data. From RP#HPLC data at all temperatures and for all time points, 
#20°C and #70°C were observed to be optimum for storage of the protein up to six 
months. 
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5.4 Discussion 
 
Protein stability studies are carried out to in order to ensure maintenance of quality and 
efficacy of a biological product intended for therapeutic use, for determining safety in 
a given formulation buffer, and predicting shelf#life and storage conditions [283]. 
Biopharmaceutical stability studies undertaken for therapeutics are indispensable to 
assess sensitivity to environmental factors that could cause aggregation and 
degradation/clipping, which impacts biological function, safety and quality of the 
product [284]. Variations in stability due to degradation or chemical and physical 
instability of the protein, can alter protein folding and three dimensional structure, thus 
affecting efficacy.  
 
An accelerated degradation study for a period of 6 months was undertaken for 
assessing stability of the recombinant Fc#fusion protein. Western blot, SDS#PAGE and 
RP#HPLC data suggested that VEGFR1(D1#D3)#Fc protein was stable at both #70°C 
and #20°C during the 6#month period, with #70°C being marginally better than #20°C 
for the later periods. The process of degradation started in protein samples stored at 
temperatures of 25°C and higher (40°C) within 15 days of storage. By the end of the 
second month of storage, protein subjected to 40°C, was almost fully degraded to its 
clipped forms. At 2#8°C, the protein started to undergo degradation after the second 
month, as was evident from the reducing Western blot image under this condition. 
From RP#HPLC elution data of protein at different temperatures and time, the 
emergence of additional peaks representing impurities or degradation products of 
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protein oxidation and deamidation processes, also indicated protein instability at 
temperatures higher than #20°C beyond one month. Overall, #70°C, and to some extent, 
#20°C, appear to be the optimum temperatures for storage of VEGFR1(D1#D3)#Fc 
protein (for up to 6 months).  
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Chapter 6: In vitro studies for determination of biological 
activity of VEGFR1(D1-D3)-Fc protein 
 
Aim: The present chapter aims at determination of biological activity of VEGFR1(D1#
D3)#Fc under in vitro conditions. It deals with the studies performed on primary 
vascular endothelial cell line, HUVEC, to determine the predicted biological functions 
of VEGFR1(D1#D3)#Fc. The ability of the anti#VEGF decoy receptor to inhibit VEGF#
induced cellular functions such as proliferation and capillary network/ tube formation 
in endothelial cells, was evaluated. 
 
6.1 Introduction 
 
Assessment of the biological activity of VEGFR1(D1#D3)#Fc fusion protein was 
necessary for its development as an anti#angiogenic drug, in the future. Angiogenic 
factors including VEGF, can promote cell proliferation, chemotactic migration and 
capillary/tube#like network formation of vascular endothelial cells in vitro and in vivo. 
Hence, functionality evaluation included assays which investigated the inhibitory 
effects of the decoy receptor fusion protein, on endothelial cell proliferation and 
capillary tube formation. HUVEC was chosen as the laboratory model cell line in order 
to study the physiological process of angiogenesis, which is inhibited by anti#VEGF 
agents. HUVECs are not only good representatives of endothelial cells, they are 
relatively easy to harvest from large blood vessels [285]. VEGF, an important signaling 
molecule, is known to promote angiogenesis by stimulating endothelial cell 
proliferation, migration, sprouting, tube formation and microvascular permeability.  
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6.2 Materials and Methods  
 
The following bioassays were performed for analyzing the inhibitory functions of 
VEGFR1(D1#D3)#Fc in vitro: 
1. Inhibition of endothelial cell proliferation 
2. Inhibition of endothelial tube formation 
 
6.2.1 Inhibition of endothelial cell proliferation by VEGFR1(D1-D3)-Fc 
 
6.2.1.1 Introduction 
 
Proliferation of endothelial cells is required for the growth of blood capillaries in a 
living animal. The newly created blood vessels are in charge of delivering oxygen and 
nutrients to different tissues, taking away waste products and stimulating immune 
surveillance. VEGF is the most potent and well#studied proangiogenic factor 
promoting proliferation of endothelial cells. The angiogenic effects of VEGF on cell 
proliferation can be studied using several methods such as direct cell count, cellular 
metabolic activity or DNA synthesis [286, 287].  
 
For assessing the anti#angiogenic activity of VEGFR1(D1#D3)#Fc, serum#starved 
HUVECs were treated with VEGF165 to induce proliferation (in control) and also 
grown in presence of VEGFR1(D1#D3)#Fc, which neutralizes VEGF165 by binding and 
sequestering the growth inducer, to inhibit proliferation (experimental). After about 72 
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hr, alamarBlue® reagent was added to quantitatively measure the proliferation of 
HUVEC. AlamarBlue® is a non#toxic, cell permeable, water#soluble growth indicator. 
It is a fluorimetric and colorimetric redox indicator exhibiting both fluorimetric as well 
as colorimetric change depending on the oxidation#reduction state of the cellular 
environment. Continued and sustained cellular growth, produces a reduced 
environment in the growth medium, whereas growth inhibition creates an oxidized 
environment. Chemical reduction of alamarBlue® takes place as a result of cellular 
metabolic activity in growing and proliferating cells, causing the oxidized redox 
indicator (non#fluorescent and blue in colour) to change to its reduced form 
(fluorescent and red in colour). Fluorescence data gives a measure of inhibition of cell 
proliferation in presence of the anti#VEGF molecule [288, 289]. 
 
6.2.1.2 Materials and Methods 
 
In a T#75 cm2 tissue culture flask, 3 mL of 0.2% gelatin (from bovine skin; Sigma, 
Catalogue# G9391) was uniformly distributed and kept for 2 hr at 37°C in a humidified 
incubator with 5% CO2. After 2 hr, gelatin was decanted and washed twice with 10 
mL of sterile 1 x PBS or HBSS (Catalogue# 14175#095; Gibco, Carlsbad, California, 
USA). The HUVECs were cultured in 0.2% gelatin coated T#75 cm2 tissue culture 
flask. 
The vial containing the HUVEC cell line (Catalogue# PCS#100#013; ATCC, 
Manassas, Virginia, USA) was removed from liquid nitrogen and cells were thawed in 
a 37°C water bath for a minute. The cells were transferred to a 50 mL centrifuge tube 
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containing 10 mL of growth medium and pelleted at 1000 rpm for 5 min. Growth media 
consisted of EBM™#2 Basal Media (Catalogue# CC#3156; Lot# 442169; Lonza, 
Basel, Switzerland) and growth supplements (EGM™#2 Bullet kit with single quotes; 
Lonza; Catalogue# CC#4176). The spent media was discarded and the pellet was 
resuspended in 5 mL of growth medium. The cell count was taken and the cells were 
seeded at 5 x 105 cells /mL in 0.2 % gelatin coated T#75 cm2 flask in 10 mL of growth 
medium and incubated at 37°C in a humidified incubator with 5% CO2. Growth 
medium was changed every alternate day.  
 
After 3#4 days, i.e., on the day of experiment, the spent media was discarded and the 
monolayer was washed twice with 10 mL of HBSS. The cells were dissociated by 
trypsinization using 2 mL of TrypLETM Select (Gibco; Catalogue# 12563#011) for a 
T#75cm2 tissue culture flask. The TrypLETM select was spread uniformly across the 
monolayer and the flask was incubated for 2–3 min at room temperature. The flask 
was gently tapped on sides and bottom to dislodge cells. After 2#3 min, trypsin was 
neutralized with 10 mL of neutralization media, which was medium containing 10% 
heat#inactivated FBS (Hyclone; Catalogue# SH30070.03). The cells were transferred 
to a 50 mL centrifuge tube, pelleted at 1000 rpm for 5 min at room temperature. The 
cells were washed with assay media (EBM™#2 Basal Medium; Lonza; Catalogue# 
CC#3156) containing 90 µg/mL heparin (Sigma; Catalogue# H3149) and 2% FBS and 
pellet was resuspended in 2 mL of assay media. Cell count was taken and the number 
of cells adjusted to 5x 104 cells/mL. To a 96#well microtiter plate (Nunc; Catalogue# 
16109), 100 aL of cell suspension containing 5000 cells was transferred to each of the 
designated wells. To the wells designated as medium control, 100 aL of assay medium 
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was transferred. The assay plates were mixed and incubated for a period of about 5 hr 
at 37°C in a humidified incubator with 5% CO2. 
Confluent cultures of HUVECs were passaged, and cells from passages 3 to 6 were 
used [290]. The cells were maintained in a uniform suspension during addition.  
 
In another 96#well microtiter plate (dilution plate), serial dilutions of VEGFR1(D1#
D3)#Fc and aflibercept (anti#VEGF positive control) were prepared in assay medium.  
To 100 aL each of sample, 100 aL of 100 ng/mL of VEGF165 (in#house produced) was 
added, mixed and incubated for not less than 3 hr at 37°C in a humidified incubator 
with 5% CO2. After incubation, 100 aL of neutralized VEGF165 was transferred to the 
wells of assay plates where cells were seeded. 100 aL of assay medium was transferred 
to the wells designated as medium control and cell control. Controls used in the assay 
were for cells alone, cells with VEGF165 and medium control. The final VEGF165 
concentrations were one#fourth of the above concentrations when added to the assay 
wells (25 ng/mL per experimental well). The assay plates were mixed and incubated 
for a period of 70 ± 2 h at 37°C in a humidified incubator with 5% CO2. The assay 
plates were removed from the incubator and 30 aL (15% of total volume) of pre#
warmed alamarBlue® reagent (Invitrogen; Catalogue# DAL1100, 10 X ready#to#use 
solution) was added to each well. The assay plates was gently agitated and incubated 
for 17 ± 3 hr at 37°C in a humidified incubator with 5% CO2. The assay plates were 
removed from the incubator and allowed to cool to room temperature by placing on a 
plate shaker for approximately 30 min. The fluorescence (relative fluorescence units, 
RFU) was measured at an excitation wavelength of 544 nm and an emission 
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wavelength of 590 nm using Polar star OPTIMA plate reader (BMG Labtech, 
Germany). 
 
6.2.2 Inhibition of endothelial capillary tube formation by VEGFR1(D1-D3)-Fc 
 
6.2.2.1 Introduction 
 
Following endothelial cell proliferation and migration towards VEGF, a proangiogenic 
growth factor stimulus, the cells form tubes with lumens in order to conduct blood 
flow. Tube formation, or tubulogenesis, represents the later stages of the angiogenesis 
involving endothelial cells differentiation [285]. The propensity of endothelial cells to 
form a three#dimensional capillary/tube#like network, is a specialized function of these 
cells. Therefore, angiogenesis was assessed in vitro by a capillary/tube#like network 
formation assay. An angiogenic parameter, namely total capillary length per field, was 
evaluated. Matrigel was added to wells of a 96#well plate and then incubated at 37 °C 
for 1 hr to allow for optimal well coating. HUVECs, previously starved overnight, 
were seeded in Matrigel#coated wells in medium containing VEGF165 at a particular 
concentration, and various concentrations of the VEGFR1(D1#D3)#Fc trap protein. 
Plate was incubated at 37 °C for 18 hr in a humidified 5% CO2 atmosphere. Wells were 
viewed for tube formation at various time#points with an inverted microscope and 
images acquired and processed with relevant software. Results scored from two 
random fields in duplicate wells were averaged. Photographs were taken under the 
microscope with an attached digital camera [291]. 
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6.2.2.2 Material and Methods 
 
To each experimental well of a 96#microwell plate (Nunc; Catalogue# 16109), 50 µL 
of growth factor#reduced Matrigel (Catalogue# 356231; Corning, New York, USA) 
thawed overnight on ice at 4°C, was added, and the plate was incubated at 37°C in a  
5% CO2 humidified chamber for 1 hr. A vial of HUVEC cell line (normal human 
pooled cells, ATCC; Catalogue# PCS#100#013) was taken from liquid N2, thawed in 
37°C water for a minute before transferring to a 50 mL tube containing 10 mL of 
growth medium (EGM#2 media Bullet kit; Catalogue# CC#3162) and pelleted at 1000 
rpm for 5 min. The pellet was resuspended in 10 mL of EGM#2, cell count taken, and 
cells were seeded at 2 x 105 cells per T#75 flask in 15 mL of growth medium, and 
incubated at  37°C in a 5% CO2  humidified chamber. 
 
Different concentrations of anti#VEGF positive control molecule, aflibercept (2 
mg/mL, 0.5 mg/mL, 0.125 mg/mL, 0.0312 mg/mL and 0.0078 mg/mL), were prepared 
in assay media (EBM#2; Lonza, Catalogue# CC#3156) containing growth supplements 
and 0.2% FBS (Hyclone; Catalogue#SH30070.03) so as to get the effective 
concentrations of 500 µg/mL, 125 µg/mL, 31.25 µg/mL, 7.81 µg/mL and 1.95 µg/mL 
in the respective wells. Similarly, dilutions of VEGFR1(D1#D3)#Fc in assay medium, 
were also prepared. As a growth stimulator, 200 ng/mL VEGF165 was prepared in assay 
medium, so as to get an effective concentration of 50 ng/mL in each experimental well. 
For neutralization of VEGF165 by VEGFR1(D1#D3)#Fc and aflibercept, 50 µL 
VEGF165 solution was added to an equal volume of prepared dilutions of both the decoy 
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receptor traps. Assay plates with the different neutralization mixes (each 100 µL) were 
incubated at 37°C in a 5% CO2 humidified chamber for 1 hr. 
 
Following incubation, the seeded cells were washed with 10 mL sterile PBS. The cells 
were then trypsinized by adding 4 mL TrypLETM Select (Gibco; Catalogue#12563#
011) and incubated at 37°C in a 5% CO2 humidified chamber for 3 min. The dislodged 
cells were resuspended in 10 mL growth media and centrifuged at 1000 rpm for 5 min. 
The supernatant was discarded and the pellet was resuspended in 5 mL of assay 
medium. Cells were washed again by centrifuging at 1000 rpm for 5 min, discarding 
supernatant and resuspending cells in 5 mL assay media. Cell count was adjusted to 2 
x105 cells/mL. Aliquoted 50 µL cells (10,000 cells/well) in the required number of 
wells of the 96#microwell assay plate. Each of the different neutralization mixes (100 
µL) was added to the designated well containing Matrigel (50 µL) and cells (50 µL). 
The assay plate was incubated at 37°C in a 5% CO2 humidified chamber. At regular 
intervals of 2 hr, till disintegration of capillary tubes formed by HUVEC, the wells 
were viewed under phase contrast microscope (Zeiss). 
 
For analysis of images, ImageJ, an open source image processing program developed 
at the National Institutes of Health (NIH), was used 
(http://image.bio.methods.free.fr/ImageJ/Angiogenesis#Analyzer#for#ImageJ). 
Image analysis was done by “Angiogenesis Analyzer” subprogram within Image J 
software tool [292, 293]. “HUVEC phase” option was chosen and at least two images 
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of each well were taken under 10 X magnification. Total tube length for each well was 
taken into consideration. 
 
Figure 6.1 Representative image of capillary network formed by endothelial cells 
as analyzed by Image J software (NIH). Cell covered area (blue), tubes (red), loops 
(white), branching points (yellow). 
 
The software gives certain calculated values for parameters such as cell covered area 
(%), total tube length, total number of branching points, total number of loops, total 
number of connected network of tubes, mean area of loop and mean tube length. Since 
all of the key metrics would show the same characteristic over the experimental span 
of time, it was sufficient to evaluate only one parameter. The most stable and traceable 
parameter was total tube length (µm). Hence, evaluation of total tube length was 
considered among the different parameters, as a representation of formation of tubes, 
as it can be easily controlled by comparing the original images to the evaluated ones.  
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6.3 Results 
 
6.3.1 Inhibition of endothelial cell proliferation by VEGFR1(D1-D3)-Fc  
 
Inhibition of VEGF#induced HUVEC proliferation by VEGFR1(D1#D3)#Fc, was 
studied using both batches of the protein (batch#1 and batch#2). Figures 6.2 & 6.3 
show graphical representations of data for batch#1 and batch#1 protein, respectively. 
 
 
Figure 6.2 Inhibition of endothelial cell proliferation by VEGFR1(D1/D3)/Fc 
(Batch#1 protein). *, p≤0.05; **, p≤0.01; ***, p≤0.001; ****, p≤0.0001. The 
experiment was performed thrice and each time in triplicates. Data represents the 
graphical data from the best experiment. There was a significant increase in HUVEC 
proliferation upon addition of 25 ng/mL of VEGF165 to the growth medium (p≤0.01). 
Different concentrations of VEGFR1(D1#D3)#Fc were added to the growth medium. 
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In presence of increasing concentrations of VEGFR1(D1#D3)#Fc protein, the cell 
proliferation decreased significantly.  
 
Figure 6.3 Inhibition of endothelial cell proliferation by VEGFR1(D1/D3)/Fc 
(Batch#2 protein). The experiment was performed thrice in triplicates and data from 
one experiment is represented here. P#value ≤0.01 was considered to be statistically 
significant. **, p≤0.01; ***, p≤0.001; ****, p≤0.0001. 
 
The ability of VEGFR1(D1#D3)#Fc to inhibit cell proliferation in HUVEC was 
measured by fluorimetric and colorimetric assay using alamarBlue® method. In the 
assay for studying inhibitory effect of VEGFR1(D1#D3)#Fc protein from batch#1, a 
1.75#fold increase in cell proliferation was observed in HUVEC in response to 
VEGF165 (25 ng/mL), whereas a 2.4#fold increase was observed in the assay for 
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inhibitor protein from batch#2. VEGFR1(D1#D3)#Fc protein from both batches 
inhibited VEGF#stimulated cell proliferation with increasing concentrations. However, 
for both batches of inhibitor, the inhibition reached statistical significance (p≤ 0.01) at 
concentrations of 150 ng/mL and above. Cell proliferation was further inhibited at 
inhibitor concentrations of 200 ng/mL to 450 ng/mL (Figure 6.2) with even higher 
statistical significance (p≤0.001). From outcomes of batch#1 VEGFR1(D1#D3)#Fc 
protein, it was observed that inhibitor concentrations beyond 250 ng/mL, results in 
saturation of inhibition.  Overall, the results illustrated that, compared to vehicle 
control (cells and VEGF only), VEGFR1(D1#D3)#Fc treated primary endothelial cells, 
demonstrated reduction in proliferation of primary endothelial cells in a concentration#
dependent manner. 
 
6.3.2 Inhibition of endothelial capillary tube formation by VEGFR1(D1-D3)-Fc 
 
The inhibitory activity of VEGFR1(D1#D3)#Fc on endothelial cell remodeling and 
capillary network formation, was assessed in HUVEC tube formation assay. HUVECs 
(10,000 cells/well) plated on growth#factor reduced Matrigel in medium containing 
0.2% serum, formed capillary like tubular structures on the matrix#rich gel surface in 
presence of 50 ng/mL VEGF165, within the first two hours. When increasing 
concentrations of VEGFR1(D1#D3)#Fc were added to the assay medium containing 
VEGF165, the ligand (VEGF) was serially neutralized and not available to stimulate the 
endothelial cells to form three#dimensional structures of vascular tubes. At higher 
inhibitor concentrations, very small tubule#like structures were observed, which were 
not long enough to join with other smaller tubules, to form a network (Figure 6.4). 
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Hence, under the microscope, they appeared as isolated short tube#like structures, 
almost reduced to the appearance of dots, at highest inhibitor concentration (250 
µg/mL). Capillary tube lengths in varying concentrations of inhibitor, were quantitated 
using Image J software, and a graph was plotted for average tube lengths (Figure 6.5). 
 
Figure 6.4 Inhibition of endothelial tube formation by VEGFR1(D1/D3)/Fc. 
Images were taken under 10 X magnification and scale bar = 200 µm. 
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Figure 6.5 Inhibition of endothelial tube formation in HUVEC by VEGFR1(D1/
D3)/Fc. **, p≤0.01. The experiment was repeated at least thrice, each time with 
duplicates. Data was summed up for all experimental wells and expressed as mean ± 
standard deviation. Differences in p#value ≤ 0.01 were considered to be statistically 
significant.  
 
Images of capillary structures developed in HUVECs every two hours post addtion of 
inhibitor, were taken by microscope (Zeiss, Oberkochen, Germany) under 10 X 
magnification. For the experimental and control wells containing only cells and cells 
with VEGF165 (50 ng/mL), two images of two fields per well were taken by digital 
camera fitted to microscope. Images per field were analyzed using ImageJ software 
and several parameters including number of branch points or nodes, loops, meshes and 
number and total length of tubes were quantified as a measure of in vitro angiogenesis. 
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A graph plotted with concentrations of inhibitor against average length of tubes 
formed, revealed that with increasing concentrations of VEGFR1(D1#D3)#Fc added to 
cells treated with angiogenic stimulator, VEGF165,  there was a decrease in the tube 
length as a result of decrease in number of tubes formed (Figure 6.5). The inhibition 
of tube formation reached statistical significance (p≤0.01) at VEGFR1(D1#D3)#Fc 
concentration of 100 µg/mL and above (250 µg/mL). 
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6.4 Discussion 
 
HUVEC offer a classic in vitro model system to study several facets of endothelial cell 
functions including proliferation and tube formation.  
 
Anti#angiogenic effects of VEGFR1 (D1#D3)#Fc were evaluated in cell#based assays 
where anti#proliferative activity of the protein was assessed by studying its ability to 
reduce proliferation of HUVECs. VEGF acts as a chemotactic and mitogenic agent on 
vascular endothelial cells [294]. It interacts with its cell surface receptors on 
endothelial cells that form capillaries and blood vessels, and is the most potent 
angiogenic factor. On  the surface of endothelial cells, there are higher number of 
VEGFR2 receptors as compared to VEGFR1, and VEGF#A isoforms (such as VEGF165 
and VEGF121) interact with cell surface VEGFR2 to mediate endothelial cell 
proliferation via ERK1/2 MAPK phosphorylation [295]. VEGF#binding and activation 
of both the cellular cognate receptors, lead to phosphorylation of the receptor cytosolic 
domains. However unlike VEGFR1, phosphorylation of VEGFR2 activates several 
cell signaling pathways such as PI3K (activation leads to phosphorylation of Akt 
resulting in increased cell survival and vascular permeabilization), MEK (activation 
leads to phosphorylation of p38 resulting in increased cell migration) and PLCγ 
(activation leads to ERK phosphorylation which increases cell proliferation).  In fact, 
it has been reported that VEGFR1 induces nitric oxide (NO) synthesis in endothelial 
cells which inhibit proliferation [296]. 
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VEGF165 stimulated proliferation of HUVEC to about 2#fold in 72 hr as compared to 
cells grown without VEGF165. Upon addition of VEGFR1(D1#D3)#Fc to medium 
containing VEGF165, the ligand was neutralized, as it was no longer available to bind 
to the cognate cellular receptors, VEGFR1 and VEGFR2. This resulted in a decrease 
in HUVEC proliferation in a VEGFR1(D1#D3)#Fc concentration#dependent manner. 
 
The tube formation assay is the preferred angiogenesis assay in vitro, as other assays 
such as cell adhesion, cell migration and invasion, measure only limited steps in the 
angiogenic process [297]. The assay is expeditious, easy to set up, requires a short 
culture period and quantifiable, as it measures the number, length and area of the 
capillary network in two dimensional microscopic images of microwells of 96#well 
plate. Endothelial cells in response to VEGF165 began to align themselves within 1 hr 
and start forming sprouts or lumen#containing tubules within 2 hr of plating on 
Matrigel, (a gel product of basement membrane extract derived from Engelbreth–
Holm–Swarm tumor cells containing laminin as a major component). The developing 
tubes contained a lumen surrounded by a lining of endothelial cells. They connected 
with similar projections originating from neighboring cells to form cell#cell contact at 
junction complexes. The process of joining of cells continued till multiple projections 
from the same cell formed a series of polygonal or “honeycomb” structures which were 
viewed under microscope [298]. The cells formed interconnected capillary network 
within 3 hr and once formed, they were maintained for about 24 hr. The tubes were 
visualized under a phase contrast inverted microscope and the number of branch 
sites/nodes, loops or meshes as well as number and length of tubules were determined 
following analysis of images with ImageJ software. The entire assay can be completed 
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within one day. However, the disadvantage of this assay is the large variation of the 
tube forming ability among different lots of endothelial cells and Matrigel. 
 
Decrease in endothelial tube length in HUVEC was observed with increase in 
concentration of VEGFR1(D1#D3)#Fc as a result of binding and neutralization of 
VEGF165. Even though there was not a perfect correlation between visual observation 
of the number of endothelial tubes in experimental wells under microscope, and tube 
lengths analyzed by Image J, a trend was observed in the plotted graph of inhibitor 
concentration versus average tube length (Figure 6.5). VEGFR1(D1#D3)#Fc 
concentrations of 100 µg/mL and above were able to significantly inhibit formation of 
endothelial tubes in HUVECs (p≤0.01) [299].  
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Chapter 7: In vivo efficacy assessment of VEGFR1(D1-D3)-Fc 
protein  
 
Aim: The current chapter deals with studies on   efficacy assessment of 
VEGFR1(D1/D3)/Fc protein. Ability of the anti#VEGF protein to reduce tumor 
burden in immunocompromised SCID mice, was studied in this section. Assessment 
of efficacy of the proposed drug, in human A549 tumor cell#derived xenografts in mice 
models, was carried out. The ability of the drug to reduce tumor volume by 
subcutaneous dosing in xenografted SCID mice, was assessed. Immunohistochemistry 
and histopathological analyses in tumor sections were carried out in order to assess 
reduction in tumor cell proliferation and angiogenesis, with VEGFR1(D1#D3)#Fc 
treatment. 
 
7.1 Introduction 
 
The biological activity of VEGFR1(D1#D3)#Fc protein in vivo was assessed in SCID 
mice. The antitumoral activity of VEGFR1(D1#D3)#Fc was determined using 
xenograft mice models of human cancer. Reduction in tumor growth and tumor 
neovasculature formation, upon administration of the fusion protein in mice, was 
analyzed by histopathological and immunohistochemical methods, in order to establish 
the anti#angiogenic properties of the molecule. 
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7.1.1 Introduction to in vivo studies 
 
Preclinical animal models of human diseases contribute significantly to the 
development of any new therapeutic agent in terms of its efficacy and safety [300]. 
Several animal models of human cancers have been developed in order to investigate 
the role of particular factors responsible for cellular transformation, cancer initiation, 
invasion, progression and metastasis. The best#known and most widely used animal 
models are those in which human cancer cells are xenotransplanted, either below the 
skin or into the organ type in which the tumor had originally formed. The xenografts 
(of human origin) are not rejected by the recipient animals because they are chosen to 
be either athymic nude mice, severely compromised immunodeficient mice (SCID) or 
any other type of immunocompromised murines/rodents. For the current study, a cell 
line of human origin, known to induce significant neo#angiogenesis during tumor 
formation, was utilized for xenograft development in SCID mice. Once a tumor 
developed in the SCID mice, the proliferative and angiogenic properties of the growing 
tumor were determined by the presence of Ki#67 [301] protein in the tumor cell 
nucleus, which is a marker for mitosis and cellular division. Angiogenesis marker 
CD31 antigen present in the developing tumor was assessed by detecting its presence 
on mice blood vessels supporting the tumor [302, 303]. 
 
7.2 Materials and Methods 
 
For this study, sixteen male SCID mice were sourced from Animal Breeding and 
Housing Facility, Laboratory Animal research Services (LARS), Reliance Life 
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Sciences, Navi Mumbai, India. The mice were maintained in pathogen#free conditions 
and well fed. All experimentation involving laboratory animals were approved by the 
Institutional Animal Ethics Committee (IAEC) [Registration number: 
423/01/a/CPCSEA; Protocol number: 20/15; Date of approval: 08 June 2015]. 
Human lung adenocarcinoma alveolar basal epithelial cells, A549, were used to 
generate tumors in mice. Cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% fetal calf serum and 1% penicillin#streptomycin, in 
a 5% CO2 incubator at 37°C. Five million cells, mixed with 50 µL DMEM medium 
and suspended in 50 µL Matrigel (Catalogue# 356231; Corning, New York, USA), 
were injected sub#cutaneously into the right flank of each of the experimental animals. 
Male SCID mice used for the study were six to seven weeks old.  All animals 
developed single palpable tumors within the second to the third week of injection of 
cells. The size of the developing tumors in mice xenotransplanted with A549 tumor 
cells (ATCC; Catalogue# CCL#185, Manassas, Virginia, USA) were measured 
externally using digital calipers, after every 3 days. Tumor volumes were calculated 
using the modified ellipsoidal formula:  Volume = (Length × Width2)/2; where length 
is the longest axis or greatest longitudinal diameter, and width denotes the 
measurement at a right angle to the length, or the greatest transverse diameter [304]. 
Tumors of required volume, developed after about three to four weeks. Animals with 
similar tumor volumes (~80#100 mm3) were grouped and subjected to treatments as 
follows: Group 1: Untreated; Group 2: Placebo treated; Group 3: Aflibercept as 
positive control; Group 4: VEGFR1(D1#D3)#Fc. Groups 1 and 2 had three animals 
each, whereas, groups 3 and 4 had five animals each.   
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Xenografted mice in the respective groups, except for those in the control group, were 
injected with either 200 µL formulation buffer (placebo), aflibercept or VEGFR1(D1#
D3)#Fc, subcutaneously in the opposite flank to where the implanted tumor had 
developed, every third day. For both VEGFR1(D1#D3)#Fc and aflibercept, a dose of 
15 mg/kg body weight of mice, was injected in each mouse in the respective group. 
Subcutaneous injections were given contralaterally twice a week, for four weeks. Thus 
a total of eight doses were given in experimental mice. Tumor volumes were measured 
on each of these days when the drugs were injected. To assess the in vivo anti#tumor 
activity of VEGFR1(D1#D3)#Fc and aflibercept, mean tumor volumes measured on 
days of dosing, were plotted against duration of treatment, and degree of statistical 
significance of tumor reduction data was determined. 
 
Three days after the last dose was injected, the animals were sacrificed by cervical 
dislocation and dissected to expose tumors [305]. The sacrificed animals with tumors, 
as well as the excised tumors, were photographed. Following imaging, the tumors were 
sectioned. Along with tumors, the other important organs (heart, brain, liver, lungs, 
spleen and kidneys) were also excised and collected in formalin before sectioning and 
subsequently subjected to Haemotoxylin and Eosin (H&E) staining. Tumor sections 
were subjected to H&E and immunohistochemistry.   
 
Microscopic examination of H&E stained tumor sections were performed, to indicate 
necrotic and neoplastic areas, as well as extent of neo#angiogenesis inhibition. Cell 
proliferation marker (Ki#67) was utilized to determine overall status of proliferating 
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cells in excised tumors. CD31 was used as an angiogenic marker for newly formed 
blood vessels (mice origin) which supported the tumor xenograft (human origin). 
Immunohistochemistry with fluorescence detection was used to detect CD31 antigen, 
present on vascular lining of mice blood vessels supporting tumor growth. 
 
The combinatorial effect of VEGFR1(D1#D3)#Fc with an anti#VEGF DNA aptamer, 
RNV66, was tested in another study on A549 tumor bearing 4#5 weeks old female 
SCID mice. The aptamer (Figure 7.1) was a kind gift from Professor Jagat Kanwar’s 
laboratory at Deakin University, Australia. After generating tumors in the mice, the 
mice were treated with (a) DNA aptamer, RNV66 (b) VEGFR1(D1#D3)#Fc (c) 
aflibercept (d) RNV66 and VEGFR1(D1#D3)#Fc and (e) formulation buffer (placebo). 
The number of animals in the groups treated with aptamer, and that with combination 
of aptamer and VEGFR1(D1#D3)#Fc, was five each, whereas, the other groups except 
placebo, had two animals each. Three animals were grouped under placebo#control. 
The dosing regimen comprised 3 doses of aptamer (0.05 millimoles) as well as the 
drug combination. VEGFR1(D1#D3)#Fc dose was kept at 15 mg/kg, in both drug alone 
and combination group. For both aflibercept and VEGFR1(D1#D3)#Fc, animals were 
given three doses of 15 mg/kg body weight of the animal. Experimental drug doses 
were given every alternate day for three dosings, and thereafter a treatment#free period 
of four weeks preceded animal sacrifice according to animal ethics approvals. 
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Figure 7.1 Structure of RNV66 aptamer (Reproduced from Edwards, S.L., et al., 
Targeting VEGF with LNA#stabilized G#rich oligonucleotide for efficient breast 
cancer inhibition. Chemical Communications, 2015. 51(46): p. 9499#9502. DOI: 
10.1039/C5CC02756J [306]; with permission from the Royal Society of Chemistry). 
  
7.2.1 Histopathological analysis 
 
Tumors from all SCID mice were harvested and fixed with formalin, and tumor tissues 
were paraffin#embedded. Fixation was done to preserve the tissue permanently in a 
near life#like state. A 10:1 ratio of fixative to tissue was used, in which, the fixative, 
formalin or formaldehyde (10% neutral buffered formalin or formaldehyde in 
phosphate buffered saline, pH 6#8), penetrates the tissue well and fixes it by cross#
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linking the lysine residues without compromising the protein structure or antigenicity. 
The formalin fixed tissue was then dehydrated using an alcohol gradient (50%, 70%, 
95% and 100%), followed by treatment with a “clearing” agent (xylene) which 
removes the dehydrant and is miscible with the embedding agent.  Tissue processor 
(Thermo Electron Corporation, Model#Shandon Citadel 2000) was used to perform 
fixation, dehydration, clearing and paraffin infiltration steps. The tissue was then 
embedded in paraffin using an automated tissue embedding system (Labcon, Model#
Myr; California, USA). Since tissues cannot be viewed under microscope owing to 
their thickness, thin sections (3#4 am in thickness) were cut using a microtome 
(Thermo Electron Corporation, Model#Finesse ME, Waltham, Massachusetts, USA) 
and the sections were placed in a warm floatation bath to remove wrinkles, from where 
they were picked up on frosted egg albumin coated glass slides as well as poly#L lysine 
charged slides. The slides with sections were left to dry overnight at 56#58°C for 
melting of paraffin and proper adhering of the tissues. The sections were kept in xylene 
in order to remove paraffin out of the tissue and allow penetration of water#soluble 
dyes, by running them through decreasing alcohol gradient (100%, 95%, 70% and 
50%) to water. After haematoxylin (Sigma#Aldrich, Catalogue# HHS16) & eosin 
(Sigma#Aldrich; Catalogue# E4382) staining using an automated stainer (Thermo 
Electron Corporation, Model#Veristain Gemini), the slides were washed through water 
to alcohol gradient (50%, 70%, 95% and 100%) to xylene, and mounted with non#
aqueous DPX mountant and analyzed via light microscopy. An Olympus BX51 
microscope (Olympus, Tokyo, Japan) with ProgRes C3 image documentation camera 
software was used to acquire color images of H&E#stained tumor sections at 400× 
magnification. 
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Histopathological analysis was performed for all animals including untreated, placebo#
control and test drug. H&E provided a broad picture of the microanatomy of tissues 
and cells. Hematoxylin acts as a basic dye by binding to a compound that helps in 
linking it to tissue (mordant), such as aluminium salts and thus stains acidic or 
basophilic structures like DNA in the nucleus and RNA in ribosome and rough 
endoplasmic reticulum, purple. Eosin is an acidic or negatively charged dye that binds 
to positive or eosinophilic structures. Since most proteins in the cytoplasm are basic 
owing to presence of arginine and lysine side chains, the cytoplasm and cytoplasmic 
components including collagen and elastic fibres, muscle fibres and red blood cells are 
stained pink to red by eosin.   
 
7.2.2 Immunohistochemistry 
 
Immunohistochemistry (IHC) is a process for identification of the location or 
distribution (or demonstrating the presence) of a target protein (antigen) in a section of 
a tissue or cells, by staining with a specific antibody. Since the primary antibody used 
is highly specific to the antigen, it will only bind to the target protein of interest. The 
antigen#antibody interaction can then be viewed under microscope by either 
chromogenic detection, where an enzyme conjugated to the secondary antibody 
cleaves a substrate producing a colored precipitate at the site of target localization, or 
by fluorescence detection, where a fluorophore conjugated to the secondary antibody 
can be viewed by fluorescence microscopy. Schematic representation of IHC is given 
in Figure 7.2.  
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1. Tissue fixing and embedding 
The tumor and other tissues were first fixed in 10 times their volume of 10% neutral 
buffered formalin for overnight. Fixation preserves biological tissue from decay thus 
averting autolysis, necrosis and putrefaction. Fixation preserves antigenicity of the 
tissue, increases refractive index of the tissue constituents and resistivity of the cellular 
components to tissue processing including dehydration, clearing of dehydration agents, 
embedding and sectioning. However, during the process of fixation, methylene bridges 
are formed which cross#links proteins thereby masking the antigenic epitopes [107]. 
Embedding preserves the morphology of the tissue while giving support to the tissue 
during microtomy. Since paraffin wax is immiscible in water (which is the chief 
constituent of tissue), the tissues were dehydrated using progressively concentrated 
ethanol baths. This was followed by treatment with a clearing agent (xylene) which 
removed ethanol, after which molten paraffin infiltrated the tissue and replaced xylene. 
 
2. Cutting of section 
Following trimming to remove excess paraffin in order to ‘expose’ the tissue, the 
paraffin#embedded tissues were cut on a microtome to 3#4 µm thickness and mounted 
on charged poly L#lysine coated glass slides. The slides were left to dry overnight at 
56#58°C in order to remove any traces of water trapped under the tissue sections, to 
ensure proper adherence of sections to slides, and to melt the paraffin. 
 
 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
324 
  
3. Deparaffinization and rehydration of section 
Paraffin#embedded tissue sections were deparaffinized/ dewaxed by incubation of 
slides containing sections overnight at 56#58°C followed by immersing in xylene for 
15 min. The sections were rehydrated using graded concentrations of ethanol (100%, 
95%, 70% and 50%) to deionized water. The slides were kept in water and not allowed 
to dry from this point onwards, as dried out sections may cause non#specific antibody 
binding leading to high background staining.  
 
4. Antigen retrieval 
Most tissues require a step of antigen retrieval where the methylene bridges formed 
during fixation are broken and the antigenic sites are exposed to allow them to bind to 
the antibody [104]. Antigen retrieval can be achieved in two ways: Proteolytic#induced 
Epitope Retrieval (PIER) using enzymes like Proteinase K, trypsin or pepsin, or Heat#
induced Epitope Retrieval (HIER) using heat from a variety of sources like microwave, 
pressure cooker, steamer, water bath or autoclave. In this case, the heat#induced 
method of antigen retrieval was carried out using a microwave with maximum power 
for 5 cycles of 5 min each (with 3 cycles at 100°C and 2 cycles at 50°C) after the 
antigen retrieval buffer (Tars/EDTA, pH 9.0) in which the slides are placed, starts to 
boil [106]. Slides were allowed to cool for 50–60 min. 
 
 
 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
325 
  
5. Blocking of peroxidase activity  
For the chromogenic method of detection, an enzyme#conjugated secondary antibody 
is used to visualize antigen localization using enzyme substrate reaction yielding a 
colored precipitate. In the case of HRP#conjugated secondary antibody, a blocking step 
has to be performed to eliminate endogenous peroxidase activity of cells or tissue 
giving rise to high background or non#specificity. When quenching is not performed, 
the endogenous peroxidase activity of cells like red blood cells in vascular tissue, will 
cause non#specific staining and lead to false positive results. Blocking was achieved 
by incubating the slides with 3% H2O2 solution in methanol at room temperature for 
20 min. For tissue sections which were used to detect Ki#67 using HRP#conjugated 
secondary antibody, blocking was performed for endogenous peroxidase activity. 
Following incubation with blocking agent, the slides were rinsed 4–5 times with water. 
 
6. Blocking with serum 
IHC relies on specific antigen#antibody binding which in turn is dependent on the 
hydrophobic interactions, ionic interactions, hydrogen bonding, Van der Waal’s force 
and several other intermolecular forces. However, these interactions are also capable 
of promoting non#specific binding. Hence, in order to avoid non#specific antibody 
binding, serum from an unrelated species (horse serum) was used as the blocking agent 
for tissue sections before addition of primary antibody, in order to reduce background 
signal/ noise and false positive results. The antibodies in horse serum bind to the non#
specific (reactive sites) of the tissue, thereby preventing non#specific binding of the 
primary and secondary antibodies. The tissue sections were incubated with 100 µL of 
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5% horse serum (Catalogue# 16050#122; Gibco) in Tris buffer (pH 7.4) for 30 min. 
Following incubation, the slides were rinsed with water 5 times. Blocking with serum 
was performed in case of tissue sections in which angiogenic marker, CD31 was 
detected using fluorescence with (FITC)#conjugated secondary antibody. 
 
7. Immunohistochemical staining with primary antibody  
For Ki/67 staining: 
The slides were incubated in Tris buffer, pH 7.4 for 5#10 min before addition of 
primary antibody. Monoclonal mouse anti#human Ki#67 antigen (Clone MIB#1; Code 
no. M7240; Dako, Glostrup, Denmark) [307] was diluted 1:200 times in antibody 
diluent (Catalogue# S0809, DAKO, Glostrup, Denmark). Tissue samples were 
incubated with 50#100 µL of diluted antibody for 1 hr at room temperature in a 
humidifying chamber. The slides were rinsed 4#5 times with Tris buffer, pH 7.4. 
 
For CD31 staining: 
Goat anti#mouse CD31 (mouse/rat CD31/PECAM#1 affinity#purified polyclonal 
antibody, catalogue# AF#3628, R&D Systems, Minneapolis, Minnesota, USA) was 
diluted 1:100 times in antibody diluent. About 50#100 µL of diluted antibody was 
added to cover the entire tissue section in each slide. The slides were incubated in a 
humidifying chamber for 1 hr at room temperature. Following incubation, the slides 
were rinsed with Tris buffer, pH 7.4. 
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9. Incubation with HRP/conjugated secondary antibody 
For Ki#67 stained slides, peroxidase#conjugated goat anti#mouse immunoglobulin G 
antibody (Dako REALTM EnVision Detection System, Peroxidase/DAB+, 
Rabbit/Mouse; Code K5007; Dako) was used as secondary antibody. About 100 µL of 
it was added to the slides. The slides were incubated for 30 min at room temperature, 
after which the slides were rinsed 4#5 times with Tris buffer, pH 7.4.  
 
9. Incubation with FITC/conjugated secondary antibody 
Affinity#purified anti#goat IgG (whole molecule)#FITC labeled polyclonal antibody 
produced in rabbit (Catalogue# F7367, Sigma Aldrich, St. Louis, Missouri, USA) was 
used as secondary antibody. A 1:400 dilution of the antibody in antibody diluent 
(Dako) was used followed by incubation with tissue section for 1 hr at room 
temperature in a humidifying chamber. The slides were rinsed with Tris buffer, pH7.4, 
following incubation. 
 
10. Detection  
For Ki/67 
The substrate system consisted of DAB and Chromogen which were diluted in 
Substrate buffer (1:50) before use (Dako REALTMEnVisionTM detection system). The 
slides were incubated with this solution for 2#4 min during which a crisp brown end 
product was formed at the site of the target antigen. To stop the reaction, the slides 
were rinsed with water, following which they were counterstained with diluted 
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haemotoxylin (which provided a clear blue nuclear staining) to analyze tissue viability 
and morphology. 
 
For CD31 
Sections were counterstained by incubating the slides with about 150#200 µL of DAPI 
(4′,6#Diamidino#2#phenylindole dihydrochloride; Catalogue# D9542, Sigma Aldrich) 
for 5 min in dark at room temperature followed by rinsing with buffer. Direct 
measurement of fluorescence was performed under fluorescence microscope after 
mounting of slide. 
 
11. Slide mounting 
The slides were washed with water and dehydrated in an increasing ethanol gradient 
(50%, 70%, 95% and 100%). The slides were then dried and rinsed with xylene to clear 
the sections. The stained tissue sections were mounted with synthetic non#aqueous 
mounting medium, DPX, in the case of chromogenic detection method, and with an 
aqueous mounting medium containing antifade reagent (Fluoroshield, Catalogue# 
F6182, Sigma) in the case of fluorescence detection, to prevent rapid photo bleaching 
of fluorescein dye. For Ki#67 stained slides, images were viewed with a microscope 
(Olympus BX51) equipped with ProgRes C3 capture software. For CD31 stained 
slides, images were observed with a fluorescence phase contrast microscope (Zeiss). 
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Figure 7.2 Immunohistochemistry flowchart with different methods of antigen 
detection. In enzyme#linked detection system, primary antibody is first used to bind 
to target antigen expressed by the cells in the tissue section. This is followed by binding 
of secondary antibody which is linked to an enzyme (HRP; horseradish peroxidase or 
ALP; alkaline phosphatase). In case of HRP#conjugated secondary, HRP catalyzes the 
oxidation of soluble substrates by hydrogen peroxide, resulting in an easily detectable 
insoluble colored product as a byproduct of the reaction, localized at the site of 
antigenic expression. In the other detection method, the secondary antibody is 
conjugated to a fluorophore (e.g. FITC) which produces an intense fluorescent signal 
for detection. 
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7.2.3 Statistical analysis 
 
Raw data of tumor volume was processed to get group mean and standard deviation 
within each group containing 3#5 mice. Statistical differences between two groups 
were determined using the two#sample Student's t#test using Microscoft Excel 
(Microsoft Inc., USA). 
 
7.2.4 Analysis of microvessel density (MVD) 
 
Fluorescently stained sections (mouse CD31 antigen) were microscopically examined 
under low (200x) and high (400x) magnification. Under low magnification, 
representative areas of the tumor neovascularization were marked. Under 400× 
magnification, ten high power fields were selected randomly within these areas, and 
blood vessels were counted by an expert pathologist. The counts were averaged to 
determine the MVD of mouse CD31#positive vessels [308]. 
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7.3 Results 
 
7.3.1 Tumor volume measurement 
 
SCID mice xenotransplanted with A549 human lung adenocarcinoma, were grouped 
as untreated controls, placebo#treated and treatment groups. The three treatment groups 
included one group treated with known anti#angiogenic drug, aflibercept, the other 
group treated with an anti#VEGF aptamer, and the last one treated with experimental 
drug, VEGFR1(D1#D3)#Fc. During the period of drug dosing, the tumor dimensions 
(length and width) were measured using digital calipers at regular intervals and tumor 
volumes calculated. 
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Table 7.1 Tumor volume measurement in xenograft mice model up to a 27/day period. 
Groups 
Number of days 
0 3 7 10 14 17 20 24 27 
Average tumor volumes (mean ± SD) in mm3 
Control (untreated) 
[n=3] 
77.35  
±38.08 
115.75     
±67.64 
354.47  
±290.61 
502.05   
±377.88 
630.99 
±432.05 
730.89 
±444.33 
840.74 
±455.87 
1096.80 
±545.89 
1125.11 
±567.37 
Placebo 
[n=3] 
81.19  
±31.99 
136.56  
±37.39 
253.60  
±111.70 
392.61   
±173.06 
416.58 
±160.48 
537.63 
±212.58 
558.06 
±200.05 
736.32 
±311.11 
856.04 
±398.61 
Aflibercept [n=5] 
72.72  
±15.88 
54.41  
±31.22 
41.20  
±30.71 
32.38      
±20.19 
26.09 
±18.06 
23.38 
 ±17.56 
13.85 
±10.29 
10.19 
 ±9.71 
7.38 
±9.30 
VEGFR1(D1#D3)#Fc 
[n=5] 
69.44  
±15.74 
81.61  
±48.69 
90.73  
±62.34 
106.32     
±80.17 
120.73 
±93.89 
126.37 
±100.11 
148.67 
±138.45 
171.20 
±158.78 
195.89 
±177.75 
 
 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
333 
  
Results are presented as mean tumor volume ±standard deviation (SD) for each of the 
four groups for each day of tumor volume measurement (Table 7.1 & Figures 7.3 & 
7.4). Changes in tumor volumes were compared using a two#sided, two sample t#test 
that is considered statistically significant when p#value is less than 0.05. A total of 8 
doses of VEGFR1(D1#D3)#Fc protein, each of 15 mg/kg of mice body weight, was 
administered subcutaneously on the right flank of each of 5 SCID mice. Dosing was 
done twice a week for four weeks. As a positive control anti#angiogenic drug, 
aflibercept, was subcutaneously administered in a similar dosing regimen in 5 SCID 
mice. All animals were humanely sacrificed three days post the last dose. 
 
Figure 7.3 Dosing regimen of VEGFR1(D1/D3)/Fc for reduction of tumors in 
xenotransplanted SCID mice. *; p<0.05, **; p<0.01. Untreated control mice (n=3) 
and placebo control mice (n=3) showed very rapid increase in tumor volume, whereas 
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mice treated with eight doses, each of 15 mg/kg of VEGFR1(D1#D3)#Fc, (n=5), 
showed significant reduction in tumor burden (p<0.05). Mice treated with eight doses 
of 15 mg/kg of aflibercept (n=5) showed highly significant reduction in tumor volume 
(p<0.01) throughout treatment period.  
 
 
Figure 7.4 Tumor growth curve in response to anti/angiogenic treatment. P#value 
for VEGFR1(D1#D3)#Fc treated mice (n=5) as compared to placebo control mice was 
less than 0.05. P#value was less than 0.01 for aflibercept#treated mice (n=5) suggesting 
highly significant tumor reduction with treatment. 
 
The anti#tumor effect of treatment with VEGFR1(D1#D3)#Fc was investigated in 
immunocompromised mice. Five million A549 human lung cancer cells were injected 
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subcutaneously in the right flank of each of 16 six to seven weeks old male SCID mice, 
and tumors developed within three to four weeks to the desired volume of 80–100 
mm3. The mice with transplanted tumor xenografts, were grouped into four clusters 
including untreated control, placebo#treated, positive control and test drug group. Over 
four weeks, a total of eight doses of 15 mg/kg body weight of animal, of anti#
angiogenic proteins, VEGFR1(D1#D3)#Fc as well as aflibercept (positive control), 
were subcutaneously administered to individual members of respective groups. Tumor 
length and width were measured every three days using digital calipers, until the time 
animals were sacrificed (Figures 7.6 & 7.7). Tumor volumes were calculated from 
length and width data using the formula: Volume = (Length × Width2)/2. It was 
observed that as opposed to control and placebo, there was a significant reduction in 
tumor volume in mice treated with aflibercept, from the first dose onwards (n=5, 
p≤0.01). VEGFR1(D1#D3)#Fc also showed significant tumor growth inhibition after 
administration of the fifth dose (n=5, p≤0.01). Overall, there was an extremely slow 
rise in tumor volume in mice bearing xenografts over the four weeks of dosing with 
VEGFR1(D1#D3)#Fc, as compared to untreated or placebo#treated animals. This 
indicated that VEGFR1(D1#D3)#Fc undeniably has anti#tumor activity as a result of its 
anti#angiogenic properties, as was also evident from in vitro assays. 
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Figure 7.5 Plot of mean tumor volume in SCID mice versus duration of treatment 
with 15 mg/kg dose of anti/VEGF molecules. 
 
In order to investigate the anti#tumor activity of VEGFR1(D1#D3)#Fc in combination 
with other anti#VEGF investigational drugs, SCID mice bearing A549 tumor 
xenografts, were treated with three doses each, of VEGFR1(D1#D3)#Fc alone, and in 
combination with anti#VEGF DNA aptamer (RNV66). It was observed that while 
aptamer alone was not able to reduce lung cancer tumor burden with the three 
administered dosages, a combination of aptamer (0.05 millimoles) and VEGFR1(D1#
D3)#Fc (15 mg/kg) was able to significantly reduce tumor volume (n=5, p≤0.01) until 
the dosing was completed. Thereafter the combination was able to control tumor 
growth up to another week, after which tumor rebounded. After completion of three 
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doses, the anti#VEGF positive control (aflibercept), as also VEGFR1(D1#D3)#Fc, 
maintained the reduced tumor volume until the time of animal sacrifice, whereas this 
was not the case for aptamer alone or aptamer#VEGFR1(D1#D3)#Fc combination 
(Figures 7.5, 7.8 & 7.9). 
 
 
Figure 7.6 SCID mice displaying xenografts on their right flank. The top panel (A) 
shows the mice bearing A549 human tumor xenografts, from group 1 (untreated 
control); where C#1 represents animal#1 and C#2 represents animal#2; Group 2 
(placebo#treated); where P#1 is animal#1 and P#2 is animal#2; Group 3 (aflibercept#
treated); where A#1 represents animal#1 and A#2 represents animal#2. The bottom 
panel (B) represents tumors excised from the corresponding animals after sacrifice 
following completion of drug dosing regimen.  
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It can be clearly observed from the top and bottom panels, that both aflibercept#treated 
mice (A#1 and A#2) have reduced tumor size as compared to untreated control mice 
and placebo.  
 
 
Figure 7.7  therapeutic efficacy of VEGFR1(D1/D3)/Fc to reduce xenograft 
tumor in SCID mice model. (A) Pictorial representation of VEGFR1(D1#D3)#Fc#
mediated regression of A549 xenograft tumor in SCID mice. This represents the 
animals from group 4 (VEGFR1(D1#D3)#Fc#treated); where V#1 represents animal#1, 
V#2 represents animal#2, V#3 represents animal#3 and V#4 represents animal#4. (B) 
Pictorial representation of size of excised tumor in VEGFR1(D1#D3)#Fc#treated mice 
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In animals V#3 and V#4, tumor size reduction was not as significant as seen in tumors 
excised from animals V#1 and V#2.  
 
It can be clearly observed from the top and bottom panels, that both aflibercept and 
VEGFR1(D1#D3)#Fc had shrunk the tumors in the experimental mice as compared to 
untreated control mice and placebo. Tumor dimensions were measured by external 
calipers and tumor volume derived using the formula: Volume = (Length × Width2)/2. 
 
 
Figure 7.8  therapeutic efficacy of aptamer, RNV66 to reduce tumor in 
SCID mice model. The top panel (A) gives pictorial representation of aptamer and 
VEGFR1(D1#D3)#Fc#treated SCID mice at the end of the treatment period. The bottom 
panel (B) shows pictorial representation of excised tumors in aptamer and 
VEGFR1(D1#D3)#Fc#treated mice.  
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Figure 7.9   therapeutic efficacy of a combination of RNV66 and 
VEGFR1(D1/D3)/Fc to reduce xenograft tumor in SCID mice model. The top 
panel (A) shows pictorial representation of aptamer and VEGFR1(D1#D3)#Fc#treated 
SCID mice as well as placebo#treated mice at the end of the treatment period. The 
bottom panel (B) shows pictorial representation of excised tumors in combination#
treated mice as compared to placebo.  
 
7.3.2 Histopathological Analysis 
 
 
Histopathology of tissue sections provides the gold standard for diagnosing the 
intricacies of a disease like cancer at the sub#cellular level. H&E staining which is 
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traditionally used for histopathological analysis, helps to identify oncogenesis#induced 
changes in tissues and protein localization patterns inside cells [309]. A combination 
of H&E is the most widely used stain in histopathology, which can give valuable 
information about normal and abnormal tissues and cells by binding to different cell 
components through ionic interactions and imparting differential colours based on 
tissue chemistry. Haematoxylin stains nuclei deep blue#purple and eosin stains 
cytoplasm and extracellular matrix with varying shades of pink staining [310]. Figure 
7.10 shows representative images of H&E#stained tumor sections obtained from 
untreated mice as well as mice treated different anti#VEGF molecules. 
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Figure 7.10 Representative images of histological sections of tumors. (A, B) Images 
of C/1 & C/2 which represent sections from control (untreated) tumors; (C, D) Images 
of P/1 & P/2 which represent placebo#treated tumors; (E, F) Images of A/3 & A/4 
which represent aflibercept#treated tumors; (G, H) Images of V3 & V/4 which 
represent VEGFR1(D1#D3)#Fc#treated tumors. (I) Image of RNV66#3, which 
represents aptamer#treated tumor in animal#3; (J) Image of VEGFR1(D1#D3)#Fc and 
RNV66, animal#5, which received a combination of VEGFR1(D1#D3)#Fc and 
aptamer, RNV66 as treatment. 
Arrow heads indicate tumor cells in a pool of normal cells. Slides were stained with 
H&E to allow for assessment of tumor cell proliferation and necrosis. 
 
Figure 7.11 shows histogram representing percentage of viable cancer cells in 
untreated tumors and tumors treated with VEGFR1(D1#D3)#Fc as well as positive anti#
angiogenic agent, aflibercept.  
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Figure 7.11 Histogram showing percent viable adenocarcinoma in untreated and 
treated tumors. **; p<0.01 
Brightfield microscopic images of H&E stained slide (Figure 7.10) from tumor section 
of control (untreated) mice, C#1, revealed the presence of 80% of the cells showing 
viable adenocarcinoma, whereas C#2 demonstrated about 75% of viable cancer cells. 
For the untreated control sections, mass of tumorous growth encircled by fibrous tissue 
was observed beneath the skin subcutaneously. Histopathological observations of 
surrounding skin were found within normal histological limits. Tumor mass showed 
predominant solid pattern of neoplastic growth. Minimal fibrous tissue proliferation 
along with mucin, was evident in the mass. Diffuse mild to moderate liquefactive 
necrosis was observed with nuclear dust throughout the core of tumor mass. As tumor 
mass showed necrosis, it can be classified as a malignant tumor. As tumor was induced 
by injecting a culture of adenocarcinoma of lung, it could be classified as invasive 
adenocarcinoma with predominant solid mucinous pattern. 
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In placebo#treated mice P#1 and P#2, about 80#90% of viable tumor was detected by 
H&E staining of tumor. Broadly, in the placebo#treated sections, tumor mass showed 
minimal to moderate liquefactive necrosis. Mass was surrounded by fibrous tissue 
restricting further proliferation of neoplastic growth. Fibrous tissue proliferation, along 
with mucin, was evident in the mass. Microscopic observation revealed minimal focal 
vacuolar degeneration in the mass.  
Tumor sections from aflibercept#treated mice, A#2 and A#3, demonstrated small mass 
of tumor with 10% and 2% of viable tumor cells respectively. Extensive necrosis and 
calcification was observed in A#2 while necrosis with significant inflammatory 
response, was observed in A#3, suggested response to the treatment. Complete tumor 
mass was liquefied except fibrous capsule surrounding the mass. Neoplastic growth 
was replaced by vacuole and adipose tissue with sparse amount of fibrovascular tissue. 
Calcified foci was observed with minimal focal mononuclear and polymorphonuclear 
cell infiltration. 
 
H&E staining of VEGFR1(D1#D3)#Fc –treated tumor slide detected presence of 70% 
of viable tumor (animal# V#3) and 60% viable tumor (animal# V#4). Neoplastic growth 
was found to be restricted by surrounding with fibrous tissue. Minimal to mild 
multifocal liquefactive necrosis was observed. Fibrous tissue proliferation, along with 
mucin, was evident in the mass. Surrounding skin was found within normal 
histological limits. However, the presence of fibrous tissue proliferation was indicative 
of reparative or reactive processes by tissue itself as self#limiting mechanism in 
response to tissue damage.  
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In anti#VEGF aptamer, RNV66#treated tumors, the H&E staining of sections revealed 
tumor mass which showed mild to moderate liquefactive necrosis with nuclear dust. 
Minimal mucinous component was observed with fibrous tissue proliferation. 
Mucinous component was more pronounced in mice, RNV66#3. This section 
demonstrated presence of 85% viable tumor. Focal congestion was also observed in 
mice, RNV66#2, which also had 85% of viable tumor. In the remainder 15%, necrotic 
tissue was prevalent. 
 
In tumors treated with a combination of VEGFR1(D1#D3)#Fc and aptamer, RNV66, 
H&E staining of sections showed the presence of 40#85% of viable tumor cells. Tumor 
mass showed moderate (about 15%) liquefactive necrosis. Fibrous tissue proliferation 
along with minimal mucinous component and focal calcification, was evident in the 
mass. Mucinous component was more pronounced in mice, VEGFR1(D1#D3)#Fc + 
RNV66, animal#5, with minimal focal calcification. 
 
7.3.3 Immunohistochemical analysis 
 
7.3.3.1 Staining with anti-Ki-67 antibody 
 
Tumor sections were stained with Ki#67, a nuclear marker for cell proliferation, which 
positively stained nucleus with a brown coloration. Figure 7.12 gives representative 
images of treated and untreated tumor sections stained with Ki#67. 
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Figure 7.12 Representative images of Ki/67 staining of tumor sections.  
Image shows immunohistochemical staining of paraffin‐embedded human A549 
xenograft tumor sections stained with anti#Ki#67 antibody using the Dako’s Ki#67 
clone MIB#1. Ki#67 (dark brown) displayed a nuclear localization pattern which 
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correlated with its function in cell cycle progression (400x, counterstained with 
haematoxylin). 
Figure 7.13 represents the histogram for percentage of Ki#67#stained cells in sections 
of untreated tumors and tumors treated with VEGFR1(D1#D3)#Fc. 
 
Figure 7.13 Histogram representing percent positive Ki/67 cells in untreated and 
treated tumors. **; p<0.01 
Ki#67#positive tumor cells were easily identified by their characteristic brown globular 
or diffuse granular nuclear staining. Immunoquantitation of Ki#67 was accomplished 
using light microscopy at 400x magnification, in the areas containing the largest 
number of Ki#67#positive cells or the highest proliferating regions. A total of 1000 
cells were counted in 10 high power fields (HPF) and the percentage of positively 
stained cells was calculated. The scores were then averaged to give Ki#67 index (the 
number of Ki#67#positive tumor cells/HPF) in each case. The percentage of Ki#67 
positive nuclei was reported with its mean and standard deviation (Figure 7.13). 
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 For each case/ group, a representative slide was chosen by an expert pathologist for 
analysis of image. In control slides, C#1 and C#2, 60% of the tumor cells showed Ki#
67 staining in the highest proliferating region. Placebo#control slide, P#1 and P#2 
however, demonstrated about 55% of tumor cells showing Ki#67 staining, as opposed 
to VEGFR1(D1#D3)#Fc treated tumor (slides V#3 and V#4), which showed 41% of Ki#
67 stained proliferating tumor cells. Tumors treated with aflibercept (positive control) 
showed 10#15% of proliferating cells stained with anti#Ki#67 antibody) (Ki#67 index). 
For tumors treated with anti#VEGF aptamer, RNV66 DNA, the sections showed on an 
average about 55% viable tumor cells. Representative aptamer#treated tumor of 
animal#3 showed focally about 50% of viable tumor in the highest proliferating area. 
Tumor sections obtained from xenografted mice treated with a combination of 
VEGFR1(D1#D3)#Fc and RNV66 demonstrated a decreased 40% of viable or 
proliferating cells. Representative image of combination drug treated animal #5 
demonstrated the same. 
 
7.3.3.2 Staining with anti CD31 antibody 
 
CD31, a vascular endothelial cell marker was detected in the newly formed or 
developing blood vessels supplying nutrients to the tumor, by fluorescence detection 
in IHC analysis. Anti#mouse CD31 antibody was used as the primary antibody in order 
to detect CD31 protein on mouse vascular endothelial cells, as the tumor xenograft 
(human in origin) is supported by blood vessels of mouse origin, with the stroma being 
recruited and derived from the host [311].  
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Figure 7.14 Representative images of immunofluorescence staining of CD31 in 
mouse vasculature in tumor sections. (A) Untreated control (B) Placebo#treated (C) 
VEGFR1(D1#D3)#Fc#treated (D) Aflibercept#treated (E) RNV66#treated (F) 
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VEGFR1(D1#D3)#Fc plus RNV66#treated tumor. All images were captured in high 
power field, under 400x magnification. Scale bar=100µm. 
 
From IHC images on tumor sections from untreated and placebo#treated controls, the 
CD31# immunopositive blood vessels in tumor xenograft indicated the presence of 
high vascularization (green FITC dye), as opposed to treated mice with VEGFR1(D1#
D3)#Fc (Figure 7.10 C). This clearly demonstrated the anti#angiogenic properties of 
the Fc#fusion protein, whereby formation of new blood vessels was inhibited by the 
anti#VEGF agent, which is indicated by the reduction in the CD31 antigenic protein 
marker of endothelial cells. Tumors treated with aflibercept (anti#angiogenic positive 
control drug) showed a very low microvessel density, validating the anti#angiogenic 
effects of the drug. However, the anti#VEGF aptamer, RNV66 was unable to inhibit 
angiogenesis as was evident by the presence of large number of microvessels within 
the section of the tumor treated with the molecule. But, when a combination of 
VEGFR1(D1#D3)#Fc and aptamer was used to treat the tumor, the Fc#fusion partner 
was able to salvage some of the anti#angiogenic property of these anti#VEGF agents 
and decrease blood vessel formation. As compared to Figure 7.14 E, where only 
aptamer was used to treat the tumor, Figure 7.14 F clearly indicated a reduction in 
number of blood vessels in the tumor section of mice treated with the combination. 
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7.3.3.3 Microvessel density (MVD) of tumor vasculature 
     
For analysis of MVD, the entire section on each slide was viewed at low magnification 
(200x) and “hot spot” regions or the areas of highest neovascularization were observed. 
However, individual microvessels in the entire viable section were counted manually 
by a trained pathologist in ten random fields under high magnification (400x) and 
average count was taken as a measure of microvessel density for each study group. 
Figure 7.15 gives graphical representation of microvessel density in untreated tumors 
and tumors treated with VEGFR1(D1#D3)#Fc, aflibercept (positive control) and anti#
VEGF aptamer. 
 
 
Figure 7.15 Graph showing microvessel density (MVD) of tumor vasculature.  
***, p≤0.001; ****, p≤0.0001 
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Results were reported as the mean MVD in 10 HPF (Figure 7.15). Tumor sections 
obtained from control and placebo group of mice were observed to be well vascularized 
in comparison to anti#VEGF#treated tumors. Mean MVD for control (n=3) and placebo 
(n=3) tumors were determined to be 42.2 and 56.3, respectively. A significant 
reduction (MVD ∼35) was observed in VEGFR1(D1#D3)#Fc#treated tumors (p≤0.001, 
n=5). Treatment with Aflibercept (MVD <5) revealed a significant reduction in 
microvessel formation in A549 xenografted tumors (p≤0.0001; n=5). The effect of 
anti#VEGF, DNA Aptamer, RNV66, was not significant in reducing tumor 
vasculature. Tumor sections had good vasculature in aptamer#treated samples with a 
mean MVD of 54, similar to that of the placebo. This result was consistent with the 
tumor volume data in which the effects of treatment with aptamer and placebo were 
very similar in terms of volume of excised tumor from SCID mice. 
A combination of aptamer and VEGFR1(D1#D3)#Fc appeared to have a synergistic 
effect in reducing tumor microvessels as observed from the mean MVD (51.8), even 
though the effect was not overwhelming or statistically significant.  
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7.4 Discussion 
 
Tumor blood vessels are fundamentally different from normal blood vessels. They are 
typically irregular, tortuous, disorganized, leaky and hemorrhagic. They generally 
carry poorly oxygenated blood which can flow forward and backward in the same 
vessel [312]. This presents an opportunity for anti#angiogenic therapy with drugs 
targeted to disrupt the atypical tumor angiogenesis.  
 
SCID mice were subcutaneously injected with human lung cancer forming cells, A549, 
and tumors developed in the right flanks within few weeks. In order to assess the anti#
tumor activity as a result of anti#angiogenic properties of VEGFR1(D1#D3)#Fc, the 
protein was injected subcutaneously in close proximity to the developing tumor 
without injuring the tumor site in mice. A total of 8 doses of the protein were 
administered over a period of four weeks and tumor dimensions were measured at 
regular periods. As a positive control, known anti#angiogenic Fc#fusion protein, 
aflibercept, was similarly administered in mice and tumor volumes determined. Mice 
with untreated tumors were taken as negative controls. A significant reduction in tumor 
volume with VEGFR1(D1#D3)#Fc treatment was observed (n=5, p≤0.01) after 
administration of 5 out of 8 doses. Moreover, throughout the treatment period, there 
was only a slight increase in tumor volume (1.8 fold), as opposed to untreated control 
and placebo#treated mice where the tumor volume increased approximately 13.5 fold 
and 9.5 fold from the original volume at the start of treatment, respectively. Aflibercept 
significantly reduced tumor volume by 8.8 fold (n=5, p p≤0.01).  
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
355 
  
H&E staining of tissue sections revealed the highest percentage of tumor cells and 
minimal liquefactive necrosis along with invasive tumor mass with solid mucinous 
pattern of neoplastic growth in the tissue in untreated controls. In VEGFR1(D1#D3)#
Fc–treated tumors, sections revealed 60#80% of viable tumor cells with the presence 
of fibrous tissue proliferation, indicative of reactive processes by tissue in response to 
treatment. Aflibercept#treated tumor sections demonstrated liquefied tumor mass, 
calcified foci and inflammatory responses suggesting response to treatment. About 2#
10% of viable tumor was observed upon H&E staining of aflibercept#treated sections. 
 
Ki#67 is a human nuclear and nucleolar protein whose expression is strictly associated 
with somatic cell proliferation. The protein is present at low levels in non#dividing or 
resting cells (G0 phase), but its expression increases in proliferating cells, particularly 
in the active phases of the cell cycle such as G1 (gap1), G2 (gap2), M (mitosis) and 
later half of S (synthesis) phase. The protein can be exclusively detected within the 
nucleus during interphase, but relocates to the surface of the chromosomes during 
mitosis. Hence Ki#67 is extensively used as a cell proliferation marker and the fraction 
of Ki#67 positive tumor cells can be positively correlated to the extent of cancer. 
Staining of untreated control tumor sections revealed 60% Ki#67 positive tumor cells 
in the highest proliferating zone of the tissue. VEGFR1(D1#D3)#Fc –treated sections 
demonstrated a much decreased 40#45% of Ki#67 positive proliferating tumor cells, 
evident of tumor#reduction ability of the fusion trap molecule. The known anti#
angiogenic Fc#fusion protein, aflibercept, demonstrated only 10#20% of Ki#67 positive 
tumor cells in the corresponding sections, consistent with its established antitumoral 
activity. 
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CD31, which is a 130 kDa heavily glycosylated surface protein, also known as platelet#
endothelial cell adhesion molecule#1 (PECAM#1), belongs to the type I 
transmembrane glycoprotein adhesion molecule in the immunoglobulin superfamily. 
The protein is expressed at high levels by endothelial cells and at low levels by other 
cells involved in circulation including platelets, granulocytes (neutrophils), 
agranulocytes (monocytes, lymphocytes, macrophages), dendritic cells, natural killer 
cells, T cells and B cells. It is required for cell#cell adhesion, cell#matrix interaction, 
signal transduction and migration of leucocytes through tight junctions. Hence, CD31 
is used as a vascular endothelial cell marker as it is highly expressed on outer lining of 
blood capillaries and marks the newly developing microvessels via angiogenesis, in 
human cancer xenografts in mice.  
 
In vivo detection of mouse vascular marker CD31 using fluorescent labeled secondary 
antibody, revealed the presence of adequate microvessels in the control and placebo 
groups of untreated tumors. Strong staining with anti#CD31 antibody around the blood 
vessels in the tumor sections was observed in these cases, suggesting uninhibited 
angiogenesis in the tumor microenvironment. The CD31#positive intratumoral blood 
vessels on each slide, were counted at 400× magnification in each individual 
microscopic field, on viable parts of the entire tumor. The CD31#positive endothelial 
cells were observed to be with visible lumen with or without red blood cells. Tumors 
treated with VEGFR1(D1#D3)#Fc exhibited a lower number of microvessels in the 
developing mass, whereas treatment with aflibercept almost completely inhibited the 
formation of intratumoral microvessels. Hence, the anti#angiogenic and antitumoral 
activities of VEGFR1(D1#D3)#Fc were effectively demonstrated. Although, 
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aflibercept, the commercial Fc#fusion trap, was observed to be an extremely efficient 
anti#angiogenic drug, VEGFR1(D1#D3)#Fc also demonstrated anti#angiogenic 
properties. 
 
Aptamers are synthetic single#stranded nuclei acid molecules (DNA or RNA) or 
peptides capable of binding to protein targets with affinity comparable to that of MAbs 
[313]. The anti#VEGF DNA aptamer, RNV66, did not inhibit tumor growth in the 
SCID mice model of human lung cancer. However, the aptamer in combination with 
VEGFR1(D1#D3)#Fc (n=5), significantly inhibited tumor growth (p<0.05) after 
administering a second dose of the drug combination. VEGFR1(D1#D3)#Fc (n=5, 
p≤0.01) and aflibercept (n=2, p≤0.005) were able to independently inhibit tumor 
growth in mice model. From immunohistochemistry on tumor sections obtained from 
mice treated with aptamer, it was observed that the molecule was not able to inhibit 
the formation of blood vessels, as was evident from the presence of large number of 
mouse CD31#positive vessels within the tumor. Even though a combination of 
VEGFR1(D1#D3)#Fc and aptamer was able to reduce angiogenesis to a small extent, 
the anti#angiogenic effect of the combination was not statistically significant. The 
number of microvessels (green, CD31–FITC labeled) was quantitated by manual 
counting in ten random fields under the microscope. Microvessel density was observed 
to be reduced in tumors treated with aflibercept and VEGFR1(D1#D3)#Fc, but not with 
the aptamer. RNV66, which binds to VEGF and sterically blocks VEGF#VEGFR2 
interaction, had earlier been shown to successfully inhibit the proliferation of the breast 
cancer cell line MDA#MB#231 in vitro as well as tumor xenografts in mice breast 
cancer model [306]. Most probably, the dose of aptamer for this study was insufficient 
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to achieve the expected results in terms of tumor regression and angiogenesis. 
Increasing the concentration and number of doses of aptamer might overcome this 
problem.  
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Chapter 8: Discussion and future work  
 
8.1 Discussion 
 
 
Angiogenesis, the crucial process of blood vessel formation and maintenance, is not 
only an important physiological phenomenon in wound healing, female reproductive 
cycle and embryo development, it is also an essential trigger in pathological conditions 
such as tumor development, cancer metastasis, inflammatory diseases (rheumatoid 
arthritis, psoriasis), age#related macular degeneration and other retinopathies involving 
neovascularization. It is mediated by several cellular growth factors including VEGF 
which mediate their effect by binding to and stimulating cell surface receptors. In 
normal or physiological conditions, angiogenesis is initiated during growth, injury or 
hypoxia in growing tissues, which produces VEGF that binds to its receptors in 
neighboring endothelial cells. This activates the endothelial cells, which start 
proliferating, leading to basement membrane degradation, sprout formation and blood 
vessel structure stabilization. In pathological angiogenesis, such as, in tumor 
development, the growing avascular mass of proliferative neoplastic cells, which 
derive growth requirements from neighboring cells and vessels, becomes mostly 
apoptotic after tumor cell diameter increases to 1–3 mm as a result of unavailability of 
oxygen and nutrients. However, after a brief latency, the cells start acquiring mutations 
leading to development of aggressive clones that overexpress VEGF and other growth 
factors, which tilt the balance of pro# and anti#angiogenic factors towards angiogenesis 
(Figure 1.1). The fact that VEGF plays a pivotal part in being an effector for both 
vasculogenesis and angiogenesis, is evident from the fact that loss of one allele causes 
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early embryonic lethality [213, 314].  VEGF mediates its functions by binding to, and 
stimulating endothelial#specific cell surface tyrosine kinase receptors, VEGFR1/Flt#1 
and VEGFR2/ KDR/Flk#1. While VEGFR1 binds to VEGF with a higher affinity (Kd 
∼10#20 pM) [315, 316], VEGFR2 binds with a lower Kd of ∼100#125 pM [317, 318]. 
VEGFR2 binds to VEGF alone, whereas, VEGFR1 binds to both VEGF and PlGF, a 
growth factor having significant structural homology to VEGF [319]. Although 
VEGFR1 undergoes autophosphorylation upon binding to VEGF and the binding 
affinity is much stronger than that of VEGFR2, the downstream signaling is weak as 
compared to VEGFR2 mediated signal [213]. Most of the cellular response of VEGF, 
is mediated by binding of the ligand to VEGFR2. Hence the most strategic way to 
inhibit angiogenesis is to block either VEGF or VEGF receptors [188]. Inhibition of 
tumor growth by VEGF neutralizing antibodies, small molecule tyrosine kinase 
inhibitors and other anti#VEGF molecules have been observed in a wide range of tumor 
cell lines and mice models with tumor xenografts [320, 321]. MAbs (bevacizumab, 
ranibizumab, ramucirumab), small molecules (sunitinib, sorafenib, pazopanib) and 
aptamer (pegaptanib) are some of the approved anti#VEGF/VEGFR anti#angiogenic 
drugs widely used for treatment of a variety of diseases involving neoangiogenesis. 
 
Most of the inhibitors of angiogenesis, that have been developed, or are in different 
phases of development, are against VEGF. Some of them are anti#VEGF antibodies, 
aptamers, siRNA [322, 323], fusion protein, peptibodies or mimetobodies. Other 
molecules which act as angiogenic inhibitors include small molecules # tyrosine kinase 
inhibitors and anti#VEGFR2 antibodies.  
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Fc#fusion proteins have several advantages over classical antibodies or non#Fc proteins 
by virtue of their IgG#Fc domain, in terms of increased serum half#life, stability, 
solubility, expression, ease of purification, less patient dosing and improved patient 
compliance [324]. Due to recent advances in protein engineering of the Fc region, it is 
also possible to modulate the immune system and achieve desired product#specific 
outcomes [163, 206]. 
 
Decoy receptors or sink receptors are commonly known as molecular traps, and are 
soluble receptor mimics of the cellular receptors. Mostly these are fused to the Fc 
region of immunoglobulin, mainly IgG, making them soluble Fc#fusion proteins. Anti#
VEGF decoy receptors may consist of all or some extracellular ligand binding domains 
of VEGFR1 or VEGFR2 receptor or a fusion of both. The circulating receptor decoy 
will bind and neutralize the cellular ligand (VEGF) making it unavailable to its cellular 
receptor, VEGFR2, thus inhibiting downstream signaling for cell proliferation and 
survival, and subsequently blocking angiogenesis. There have been reports of initial 
VEGF trap, VEGFR1(D1#D7)#Fc, containing all the seven extracellular IgG#like 
domains of VEGFR1 fused to IgG#Fc, having the same affinity as the wild type soluble 
and cognate receptor Flt#1(1#7)#IgG, as well as a truncated trap, containing the first 
three domains only [212]. Regeneron Pharmaceuticals Inc. developed a VEGF trap 
(aflibercept) in early 2000, which is a soluble decoy receptor that binds VEGF#A, on 
the basis of molecular interaction between the ligand (VEGF) and its cognate cellular 
receptors (VEGFR1 and VEGFR2). It also has a broader specificity due to its ability 
to bind PlGF, in addition to VEGF#A and VEGF#B. This was followed by the 
development of a trap for VEGF, which consisted only of the first three domains of 
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VEGFR1 fused to the constant region of IgG1#Fc, giving rise to a forced homodimer 
with a very high VEGF#binding affinity of 5#20 pM. This molecule had similar binding 
affinity as the initial trap (Flt#1(1#7)#Fc). In in vivo mice models, this protein was 500 
– fold more efficacious than its VEGFR2 counterpart, as VEGFR1 and VEGFR1#Fc is 
known to have a much higher binding affinity for VEGF, than VEGFR2 or VEGFR2#
Fc (30 vs. 300 pM and 9.33 vs. 88.8 pM respectively) [325]. However, due to a basic 
stretch of 10 amino acids in the third receptor domain (D3), this protein had a higher 
isoelectric point (pI of 9.4), leading to poor pharmacokinetics, as a result of non#
specific ECM binding and rapid clearance or shortened half#life, low efficacy and toxic 
side effects [208]. This led to the development of a trap with removal of the 10 amino 
acid stretch followed by removal of the entire Ig domain 1 (D1) of VEGFR1, which 
decreased the pI to 9.1 and 8.9, respectively [93]. Regeneron Pharmaceuticals Inc. 
created chimeric fusion proteins with minimal binding domains from the two VEGF 
receptors, VEGFR1 and VEGFR2, before coming up with aflibercept or VEGF#
TrapR1R2, which consists of domain 2 (D2) or VEGFR1 and domain 3 (D3) of VEGFR2 
fused to the Fc region of human IgG1 having a pI of 8.82 and a very high binding 
affinity for VEGF (Kd≈0.49 pM). It had been earlier reported that the ligand binding 
determinants of both VEGF receptors are contained in second and third extracellular 
domains, while the minimal and sufficient ligand binding domain was mapped to 
domain D2 [89, 326, 327].  
 
As earlier reports indicate, a group of scientists from China cloned recombinant human 
VEGFR1#Fc (rhVEGFR1D1#3/Fc) by fusing  D1, D2 and D3 domains of VEGFR1, to 
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Fc region of human IgG1#Fc [328]. The Fc region consisted of CH2 and CH3 domains 
of the human IgG1 heavy chain and the hinge region. The hinge served as a flexible 
spacer between the two parts of the Fc#fusion protein, allowing each part of the 
molecule to function independently [329]. A short intron was present between each 
region (one intron between the hinge and CH2 and one intron between CH2 and CH3). 
The presence of introns is known to enhance the level of gene expression [330] as 
splicing is known to promote rapid and efficient mRNA export. 
 
With this previous knowledge, we developed a VEGF trap protein containing the first 
to third extracellular domains of VEGFR1 which was characterized and tested for 
efficacy both in vitro and in vivo. The D1#D3 gene domains of VEGFR1were obtained 
by amplifying the same from a pre#existing VEGFR1 gene cloned in an expression 
vector. The human IgG1 constant region (Fc portion) was amplified from a monoclonal 
antibody clone pre#existing in our laboratory. During the fusion gene amplification, 
primers were designed so as to delete the nucleotide sequence encoding five amino 
acids residues from the N#terminal of the hinge region of IgG1. This was done to 
remove the cysteine residues present in the hinge sequence, which form intermolecular 
disulfide bonds with the light chain of IgG1. The Fc portion of the protein imparts 
enhanced solubility and stability to the fusion partner owing to its independent folding, 
along with increasing serum half#life due to interaction with Fc receptors. It also helps 
in easy purification of the expressed protein from culture supernatant, on the basis of 
its affinity towards Protein A. The fusion gene was cloned in TOPO cloning vector 
followed by subcloning in mammalian expression vector, pXC17.4. Mammalian cells, 
CHOK1SV GS#KO were stably transformed with the plasmid carrying the gene of 
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interest by electroporation. The VEGFR1(D1#D3)#Fc protein by virtue of its signal 
sequence, was expressed in the culture medium from which it was purified by Protein 
A affinity chromatography, followed by further purification using strong cation 
exchange SP Sepharose chromatography. However, as is the case of several reported 
Fc#fusions, the VEGFR1(D1#D3)#Fc protein was also found to be undergoing clipping 
in cell culture. The presence of additional protein species (40 kDa and 30 kDa) were 
observed along with the expected 78 kDa monomer under reducing conditions. Partial 
cleaving of expressed protein, initiated early on in cell culture. The clipping process 
was exacerbated with increased time in culture and also on storage. An alternate 
strategy of developing a new construct with complete removal of VEGFR1 D1 domain 
and a modified D3 domain (arginine#glycine replaced by lysine alanine), yielded a 
clipped protein in culture and hence was abandoned. Furthermore, a range of 
parameters were explored in an attempt to inhibit clipping in the fusion protein The 
effects of culture temperature, duration of culture, addition of anti#clumping agent, 
ferric citrate and the use of protease inhibitor cocktail on inhibition of proteolysis of 
the Fc#fusion, were studied. It was observed that degradation was independent of host 
cell, as VEGFR1(D1#D3)#Fc expressed in both HEK293T and CHOK1SV GS#KO 
cells was undergoing clipping in culture. Proteolysis was also independent of clones 
expressing the protein. Lowering of culture temperature from 37°C to 30°C alone 
appeared to be the best solution for reducing protein degradation from the quality and 
cost of production perspective.  
 
Since the most potent and well characterized ligand for VEGFR1 is VEGF165, this 
protein was also developed by recombinant technology and purified by strong cation 
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exchange chromatography followed by heparin Sepharose affinity chromatography, 
and used in all the in vitro assays and receptor binding assay presented in the thesis.   
 
Characterization of the Fc#fusion protein, VEGFR1(D1#D3)#Fc, incorporated multiple 
analyses aimed at investigating protein quantification, identification, purity, structure, 
physicochemical properties, stability and functional activity. The protein was 
quantitated using Bradford’s assay [331]. MW of the protein was determined by SDS#
PAGE. Western blotting using IgG1#Fc#specific antibody, was used for detection of 
the protein and validation of its MW. The MW of intact VEGFR1(D1#D3)#Fc protein 
monomer was observed to be 78 kDa. Purity of the protein was assessed by RP#HPLC, 
SEC#HPLC and capillary electrophoresis (CE#SDS). SEC with purified protein 
determined presence of about 87% of intact protein along with about 8% high MW 
aggregates and about 5% low MW impurities in the form of degraded products. Thus, 
maintaining a low culture temperature of 30°C during VEGFR1(D1#D3)#Fc 
production, was able to reduce the degree of proteolysis to a large extent but not 
completely inhibit it. 
 
Broad spectrum of protein characterization techniques was utilized in order to get a 
comprehensive idea regarding various aspects of the protein developed in#house. 
Higher order structures including secondary structure prediction was done using CD, 
and tertiary structure and folded state was analyzed by FS. Molecular mass was 
determined by MALDI#TOF MS. DSC was performed in order to determine the 
stability of the protein in its native folded form. From CD, FS and DSC data, the protein 
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appeared to be in the correct active folded stable state with overall intact secondary 
and tertiary structures. Stability of VEGFR1(D1#D3)#Fc was also analyzed at different 
temperatures (#70ºC, #20ºC, 2#8ºC, 25ºC and 40ºC) at various time points (0 day, 15 
days, 1 month, 3 months and 6 months) by SDS#PAGE, Western blots and RP#HPLC. 
Data after six months indicated that the protein was stable at #70ºC and #20ºC, and 
gradually started degrading at higher temperatures. Affinity of VEGFR1(D1#D3)#Fc 
protein towards its ligands, VEGF165 and VEGF121, was checked using ELISA, and 
compared to the affinity of aflibercept/ VEGF#TrapR1R2. VEGFR1(D1#D3)#Fc 
exhibited a strong affinity towards its natural ligands, and its affinity towards both the 
VEGF ligands was very similar to that of aflibercept. The isoelectric point of the 
protein was in the pH range of 8.2#9.4 as determined by CE (cIEF). The range of pH 
indicated presence of different isoforms of the protein. N#glycosylation of the Fc#
fusion protein, achieved by expressing protein in mammalian CHO cells, was required 
to elicit effector function, improve stability and folding and reduce aggregation. The 
protein was found to be glycosylated at the predicted six N#glycan sites as assessed by 
CE. The major glycan forms present in VEGFR1(D1#D3)#Fc protein are G2FS1, G0F, 
Man5, G1F (1, 6), G1F(1, 3), G2F and four unidentified minor peaks. The protein has 
a high content of sialated form of N#glycan (30% G2FS1) and N#glycan with terminal 
GlcNAc (29.8%), which impact pharmacokinetics by affecting clearance rate of serum 
half#life. 
 
The biological activity of the protein was also determined using in vitro and in vivo 
studies in comparison to known Fc#fusion protein, aflibercept. VEGFR1 (D1#D3)#Fc 
exhibited inhibitory effects on VEGF#stimulated cell proliferation and capillary 
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network formation in primary endothelial cells (HUVEC). Proliferation of HUVEC 
was increased upon addition of 25 ng/ml of in#house VEGF165, by about two folds. 
Upon addition of increasing concentrations of VEGFR1(D1#D3)#Fc to the VEGF#
induced cells, VEGFR1(D1#D3)#Fc acted as an inhibitor, by binding to and 
neutralizing the effects of VEGF165. A significant decrease in cell proliferation was 
observed with VEGFR1(D1#D3)#Fc concentrations of 150 ng/ml (p≤0.01), 200 – 450 
ng/ml (p≤0.001) and 750 ng/ml (p≤0.0001).  Another in vitro assay was used to study 
the protein’s inhibitory effect on endothelial cells’ intrinsic ability to self#organize to 
form capillary network.  Capillary network formation of primary vascular endothelial 
cells (HUVEC) in Matrigel, was increased by addition of 50 ng/ml of in#house 
VEGF165. Increasing concentrations of VEGFR1(D1#D3)#Fc added to VEGF#induced 
cells, led to decrease in endothelial tube formation as quantitated by Angiogenesis 
Analyzer of Image J software. Both the batches of VEGFR1(D1#D3)#Fc, irrespective 
of the day of harvest of the protein and amount of clipped protein, demonstrated 
inhibition of tube formation. A concentration of 250 µg/ml of protein significantly 
reduced formation of endothelial capillary network in Matrigel (p≤0.01). For 
demonstrating inhibitory effect of VEGFR1(D1#D3)#Fc, two images per well for each 
inhibitor concentration, were taken and analyzed for average tube length. These in vitro 
assays were standardized in#house, and clearly established the anti#angiogenic ability 
of VEGFR1(D1#D3)#Fc. 
 
In in vivo efficacy studies, human lung cancer xenografts in SCID mice, served as a 
model for studying tumor angiogenesis [332]. Xenografts were ectopic in nature, such 
that the site of transplantation was different from the site of the origin of the cell line 
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injected. In humans, since lung cancer is the leading cause of all cancer related deaths, 
with non#small cell lung cancer (NSCLC) accounting for almost 85#90% of cases, 
NSCLC cell line, A549, was used as a model of human cancer in in vivo studies [333]. 
Animal models of lung cancer were generated in#house. Sixteen SCID mice were 
subcutaneously injected with A549 bronchoalveolar carcinoma cells, and on 
development of tumors, divided into four groups; untreated (n=3), placebo#treated 
(n=3), aflibercept#treated (n=5) and VEGFR1(D1#D3)#Fc#treated (n=5). A total of 
eight doses (15 mg/kg body weight) of drugs (control drug aflibercept and test drug 
VEGFR1(D1#D3)#Fc) were given to the mice at two doses per week, and tumor 
volumes measured. The dose and dosing regimen were greatly followed from the 
published data of tumor studies for aflibercept [93]. Significant reduction in tumor 
volume was observed (p<0.05) in mice treated with VEGFR1(D1#D3)#Fc as compared 
to mice in the placebo group, indicating the anti#cancer activity of the protein. 
Histological analysis using H&E staining was performed according to standard 
procedures on 3#4 am paraffin sections. Changes in tumor growth kinetics upon 
treatment with different anti#VEGF molecules, such as Fc#fusion proteins (aflibercept 
and VEGFR1(D1#D3)#Fc) and aptamer (RNV66), were reflected in their difference in 
proliferation, as assessed by immunohistochemistry of cell proliferation marker, Ki#67 
and angiogenesis marker, CD31.  
 
Tumor cell nucleus marker protein Ki#67, was stained with a primary anti#Ki#67 
antibody, in immunohistochemical analysis. Ki#67 reactivity, which is defined as 
percent tumor cells staining positive for the nuclear antigen, was used as a definite 
marker for cell proliferation. The Ki#67 index in tumor sections of untreated and 
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placebo#treated control mice was ~60% indicative of high tumor cell proliferation in 
these sections (Figure 7.13). Ki#67 index decreased for VEGFR1(D1#D3)#Fc#treated 
tumors to ~40% signifying inhibition of tumor cell proliferation by the Fc#fusion 
protein (p<0.01). For tumors treated with aflibercept (positive control), the Ki#67 cell 
proliferation index dropped to less than 10%, demonstrating the anti#proliferative and 
anti#cancer effects of VEGF#TrapR1R2 molecule. 
 
Upon staining of A549 tumors treated with an anti#VEGF aptamer, RNV66, the Ki#67 
index in the highest proliferating region was observed to be about 50% on average for 
five mice. This indicated that the aptamer was unable to inhibit tumor cell proliferation 
to a large extent. However, when a combination of VEGFR1(D1#D3)#Fc and RNV66 
were administered to tumor#bearing mice, Ki#67 staining of tumor sections revealed a 
decreased 40% Ki#67#stained proliferating cells in the highest proliferating region. 
This enhanced effect of treatment may be attributed to a synergistic effect of 
VEGFR1(D1#D3)#Fc and aptamer.  
 
Slides were stained with mouse CD31 antibody for detection of tumor blood vessel 
endothelial cells, as the human tumor xenograft was supported by vasculature of host 
mouse origin. The anti#angiogenic properties of VEGFR1(D1#D3)#Fc were 
demonstrated by the reduction of CD31#positive blood vessels within the tumor section 
obtained from SCID mice treated with VEGFR1(D1#D3)#Fc, as compared to untreated 
and placebo#controlled mice. Aflibercept#treated tumors demonstrated almost 
complete absence of mouse blood vessels in the small tumor mass, validating the 
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known anti#angiogenic function of the molecule. However, in A549 tumor sections of 
mice treated with the anti#VEGF DNA aptamer, RNV66, plenty of CD#31 positive 
blood vessels were present, indicating that the molecule was not as effective as the 
others as an anti#angiogenic agent. Microvessel density quantified for each of the 
treatments, corroborated these findings. Since RNV66 had earlier demonstrated its 
anti#proliferative activity against breast cancer animal models, one possibility for its 
failure as an anti#tumor molecule here, may be due to the insufficient dose 
administered in the current study. However, when acting in combination with 
VEGFR1(D1#D3)#Fc, the Fc#fusion protein was able to rescue anti#angiogenic 
properties of its aptamer partner to some extent, though not significantly, suggesting a 
strong anti#angiogenic, anti#proliferative and anti#tumor role of the developed Fc#
fusion protein, VEGFR1(D1#D3)#Fc. No drug#induced toxicity was observed in any 
of the treated animals as suggested from the normal histopathology of different organs 
including liver, lungs, brain and heart. 
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8.2 Conclusion 
 
 
An anti#VEGF, Fc#fusion protein, VEGFR1(D1#D3)#Fc, was developed using 
recombinant DNA technology in the laboratory, from scratch. The VEGFR1(D1#D3)#
Fc fusion gene was generated from amplification followed by fusion of genes encoding 
the first three extracellular domains of VEGFR1 and human IgG1#Fc region. Gene 
sequence for Fc region was slightly altered (five amino acid deletion in hinge) as is the 
case in commercially successful anti#VEGF fusion protein, aflibercept. Protein 
degradation was reported during production of indigenous VEGFR1(D1#D3)#Fc, and 
measures were taken to inhibit proteolytic cleavage of the fusion trap. Protein 
chemistry studies were performed to characterize the Fc#fusion protein in terms of 
MW, secondary and tertiary structure, thermal stability, purity, isoelectric point and 
glycosylation profiling. Strong binding affinity of the fusion trap for VEGF#A was 
demonstrated, and the angiogenesis#inhibitory functions were confirmed, both in cell#
based assays, as well as a xenograft animal model.  
 
This project, aimed at drug development, was not a commercial project, but a 
completely indigenous project, exploring basics of cell biology, protein chemistry, 
bioassay development and animal studies. The goal of the project was to develop an 
effective anti#angiogenic and anti#cancer agent, which in future, would hold promise 
in treatment of millions affected with serious life#threatening conditions, in developing 
countries, in a cost#effective manner. 
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8.3 Future work  
 
Angiogenesis is a hallmark of cancer and the anti#angiogenic molecule, VEGFR1(D1#
D3)#Fc, holds promise in advancing in the pipeline of anti#cancer drug development.  
Additional human cancer models in animals, need to be evaluated to test the efficacy 
of the drug, since only the lung cancer, A549 model, was tested in the current study. 
Further to the in vitro and in vivo studies demonstrating anti#angiogenic properties of 
the protein, studies determining drug toxicity in animal models, maximum tolerable 
dose and precise duration of treatment are required.  
In future, PK/PD studies need to be carried out for the protein in order to ascertain its 
efficacy in humans. Pharmacokinetics, which is the study of time course of drug 
absorption, distribution, metabolism and excretion, enhances a patient’s response to 
treatment in terms of safety and efficacy, eventually helping in improvement and 
optimization of the design of the drug molecule. Since pharmacologic response is 
closely related to plasma drug concentration, the therapeutic index for the drug, needs 
to be determined. Pharmacodynamic studies will help to determine the biochemical 
and physiological effects of a drug and its mechanism of action. Overall, PK/PD 
studies should be carried out in order to improve the translation of findings from pre#
clinical to clinical settings and towards improved drug development. In addition to 
these studies, the mechanism of action of VEGFR1(D1#D3)#Fc protein at the genetic 
level also remains to be demonstrated. Global gene expression and protein expression 
studies using a microarray#based platform, could be carried out. RNA extracted from 
drug#treated tumor tissues will help in gene expression profiling, and cellular pathways 
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from evaluated upregulated and downregulated genes, can be mapped. Similarly, 
proteomics studies can help determine the global protein expression in response to 
treatment.  
In addition, studies pertaining to effective delivery of the protein need to be carried 
out. Targeted drug delivery using nanoparticles including functionalized liposomes, 
albumin#based particles, carbon nanotubes, nanofibres, fullerenes, polymeric micelles, 
dendrimers, quantum dots, gold nanoparticles, and cell#based nanoparticles are known 
to provide minimal or no toxicity or side effects, require less drug dose, and can be 
used to carry the protein of interest to the site of action [334#337]. Further to this, since 
VEGFR1(D1#D3)#Fc is a prospective anti#angiogenic drug, animal models of cancer 
metastasis need to be generated. For this, lung cancer models could be generated in 
liver, where human lung cancer cells would be directly injected in 
immunocompromised mice liver in order to develop metastasizing tumor, or injected 
in the lateral tail vein, which would predominantly give rise to pulmonary metastasis 
[338]. Liver cell#specific targeted biodegradable, biocompatible, nanoscale delivery 
systems including chimeric molecules containing liver cancer specific antigens, can 
help deliver the protein to the liver, in the former case. In case of metastasis models 
developed by direct injection of cells in systemic circulation, required drug dose 
concentration will be suboptimal, although there will be ease of administration. On the 
other hand, oral delivery will allow the drug to be absorbed by the highly vascularized 
oral mucosa and rapidly enter the systemic circulation, in addition to bypassing the 
gastrointestinal tract and first#pass metabolism in liver [339]. These pre#clinical studies 
will finally pave the way for clinical trials for the protein resulting in successful drug 
development. 
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Appendix 1 
 
List of Primers 
 
Primer name Primer sequence 5’/3’ 
TPG#1 AACAGCTATGACCATG 
TPG#2 GTTTTCCCAGTCACGAC 
TPG#3 TAACGGTGGAGGGCAGTGTAGT 
TPG#4 ATAAGCTGCAATAAACAAGTT 
TPG#5 GATGAATGCCTTGTCGTAGATGTG 
TPG#6 GACAAAACTCACACATGCC 
TPG#7 CAAATGTGGTATGGCTGA 
TPG#8 CATGTGTGAGTTTTGTCGATGAATGCCTTGTCGTAGATGTG 
TPG#9 ACGACAAGGCATTCATCGACAAAACTCACACATGCC 
TPG#10 GCAAGCTTGCCGCCACCATG 
TPG#11 ACAGTCCCTTATCCTTGTTCTGC 
TPG#12 CCCTGAGGTCAAGTTCAACT 
TPG#13 GCGAATTCTCATTTACCCGGAGACAGGGAGAGGCTC 
TPG#14 GGCAAACGTATCATTTGGGA 
TPG#15 CAAATGTGGTATGGCTGATTATGAT 
TPG#16 TTCTATCCCAGCGACATCGC 
TPG#17 GCAGAAACGGAAAGCAGTTC 
TPG#18 AATCGATCAGTCCAACAGCC 
TPG#19 ACTTGCATGAGTAAAAGCCG 
TPG#20 ACGGTAGCTTCGCAAGTCAG 
TPG#21 TGTCTTGGCATTATGCACCTCC 
TPG#22 CTTGCACTTGTACTCCTTGCCAT 
TPG#23 ATGAGAAGACGTTCCCCTGCTG 
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TPG#24 ATTTCTGATCGGGAATGCCC 
TPG#25 ACCACTTGAGGAACCAGTCAGC 
TPG#26 GGCCGGCCGGTATCACTACCACTTGAGGAACCAGTCAGC 
TPG#27 AGTGATACCGGCCGGCC 
TPG#28 CTGGTTCCTCAAGTGGTAGTGATACCGGCCGGCC 
TPG#29 GCACCAGGGTATGGGCTTTCAGCAGCTTGACAGGCCTG 
TPG#30 GGCCTGTCAAGCTGCTGAAAGCCCATACCCTGGTGCTGAAC
TGTAC 
TPG#31 CAGCAGCTTGACAGGCCTG 
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Appendix 2 
Chemicals and reagents 
Name Company Catalogue 
Ampicillin Sigma#Aldrich A0166 
Bacto agar Difco 214010 
Agarose Lonza 50004L 
Tris base Sigma#Aldrich T1503 
HCl Merck 100317 
Glucose Sigma#Aldrich G6152 
EDTA Sigma#Aldrich 03620 
SDS Sigma#Aldrich L4390 
NaOH Sigma#Aldrich S5881 
Potassium acetate Sigma#Aldrich P1190 
Diatomaceous earth Sigma#Aldrich D5509 
Guanidine hydrochloride Sigma#Aldrich G3272 
Ethanol Changshu Hongsheng 
Fine chemicals Co. Ltd. 
215522 
DMEM Lonza 12#614Q 
EBM#2 Basal Media Lonza CC#3156 
EGM#2 Bullet kit with single 
quotes 
Lonza CC#4176 
FBS Hyclone SH30070.03 
L#Glutamine Gibco 25030#081 
OptiMEM Gibco 31985 
LipofectamineTM2000 
Transfection Reagent 
 
Invitrogen 
11668019 
TEMED Sigma#Aldrich T7024 
Acrylamide Sigma#Aldrich 60868525001730 
Bis acrylamide Sigma#Aldrich 146072 
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Ammonium persulphate Sigma#Aldrich A3678 
DAB#urea Sigma#Aldrich D4418 
Skimmed milk Difco 232100 
TMB/H2O2 Sigma#Aldrich T0440 
Sodium acetate Sigma#Aldrich S2889 
100 bp DNA ladder Norgen Biotek 11400 
1 kb DNA ladder NEB N3232 
Recombinant Human VEGF165 ProSpec CYT421 
BSA Sigma#Aldrich A9418 
Trypan Blue stain Invitrogen 15250#061 
Kanamycin Sigma#Aldrich K0254 
CDCHO medium Gibco 10743029 
Ferric citrate Lonza BE02#043E 
Protease Inhibitor Cocktail 
Tablets 
Roche 11873580001 
Tween20 Sigma#Aldrich P7949 
Tween80 Sigma#Aldrich P4780 
TFA Sigma#Aldrich T6508 
Acetonitrile Merck A2094 
IEF marker (pH 3#10) Serva 39212 
Sodium chloride Sigma#Aldrich S7653 
Silver nitrate Sigma#Aldrich 221341 
Sodium carbonate Sigma#Aldrich 223530 
DTNB Sigma#Aldrich D8130 
Cysteine hydrochloride 
monohydrate 
Merck 102735 
Gelatin Sigma#Aldrich G9391 
HBSS Gibco 14175#095 
TrypLETM Select Gibco 12563#011 
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Matrigel Corning 356231 
Alamar Blue Invitrogen DAL1100 
Haemotoxylin Sigma#Aldrich HHS16 
Eosin Sigma#Aldrich E4382 
Xylene Thomas Baker 167228 
Methanol Merck M0275 
Horse serum Gibco 16050#122 
Yeast extract Difco 212750 
DMSO Sigma#Aldrich D 2438 
Coomassie brilliant blue G#250 Sigma#Aldrich B0770 
Ponceau S stain USB US32819 
Bromophenol blue USB US12370 
Orange G dye Sigma#Aldrich 03756 
Glycerol Merck 17560 
β mercaptoethanol Sigma#Aldrich M7154 
Tryptone B D Diagnostic Systems 211699 
Heparin sodium salt Sigma#Aldrich H3149 
High range rainbow molecular 
weight marker 
Amersham RPN756 
Acetic acid; GR grade Merck 1.93402.0521 
Ferric citrate Lonza BE02#043E 
Formaldehyde Merck 104003 
Sucrose Sigma#Aldrich S0389 
Fluoroshield Sigma#Aldrich F6182 
DAPI Sigma#Aldrich D9542 
dNTP mix Invitrogen 1827088 
Ethidium bromide USB US32813 
rATP Stratagene 211190#56 
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Appendix 3 
 
Cells 
Cell Type Company Catalogue 
E.coli XL1#Blue B.D. Biosciences 352059 
TOP10F’ Thermo Fisher Scientific C3030#03 
HUVEC ATCC PCS#100#013 
HEK293T ATCC CRL#11268 
A549 ATCC CCL#185 
 
 
Kits and vectors 
Name Company Catalogue 
pGEMT#T Easy Promega A137A 
MontageTM SEQ96 Sequencing reaction 
cleanup kit 
Millipore LSKS09624 
Plasmid Mega prep kit Qiagen 12181 
QIAquick gel extraction kit Qiagen 28704 
pCR#Blunt II#TOPO vector Invitrogen 45#0031 
Plasmid Maxi prep kit Qiagen 12162 
PrepSEQ™ residual DNA sample 
preparation kit 
Thermo Fisher 4413686 
ResDNASEQ™ quantitative CHO DNA kit Thermo Fisher 4413713 
Big Dye terminator kit ABI 4336915 
Dako REALTM EnVision Detection System, 
Peroxidase/DAB+ 
Dako K5007 
EGM#2 Bullet kit Lonza CC#3162 
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Enzymes and antibodies 
Name Company Catalogue 
EcoR1 NEB R0101S 
HindIII NEB R0104S 
RNaseA Sigma#Aldrich R6513 
Aflibercept Bayer 34065C 
Peroxidase#AffiniPure Goat Anti#
Human IgG (H+L) 
Jackson ImmunoResearch 
Labs 
109#035#088 
Peroxidase#AffiniPure F(ab')2 
Fragment Goat Anti#Human IgG, Fc 
gamma Fragment Specific 
Jackson ImmunoResearch 
Labs 
109#036#098 
PvuI NEB R0150L 
T4 DNA ligase NEB M02025 
Human Ki#67 antibody Dako M7240 
Mouse CD31 antibody R&D Systems 3628 
Antibody diluent Dako S0809 
Rabbit anti#goat IgG (whole 
molecule)#FITC labeled polyclonal 
antibody 
Sigma#Aldrich F7367 
Pfu Turbo DNA polymerase Agilent 600252#52 
Pfu Native DNA polymerase Agilent 600135 
T4 DNA ligase NEB M0202S 
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Appendix 4 
 
Materials 
Name Company Catalogue 
ELISA MaxiSorpTM micro#titer plate Nunc 439454 
Amicon ultra#15; ultracel#5 Millipore UFC900524 
96#well tissue culture plate Nunc 16109 
Charged L#lysine slides Dako K8020 
Nitrocellulose MDI SCNX8402XXXX101 
Roller bottle Corning 431198 
Gene pulser cuvette,0.4cm Bio#Rad Labs 165#2088 
Cryogenic vial sterile PP 2.0 mL Nunc 5000#0020 
24 well cell culture plate Falcon 353047 
PCR vials (0.2 mL) Sarstedt 72.990.002 
T25 cell culture treated flask Nunc 136196 
T75 cell culture treated flask Nunc 156499 
T175 cell culture treated flask Nunc 178883 
 
 
Instruments 
Instrument Company 
NanoDropTM 1000 Spectrophotometer NanoDrop® Technologies Inc. 
ABI Prism 3100 Genetic Analyzer Applied Biosystems 
Electroporator Bio#Rad Laboratories 
AKTA protein purification system GE Healthcare Life Sciences 
Gel documentation system# Image Master 
VDS 
GE Biosciences, Pharmacia Biotech 
MALDI#TOF 5800 AB Sciex 
Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion 
Protein 
 
408 
  
Instrument Company 
CZE PA800 Plus Beckman Coulter 
J#710 CD spectropolarimeter Jasco 
Liquid Chromatographic system Shimadzu 
FP#8000 spectrofluorometer Jasco 
MicroCal VP#DSC calorimeter Malvern Instruments 
Plate reader Polar Star Optima BMG Labtech 
Microtome Thermo Electron Corporation 
Tissue processor Thermo Electron Corporation 
Tissue embedding system Labcon 
Automated stainer Thermo Electron Corporation 
 
 
Softwares 
Software Source 
Vector NTI® Thermo Fisher Scientific 
Image J National Institute of Health 
GelQuant.NET BiochemLabSolutions.com 
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Appendix 5 
 
 
Thesis Publications (Links to PDF) 
 
1. Sanjukta Chakrabarti, Colin J. Barrow, Rupinder K. Kanwar, Venkata 
Ramana and Jagat R. Kanwar. Current Protein#based anti#angiogenic 
therapeutics. Mini#Reviews in Medicinal Chemistry. 2014 Mar; 14(3): 291#
312. 
Link: http://hdl.handle.net/10536/DRO/DU:30062739 
 
 
2. Sanjukta Chakrabarti, Colin J. Barrow, Rupinder K. Kanwar, Venkata 
Ramana and Jagat R. Kanwar.  Studies to prevent degradation of recombinant 
Fc#fusion protein expressed in mammalian cell line and protein 
characterization. Int. J. Mol. Sci. 2016, 17(6); 913. 
Link: http://www.mdpi.com/1422#0067/17/6/913/pdf 
